<?xml version="1.0" encoding="utf-8"?>
<add>
	<doc>
		<field name="docid">BR-TU.13298</field>
		<field name="filename">19217_Adrag%c3%a3o%20Teresa%20TD%202011.pdf</field>
		<field name="filetype">PDF</field>
		<field name="text">
CALCIFICAÇÕES VASCULARES 
NOS DOENTES EM DIÁLISE: 

ELO DE LIGAÇÃO ENTRE DOENÇA ÓSSEA 
E DOENÇA VASCULAR

TERESA ADRAGÃO

2011





1

ÍNDICE

Agradecimentos .............................................................................................................. 3

Capítulo 1
Prefácio – Calcifi cação vascular nos doentes em diálise: Elo de ligação entre doença 
óssea e doença vascular .................................................................................................. 5

Capítulo 2
Criação de um score semiquantitativo para avaliar a calcifi cação nos doentes em diálise ... 9

Capítulo 3
Calcifi cação vascular: Prevalência e associação com mortalidade e morbilidade .......... 17

Artigo 1. A simple vascular calcifi cation score predicts cardiovascular risk 
in haemodialysis patients ..................................................................... 29

Capítulo 4
Calcifi cação vascular e rigidez arterial ........................................................................... 39

Artigo 2. A plain X -ray vascular calcifi cation score is associated with arterial 
stiffness and mortality in dialysis patients ........................................... 45

Artigo 3. Vascular calcifi cation, cardiovascular risk and arterial stiffness in 
hemodialysis patients ........................................................................... 51

Capítulo 5
Calcifi cação valvular cardíaca nos doentes em diálise ................................................... 57

Artigo 4. Vascular and valvular calcifi catons. The same pathogenesis? ............. 61

Capítulo 6
Existe um elo de ligação entre o osso e o vaso nos doentes em diálise? (1.ª parte)
Calcifi cação vascular e análise histomorfométrica de biopsias ósseas ........................... 69

Artigo 5. Low bone volume – a risk factor for coronary calcifi cations 
in hemodialysis patients ...................................................................... 75



2

Artigo 6. Editorial de London G. Bone -vascular axis in chronic kidney disease: 
a reality? .............................................................................................. 81

Artigo 7. Is there a link between bone and vessel in dialysis patients? .............. 85
Artigo 8. Treatment of hyperphosphatemia with sevelamer hydrochloride in 

dialysis patients: Effects on vascular calcifi cation, bone and a close 
look into the survival data ................................................................... 93

Capítulo 7
Existe um elo de ligação entre o osso e o vaso nos doentes em diálise? (2.ª parte)
Densidade mineral óssea, histomorfometria óssea e calcifi cações vasculares ............... 99

Artigo 9. Bone mineral density, vascular calcifi cations, and arterial stiffness 
in peritoneal dialysis patients .............................................................. 107

Artigo 10. Femoral bone mineral density refl ects histologically determined 
cortical bone volume in hemodialysis. patients ................................... 113

Capítulo 8
Métodos para avaliar a calcifi cação vascular .................................................................. 121

Artigo 11. Cardiovascular risk in dialysis patients: an X -ray vision on vascular 
calcifi cations ........................................................................................ 127

Artigo 12. Evaluation of vascular calcifi cations in CKD patients ........................ 131

Capítulo 9
Comentários fi nais .......................................................................................................... 137

Capítulo 10
Resumo da dissertação .................................................................................................... 153
Abstract ........................................................................................................................... 155

Autorização de publicação
A reprodução dos artigos e tabelas publicados foi objecto de autorização expressa dos respectivos editores.

Segundo o acordo ortográfi co em vigor.



3

AGRADECIMENTOS

A presente dissertação é o resultado de um esforço individual apoiado e amplifi cado por 
diversas contribuições valiosas que desejo aqui recordar e agradecer.

Em primeiro lugar, agradeço ao Sr. Professor Doutor Jacinto Simões, ao Dr. José Miguel 
Boquinhas, à Dra. Maria João Pais e ao Dr. José Diogo Barata que, na sua função de Diretores 
do Serviço de Nefrologia de Hospital de Santa Cruz, confi aram em mim e de diversas maneiras 
estimularam esta vertente de investigação clínica.

Gostaria de exprimir a minha gratidão ao Sr. Professor Doutor Fernando Nolasco, pela 
forma enriquecedora com que me orientou durante o período de preparação desta tese. Os 
diversos trabalhos feitos e publicados durante este período confi rmaram a relevância e a 
utilidade clínica deste score de calcifi cação vascular simples.

Agradeço ao Dr. Acácio Pita Negrão e à Dra. Helena Boquinhas, diretores médicos, 
respectivamente das clínicas de diálise Diaverum Nefroclínica do Estoril e de Linda -a -Velha, 
pela confi ança e apoio que prestaram e continuam a prestar na realização de diversos estudos 
clínicos nestas duas unidades.

Quero agradecer ao Dr. Domingos Machado, coordenador da Unidade de Transplantação 
Renal do Hospital de Santa Cruz, pela amizade e o incentivo sempre demonstrados ao longo 
destes anos. O trabalho desenvolvido na equipa de transplantação renal constituiu um dos 
períodos mais estimulantes da minha atividade clínica.

A todos os coautores dos trabalhos em que participei agradeço a preciosa ajuda manifestada 
de diversas maneiras, sem a qual não seria possível a realização destes estudos. Quero em 
particular agradecer à Dra. Ana Pires, à Dra. Patrícia Branco, à Dra. Rita Birne, à Dra. Cristina 
Jorge e à Dra. Célia Nascimento a amizade, o entusiasmo e o empenho sempre presentes nos 
bons e nos maus momentos.

Quero agradecer a todos os meus colegas do Serviço de Nefrologia do Hospital de Santa 
Cruz que, pela sua competência e amizade, contribuíram para o meu enriquecimento como 
médica e como pessoa.

Ao Dr. Fernando Carrera, Editor da revista Portuguese Journal of Nephrology and 
Hypertension e grande impulsionador da projeção internacional da Nefrologia portuguesa, 
agradeço muito a sua amizade e, concretamente, o ensino dos fundamentos básicos necessários 
para a redação de um artigo científi co.



4

Ao Dr. Carlos Aguiar, cardiologista do Hospital de Santa Cruz, agradeço a sua amizade 
sempre disponível, os conselhos estatísticos preciosos e a revisão avisada e crítica do meu 
primeiro artigo publicado na Nephrology, Dialysis and Transplantation, que constituiu o 
baluarte da atual dissertação.

Ao Sr. Professor José Dias Curto, doutorado em Métodos Quantitativos de Gestão e 
Professor Auxiliar no Departamento de Métodos Quantitativos da ISCTE – IUL Business 
School, agradeço toda a colaboração prestada na análise estatística de diversos artigos 
publicados.

Aos meus queridos amigos Sr. Professor Doutor João Frazão e ao Dr. Aníbal Ferreira, 
nefrologistas, investigadores e líderes de opinião com merecida projeção nacional e 
internacional, quero agradecer a amizade com que me honram e o apoio e confi ança prestados 
em diversos projetos de investigação comuns.



5

CAPÍTULO 1

PREFÁCIO

Calcifi cações vasculares nos doentes em diálise: Elo de ligação 
entre doença óssea e doença vascular

Apesar dos grandes progressos no tratamento dos doentes renais crónicos em diálise, a 
mortalidade mantém-se muito elevada, verifi cando-se em algumas séries que a sobrevida aos 
5 anos pode ser de apenas 30%1. A principal causa de morte é a cardiovascular, que atinge 
valores 100 vezes superiores aos dos indivíduos da população geral do mesmo grupo etário2.

Esta elevada mortalidade cardiovascular dos doentes renais crónicos não é totalmente 
explicada pelos fatores de risco tradicionais2,3, e múltiplos fatores não tradicionais parecem 
contribuir para este elevado risco nesta população. O esclarecimento destes processos poderá 
representar um dos avanços mais signifi cativos no tratamento do doente renal crónico.

Em 2001 foi publicado o primeiro estudo que mostrou que as calcifi cações vasculares 
nos doentes em diálise são preditoras de mortalidade4 e, no momento atual, é universalmente 
reconhecido que as calcifi cações vasculares são um fator de risco cardiovascular na doença 
renal crónica5. As alterações do metabolismo fosfocálcico e a patologia óssea destes doentes 
são alguns dos fatores que se associam ao desenvolvimento e à progressão das calcifi cações 
vasculares.

A presente dissertação para tese de doutoramento apresenta o desenvolvimento e a 
validação de um método simples e original para o diagnóstico de calcifi cações vasculares em 
doentes em diálise, utilizando um score semiquantitativo obtido em RX simples da bacia e 
das mãos criado por nós. Este trabalho iniciou -se no ano 2000 e incluiu a avaliação, ao longo 
de vários anos, deste score de calcifi cação em diferentes populações de doentes em diálise e 
da sua relação com a mortalidade, com o risco cardiovascular, com a rigidez arterial e com a 
doença óssea. Em inúmeros trabalhos publicados demonstramos que este score é preditor, 
nos doentes em diálise, de mortalidade cardiovascular e global, de internamentos 
cardiovasculares, de doença vascular e de doença arterial periférica6,7. É igualmente preditor 
de rigidez arterial avaliada por velocidade de onda de pulso e por pressão de pulso7. Este 
score de calcifi cação apresenta uma relação inversa com a densidade mineral óssea avaliada 
por DXA (dual -energy x -ray absorptiometry)8. Demonstramos que este score é um instrumento 



6

útil e barato para a avaliação de calcifi cações vasculares, permitindo de forma simples 
identifi car os doentes com mais elevado risco cardiovascular.

Salienta -se que dois dos trabalhos incluídos nesta dissertação foram referenciados nas 
guidelines publicadas pela KDIGO (Kidney disease improving global outcomes) em 2009 
para validar a associação entre calcifi cações vasculares e mortalidade cardiovascular nos 
doentes renais crónicos (KDIGO 2009: Tabela suplementar 12; Fig.3.7)5. O primeiro trabalho 
foi publicado em 2004 e demonstrou a existência de uma associação entre este score vascular 
simples de calcifi cação e a mortalidade cardiovascular num grupo de doentes em diálise 6. O 
segundo trabalho foi publicado em 2009 e demonstrou que o score vascular simples se associa 
diretamente à pressão de pulso e à velocidade de onda de pulso e que estes três fatores são 
preditores de mortalidade 7.

O diagnóstico de calcifi cações vasculares tem um interesse prático para os doentes renais 
crónicos. A presença de calcifi cações vasculares é um sinal de alerta para a existência de um 
elevado risco cardiovascular, e esta informação pode ser utilizada para modifi car a terapêutica 
nestes doentes. No momento atual podemos atuar em alguns destes fatores, nomeadamente 
nas alterações do metabolismo mineral e ósseo, como sugerido nas guidelines KDIGO de 
2009 5.

A apresentação desta dissertação será dividida em diferentes capítulos, cada um deles 
correspondendo às distintas vertentes resultantes da análise do score de calcifi cação vascular 
simples na sua relação com os vários desfechos e parâmetros clínicos avaliados por nós: 
mortalidade, risco cardiovascular, rigidez arterial e doença óssea. Cada um destes temas foi 
analisado em diversos trabalhos apresentados em congressos nacionais e internacionais e 
publicados na revista Portuguese Journal of Nephrology and Hypertension e em revistas 
internacionais de elevado prestígio.

Referências

1. US Renal Data System, USRDS 2009 annual data report: Atlas of end -stage renal disease in the 
United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney 
Diseases Bethesda, MD, 2009.

2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal 
disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112–S119.

3. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffi th JL. The Framingham predictive instrument in 
chronic kidney disease. J Am Coll Cardiol 2007; 50: 217 -224



7

4. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular 
risk in end -stage renal disease. Hypertension 2001;38:938 -942.

5. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global 
outcomes (KDIGO). Kidney Int 2009; 76 (Suppl)113. [Supplementary tables.]

6. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004;19(6):1480 -1488. [Epub 2004 Mar 19.]

7. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP. A plain X -ray vascular 
calcifi cation score is associated with arterial stiffness and mortality in dialysis patients.Nephrol 
Dial Transplant 2009; 24(3):997 -1002. [Epub 2008 Oct 24.]

8. Adragão T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ. Bone mineral density, 
vascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; 
28(6):668 -672.





9

CAPÍTULO 2

CRIAÇÃO DE UM SCORE SEMIQUANTITATIVO PARA AVALIAR 
A CALCIFICAÇÃO VASCULAR NOS DOENTES EM DIÁLISE

Nos doentes em diálise, as calcifi cações vasculares e as alterações do metabolismo 
fosfocálcico têm sido associadas de forma consistente em diversos estudos a uma maior 
mortalidade, sendo consideradas atualmente fatores de risco cardiovascular nesta população. 
Em 1998, foi publicado o primeiro estudo observacional1 que mostrou que nos doentes em 
diálise existe uma associação independente entre as frequentes alterações do metabolismo 
mineral, como a hiperfosfatemia, a hipercalcemia e as alterações da paratormona (PTH), e a 
mortalidade. Após este primeiro estudo, muitos outros se sucederam revelando a existência 
de uma associação consistente entre a hiperfosfatemia e a mortalidade nos diferentes estádios 
da doença renal crónica (3 a 5 e 5D)2 -4.A associação entre hiperfosfatemia e mortalidade não 
é exclusiva da doença renal crónica, pois também em doentes sem insufi ciência renal se 
verifi cou que níveis mais elevados de fósforo sérico, embora ainda dentro dos limites normais, 
são preditores de mortalidade 5.

Os mecanismos que associam a hiperfosfatemia e a hipercalcemia à mortalidade são 
parcialmente explicados por estudos in vitro realizados em células musculares lisas em cultura 
provenientes de aorta humana6,7. Nestes estudos foi demonstrado que níveis elevados de 
fósforo e de cálcio promovem a calcifi cação vascular através da expressão de um fator de 
transcrição genético Cbfa1 (core binding factor alpha 1), atualmente conhecido por RunX2 
(runt related transcription factor 2), pertencente à família dos fatores de transcrição RunX. 
Este fator codifi ca uma proteína essencial para a diferenciação osteoblástica. Verifi ca -se, deste 
modo, que a alteração da ativação de determinados genes torna as células musculares lisas 
capazes de sintetizar matriz óssea e de promover a calcifi cação dessa matriz. Demonstrou -se 
assim que a calcifi cação vascular é um processo ativo que resulta de uma diferenciação das 
células musculares lisas em osteoblastos em resposta a diferentes estímulos.

Além destas alterações de expressão genética, sabemos atualmente que a calcifi cação 
vascular resulta de um equilíbrio complexo entre fatores indutores e inibidores, verifi cando-
-se o aumento de alguns fatores indutores e por vezes também a diminuição de fatores 
inibidores. Nos doentes em diálise, a hiperfosfatemia e a hipercalcemia são alguns dos 
fatores indutores de calcifi cação. Verifi ca -se igualmente o défi ce de diversos fatores 
inibidores da calcifi cação, entre os quais se identifi cam o défi ce de fetuína A8 geralmente 



10

em relação com infl amação, e o défi ce de matrix -gla em consequência de um défi ce de 
vitamina K9.

A hiperfosfatemia e a hipercalcemia são frequentes nos doentes em diálise e surgem 
habitualmente em duas situações opostas: no hiperparatiroidismo secundário e na doença 
óssea adinâmica. No hiperparatiroidismo o osso apresenta uma elevada remodelação óssea e 
liberta cálcio e fósforo para a circulação. Na doença adinâmica, o osso é incapaz de incorporar 
cálcio e fósforo por apresentar uma baixa remodelação óssea e o cálcio e o fósforo que o 
doente recebe na sua dieta habitual (ou no caso do cálcio também na terapêutica) acumulam-
-se. Quer num caso quer noutro a consequência desta alteração do metabolismo do cálcio e 
do fósforo é o seu depósito extraósseo nos tecidos moles e na parede dos vasos.

Estas são as bases para a presente hipótese da existência de um elo de ligação entre a 
doença óssea e a doença vascular nos doentes em diálise. A iniciativa mundial KDIGO (Kidney 
disease improving global outcomes), que tenta unifi car recomendações para o tratamento da 
doença renal crónica, propôs em 200610 que as calcifi cações vasculares fossem incluídas no 
diagnóstico da doença mineral e óssea da doença renal crónica. As guidelines publicadas pela 
KDIGO em 200911, referentes à doença mineral e óssea da doença renal crónica consideram 
que os doentes renais crónicos com calcifi cações vasculares sejam reconhecidos como 
apresentando elevado risco cardiovascular e sugerem que o RX simples de perfi l da aorta 
abdominal e o ecocardiograma sejam usados para detetar, respetivamente, a presença de 
calcifi cações vasculares e valvulares nestes doentes.

Tipos de calcifi cações vasculares

Existem dois tipos histológicos de calcifi cações arteriais: calcifi cações da íntima e 
calcifi cações da camada média. Estes dois tipos de calcifi cações têm sido considerados como 
duas entidades distintas com diferente signifi cado clínico e diferente prognóstico. A calcifi cação 
da íntima ocorre durante a evolução da placa aterosclerótica e relaciona -se com a dislipidemia. 
A calcifi cação da média está presente na arteriolosclerose e desenvolve -se sobretudo em 
doentes renais crónicos, diabéticos e em indivíduos idosos.

Foi levantada a hipótese de estes dois processos poderem corresponder a um fenómeno 
contínuo da patologia vascular12 mas, nos doentes renais crónicos, a calcifi cação da camada 
média pode preceder o aparecimento de placas ateroscleróticas e surge na ausência de depósitos 
lipídicos, tendo esta hipótese sido contestada13.

As manifestações clínicas da calcifi cação da íntima relacionam -se com a presença de placas 
ateroscleróticas que estenosam as artérias devido a fenómenos de rotura da placa ou de trombose. 



11

Considera -se que a carga de cálcio se relaciona com a carga aterosclerótica e o score de cálcio avaliado 
pelo método de Agatston é usado como preditor do risco cardiovascular na população geral14.

A calcifi cação da média não causa estenose arterial e, por esta razão, foi considerada no 
passado como um achado radiológico sem consequências clínicas. Sabemos atualmente que 
este tipo de calcifi cação modifi ca as propriedades da parede arterial e é um dos fatores que 
contribui para a rigidez arterial. A rigidez arterial provoca uma perda de distensibilidade 
aórtica. A onda de refl exão sanguínea habitual acontece mais precocemente devido à perda 
de elasticidade da aorta e encontra a válvula aórtica ainda aberta, contribuindo para o aumento 
do volume do ventrículo esquerdo. A consequência é o aumento da pressão sistólica e uma 
diminuição da pressão diastólica que se manifestam clinicamente por hipertensão sistólica e 
por aumento de pressão de pulso15,16. O aumento da pressão sistólica contribui para o 
desenvolvimento de hipertrofi a ventricular esquerda. A diminuição da pressão diastólica 
compromete a perfusão coronária que ocorre durante a diástole17. Deste modo, a calcifi cação 
da camada arterial média pode associar -se a doença coronária sintomática, mesmo na ausência 
de lesões estenóticas das artérias coronárias. A compreensão desta fi siopatologia é fundamental 
para interpretar os resultados por vezes contraditórios entre a coronariografi a e a avaliação 
quantitativa das calcifi cações coronárias nos doentes renais crónicos18.

O diagnóstico diferencial entre calcifi cação da íntima e da média é feito através do exame 
histológico. Letho et al19 propuseram uma metodologia simples, usando RX simples para avaliação 
das calcifi cações da camada média em doentes diabéticos, e este grupo foi o primeiro a demonstrar 
que estas calcifi cações não estenosantes se associavam a maior morbilidade. London et al20 utilizaram 
esta mesma metodologia nos doentes renais crónicos e demonstraram que a calcifi cação da média 
e a calcifi cação da íntima eram preditores independentes de mortalidade nesta população.

O score de Agatston, avaliado por tomografi a computorizada de feixe de eletrões ou por 
tomografi a axial computorizada multicorte, não distingue a calcifi cação da íntima e da média. 
Estes dois tipos de calcifi cação podem estar presentes no mesmo doente e no mesmo vaso. 
O score de calcifi cação vascular simples criado por nós21 considera apenas a presença ou 
ausência de calcifi cação vascular nos diferentes setores, sem distinguir estes dois tipos de 
calcifi cação. Esta metodologia simplifi ca a sua utilização pelo nefrologista, pois não é 
necessária a interpretação por um radiologista.

Desenvolvimento do score de calcifi cação vascular simples

Apercebemo -nos cedo da elevada prevalência da doença arterial periférica nos doentes 
em diálise e das suas consequências clínicas dramáticas: claudicação incapacitante, úlceras 



12

isquémicas e elevado número de amputações22. No estudo radiológico simples do esqueleto, 
que nessa altura era feito rotineiramente para avaliar as manifestações ósseas do 
hiperparatiroidismo secundário dos doentes em diálise, era frequente observar o que se 
denominava “arteriografi as espontâneas” e que resultavam da presença de calcifi cações 
vasculares desenhando as paredes vasculares.

A existência de uma aparente discordância entre as manifestações clínicas de doença 
arterial periférica e os dados laboratoriais do metabolismo mineral e ósseo nos doentes em 
diálise foram a razão e o incentivo para a criação de um método simples e acessível para 
avaliar as calcifi cações vasculares nestes doentes.

No início da década de 90, a existência de calcifi cações vasculares e de partes moles 
observada nos doentes em diálise era habitualmente explicada como sendo devida ao 
hiperparatiroidismo secundário, provavelmente em relação com o elevado produto fosfocálcico 
destes doentes. No entanto, só em 2000 fi cou demonstrado, num modelo celular in vitro, usando 
células musculares lisas da aorta humana, que a hiperfosfatemia causava calcifi cação por um 
mecanismo ativo de transcrição genética6. Só em 2004, no mesmo modelo, foi feita uma 
demonstração semelhante para a hipercalcemia23. A arteriolopatia urémica cálcica, ou calcifi laxis, 
uma entidade clínica catastrófi ca causada por calcifi cações vasculares das arteríolas subcutâneas 
e que origina extensas áreas de necrose cutânea, era também classicamente atribuída ao 
hiperparatiroidismo secundário. Preconizava -se a paratiroidectomia de urgência nestes doentes 
para reverter este quadro clínico, muitas vezes fatal. Contudo, os níveis de paratormona (PTH) 
destes doentes nem sempre eram elevados, contrariamente ao que estava descrito.

A existência de valores baixos ou normais de PTH em doentes com extensas calcifi cações 
vasculares e com manifestações clínicas de calcifi laxis ou de doença arterial periférica foram a 
base para a criação de um método para avaliar as calcifi cações vasculares e de partes moles e tentar 
correlacioná -lo com as alterações do metabolismo mineral e ósseo dos doentes em diálise.

Com base nas calcifi cações detetadas no RX simples do esqueleto, realizamos um primeiro 
estudo transversal em que relacionamos a presença de calcifi cações vasculares e de partes moles 
com as alterações do metabolismo mineral e ósseo dos doentes em diálise. Nesse estudo, as 
calcifi cações das partes moles foram pesquisadas na região periarticular das articulações 
acromioclavicular e coxofemoral. As calcifi cações vasculares foram avaliadas nas artérias ilíacas 
e femorais. A hipótese de avaliar as artérias dos membros inferiores foi também considerada, 
mas, devido aos inúmeros casos de amputações, consideramos que não seria um método 
comparativo fi ável. Optamos então por pesquisar as calcifi cações vasculares noutro território 
com artérias distais, tendo por esta razão incluído a avaliação das artérias das mãos.

Com base nestes estudos radiológicos criamos um score de calcifi cação global (vascular 
e partes moles) que resultava da presença de calcifi cação em cada território avaliado. Neste 



13

primeiro estudo, apresentado no ano 2000 no Congresso da Sociedade Portuguesa de 
Nefrologia24, foram estudados 183 doentes em diálise, e neste grupo de doentes, em análise 
multivariada, verifi camos uma correlação inversa entre o score de calcifi cação e os níveis de 
PTH e de albumina e uma correlação positiva com os valores de pressão sistólica e com o 
tempo de permanência em diálise. Não encontramos correlação entre o score de calcifi cação 
e os níveis de fósforo ou cálcio séricos, e estes resultados foram considerados discordantes 
dos conhecimentos prevalentes à data.

No entanto, no ano seguinte (2001), Blacher demonstrou pela primeira vez uma associação 
independente entre as calcifi cações vasculares e a mortalidade nos doentes em diálise25. Neste 
estudo, as calcifi cações vasculares tinham sido avaliadas por ecografi a na aorta e nas artérias 
carótidas, ilíacas e femorais. Os autores não encontraram igualmente nenhuma correlação 
entre as calcifi cações e os níveis séricos de cálcio ou de fósforo. Encontraram uma associação 
directa com a mortalidade e, tal como nós, uma relação inversa com os níveis de albumina 
sérica.

Num estudo prévio deste mesmo grupo, Guérin et al tinham mostrado uma associação 
independente entre as calcifi cações vasculares e a rigidez arterial nos doentes em diálise26. 
Neste estudo, os valores de PTH apresentavam uma correlação inversa com as calcifi cações 
vasculares e também não havia correlação entre as calcifi cações e o produto fosfocálcico. 
Estes dois estudos foram a confi rmação da veracidade dos nossos resultados prévios.

Decidimos então avaliar prospetivamente a mortalidade associada às calcifi cações vasculares 
avaliadas por RX simples e criamos, para este fi m, um método semiquantitativo para avaliar 
as calcifi cações vasculares nos mesmos territórios que tínhamos previamente analisado. O RX 
da bacia foi dividido por duas linhas imaginárias em quatro setores: uma linha vertical sobre a 
coluna vertebral e uma linha horizontal tangencial à extremidade superior da cabeça dos fémures. 
O RX das mãos foi dividido em cada mão por uma linha horizontal tangencial à extremidade 
superior dos metacarpos. Ficaram assim defi nidos quatro setores no RX da bacia e quatro no 
RX das mãos (Fig 2.1). A presença de alguma calcifi cação vascular em qualquer setor era 
contada como 1 e a ausência como 0. Os limites deste score de calcifi cação eram 0 e 8.

Avaliamos as calcifi cações vasculares num grupo de 123 doentes em diálise. Após um 
seguimento de 37 meses, verifi camos que um score vascular superior a 3 se associava a maior 
mortalidade cardiovascular e que este score, em análise multivariada, se associava a maior 
risco de morte cardiovascular, a internamentos cardiovasculares, a doença arterial periférica 
e a doença vascular em geral. Este trabalho foi publicado como artigo original na revista 
Nephrology Dialysis and Transplantation em 2004 21.

Estava assim definido um método simples e económico para avaliar as calcificações 
vasculares e predizer o risco cardiovascular nos doentes em diálise. Foi este método que 



14

constituiu a base de um trabalho de investigação clínica que avaliou a existência de 
correlações entre as calcificações vasculares e a doença vascular e óssea nos doentes 
em diálise.

Score de calcifi cação vascular simples (SCVS)

Fig. 2.1. Calcifi cações vasculares no RX bacia (artérias ilíacas e/ou suas colaterais e artérias femorais) e 
no RX das mãos (artérias radiais e digitais). O SCVS é a soma da presença (1) ou ausência (0) das 
calcifi cações vasculares em cada setor defi nido pelas linhas horizontais e verticais. Neste exemplo, o score 
da bacia = 1+1+1+1=4 e o score das mãos = 1+1+1+1=4. O score total é o SCVS = 8.

Referências

  1. Block GA, Hulbert -Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium 
x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J 
Kidney Dis 1998; 31(4):607 -617.

  2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, 
mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15(8):2208-
-2218.

  3. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, 
Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different 
levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study 
(DOPPS). Am J Kidney Dis 2008; Sep;52(3):519 -530. [Epub 2008 Jun 2.]

  4. Kalantar -Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, et al. Survival predictability of time-
-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 
771 -780.



15

  5. Dhingra R, Sullivan LM, Fox CS, Wang TJ, et al. Relations of serum phosphorus and calcium 
levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167(9):879-
-885.

  6. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate 
regulation of vascular smooth muscle cell calcifi cation. Circ Res 2000; 87(7):E10 -17.

  7. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004; 15:2959 -2964.
  8. Ketteler M, Vermeer C, Wanner C et al. Novel insights into uremic vascular calcifi cation: role of 

matrix Gla protein and alpha -2 -Heremans Schmid glycoprotein/fetuin. Blood Purif 2002;20(5):473-
-476. [Review.]

  9. Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein 
(ucMGP) as a biomarker for cardiovascular calcifi cation. J Vasc Res 2008;45(5):427 -36. [Epub 
2008 Apr 10.]

10. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of 
renal osteodystrophy: A position statement from kidney disease: Improving global outcomes 
(KDIGO). Kidney Int 2006; 69: 1945 -1953.

11. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney Disease: Improving 
global outcomes (KDIGO). Kidney Int 2009; 76 Suppl.S113.

12. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcifi cation and 
Monckeberg’s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. 
Clin J Am Soc Nephrol 2008; 3: 1585 - 1598.

13. Amann K. Media calcifi cation and intima calcifi cation are distinct entities in chronic kidney 
disease. Clin J Am Soc Nephrol 2008; 3: 1599 -1605.

14. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcifi cation: Patophysiology, epidemiology, 
imaging methods and clinical implications. A statement for health professionals from the American 
Heart Association. Circulation 1996; 94: 1175 -1192.

15. London GM, Guérin A. Infl uence of arterial pulse and refl ective waves on systolic blood pressure 
and cardiac function. J Hypertens 1999; 17(Suppl 2):S3 -6. [Review.]

16. London GM, Blacher J, Pannier B et al. Arterial wave refl ections and survival in end -stage renal 
failure. Hypertension 2001; 38: 434 -438.

17. Watanabe H, Ohtsuka S, Kakihana M, et al. Coronary circulation in dogs with an experimental 
decrease in aortic compliance. J Am Coll Cardio 1993;21:1497 -1506.

18. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcifi cation is related to coronary 
atherosclerosis in chronic renal disease patients: a study comparing EBCT -generated coronary 
artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307 -2312.

19. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of 
cardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb 
Vasc Biol 1996; 16: 978 -983



16

20. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: 
impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731 -1740

21. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004; 19(6):1480 -1488. [Epub 2004 Mar 19.]

22. O’Hare A, Johansen K. Lower -extremity peripheral arterial disease among patients with end -stage 
renal disease. J Am Soc Nephrol 2001; 12: 2838 -2847.

23. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle 
cell matrix mineralization in vitro. Kidney Int 2004;66:2293 -2299.

24. Pires A, Adragão T, Carilho P, Magalhães L, Gonçalves M, Gusmão L, Silva M, Andrade S, Negrão 
AP, Boquinhas H. Calcifi cações vasculares e das partes moles em doentes em hemodiálise. Abstract. 
CPN 2000.

25. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular 
risk in end -stage renal disease. Hypertension 2001; 38:938 -942.

26. Guérin AP, London GM, Marchais SJ, Metivier F Arterial stiffening and vascular calcifi cations 
in end -stage renal disease. Nephrol Dial Transplant 2000; 15(7):1014 -1021.



17

CAPÍTULO 3

CALCIFICAÇÕES VASCULARES NOS DOENTES RENAIS CRÓNICOS: 
PREVALÊNCIA E ASSOCIAÇÃO COM MORTALIDADE E MORBILIDADE

Prevalência de calcifi cações vasculares em doentes em diálise

A prevalência de calcifi cações vasculares é elevada nos doentes renais crónicos, variando com 
o estádio da doença renal crónica e com o método utilizado no seu diagnóstico. Métodos quantitativos, 
como a tomografi a axial computorizada helicoidal multicorte ou a tomografi a computorizada de 
feixe de eletrões, mostraram que nos doentes prevalentes em diálise as calcifi cações coronárias 
estão presentes em cerca de 80% dos casos1,2. Utilizando métodos menos sensíveis, como a 
ecografi a, Blacher et al diagnosticaram calcifi cações vasculares em 66% de um grupo de 110 
doentes em diálise3. Em quatro estudos analisando diferentes populações de doentes e utilizando 
o score de calcifi cação vascular simples avaliado no RX simples da bacia e das mãos, verifi camos 
a presença de calcifi cações vasculares em 75% de 123 doentes4, em 76% de 101 doentes5, em 
70% de 219 doentes6 em hemodiálise e em 61% de 70 doentes em diálise peritoneal7.

Para avaliação da prevalência das calcifi cações vasculares nos doentes renais crónicos, 
as KDIGO 20098 selecionaram 22 estudos publicados entre 2003 e 2009, entre os quais foi 
também incluído o nosso estudo, publicado em 2004, no qual defi nimos o score de calcifi cação 
vascular simples4 (KDIGO 2009: Tabela suplementar 10; Fig. 3.6). Para avaliação da associação 
entre calcifi cações e mortalidade, as KDIGO 2009 selecionaram apenas 12 estudos publicados 
entre 2001 e 2009, nos quais foram também incluídos o nosso primeiro estudo4, que mostrou 
uma associação entre o score de calcifi cação vascular simples e mortalidade, e um segundo 
estudo, publicado em 20095, mostrando que o score vascular simples é preditor de rigidez 
arterial (KDIGO 2009: Tabela suplementar 12).

A inclusão de estudos observacionais nas presentes recomendações KDIGO 20098 baseou-
-se em conceitos defi nidos pelo sistema GRADE9 (Grades of recommendation, assessment, 
development, and evaluation). O sistema GRADE considera que os estudos observacionais 
podem ter elevada qualidade de evidência se avaliarem parâmetros de segurança e de efi cácia 
importantes, se mostrarem uma associação forte com estes parâmetros e se a metodologia 
utilizada for de elevada qualidade. A inclusão dos nossos estudos nas referências das KDIGO 
2009, em que foi utilizado um método de selecção muito exigente, valida o interesse científi co 
do nosso trabalho.



18

Associação entre calcifi cações vasculares e mortalidade nos doentes em diálise

A mortalidade cardiovascular nos doentes renais crónicos é superior à da população geral, 
quer nos doentes em diálise, quer nos doentes em estádios pré -diálise10,11. Os fatores de risco 
tradicionais não explicam integralmente este elevado risco cardiovascular12, e considera -se 
que inúmeros fatores de risco não tradicionais possam contribuir para este resultado.

Nos últimos anos, um novo fator foi acrescentado à já extensa lista de fatores de risco 
cardiovascular dos doentes renais crónicos. Demonstrou -se que nestes doentes as calcifi cações 
vasculares apresentam uma associação consistente com a mortalidade. Blacher et al3, em 
2001, foram os primeiros a demonstrar esta associação. O método que utilizaram para 
diagnosticar as calcifi cações vasculares foi a ecografi a de grandes vasos: aorta, carótidas, 
artérias ilíacas e femorais. Em 110 doentes, com um seguimento de 80 meses, estes autores 
demonstraram que, quanto maior o número de vasos afetados, menor a sobrevida dos doentes. 
London et al13, em 2003, demonstraram que calcifi cações vasculares avaliadas por RX simples 
eram preditoras de mortalidade. Neste estudo de London, as calcifi cações foram avaliadas em 
202 doentes em diálise, nas artérias ilíacas e femorais visualizadas num RX simples do 
abdómen. Utilizando uma metodologia previamente descrita por Letho em doentes diabéticos14, 
estes autores distinguiram calcifi cação da íntima e calcifi cação da média e verifi caram que, 
durante um seguimento de 80 meses, estes dois tipos de calcifi cação foram preditores 
independentes de mortalidade global e cardiovascular nos doentes em diálise. Alguns meses 
após esta publicação, publicamos o nosso estudo, que utilizou um score de calcifi cação vascular 
avaliado em RX simples da bacia e das mãos4. Verifi camos que em 123 doentes prevalentes 
em diálise, durante um seguimento de 37 meses, um score de calcifi cação superior ou igual 
a 3 se associou a 14 mortes cardiovasculares, enquanto nos doentes com um score de calcifi cação 
inferior a 3 se verifi caram apenas três mortes (Fig. 3.1). Esta associação foi confi rmada em 
análise multivariada, ajustando para idade, sexo, tempo em hemodiálise, diabetes, produto 
fosfocálcico, níveis séricos de PTH e albumina. Um score de calcifi cação vascular simples 
superior ou igual a 3 associou -se a um risco 3,9 vezes superior de morte cardiovascular, quando 
comparado com um score inferior a 3 (HR=3,9; IC 95% 1,1 a 13,4, p=0,03) (Fig. 3.2).

Noutra população de 101 doentes em diálise, em que analisamos a associação entre 
calcifi cações vasculares e rigidez arterial avaliada por velocidade de onda de pulso e pela 
pressão de pulso, verifi camos que um score de calcifi cação superior a 3 foi preditor de 
mortalidade de causa global 5. Em análise multivariada e ajustando para a idade, a duração 
da hemodiálise, a diabetes, a doença vascular prévia, o índice de massa corporal, a pressão 
sistólica, as doses de calcitriol e o carbonato de cálcio, os doentes com score de calcifi cação 
vascular superior a 3 apresentaram um risco de morte 3,3 superior, quando comparados com 



19

os doentes com score inferior ou igual a 3 (HR=3,3; IC 95% 1,1 a 9,8, p=0,03). Outros estudos, 
utilizando diferentes metodologias, confi rmaram esta associação entre calcifi cações vasculares 
e mortalidade2,15,16.

Fig. 3.1. O score de calcifi cação vascular simples, SCVS ? 3, associou -se a uma maior mortalidade cardiovascular

Fig. 3.2. Risco cardiovascular em relação com o score de calcifi cação vascular simples, SCVS?3, sendo a 
referência o SCVS&amp;lt;3. O risco foi calculado por odds ratio com regressão logística (doença arterial periférica 
e doença coronária) e por hazard ratio com regressão COX (internamentos cardiovasculares e morte 
cardiovascular)



20

Associação entre calcifi cações vasculares e morbilidade nos doentes 
em diálise

Neste primeiro estudo, publicado em 20044, demonstrámos também que o score de 
calcifi cação vascular simples foi um preditor independente de morbilidade cardiovascular 
avaliada pelos internamentos cardiovasculares e pela presença de doença coronária, doença 
arterial periférica e doença vascular em geral (Fig. 3.2). As doenças coronária, arterial 
periférica e cerebrovascular foram defi nidas por critérios clínicos. Diagnosticamos doença 
coronária nos doentes com sintomas inequívocos de angina de peito ou com uma prova 
de esforço ou ecografi a de stress positivos ou que tivessem tido um enfarte do miocárdio 
ou sido submetidos a angioplastia coronária ou cirurgia de revascularização coronária. 
Consideramos a existência de doença arterial periférica nos doentes com história de 
claudicação intermitente ou úlceras isquémicas ou com diagnóstico de obstrução arterial 
por doppler ou angiografi a ou que tivessem sido submetidos a revascularização arterial 
ou a amputações distais dos membros inferiores. Consideramos a existência de doença 
cerebrovascular nos doentes com o diagnóstico de acidente vascular cerebral ou acidente 
isquémico transitório ou com evidência de um enfarte na tomografi a axial computorizada 
cranioencefálica. No fi nal do estudo, 43 doentes (35%) tinham o diagnóstico de doença 
coronária, 33 (27%) o diagnóstico de doença arterial periférica, 16 (13%) o diagnóstico 
de doença cerebrovascular e 61 doentes (50%) tinham pelo menos um destes três tipos de 
doença vascular.

Em análise multivariada e ajustando para idade, sexo, tempo em hemodiálise, diabetes, 
produto fosfocálcico, níveis séricos de PTH e albumina, um score superior ou igual a 3 
associou -se a um risco aumentado de internamentos cardiovasculares (HR=4,4; IC 95% 
2,1 a 10,2, p=0,02), de doença arterial periférica (OR=10,4; IC 95% 2,7 a 40,3), de doença 
coronária (OR=3,2; IC 95% 1,4 a 7,4) e de doença vascular em geral (OR=4,3; C 95% 1,9 
a 9,9) (Fig. 3.2).

Calcifi cações vasculares e doença arterial periférica

Desde logo, na primeira avaliação do score de calcifi cação vascular simples, detectamos 
que este score se relacionou fortemente com a doença arterial periférica4. Os doentes com 
um score superior ou igual a 3 apresentaram um risco 10,4 vezes aumentado de associação 
a doença arterial periférica sintomática (Fig. 3.2). Neste primeiro estudo, a doença arterial 
periférica foi diagnosticada com base em critérios clínicos. Nos doentes em diálise, a doença 



21

arterial periférica é frequentemente de diagnóstico tardio, porque a neuropatia periférica 
mascara os sintomas de claudicação intermitente e as artérias rígidas distais continuam a 
apresentar pulso palpável. Um método simples e não invasivo de avaliar a doença arterial 
periférica é através do índice tornozelo -braço. Nos doentes em diálise existe até ao momento 
apenas um estudo que demonstrou associação entre mortalidade e este índice17, verifi cando-
-se maior mortalidade nos doentes com um índice inferior a 0,9 ou superior a 1,3. Um índice 
superior a 1,3 é considerado um falso negativo no diagnóstico de doença arterial obliterativa 
e resulta de artérias rígidas e não compressíveis, provavelmente devido à presença de 
calcifi cações vasculares.

Iniciamos em 2008 um estudo com o objetivo de analisar a correlação entre calcifi cações 
vasculares avaliadas por RX simples e o índice tornozelo -braço (ITB) avaliado por doppler. 
Os resultados preliminares deste estudo foram apresentados sob a forma de poster no 
EDTA Congress of Nephrology 20106. Neste estudo analisamos 219 doentes em hemodiálise. 
As calcifi cações vasculares foram avaliadas por RX simples usando dois métodos diferentes: 
o score de calcifi cação vascular simples no RX simples da bacia e das mãos e o score de 
calcifi cação aórtico avaliado no RX simples de perfi l da aorta abdominal, de L1 a L4, 
descrito por Kauppila L18. Em análise multivariada e ajustando para a idade, o sexo, a 
duração de hemodiálise, a diabetes, os hábitos tabágicos, a pressão de pulso e os níveis 
séricos de albumina verifi camos um associação independente entre as calcifi cações 
vasculares das grandes artérias (aorta, ilíacas e femorais) e um ITB&amp;lt;0,9 e entre as 
calcifi cações vasculares de artérias colaterais da bacia e periféricas das mãos com um ITB 
&gt;1,3 (Fig. 3.3).

Neste grupo de doentes, um ITB&amp;lt;0,9 e um ITB &gt;1,3 associaram -se a um aumento 
de risco de morte ajustando para idade, duração da hemodiálise, diabetes e níveis de 
albumina sérica. O tipo de calcificações nas grandes artérias é irregular e corresponde a 
calcificações da íntima13, às quais se podem associar ou não calcificações da média. O 
tipo radiológico das calcificações nas artérias colaterais e periféricas é linear e contínuo, 
o que, segundo Letho14 e London13, corresponde a calcificação da camada média da 
parede arterial. A associação das calcificações de grandes vasos com um ITB &amp;lt;0,9 sugere 
uma contribuição da aterosclerose na doença arterial obliterativa. A associação das 
calcificações das artérias colaterais e periféricas com um ITB &gt;1,3 sugere que este tipo 
de calcificações da camada média arterial pode contribuir para a rigidez das artérias 
distais, que se tornam não compressíveis, razão pela qual apresentam um aumento do 
índice tornozelo -braço.



22

OR, odds ratio; ITB, índice tornozelo -braço; SCAA, score de calcifi cação na aorta abdominal; SCVS, score 
de calcifi cação vascular simples; M+P, calcifi cações vasculares mãos ou pélvis.

Fig. 3.3. Risco de ITB&amp;lt;0,9 associou -se a calcifi cações vasculares nos grandes vasos. Risco de ITB &gt; 1,3 
associou -se a calcifi cações vasculares nos vasos colaterais ou distais (regressão logística).

Este estudo permitiu ainda a comparação entre o score vascular simples de calcifi cação 
e o score de calcifi cação da aorta abdominal (SCAA). Esta comparação é atualmente importante, 
pois a avaliação da calcifi cação na aorta abdominal por RX simples é o método sugerido pelas 
guidelines KDIGO 2009 para a avaliação das calcifi cações vasculares como alternativa 
razoável à tomografi a computorizada. Verifi camos que valores mais elevados do score vascular 
simples se associam a valores mais elevados do SCAA (Fig. 3.4) e, em análise de curvas 
ROC, o score vascular simples de calcifi cação superior a 3 apresentou uma alta sensibilidade 
(73%) e especifi cidade (86%) para detetar um SCAA &gt; 6 (Fig. 3.5).

Noutro estudo, ainda não publicado, avaliamos os padrões histológicos da doença 
arterial periférica distal em 56 doentes submetidos a amputações distais. Trinta e nove 
destes doentes faziam diálise, 10 eram diabéticos não em diálise e 7 não tinham nem 
diabetes mellitus nem doença renal crónica. Em análises histológicas em 65 amostras de 
material de amputação verifi camos a presença de placas ateroscleróticas classe II/III em 
24 (38%), de calcifi cações vasculares da camada média em 31 (48%), e não encontramos 
evidência de calcifi cação da íntima. As calcifi cações vasculares associaram -se a placas 
ateroscleróticas em 50% dos casos. As calcifi cações da média, as placas ateroscleróticas 
ou ambas apresentaram uma distribuição semelhante nas diferentes entidades clínicas. 
Estes dados confi rmam a associação de calcifi cações da camada média à doença arterial 
crónica distal19,20.



23

Nestes dois estudos, ainda não publicados, quer com avaliação clínica quer histológica 
da doença arterial periférica, constatamos que as calcifi cações vasculares se associam a esta 
patologia. No caso particular dos doentes renais crónicos, em que as alterações do metabolismo 
mineral e ósseo se associam ao desenvolvimento e à progressão das calcifi cações vasculares, 
surge a possibilidade de um novo campo de intervenção terapêutica na doença arterial periférica 
diferente do da população geral. É necessário avaliar se o manejo das alterações do metabolismo 
mineral e ósseo pode ter um papel na evolução e no prognóstico da doença arterial periférica 
nos doentes renais crónicos.

Fig. 3.4. Valores mais elevados de score de 
calcifi cação vascular simples SCVS associam -se a 
valores mais elevados de score de calcifi cação na 
aorta abdominal SCAA (Kruskal -Wallis)

Fig. 3.5. Um SCVS&gt;3 teve uma sensibilidade de 73% 
e uma especificidade de 86% de diagnosticar um 
SCAA&gt;6 (análise de curvas ROC)

Em conclusão, nestes diferentes estudos4,5,7,19,20 demonstramos que o score de calcifi cação 
vascular simples é um método acessível e barato que permite identifi car o risco cardiovascular 
nos doentes em diálise. A simplicidade e baixo custo deste score tornam a sua utilização 
passível de ser aplicada em larga escala, fornecendo dados muito importantes para o 
acompanhamento dos doentes insufi cientes renais.



24

Supplemental table 10. Overview Table of selected studies presenting data on calcifi cation prevalence

Author, Year
Study Design

Country

N
Population

Representative
Test (s)

Prevalence of 
Calcifi cation

Hernandez, 200559
Chart Review
Spain

1117
CKD 5D, At transplant

Plain X-ray of abdomen 
and pelvis

24.4%

Honkanen, 200860
Cross-sectional
Belgium, Netherlands, 
Sweden, Denmark, Finland, 
Norway

933
CKD 5D on HD/PD

Abdominal aorta 
calcifi cation by lumbar 
(L1-L4) radiographs

81%

Ix, 200761
Cross-sectional
USA

653
CKD 3-5

Valvular calcifi cation 
by MSCT/EBCT

20/25%

Okuno, 200762
Prospective
Japan

515
CKD 5D, HD

Plain X-ray 56.5%

Adeney, 200863
Retrospective
US

439
CKD Stage 3-5

CAC and valvular 
calcifi cations by EBCT 
or multi-detector CT

67% coronary
49% aortic
20% mitral valve
25% aortic valve

Panuccio, 200464
Prospective
Italy

202
CKD 5D, HD

Valvular calcifi cation 
by echocardiography

23.3%

London, 200365
Prospective
France

202
CKD 5D, HD

Calcifi cation score by 
ultrasound and 
conventional X-ray

63.9%

Wang, 200366
Prospective
Hong Kong

193
CKD 5D, PD

Valvular calcifi cation 
by echocardiography

32.3%

Rodriguez-Garcia, 200949
Prospective
Spain

193
CKD 5D, HD

Vascular calcifi cations 
by thoracic, lumbar 
spine, pelvic and hand 
X-rays

79%

Jean, 200967
Prospective
France

161
CKD 5D on HD

Vascular calcifi cation 
by plain radiograph

83%

Kronenberg, 200368
Prospective
Austria

155
CKD 5D on Incident 
HD and PD

Conventional X-ray of 
pelvis and calves

67%

Sharma, 200769
Prospective
UK

140
CKD 4-5D, Predialysis, 
HD and PD on 
transplant waiting list

Valvular calcifi cation 
by echocardiography

40%

Varma, 200570
Chart review
USA

137
CKD 5D, HD

Valvular calcifi cation 
by echocardiography

47%

(Continua)



25

Author, Year
Study Design

Country

N
Population

Representative
Test (s)

Prevalence of 
Calcifi cation

Sigrist, 200652
Sigrist, 200771
Prospective
UK

134
CKD 4, 5D on HD/PD

Arterial calcifi cation by 
MSCT

CKD 4: 47%
PD: 71%
HD 73% + higher 
scores

Adragão, 200472
Prospective
Portugal

123
CKD 5D, HD

Calcifi cation score by 
conventional X-ray

61% iliac
60% femoral
36% radial
5% digital

Garland, 200873
Cross-sectional
Canada

119
CKD 3-5

CAC by MSCT 83.2%

Blacher, 200174
Prospective
France

110
CKD 5D, HD

Calcifi cation score by 
ultrasound and 
conventional X-ray

66.4%

Matsuoka, 200475
Prospective
Japan

104
CKD 5D, HD

CAC by EBCT 81.7%

Russo, 200776
Prospective
Italy

90
CKD Stage 3-5

CAC by MSCT 83%

Shroff, 200755
Retrospective
USA

85
Children aged 5-18 y
CKD 5D

CAC by MSCT 20%

Chertow, 200277
Raggi 200478
RCT
USA, Germany, Austria

70
CKD Stage 5D on HD

CAC by EBCT
Valvular calcifi cation 
by EBCT

83% coronary
80% aortic
46% mitral valve
33% aortic valve

Stompor, 200656
Prospective
Poland

61
CKD 5D on PD

Total CAC by MSCT &gt;51% (51% w/ a CAC 
score of&amp;lt;10, median 0)

Russo, 200779
Prospective
Italy

53
CKD Stage 3-5

CAC by MSCT 51%

Block, 200580
RCT
USA

53
CKD 5D on Incident 
HD

CAC by EBCT 63%/69%

Nitta, 200458
Prospective
Japan

53
CKD 5D on HD

CAC by MSCT 92.5%

CAC, coronary artery calcifi cation; CKD, chronic kidney disease; CT, computed tomography; EBCT, electron-
beam CT; HD, hemodialysis; MSCT, multislice spiral computed tomography; N, number of subjects; PD, 
peritoneal dialysis; RCT, randomized controlled trial.

Fig. 3.6. KDIGO Guidelines 2009: Tabela suplementar 10

(Supplemental table 10. – Continuação)



26

Supplemental table 12. Overview table of selected studies demonstrating the risk relationship 
between vascular calcifi cation and mortality in CKD

Study Design
Country

N
Population
Follow-up

Vascular Calcifi cation Mortality
CategorizationTechnique Categorization

Hernandez, 200559
Chart Review
Spain

1117
At transplant
Median 49 mo

Plain X-ray of 
abdomen and 
pelvis

–  Vascular 
calcifi cation

– None

– All cause
– Cardiovascular

Okuno, 200762
Prospective
Japan

515
HD
51 mo

Plain –  Abdominal aortic 
calcifi cation

– None

– All cause
– Cardiovascular

London, 200365
Prospective
France

202
HD
Up to ~100 mo

B-mode US – Arterial medial
– Arterial intimal
– None

– All cause
– Cardiovascular

Rodriguez-Garcia, 200949
Prospective
Spain

193
HD
24 mo

X-ray of thoracic, 
lumbar spine, 
pelvis and hands

–  Vascular 
calcifi cations

–  Abdominal aortic 
calcifi cations

– All-cause

Block, 200783
RCT
USA

127
HD
Median 44 mo

EBCT CAC score 0, 
1-400, &gt;400

– All cause

Adragão, 200484
Prospective
Portugal

123
HD
37 mo

Plain X-ray of 
pelvis and hands

Vascular 
calcifi cation score 
&lt;or ? 3

– Cardiovascular

Blacher, 200174
Prospective
France

110
HD
53 mo

US Arterial calcifi cation 
score 0-4

– All cause
– Cardiovascular

Matsuoka, 200475
Prospective
Japan

104
HD
44 mo

EBCT CAC score
&lt;or ? 200

– Cardiac
– Stroke
– Infection
– Other

Adragão, 200972
Prospective
Portugal

101
HD
43 mo

Plain X-ray of 
pelvis and hands

Vascular 
calcifi cation score &amp;lt;
or ?3

– All-cause

Kushiya, 200585
Prospective
Japan

84
HD
24 mo

CT ACI &gt; or&amp;lt;0.3 – All cause

ACI, aortic calcifi cation index; AVC, aortic valve calcifi cation; CAC, coronary artery calcifi cation; CKD, chronic 
kidney disease; CT, computed tomography; EBCT, electron-beam CT; HD, hemodialysis; N, number of subjects; 
PD, peritoneal dialysis; RCT, randomized controlled trial; US, ultrasound.

Fig. 3.7. KDIGO Guidelines 2009: Tabela suplementar 12

Referência: KDIGO, Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global outcomes 
(KDIGO). Kidney Int 2009; 76 (Suppl): S113. [Supplementary tables.] 



27

Referências

  1. Chertow GM, Burke SK, Raggi P Sevelamer attenuates the progression of coronary and aortic 
calcifi cation in hemodialysis patients.Treat to Goal Working Group. Kidney Int 2002;62(1):245-
-252.

  2. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcifi cation score 
(CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8(1):54 -58.

  3. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular 
risk in end -stage renal disease. Hypertension 2001;38:938 -942

  4. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004;19(6):1480 -1488.

  5. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP A plain X -ray vascular 
calcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol 
Dial Transplant 2009;24(3):997 -1002.

  6. Adragão T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle 
brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3 
(Suppl 3): 492. [Abstract Su545.]

  7. Adragão T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ. Bone mineral density, 
vascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; 
28(6):668 -672.

  8. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global 
outcomes (KDIGO). Kidney Int 2009; 76 (Suppl): S113.

  9. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. 
GRADE Working Group. BMJ 2004;19;328(7454):1490.

10. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic 
renal disease. Am J Kidney Dis 1998; 32 (5) (Suppl3): S112–S119.

11. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular 
events, and hospitalization. N Engl J Med 2004; 23;351(13):1296 -1305.

12. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic 
hemodialysis patients. Kidney Int 2000; 58(1):353 -362

13. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: 
impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-
-1740.

14.  Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of 
cardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb 
Vasc Biol 1996; 16: 978 -983.



28

15. Okuno S, Ishimura E, Kitatani K, et al. Presence of abdominal aortic calcifi cation is signifi cantly 
associated with all -cause and cardiovascular mortality in maintenance hemodialysis patients. Am 
J Kidney Dis 2007;49 (3):417 -425.

16. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and binder choice 
in incident hemodialysis patients. Kidney Int 2007;71:438 -441.

17. Ono K, Tsuchida A, Kawai H, et al. Ankle -brachial blood pressure index predicts all -cause and 
cardiovascular mortality in hemodialysis patients. J Am Soc Nephro 2003;14(6):1591 -1598.

18. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression 
of calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-
-250.

19. Adragão T, Gouveia R, Birne R, et al. Histological vascular patterns in lower limb amputations 
in distal artery disease. JASN 2005; 16: 474. [Abstract (PO639).]

20. Adragão T. Vascular calcifi cation, cardiovascular risk and arterial stiffness in hemodialysis patients. 
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 51 -56.



29

Nephrol Dial Transplant (2004) 19: 1480–1488

DOI: 10.1093/ndt/gfh217

Advance Access publication 19 March 2004

Original Article

A simple vascular calcification score predicts cardiovascular risk in

haemodialysis patients

Teresa Adragao, Ana Pires, Carlos Lucas, Rita Birne, Lu??s Magalhaes, Margarida Gonc?alves and
Aca?cio Pita Negrao

Nefroclinica-Estoril, Rua Vale de S Rita, 19, 2765-293 Esteril, Portugal

Abstract

Background. Cardiovascular morbidity and mortality
are highly prevalent in haemodialysis (HD) patients
and have been recently associated with vascular
calcifications. The objective of our study was to
assess the value of a simple vascular calcification
score for the prediction of cardiovascular death,
cardiovascular hospitalizations and fatal and non-
fatal cardiovascular events in HD patients, and to
correlate this score with cardiovascular disease and
with other known predictors of vascular disease.
Methods. In this observational, prospective study 123
chronic HD patients (75 males and 48 females; 20%
diabetic) were included, who were on low-flux HD
treatment for 46.6±52 months (mean±SD). We set up
a simple vascular calcification score based on plain
radiographic films of pelvis and hands. Brachial pulse
pressure and mean arterial pressure (MAP) were
measured and cardiovascular events and hospitaliza-
tion episodes were assessed.
Results. During an observational period of 37 months
there were 17 cardiovascular deaths; 28 patients needed
cardiovascular hospitalizations and 32 patients suf-
fered fatal and non-fatal cardiovascular events.
Coronary artery disease was diagnosed in 43 patients
(35%), peripheral arterial disease in 33 patients
(26.8%), cerebrovascular disease in 16 patients (13%)
and vascular disease (coronary artery disease or
peripheral arterial disease or cerebral vascular disease)
in 61 patients (49.6%). By binary logistic regression,
diabetes (P ¼ 0.01), male sex (P&lt;0.001), age
(P ¼ 0.02), HD duration (P ¼ 0.02) and MAP
(P ¼ 0.03) were independently associated with a
vascular score ?3. This score ?3 was independently
associated with coronary artery disease (P ¼ 0.008),
peripheral arterial disease (P&lt;0.001) and vascular

disease (P ¼ 0.001). Patients with a vascular calcifica-
tion score ?3 had a 3.9-fold higher risk of cardio-
vascular mortality (P ¼ 0.03), a 2.8-fold higher risk of
cardiovascular hospitalizations (P ¼ 0.02) and a 2.3-
fold higher risk of fatal or non-fatal cardiovascular
events (P ¼ 0.04).
Conclusions. The present vascular calcification scoring
represents a simple tool for the assessment of
cardiovascular risk related with vascular calcifications
in chronic HD patients.

Keywords: haemodialysis; mortality; vascular calcifi-
cation; vascular disease

Introduction

Cardiovascular mortality is the main cause of death in
haemodialysis (HD) patients and can be 20-fold higher
than in the general population, with greater differences
in the younger population [1,2].

There are two main types of vascular calcifications
in HD patients: (i) common atherosclerosis, with
intimal patchy calcifications of atherosclerotic plaques
and (ii) mediasclerosis with medial linear calcifications
that seem to be related to mineral metabolism
disturbances [3,4]. It has been recently demonstrated
that mediasclerosis is an active cellular process,
similar to bone formation [4,5] and is not the result
of a passive metastatic calcification. Vascular muscle
cells can differentiate into osteoblasts due to different
stimuli, one of which may be hyperphosphataemia
[3,4,6]. Deposition of bone matrix proteins can
precede vascular calcification [5]. Different vascular
calcification scores have been evaluated in HD
patients by various methods, mainly using B-mode
ultrasonography [7] and electron beam computed
tomography [8,9]. These scores have been related to
oral calcium load [9], cardiovascular disease [9,10]

Correspondence and offprint requests to: Maria Teresa Pulido
Adragao, Nefroclinica-Estoril, Rua Vale de S Rita, 19, 2765-293
Esteril, Portugal. Email: tadragao@netcabo.pt

Nephrol Dial Transplant Vol. 19 No. 6 ? ERA–EDTA 2004; all rights reserved



30

and mortality [7,11] in HD patients. Medial artery
calcifications have already been differentiated from
intimal calcifications by plain radiography in non-
insulin diabetic patients and have been associated
with all-cause and cardiovascular mortality [12]. In
HD patients, these different calcification patterns
were both associated with cardiovascular and all-
cause mortality and intimal artery calcifications were
associated with a lower survival [13]. The early
diagnosis of vascular calcifications and the identifica-
tion of their cause raise the hope for a possible direct
therapeutic intervention that might reduce cardio-
vascular disease in HD patients. It has already been
demonstrated that calcium carbonate and calcium
acetate are associated with the progression of vascular
calcification, a phenomenon that can be attenuated
or arrested by sevelamer, a phosphorus binder that
does not increase calcium levels and also reduces
LDL-cholesterol [14,15].

The main objective of this study was to evaluate the
usefulness of a simple vascular calcification score based
on plain radiographic films, for prediction of cardio-
vascular mortality in HD patients. Secondary objec-
tives were to correlate this score with cardiovascular
hospitalizations, fatal and non-fatal cardiovascular
events, cardiovascular disease, with simple arterial
properties [pulse pressure (PP) and mean arterial
pressure (MAP)], and with calcium, phosphorus,
calcium and phosphorus product and intact parathor-
mone (iPTH) levels.

Patients and methods

Study design

An observational, prospective, single-centre study of a cohort
of prevalent patients treated with HD was used.

Population

One hundred and twenty-three patients, 75 males and
48 females, treated with low flux HD, without previous
parathyroidectomy, constituted the study population (Table
1); 25 patients (20.3%) were diabetic. On the day of the
vascular score evaluation, mean age was 62±14 years
(24–91) and mean HD duration was 46.6±52 months
(6–271). During an observational period of 37 months, 36
patients died and one patient received a renal transplant.
Mean follow-up was 32±9 months (4–37).
The primary endpoint after 37 months was cardiovascular

mortality. Secondary endpoints were cardiovascular hospi-
talizations, fatal and non-fatal cardiovascular events, and the
diagnosis of vascular disease (coronary artery disease and/or
cerebral vascular disease and/or peripheral arterial disease).
The diagnosis of vascular disease was based on a query
answered by the attending physicians of the study patients
and was dependent on clinical manifestations. Coronary
artery disease was diagnosed if the patient had developed
typical angina pectoris, had a positive stress test, suffered a
myocardial infarction, or underwent a percutaneous coron-
ary intervention or coronary bypass surgery; diagnosis of
cerebral vascular disease was based on the occurrence of

Table 1. Univariate analysis

All patients Score ?3 Score&amp;lt;3 Significance (P)

Number of patients 123 65 (53%) 58 (47%) NS
Age (years) 62.9 (14.5) 64.5 (12.8) 61.3 (16.2) NS
HD (months) 46.6 (52.) 53.0 (57.1.) 39.4 (44.1) NS
Male gender (%) 75 (61%) 51 (79%) 24 (41%)
Female gender (%) 48 (39%) 14 (22%) 34 (58%)&amp;lt;0.001
Diabetes (%) 25 (20%) 18 (28%) 7 (12%) 0.02
Ca (mg/dl) 9.9 (0.7) 9.9 (0.7) 9.8 (0.9) NS
P (mg/dl) 4.9 (1.4) 4.8 (1.5) 4.9 (1.3) NS
CaXP (mg/dl)

2
48.8 (15.4) 49 (16) 49 (15) NS

iPTH (pg/ml) 302 (379) 292 (354) 313(408) NS
Al 18.6 (7.0) 18.8 (7.2) 18.1 (6.7) NS
Albumin (g/dl) 3.72 (0.36) 3.76 (0.32) 3.68 (0.28) NS
Haemoglobin (g/dl) 11.3 (1.2) 11.5 (1.4) 11.2 (1.1) NS
Kt/v 1.38 (0.19) 1.37 (0.18) 1.42 (0.21) NS
PP (mmHg) 67.3 (17) 69.0 (18) 65.4 (15.7) NS
MAP (mmHg) 105.3 (14) 107.4 (14.9) 102.9 (12.4) NS
Initial CAD (%) 32 (26%) 20 (31%) 12 (21%) NS
Final CAD (%) 43 (35%) 28 (43%) 15 (26%) 0.03
Initial CVD (%) 6 (5%) 4 (6%) 2 (3%) NS
Final CVD (%) 16 (13%) 11 (17%) 5 (9%) NS
Initial PAD (%) 16 (13%) 12 (19%) 4 (7%) 0.06
Final PAD (%) 33 (27%) 28 (43%) 5 (9%)&amp;lt;0.001
Initial VASCD (%) 36 (29%) 22 (34%) 14 (24%) NS
Final VASCD (%) 61 (50%) 43 (66%) 18 (31%)&amp;lt;0.001
CV deaths (%) 17 (14%) 14 (22%) 3 (5%) 0.008
CV hospitalizations (%) 28 (23%) 22 (34%) 6 (10%) 0.002
CV events (%) 32 (26%) 24 (37%) 8 (14%) 0.004

Results in mean values (SD); CAD, coronary arterial disease; CVD, cerebrovascular disease; PAD, peripheral arterial disease; VASCD,
vascular disease; CV, cardiovascular; NS, not significant.

A simple vascular calcification score predicts cardiovascular risk 1481



31

stroke or transient ischaemic attack or the detection of an old
cerebral infarction using computed tomography; peripheral
arterial disease was diagnosed if there was claudication,
ischaemic ulcers, lower limbs amputation, revascularization
or diagnosis of obstruction by Doppler or angiography.
Vascular disease diagnosis was performed in two steps: at
baseline and at the end of the follow-up. For each patient,
hospitalizations during the observational period were
classified as cardiovascular, non-cardiovascular or absent.
Calcium, phosphorus, haemoglobin, albumin and Kt/V were
evaluated every month and iPTH and aluminum every 3
months, in the 6 months that preceded vascular calcifica-
tion score evaluation. Levels of iPTH were determined by
a first generation immunochemiluminometric assay. PP and
MAP were evaluated once a month, based on blood pressure
(BP) measurement before HD, on the day of the blood
chemistry analysis, during the same 6 months period. PP was
calculated by the formula PP ¼ SBP ? DBP; MAP ¼ DBP þ
(SBP ? DBP)/3 (SBP, systolic blood pressure; DBP, diastolic
blood pressure).
HD duration was evaluated on the day of vascular

calcification assessment. A simple vascular calcification
score was evaluated in all patients during a 4 month period
and marked the beginning of the study for each patient. This

vascular calcification score was evaluated in plain radio-
graphic films of pelvis and hands, performed in the same
centre. The pelvis radiographic films were divided into four
sections by two imaginary lines: a horizontal line over the
upper limit of both femoral heads and a median vertical line
over the vertebral column. The films of the hands were
divided, for each hand, by a horizontal line over the upper
limit of the metacarpal bones. The presence of linear
calcifications in each section was counted as 1 and its
absence as 0. The final score was the sum of all the sections,
ranging from 0 to 8. Vascular calcifications were deliberately
evaluated only in muscular arteries: iliac, femoral, radial and
digital. Pelvis films evaluated iliac and femoral arteries
(Figure 1); hand films evaluated radial and digital arteries
(Figure 2). The analysis of all the radiographic films was
performed by one single experienced clinician blinded to
patient information. Only linear calcifications, with or
without patchy calcifications, were considered for the final
calcification score, because they outline the vessel wall and
have undoubtedly vascular localization. Patchy isolated
calcifications that may be associated with intimal calcifica-
tions were not considered in this score because they may be
confused with other types of extra-vascular calcifications, for
instance, phleboliths.

Fig. 1. Calcification score is the sum of the presence (1) or absence (0) of parallel linear calcifications in each section. In the example,
pelvis score ¼ 1 þ 1 þ 1 þ 1 ¼ 4.

1482 T. Adragao et al.



32

Statistics

Variables were expressed as frequencies, percentages for
discrete factors, and mean value for normally distributed
continuous factors. Statistical comparison of baseline char-
acteristics and endpoints was performed using the two-tailed
chi-square test with Yates’ correction or Fisher exact test
when appropriate, for categorical variables, and the two-
tailed Student t-test for continuous variables. Kaplan–Meier
survival curves of patients with vascular calcification
score ?3 and&amp;lt;3 were compared by log-rank test. The
independent variables associated with cardiovascular death,
cardiovascular hospitalizations and fatal and non-fatal
cardiovascular events were identified by Cox regression
models. The covariates in Cox regression models were age,
sex, HD duration, diabetes, CaXP, iPTH, albumin, vascular
disease at baseline and vascular score. The independent
variables associated with PP and MAP were identified by
linear regression models. Variables included in these models
were: age, sex, diabetes, HD duration, albumin, Ca, P,
CaXP, iPTH and vascular calcification score. The indepen-
dent variables associated with vascular calcifications, vascu-
lar disease at baseline and vascular disease at the end of
follow-up were identified by binary logistic regression
models. Covariates for vascular calcification analysis were:
age, sex, diabetes, HD duration, albumin, Ca, P, CaXP and
iPTH. Covariates for vascular disease analysis were the
above plus PP, MAP and vascular calcification score. To
identify those patients at highest risk for the study endpoint,
the vascular calcification score values and the corresponding

endpoint rates were related via a receiver operating
characteristic (ROC) curve. The value associated with the
highest accuracy was considered as the cut-off point for
defining an elevated cardiovascular risk. The risk estimates
for death, cardiovascular hospitalizations and fatal and non-
fatal cardiovascular events were the adjusted hazard ratios
(HRs) obtained by Cox regression. Statistical analyses were
performed with the SPSS system 10.0 (SPSS Inc., Chicago,
IL) and the Medcalc program version 6.0 (Medcalc software;
Mariakerke, Belgium). For all comparisons, a P-value&amp;lt;0.05
was considered statistically significant.

Results

During an observational period of 37 months, there
were 36 all-cause deaths and 17 cardiovascular deaths;
28 patients needed cardiovascular hospitalizations, and
32 patients suffered fatal or non-fatal cardiovascu-
lar events. At baseline, clinical vascular disease was
diagnosed in 36 patients (29%): coronary artery disease
in 32 patients (26%), peripheral arterial disease in 16
patients (13%) and cerebral vascular disease in six
patients (5%); at the end of the follow-up coronary
artery disease had been diagnosed in 43 patients (35%),
peripheral arterial disease in 33 patients (27%), cerebral
vascular disease in 16 patients (13%) and vascular
disease in 61 patients (50%) (Table 1). Cardiovascular

Fig. 2. Hands score in this example is 4; total score is the sum of pelvis and hands score [8].

A simple vascular calcification score predicts cardiovascular risk 1483



33

death was associated with coronary artery disease in 12
patients, peripheral arterial disease in three patients
and cerebral vascular disease in two patients. Coronary
artery disease in 14 patients, peripheral arterial disease
in 12 patients and cerebral vascular disease in three
patients led to cardiovascular hospitalizations. One
patient experienced two hospitalization episodes,
one for coronary artery disease and one for cerebral
vascular disease.

Vascular calcification score frequency

Anatomical calcification distribution was the following:
iliac calcifications were present in 75 patients (61%),
femoral calcifications in 74 patients (60%), radial
calcifications in 45 patients (36.6%) and digital
calcifications in six patients (5%). The distribution of
vascular calcification score in the 123 patients was the
following: score 0 in 31 patients (25.2%), score 1 in
eight patients (6.5%), score 2 in 19 patients (15.4%),
score 3 in two patients (1.6%), score 4 in 25 patients
20.3%, score 5 in eight patients (6.5%), score 6 in 26
patients (21.1%), score 7 in zero patients and score 8 in
four patients (3.3%). This parameter does not present
a normal distribution mainly due to the less frequent
cases of unilateral vascular calcification: unilateral iliac
calcifications in three patients, unilateral femoral
calcifications in five patients, unilateral radial calcifica-
tions in 12 patients and unilateral digital calcifications
in one patient.

By ROC curve analysis, the vascular calcification
scores of the four anatomical regions (iliac, femoral,
radial and digital) showed a similar relationship with
cardiovascular mortality: iliac score &gt;0 (AUC ¼ 0.613;
95% CI 0.522–0.699); femoral score &gt;0 (AUC ¼
0.630; 95% CI 0.539–0.715); radial score &gt;0
(AUC ¼ 0.604; 95% CI 0.512–0.690); digital score &gt;0
(AUC ¼ 0.589; 95% CI 0.498–0.677).

Univariate analysis

ROC curve analysis identified vascular calcification
score ?3 as the best cut-off value associated with
cardiovascular mortality (AUC ¼ 0.716; 95% CI
0.629–0.793) and cardiovascular events (AUC ¼ 0.687;
95% CI 0.598–0.766). The vascular score ?3 was
measured in 65 patients (53%) (Table 1) and was
more frequent among men and diabetic patients.
Furthermore, a vascular score ?3 was more frequently
associated with cardiovascular hospitalizations, cardio-
vascular mortality and fatal and non-fatal cardio-
vascular events, coronary artery disease, peripheral
arterial disease and vascular disease at the end of the
follow-up period (Table 1). By univariate analysis,
there were no significant differences between higher
score and lower score patients with regards to age,
HD duration, calcium, phosphorus and iPTH levels
(Table 1). By Kaplan–Meier analysis, the cumulative
hazard for cardiovascular death at 37 months was
higher in patients with a vascular score ?3: 23 vs 5%,
log-rank ¼ 5.7; P ¼ 0.01 (Figure 3).

Multivariate analysis

Evaluation of the association of calcium, phosphorus
and iPTH with vascular calcification score and vascular
disease. Calcium, phosphorus and iPTH levels were
evaluated during the 6 months that preceded the
vascular calcification score assessment. Calcium levels
were independently associated with iliac calcifications
(P ¼ 0.03) (Table 2) and with PAD (P ¼ 0.01) (Table 3);
phosphorus levels were independently associated with
CAD (P ¼ 0.01) (Table 3). PTH levels were not
correlated with vascular calcifications or with vascular
disease in these patients.

Factors independently associated with PP and MAP. By
multiple linear regression, PP was associated with
diabetes (B ¼ 12.8; 95% CI ¼ 5.8–19.7; P&lt;0.001) and
correlated with age (B ¼ 0.33; 95% CI ¼ 0.13–0.52;
P ¼ 0.001). MAP was associated with a vascular
calcification score ?3 (B ¼ 5.6; 95% CI ¼ 0.8–10.4;
P ¼ 0.02). PP was an independent predictor of PAD
(P&lt;0.001) (Table 3).

Factors independently associated with vascular calcifi-
cation score. Binary logistic regression (Table 2)
showed that a vascular calcification score ?3 was
associated with diabetes (P ¼ 0.01), male sex
(P&lt;0.001), age (P ¼ 0.02), HD duration (P ¼ 0.02)
and MAP (P ¼ 0.03). There was no correlation between
final vascular score and calcium metabolism factors,
but when analysing the different vascular calcification
regions, in the same model, calcium levels were
independently associated with iliac calcifications
(P ¼ 0.03) (Table 2).
Factors independently associated with cardiovascular
morbidity and mortality. By binary logistic regression
(Table 3), vascular disease at the end of the follow-up
was associated with vascular calcification score

4 03 02 0100

,3

,2

,1

0 ,0

Mon t h s of  f ol l ow-u p

O
n

e
 m

in
u

s 
su

rv
iv

a
l

p=0.01

Log rank=5.7 14 deaths

23% 

3 deaths

5% 

n= 58 vsc &amp;lt;3

n= 65 vsc ? 3

Fig. 3. Higher cardiovascular death risk in patients with vascular
calcification score ?3.

1484 T. Adragao et al.



34

(P&lt;0.001), age (P ¼ 0.01) and diabetes (P ¼ 0.04);
coronary artery disease at the end of the follow-up
was associated with phosphorus levels (P ¼ 0.01) and
vascular calcification score (P ¼ 0.003); peripheral
artery disease at the end of the follow-up was associ-
ated with diabetes (P&lt;0.001), vascular calcification
score (P&lt;0.001), PP (P ¼ 0.001) and calcium levels
(P ¼ 0.02). Vascular disease at baseline was not
associated with any of these factors. Fatal and
non-fatal cardiovascular events were associated with
vascular calcification score (P ¼ 0.009); cardiovascular
hospitalizations were associated with vascular calcifica-
tion score (P ¼ 0.003); cardiovascular mortality was
associated with vascular calcification score (P ¼ 0.01).
All-cause mortality was inversely associated with
albumin levels (P&lt;0.001).

For a better evaluation of the cardiovascular risk, a
vascular calcification score cut-off defined by ROC
curve analysis was applied to the same statistical tests.
The cardiovascular risk evaluation was the HR
adjusted for sex, age, HD duration, diabetes, calcium
and phosphorus product, iPTH levels and albumin. In
patients with a vascular calcification score ?3, the HR
was 2.8 (95% CI 1.151–7.012; P ¼ 0.02) for cardio-
vascular hospitalizations, 2.3 (95% CI 1.044–5.182;
P ¼ 0.04) for fatal and non-fatal cardiovascular
events, and 3.9 (95% CI 1.108–13.422; P ¼ 0.03) for

cardiovascular mortality (Figure 4). In patients with
a vascular calcification score ?3 the odds ratio was
3.2 (95% CI 1.358–7.448; P ¼ 0.008) for association
with CAD, was 10.4 (95% CI 2.676–40.381; P ¼ 0.001)
for association with PAD and was 4.3 (95% CI
1.884–9.929; P ¼ 0.001) for association with vascular
disease (Figure 4).

Table 3. Cardiovascular morbidity and mortality: multivariate analysis

Dependent variable Independent variable Risk CI (95%) Significance (P)

Final CAD Vsc &gt;0 1.3 1.091–1.555 0.003
Phosphorus 1.5 1.094–1.967 0.01

Final PAD Vsc &gt;0 1.7 1.278–2.259 0.000
Diabetes 13.7 3.132–56.360 0.000
PP 1.1 1.024–1.101 0.001
Calcium 2.9 1.205–7.343 0.02

Final VASCD Vsc &gt;0 1.4 1.168–1.698 0.000
Diabetes 3.3 1.071–10.044 0.04
Age 1.04 1.008–1.074 0.01

CV hospitalizations Vsc &gt;0 1.3 1.093–1.554 0.003
CV events Vsc &gt;0 1.2 1.054–1.446 0.009
CV death Vsc &gt;0 1.4 1.107–1.803 0.01

Final, at the end of the follow-up; CAD, coronary artery disease; PAD, peripheral artery disease; VASCD, vascular disease; CV,
cardiovascular; Vsc, vascular calcification score.

Table 2. Vascular calcification score: multivariate analysis

Dependent variable Independent variable Risk CI (95%) Significance (P)

Vsc ?3 Diabetes 4.2 1.4–13.1 0.01
Male gender 7.47 2.9–19.1 0.000
Age 1.04 1.008–1.077 0.02
HD duration (months) 1.01 1.002–1.021 0.02
MAP 1.04 1.004–1.074 0.03

Iliac score &gt;0 Diabetes 4.6 1.4–14.7 0.01
Male gender 3.5 1.5–8.3 0.004
Age 1.04 1.012–1.072 0.005
Calcium 1.8 1.050–3.143 0.03

Vsc, vascular calcification score.

cardiovascular hospit alizations

0.01 0.1 1 10 100

peripheral vascular disease

vascular disease

cardiovascular death

9.3

3.8

3.9

4.4

Fig. 4. Cardiovascular risk for vascular calcification score ?3.

A simple vascular calcification score predicts cardiovascular risk 1485



35

In summary, this simple vascular calcification score
was independently associated with coronary artery
disease, peripheral artery disease and vascular disease
present at the end of the follow-up. A vascular
calcification score ?3 was an independent predictor of
cardiovascular mortality, cardiovascular hospitaliza-
tions, and fatal or non-fatal cardiovascular events.

Discussion

Vascular calcifications in HD patients have already
been related to arterial stiffness [7,11,16], cardiovasc-
ular disease [8,10] and cardiovascular mortality [7,11],
and are more common than in the general population
[8]. These extensive vascular calcifications, found even
in young HD patients [9], may represent one of the
factors contributing to the extremely high cardio-
vascular mortality for HD patients when compared
with the general population [1].

The diagnosis of vascular calcification is usually
made with very expensive and highly technical devices
like electron beam computed tomography or multislice
computed tomography [8,17,18]. The use of plain
radiographic films of bone has already been suggested
in the recent KDOQI clinical practice guidelines for
bone metabolism and disease [19], not for bone disease
evaluation but for vascular calcification assessment.
In our score, vascular calcifications were deliberately
evaluated only in muscular arteries: iliac, femoral,
radial and digital, because muscular arteries are more
prone to linear calcification in contrast with elastic
arteries that are more prone to intimal calcification.
Our objective was to have a simple tool for the
evaluation of peripheral muscular arteries calcifica-
tions. Lower limb arteries were not chosen because of
the high prevalence of amputations in HD patients.
The radial artery was included in our score based on
a previous evaluation by Mourad et al. [20] who
demonstrated that the radial artery, a muscular artery
devoid of atherosclerosis, had an increased stiffness
that was independent of the BP level. Intimal calcifica-
tions have already been differentiated from medial
calcifications by plain radiography and these different
calcification patterns have been associated with differ-
ent cardiovascular and all-cause mortality results [13].
In our score, only linear calcifications that outline the
vessel wall, with or without patchy calcifications, were
considered because they have an obvious vascular
origin. Patchy isolated calcifications were not consid-
ered because of their possible non-vascular origin.
These linear calcifications may correspond to the linear
railroad calcifications described by Lehto et al. [12] and
by London et al. [13] and identified by these authors as
medial calcifications. However, vascular calcifications
were evaluated in four vascular territories, and medial
and intimal calcifications may coexist in the same
patient and in the same vessel. Our vascular score does
not exclude association of intimal and medial calcifica-
tions. This would explain why this score was a good

predictor of cardiovascular mortality. In another study,
this vascular calcification score was also correlated in
univariate and multivariate analysis with pulse wave
velocity measured by Complior

?
[21]. This finding

confirms the value of this simple score, suggesting that
linear calcifications identified by this method are
associated with changes of the arterial wall properties.
This calcification score that we have developed is a very
simple tool, easy to use by the attending physician
without assistance of a radiologist and may help
identify patients at higher cardiovascular risk.

Changes of arterial wall properties with age are
associated with SBP increase and DBP decrease. PP
increase has been established as a cardiovascular
disease risk factor in the general population [22] and
in HD patients as well [23,24]. In our study, PP in
multivariate analysis was not correlated with vascular
calcification score but was correlated with age and
diabetes and was independently associated with per-
ipheral arterial disease. However, MAP, which is
related to cardiac output and vascular resistance, was
independently associated with a vascular calcification
score ?3. The fact that BP was evaluated immediately
before an HD procedure, in a clinical situation of
hypervolaemia, may have contributed to this result.

It has already been shown that PTH levels are
overestimated with the common iPTH assays because
they detect not only PTH (1–84), but also evaluate C-
terminal fragments, which can have inhibitory activity.
Newer ‘whole PTH’ assays can detect exclusively PTH
(1–84), but the predictive power of these new assays
is still unknown [19]. In the present study, vascular
calcification score was independent of PTH values. This
has already been demonstrated in other studies [8,16].
Hyperphosphataemia and high calcium phosphate
product are predictors of mortality in HD patients
[25]. In our study, there is some evidence for a
relationship between calcium or phosphorus levels
and vascular disease: phosphorus levels were correlated
with coronary artery disease and calcium levels were
correlated with peripheral arterial disease. The final
vascular calcification score was not correlated with
calcium, phosphorus or iPTH levels, but calcium levels
were correlated with the presence of iliac calcifications.
Similarly, Gue?rin et al. [16] did not find any association
between a semi-quantitative vascular calcification score
evaluated by B-mode ultrasonography and calcium,
phosphorus and iPTH levels [16]. Previous hyperphos-
phataemia episodes that would have initiated this
vascular calcification process may have been missed
because of the time limited monitoring phase in these
patients.

Vascular disease, present at the end of the follow-up,
correlated with the vascular calcification score. Con-
versely, clinical vascular disease diagnosed at base-
line did not predict vascular mortality or vascular
events and did not correlate with the vascular calcifi-
cation score. Vascular disease is oligosymptomatic in
this population and sub-clinical vascular disease was
not diagnosed at baseline, reflecting what happens in
current practice. As many patients do not have a very

1486 T. Adragao et al.



36

active life style, symptoms of cardiovascular disease
may be delayed, explaining the absence of correlation
of clinical vascular disease at baseline with cardio-
vascular death and cardiovascular events. Clinical
evidence of vascular disease at the end of the follow-
up, however, was strongly associated with the vascular
calcification score. This association strongly supports
the usefulness of this simple vascular tool at a stage of
sub-clinical vascular disease.

Limitations of this vascular calcification score

This vascular calcification score is not quantitative and
therefore is not adequate for accurately assessing the
progression of calcifications, as opposed to the scores
evaluated by electron beam computed tomography
[14,15]. However, in a retrospective study of long-term
HD patients where the authors also used a vascular
calcification score based on radiographic films [26], it
was possible to evaluate regression and aggravation of
the calcifications over time.

Conclusion

Cardiovascular morbidity and mortality in this
cohort of HD patients were related, among other
factors, to a simple vascular calcification score
evaluated by plain radiographic films of pelvis and
hands. This simple vascular calcification score was
independently associated with coronary artery dis-
ease, peripheral artery disease and vascular disease
diagnosed at the end of the follow-up. Male sex,
diabetes, age, HD duration and MAP were inde-
pendently associated with a vascular calcification
score ?3. A vascular calcification score ?3 was an
independent predictor of cardiovascular mortality,
cardiovascular hospitalizations, and fatal or non-fatal
cardiovascular events. This vascular calcification
score represents a simple and inexpensive tool for
assessing the cardiovascular risk related to vascular
calcifications in HD patients.

Acknowledgements. The authors would like to thank Dr Fernando
Carrera for critical review of the manuscript, Dr Carlos Aguiar
who supervised and revised the statistical analysis and reviewed the
manuscript and Dr Diogo Cavaco who prepared the pictures.

Conflict of interest statement. We have had no involvements that
might raise the question of bias in the work reported or in the
conclusions, implications or opinions stated.

References

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of
cardiovascular disease in chronic renal disease. Am J Kidney
Dis 1998; 32 [5 Suppl 3]: S112–S119

2. US Renal Data System. USRDS 2002. Annual Data Report:
Atlas of End-Stage Renal Disease in the United States. National
Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD: 2002

3. Jono S, McKee MD, Murry CE et al. Phosphate regulation of
vascular smooth muscle cell calcification. Circ Res 2000; 87:
E10–E17

4. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii
H. Vascular calcification and inorganic phosphate. Am J
Kidney Dis 2001; 38 [4 Suppl 1]: S34–S37

5. Moe SM, O’Neill KD, Duan D et al. Medial artery
calcification in ESRD patients is associated with deposition of
bone matrix proteins. Kidney Int 2002; 61: 638–647

6. Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX. Uremia
induces the osteoblast differentiation factor Cbfa1 in human
blood vessels. Kidney Int 2003; 63: 1003–1011

7. Blacher J, Gue?rin AP, Pannier B, Marchais SJ, London GM.
Arterial calcifications, arterial stiffness, and cardiovascular risk
in end-stage renal disease. Hypertension 2001; 38: 938–942

8. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft
FC. Electron beam computed tomography in the evaluation of
cardiac calcification in chronic dialysis patients. Am J Kidney
Dis 1996; 27: 394–401

9. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery
calcification in young adults with end-stage renal disease
who are undergoing dialysis. N Engl J Med 2000; 342:
1478–1483

10. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification
in adult hemodialysis patients. A link between end-stage renal
disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:
695–701

11. Blacher J, Gue?rin AP, Pannier B, Marchais SJ, Safar ME,
London GM. Impact of aortic stiffness on survival in end-stage
renal disease. Circulation 1999; 99: 2434–2439

12. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M.
Medial artery calcification. A neglected harbinger of cardio-
vascular complications in non-insulin-dependent diabetes
mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978–983

13. London GM, Gue?rin AP, Marchais SJ, Metivier F, Pannier B,
Adda H. Arterial media calcification in end-stage renal disease:
impact on all-cause and cardiovascular mortality. Nephrol Dial
Transplant 2003; 18: 1731–1740

14. Chertow GM, Burke SK, Raggi P, Treat to Goal Working
Group. Sevelamer attenuates the progression of coronary and
aortic calcification in hemodialysis patients. Kidney Int 2002;
62: 245–252

15. Chertow GM, Raggi P, McCarthy JT et al. The effects of
sevelamer and calcium acetate on proxies of atherosclerotic and
arteriosclerotic vascular disease in hemodialysis patients. Am J
Nephrol 2003; 23: 307–314

16. Gue?rin AP, London GM, Marchais SJ, Metivier F. Arterial
stiffening and vascular calcifications in end-stage renal disease.
Nephrol Dial Transplant 2000; 15: 1014–1021

17. Becker CR, Jakobs TF, Aydemir S et al. Helical and
single-slice conventional CT versus electron beam CT for
the quantification of coronary artery calcifications. AJR 1999;
174: 543–547

18. Goodman WG, Salusky IB. Non-invasive assessments of
cardiovascular disease in patients with renal failure. Curr
Opin Nephrol Hypertens 2001; 10: 365–369

19. National Kidney Foundation. KDOQI Clinical Practice
Guidelines for Bone Metabolism and Disease in Chronic
Kidney disease. Am J Kidney Dis 2003; 42 [Suppl 3].

20. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M,
London G. Increased stiffness of radial artery wall material in
end-stage renal disease. Hypertension 1997; 30: 1425–1430

21. Adragao T, Pires A, Lucas C et al. Pulse wave velocity
correlates with simple vascular calcification score in hemodial-
ysis patients. Nephrol Dial Transplant 2003; 18 [Suppl 4]: 702,
Abstract W487

22. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is
pulse pressure useful in predicting risk for coronary heart
Disease? The Framingham heart study. Circulation 1999; 100:
354–360

A simple vascular calcification score predicts cardiovascular risk 1487



37

23. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and
risk of total mortality and cardiovascular events in patients on
chronic hemodialysis. Kidney Int 2002; 61: 717–726

24. Klassen PS, Lowrie EG, Reddan DN et al. Association
between pulse pressure and mortality in patients undergoing
maintenance hemodialysis. J Am Med Assoc 2002; 287:
1548–1555

25. Block GA, Hubet-Shearon TE, Levin NW, Port FK.
Association of serum phosphorus and calcium phosphate
product with mortality risk in hemodialysis patients: a national
study. Am J Kidney Dis 1998; 31: 607–617

26. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular
calcification in long-term haemodialysis patients in a single
unit: a retrospective analysis. Nephron 1997; 77: 37–43

Received for publication: 11.8.03
Accepted in revised form: 13.02.04

1488 T. Adragao et al.





39

CAPÍTULO 4

CALCIFICAÇÃO VASCULAR E RIGIDEZ ARTERIAL

A rigidez arterial resulta da modifi cação das propriedades da parede arterial e é preditora 
de risco cardiovascular nos doentes com e sem doença renal crónica1,2. Diversos fatores 
contribuem para o aumento da rigidez arterial, como idade avançada, diabetes, hipertensão 
arterial e calcifi cações vasculares. Nos doentes em diálise, todos estes fatores apresentam 
elevada prevalência, e a rigidez arterial é um achado comum nesta população. Em estudos 
anteriores, a rigidez arterial foi associada a maior risco de mortalidade2, mas esta associação 
não é universal3.

As calcifi cações vasculares provocam uma diminuição da elasticidade da parede da aorta 
responsável por uma onda de refl exão mais precoce, encontrando ainda a válvula aórtica 
aberta. Esta ocorrência contribui para o aumento do volume sistólico com consequente 
hipertensão sistólica e diminuição da pressão diastólica. O aumento da pressão sistólica 
contribui para o aumento da pós -carga cardíaca e para o desenvolvimento da hipertrofi a 
ventricular esquerda. A diminuição da pressão diastólica pode comprometer a perfusão 
coronária que se faz predominantemente durante a diástole4. Objetivamente, o aumento da 
pressão sistólica e a diminuição da pressão diastólica traduzem -se por um índice clínico 
facilmente mensurável, o aumento da pressão de pulso, que se avalia simplesmente pela 
diferença aritmética entre o valor da pressão sistólica e da pressão diastólica. Na população 
geral já foi demonstrado que, em doentes com idade superior a 60 anos, é o aumento da pressão 
de pulso que se associa a maior risco cardiovascular, enquanto em indivíduos mais novos o 
aumento da pressão diastólica é que apresenta maior associação ao risco cardiovascular5. 
Também em doentes em diálise o aumento da pressão de pulso avaliado no início ou no fi nal 
de uma sessão de hemodiálise se associou a maior mortalidade em doentes não diabéticos6 
ou em todos os doentes7.

O grupo de trabalho de imagiologia da iniciativa KDIGO 20068 propôs a investigação 
clínica de diversas questões, na altura ainda sem resposta, entre as quais a análise da associação 
entre rigidez arterial avaliada por velocidade de onda de pulso e pressão de pulso e a existência 
de calcifi cações vasculares avaliadas por métodos radiológicos. Em 2000, Guérin et al tinham 
sido os primeiros a demonstrar que calcifi cações vasculares avaliadas por ecografi a em grandes 
artérias se associavam a rigidez arterial nos doentes em diálise9. Após a proposta de investigação 



40

clínica feita pela KDIGO 2006, Raggi et al analisaram a associação entre a rigidez arterial 
avaliada por velocidade de onda de pulso carotidofemoral com calcifi cações coronárias e da 
aorta abdominal10. As calcifi cações coronárias foram avaliadas por tomografi a computorizada 
de feixe de eletrões e as calcifi cações da aorta abdominal por RX simples utilizando um score 
de calcifi cação semiquantitativo descrito por Kauppila11. Neste estudo verifi cou -se que as 
calcifi cações da aorta abdominal se associaram a um aumento da velocidade de onda de pulso 
carotidofemoral. Em análise multivariada, as calcifi cações coronárias não se associaram ao 
aumento de rigidez arterial.

Em 2005, apresentamos, no XVII Congresso Português de Nefrologia, um estudo 
em que verificamos que a velocidade de onda de pulso era preditora de mortalidade num 
grupo de doentes em hemodiálise e em que demonstramos que o score de calcificação 
vascular simples se associava à velocidade de onda de pulso. Este estudo ganhou o 
prémio para a melhor comunicação oral na área da hemodiálise desse ano e foi apresentado 
como poster na 38th Annual Renal Week Meeting, da Sociedade Americana de Nefrologia. 
Aceitando a proposta da iniciativa KDIGO 2006, aprofundamos este estudo para poder 
responder a todas as questões levantadas e dispúnhamos já de um tempo de seguimento 
que nos permitiu também avaliar a associação entre a rigidez arterial e a mortalidade. 
A rigidez arterial foi avaliada por velocidade de onda de pulso carotidofemoral com um 
método não invasivo usando o Complior (Artech Medical, Pantin, France) e pela pressão 

Fig. 4.1. Um score de calcifi cação vascular simples (SCVS) &gt; 3 associou -se a valores mais elevados de velocidade 
de onda de pulso e de pressão de pulso (teste T de Student)



41

de pulso. A pressão de pulso, calculada pela diferença entre a pressão sistólica e a pressão 
diastólica, correspondeu ao valor médio da pressão de pulso medida no início de uma 
sessão de hemodiálise durante os 6 meses que precederam a medição da velocidade de 
onda de pulso. Nos nossos doentes verificamos que o score de calcificação vascular 
simples superior a 3 se associou a valores mais elevados da velocidade de onda de pulso 
e da pressão de pulso (Fig. 4.1).

Esta análise foi ajustada para idade, duração de hemodiálise, diabetes, níveis de 
colesterol, pressão sistólica, índice de massa corporal e doses de calcitriol e de carbonato 
de cálcio. A idade e a pressão sistólica foram os outros fatores preditores da velocidade 
de onda de pulso. A diabetes mellitus e a dose de carbonato de cálcio foram igualmente 
preditores da pressão de pulso. Verifi camos ainda que valores de pressão de pulso 
superiores a 70 mmHg, valores de velocidade de onda de pulso superiores a 10,4 m/s e 
um score de calcifi cação vascular simples superior a 3 se associaram a maior mortalidade 
(Fig. 4.2), com semelhante área sob a curva na análise de curvas ROC (receiver operating 
characteristic) (Fig. 4.3).

Em análise multivariada, o risco de morte ajustado para inúmeras variáveis foi semelhante 
para estes três fatores (Tabela 4.1), mas a velocidade de onda de pulso foi preditora de 
mortalidade apenas nos doentes não diabéticos. Este achado pode ser explicado pelo facto 
de, nos doentes diabéticos, a mortalidade ter sido elevada e ter -se verifi cado tanto nos doentes 
com velocidade de onda de pulso alta como normal.

Calcifi cações vasculares, rigidez arterial e mortalidade

Fig. 4.2. Um SCVS &gt;3, uma velocidade de onda de pulso (VOP) &gt;10,4 m/s e uma pressão de pulso (PP) &gt; 70 
mmHg associaram -se a menor sobrevida (Kaplan -Meier)



42

Risco de morte avaliado por Cox regression

B HR IC 95% Sig.
Todos os doentes SCVS &gt;3 1,196 3,308 1,109 -9,863 0,032
Todos os doentes PP &gt;70 mmHg 1,171 3,227 1,114 -9,347 0,031
Não diabéticos VOP &gt; 10,5 m/s 1,092 2,981 1,013 -8,775 0,047

HR, hazard ratio; IC, intervalo de confiança.

Tabela 4.1. HR ajustado para idade, duração de hemodiálise, diabetes mellitus, doença vascular prévia, 
índice de massa corporal, pressão arterial sistólica e doses de carbonato de cálcio e de calcitriol

Em resumo, demonstramos que calcifi cações vasculares avaliadas por RX simples se 
associam a um aumento da rigidez arterial. Este estudo foi publicado na revista Nephrology 
Dialysis and Transplantation em 200912 e foi um dos estudos selecionados pelas guidelines 
KDIGO 2009 para mostrar a associação entre calcifi cações vasculares e mortalidade, 
confi rmando assim a utilidade e a validade do score de calcifi cação vascular simples na 
identifi cação dos doentes com mais elevado risco cardiovascular.

Fig. 4.3. A área sob a curva em relação à mortalidade foi semelhante para o score de calcificação vascular 
simples (SCVS), para a velocidade de onda de pulso (VOP) e para a pressão de pulso (PP) (análise de 
curvas ROC)



43

Referências

  1. Sutton -Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker 
of arterial stiffness, predicts cardiovascular events in well -functioning older adults. Circulation 
2005;28;111(25):3384 -390.

  2. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end -stage renal 
disease. Circulation 1999; 11;99(18):2434 -2439.

  3. Covic A, Mardare N, Gusbeth -Tatomir P, et al. Arterial wave refl ections and mortality in 
haemodialysis patients -only relevant in elderly, cardiovascularly compromised? Nephrol Dial 
Transplant 2006;21: 2859 -2866.

  4. London GM, Guérin A. Infl uence of arterial pulse and refl ective waves on systolic blood pressure 
and cardiac function. J Hypertens 1999; 17 (Suppl 2):S3 -S6. [Review.]

  5. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart 
disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-
-1249.

  6. Tozawa M, Iseki K, Iseki C, et al. Pulse pressure and risk of total mortality and cardiovascular 
events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717 -726.

  7. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in 
patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548 -1555.

  8. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of 
renal osteodystrophy: A position statement from kidney disease: improving global outcomes 
(KDIGO). Kidney Int 2006; 69: 1945 -1953

  9. Guérin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifi cations in end-
-stage renal disease. Nephrol Dial Transplant 2000; 15 (7): 1014 -1021.

10. Raggi P, Bellasi A, Ferramosca E, et al. Association of pulse wave velocity with vascular and 
valvular calcifi cation in hemodialysis patients. Kidney Int 2007; 71: 802 -807.

11. Kauppila LI, Polak JF, Cupples LA et al. New indices to classify location, severity and progression 
of calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997; 132: 
245 -250.

12. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP. A plain X -ray vascular 
calcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol 
Dial Transplant 2009; 3:997 -1002.





Nephrol Dial Transplant (2009) 24: 997–1002
doi: 10.1093/ndt/gfn584
Advance Access publication 24 October 2008

Original Article

A plain X-ray vascular calcification score is associated with arterial
stiffness and mortality in dialysis patients

Teresa Adraga?o1, Ana Pires1, Rita Birne1, Jose Dias Curto2, Carlos Lucas1, Margarida Gonc?alves1

and Aca?cio Pita Negra?o1

1Nefrocl??nica-Estoril, Diaverum, Estoril and 2ISCTE, Business School, Lisbon, Portugal

Abstract
Background. Vascular calcifications are highly prevalent
in dialysis patients and are associated with arterial stiffness
and mortality. The use of simple and inexpensive methods
to evaluate arterial stiffness and vascular calcifications is
desired. The objective of this study was to evaluate the
relationship of a simple vascular calcification score (SVCS)
with pulse wave velocity (PWV) and pulse pressure (PP)
and to evaluate their association with all-cause mortality.
Methods. 101 haemodialysis patients (71 men; 19% di-
abetic) were evaluated. At baseline, arterial stiffness was
measured by PP and by PWV with Complior. SVCS was
evaluated in plain X-ray of pelvis and hands.
Results. During a 43-month observational period,
31 patients died. By Kaplan–Meier analysis, SVCS &gt;3
(P = 0.001), PP &gt; 70 mmHg (P = 0.001) and PWV &gt;
10.5 m/s (P &amp;lt;0.001) were found to be associated with
lower cumulative survival. Adjusting for multiple variables,
association with mortality was maintained for SVCS &gt;3
(HR = 3.308, P = 0.032) and PP &gt; 70 mmHg (HR =
3.227, P = 0.031) in all patients and for PWV &gt; 10.5 m/s
(HR = 2.981, P = 0.047) in non-diabetic patients. Age
(P &amp;lt;0.001), systolic pressure (P = 0.004) and SVCS &gt;
3 (P = 0.032) were associated with PWV. Diabetes (P =
0.031), calcium carbonate dose (P = 0.009) and SVCS &gt;
3 (P = 0.012) were associated with PP.
Conclusion. Higher SVCS, PWV and PP were associated
with higher mortality in this population. SVCS was associ-
ated with arterial stiffness. Simple and inexpensive methods
such as PP or SVCS may be used to detect mortality risk
and to provide important information that may be relevant
for guiding therapeutic intervention in dialysis patients.

Keywords: arterial stiffness; haemodialysis; mortality;
vascular calcification

Correspondence and offprint requests to: Teresa Adraga?o, Nefrocl??nica
Estoril, Diaverum, Rua Vale de S Rita 19, 2765-293 Estoril,
Portugal. Tel: +00351967037522; Fax: +00351214872931; E-mail:
tadragao@netcabo.pt

Introduction

It is clearly demonstrated that dialysis patients have a much
higher cardiovascular mortality when compared with the
general population [1]. This high cardiovascular risk in
chronic kidney disease (CKD) patients is only partly ex-
plained by traditional risk factors [2]. Vascular calcifica-
tions evaluated by ultrasonography [3], plain X-ray [4],
electron beam computed tomography [5] or multislice com-
puted tomography [6] have been associated with mortality
in dialysis patients. KDIGO has recommended a new clas-
sification for mineral and bone disorder of chronic kidney
disease patients (CKD-MBD) that includes the evaluation
of vascular calcifications [7]. Arterial stiffness is an alter-
ation of the arterial wall properties with multiple causes,
some of which are old age, diabetes, hypertension and me-
dial calcification. All these features are highly prevalent in
dialysis patients, and arterial stiffness is a common finding
in this population. In dialysis patients, arterial stiffness has
been associated with all-cause and cardiovascular mortality
[8], but this finding is not universal [9]. One of the KDIGO
Imaging Work Group research questions is the evaluation of
the relationship between the radiological vascular calcifica-
tion assessment and the measurement of vascular stiffness
by pulse wave velocity (PWV) and pulse pressure (PP) [7].
Vascular calcifications evaluated by ultrasonography [10]
and by plain X-ray [11] have already been associated with
arterial stiffness in dialysis patients. We developed a sim-
ple vascular calcification score (SVCS) evaluated in plain
X-ray of pelvis and hands that was a predictor of cardio-
vascular mortality and was associated with higher risk of
coronary disease, peripheral artery disease and cardiovas-
cular hospitalizations [12]. The objective of this study was
to evaluate the relationship of this SVCS with PWV and
PP and to evaluate the association of vascular calcifica-
tion and arterial stiffness with all-cause mortality in our
patients.

Study design

This study was a cross-sectional analysis performed in a
group of prevalent haemodialysis (HD) patients to evaluate
the relationship between a SVCS evaluated in plain X-ray

C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org



998 T. Adraga?o et al.

with PWV and PP. This group of patients was followed
prospectively during a period of 43 months for evaluation
of the impact of vascular calcifications and arterial stiffness
in all-cause mortality.

Population

One hundred and one patients (71 men and 30 women),
treated with HD for at least 6 months, with a mean age of
58.8 ± 15.5 (26–89) years and mean HD duration of 55.8 ±
54.8 (6–289) months, from a single HD unit, accepted to
participate in this study that was approved by the institu-
tional scientific board; 19 patients (18.8%) were diabetic.
In the 6 months before PWV evaluation, 89 and 41 patients
were treated with calcium carbonate and calcitriol, respec-
tively. The mean calcium carbonate and calcitriol prescribed
doses in these patients were 2.5 ± 1.3 [1–8] g/day and 1.1 ±
0.6 [0.25–3] ?g/week, respectively. Oral or intravenous cal-
citriol was administered in 25 and 16 patients, respectively.
No patients received sevelamer or cinacalcet as they were
not available at the time of the study; 71 patients received
anti-hypertensive treatment (one single medication in 25
patients and two different medications in 46 patients). At
baseline, diagnosis of vascular disease was based on a query
answered by the attending physicians, concerning previous
clinical manifestations and test results, according to the
usual standard of care. Coronary artery disease was diag-
nosed if the patient had a positive stress test, had suffered
a myocardial infarction or had been submitted to a percu-
taneous coronary intervention or coronary bypass surgery.
Diagnosis of cerebral vascular disease was based on the
occurrence of stroke or transient ischaemic attack or the
detection of an old cerebral infarction in computed tomog-
raphy. Peripheral arterial disease was diagnosed if there
was claudication, ischaemic ulcers, lower limb amputation,
revascularization or diagnosis of obstruction by Doppler
or angiography. Coronary artery disease was diagnosed in
20 patients (19.8%), peripheral artery disease was present
in 16 patients (15.8%) and cerebral vascular disease was
identified in 4 patients (4%). During a period of 43 months,
31 patients died and 8 patients received a kidney transplant.
No patient was lost for follow-up.

Vascular calcifications and arterial stiffness

Vascular calcifications were evaluated at baseline by a sin-
gle observer blind to clinical data, in plain X-ray of pelvis
and hands by a method previously described in detail [12].
Pelvis films were divided into four sections by two imag-
inary lines: a horizontal line over the upper limit of both
femoral heads and a median vertical line over the verte-
bral column. Hands films were divided for each hand by
a horizontal line over the upper limit of the metacarpal
bones. Pelvis films evaluated iliac and femoral arteries
(ileo-femoral score) and hands films evaluated radial and
digital arteries (hands score). Any vascular calcification
lining the vessel walls, either in an irregular pattern or in
a linear pattern, was considered. The presence of vascular
calcifications in each section was rated as 1 and its absence
as 0. The total vascular calcification score was the sum of

all sections and ranged from 0 to 8. Arterial stiffness was
evaluated by PWV and by PP. PWV was evaluated twice, at
baseline, 24 h after a HD session, using a non-invasive auto-
mated device, Complior. Complior measures the propaga-
tion of the same individual pulse wave between two arterial
points. The proximal and distal sensors were located in the
carotid and femoral arteries, respectively. The velocity of
the pulse wave is calculated with the formula distance/time,
where the distance corresponds to the distance between the
suprasternal notch and the femoral artery pulse at the groin,
and the time corresponds to the time that takes a pulse wave
that originates in the heart to reach the femoral artery. The
Complior software calculates the velocity of conduction.
PP was evaluated by the formula (systolic blood pressure ?
diastolic blood pressure). The mean values of PP were time
averaged for the 6-month period preceding PWV evalua-
tion, corresponding to the mid-week HD session in the day
of the monthly blood sample collection. PP was calculated
from the predialysis evaluation of blood pressure.

Biochemical analysis

Mid-week Kt/V and predialysis serum levels of the follow-
ing biochemical parameters were evaluated and time aver-
aged for the 6 months preceding the evaluation of PWV.
Kt/V, Ca, P, Ca × P product, alkaline phosphatase, albumin
and C-reactive protein (CRP) were evaluated every month.
Ca levels were adjusted to albumin levels. Total intact iPTH
(iPTH) was evaluated every 3 months by immunochemilu-
minescence (three evaluations per patient) using a second
generation assay, Elecsys 2010 from Roche Diagnostics,
Basel, Switzerland. CRP was evaluated with an immunotur-
bidimetric assay. Total cholesterol, HDL cholesterol, LDL
cholesterol and triglycerides were evaluated twice.

Statistical analysis

Data are presented as frequencies for categorical variables
and mean values with SD for continuous variables. Com-
parison between groups was performed by the indepen-
dent samples t-test, chi-square and Fisher exact test when
appropriate. Correlation was performed using the Pearson
correlation coefficient. Survival curves were estimated by
Kaplan–Meier analysis and compared by the log-rank test.
A Cox regression model was used to identify predictors
of mortality. Variables in this model, besides the vascular
calcification score, PWV and PP, were age, HD duration,
diabetes, presence of previous vascular disease, body mass
index (BMI), systolic pressure and calcitriol and calcium
carbonate doses. Separate Cox regression models using the
enter method were applied to evaluate the adjusted hazard
ratio mortality of vascular calcification score, PWV and
PP. Independent association of vascular calcification with
PWV and with PP was evaluated in linear regression models
adjusting for age, HD duration, diabetes, cholesterol levels,
systolic pressure, BMI, and calcitriol and calcium carbon-
ate doses. The absence of collinearity among explanatory
factors was checked in all models based on standard pro-
cedures. The receiver operating characteristic (ROC) curve



Arterial stiffness and mortality in haemodialysis patients 999

Table 1. Demographic, biochemical and clinical factors

All patients Pulse wave velocity (m/s) Pulse pressure (mmHg) Plain X-ray score

?10.5 &gt;10.5 ?70 &gt;70 ?3 &gt;3

N (%) 101 61 (60%) 40 (40%) 68 (67%) 33 (33%) 42 (42%) 58 (58%)
Age (years) 58.9 ± 15.5 53.1 ± 15.2 67.6 ± 11.3?? 56.2 ± 15.8 64.3 ± 13.6? 51.1 ± 15.9 64.4 ± 12.7??
Male gender

(N, %)
71 (70%) 45(74%) 26 (65%) 47 (69%) 24 (73%) 27 (64%) 44 (75%)

Diabetes (N, %) 19 (19%) 6 (10%) 13 (33%)? 8 (12%) 11 (33%)? 3 (7%) 16 (27%)?
HD duration

(months)
55.8 ± 54.8 56.7 ± 59.0 57.4 ± 45.6 54.2 ± 51.8 62.7 ± 58.3 47.8 ± 48.6 63.5 ± 56.8

Systolic pressure
(mmHg)

145.1 ± 25.7 141.3 ± 24.4 151.0 ± 26.8 133.3 ± 19.8 169.4 ± 18.5?? 136.521.4 151.3 ± 26.9??

Diastolic pressure
(mmHg)

82.7 ± 13.7 84.2 ± 14.9 80.6 ± 11.5 81.0 ± 14.0 86.3 ± 12.5 82.2 ± 13.7 83.1 ± 13.8

Mean arterial
pressure
(mmHg)

103.5 ± 16.3 103.2 ± 17.1 104.0 ± 15.1 98.5 ± 15.3 114.0 ± 13.1?? 100.3 ± 15.5 105.8 ± 16.6

Ca (mg/dL) 9.3 ± 0.9 9.3 ± 0.9 9.4 ± 0.8 9.2 ± 0.9 9.5 ± 0.8 9.2 ± 1.0 9.4 ± 0.7
P (mg/dL) 5.2 ± 1.4 5.4 ± 1.3 4.9 ± 1.5 5.4 ± 1.4 4.9 ± 1.4 5.4 ± 1.2 5.1 ± 1.5
iPTH (pg/mL) 476.4 ± 442 526.2 ± 483.7 400.3 ± 362.2 495.7 ± 441.9 436.4 ± 446.5 452.5 ± 394.3 493.3 ± 475.7
Total cholesterol
(mg/dL)

203.4 ± 49.3 201.6 ± 49.8 206.4 ± 49.1 208.4 ± 50.0 192.0 ± 46.7 207.449.5 200.6 ± 49.4

Albumin (g/dL) 4.4 ± 0.6 4.4 ± 0.7 4.3 ± 0.4 4.4 ± 0.6 4.4 ± 0.4 4.4 ± 0.7 4.4 ± 0.4
CRP (mg/dL) 1.28 ± 0.6 1.23 ± 0.3 1.35 ± 0.8 1.25 ± 0.2 1.33 ± 0.9 1.25 ± 0.36 1.31 ± 0.7
Kt/V 1.41 ± 0.2 1.43 ± 0.2 1.38 ± 0.2 1.40 ± 0.2 1.41 ± 0.1 1.43 ± 0.2 1.38 ± 0.2
Body mass index

(Kg/cm2)
24.2 ± 4.8 24.1 ± 5.2 22.9 ± 3.9 24.8 ± 5.1 23.1 ± 4.0 24.9 ± 5.7 23.7 ± 4.1

Ca dose (g/day) 2.45 ± 1.31 2.47 ± 1.22 2.41 ± 1.49 2.33 ± 1.16 2.72 ± 1.61 2.52 ± 1.55 2.39 ± 1.13
Calcitriol dose
(?g/week)

1.14 ± 0.6 1.13 ± 0.66 1.15 ± 0.52 1.14 ± 0.65 1.13 ± 0.53 1.17 ± 0.74 1.12 ± 0.53

Anti-HTA drugs
(?2) (N, %)

46 (46%) 26 (43%) 20 (50%) 20 (29%) 26 (79%)?? 12 (29%) 34 (74%)??

CAD (N, %) 20 (20%) 7 (12%) 13 (33%)? 12 (18%) 8 (24%) 7 (17%) 13 (22%)
PAD (N, %) 16 (16%) 4 (7%) 12 (30%)? 4 (6%) 12 (36%)?? 2 (5%) 14 (24%)?
Vascular disease

(N, %)
32 (32%) 11 (18%) 21 (53%)?? 16 (24%) 16 (49%)? 8 (19%) 24 (41%)?

All-cause death
(N, %)

31 (31%) 10 (16%) 21 (53%)?? 14 (20%) 17 (52%)?? 5 (12%) 26 (44%)??

CRP = C-reactive protein; CAD = coronary artery disease; PAD = peripheral artery disease.
?P &amp;lt;0.05; ??P &amp;lt;0.01.

analysis allowed the identification of the best cut-off val-
ues in relation with all-cause mortality for plain X-ray score
(SVCS &gt;3), PWV (&gt;10.5 m/s) and PP (&gt;70 mmHg). These
cut-off values were used to compare groups in univariate
analysis and to compare survival.

Statistical analyses were performed with the SPSS sys-
tem 15.0 (SPSS Inc., Chicago, IL, USA) and with the Med-
calc program version 6.0 (Medcalc software, Mariakerke,
Belgium). For all comparisons and statistical tests, a P-
value &amp;lt;0.05 implied the rejection of the null hypothesis
and the result was considered statistically significant.

Results

Descriptive and univariate analysis

In this group of 101 patients, vascular calcifications were
present in 77 patients. A SVCS &gt; 3, a PWV &gt; 10.5 m/s
and a PP &gt; 70 mmHg were observed in 59, 42 and 33 pa-
tients, respectively. In univariate analysis (Table 1), higher
PWV, higher PP and higher vascular calcification score
were associated with older age and with higher prevalence

Fig. 1. A simple vascular calcification score &gt;3 was associated with
higher pulse wave velocity and with higher pulse pressure.

of diabetes, vascular disease and all-cause mortality. The
calcium carbonate dose was correlated with systolic pres-
sure (r = 0.277; P = 0.005) and with PP (r = 0.226; P =
0.023). Patients with SVCS &gt; 3, when compared with pa-
tients with SVCS ? 3, had a higher PWV (11.2 ± 1.9 versus
9.3 ± 1.5 m/s; P &amp;lt;0.001) and a higher PP (68.2 ± 20.4
versus 54.3 ± 13 mmHg, P &amp;lt;0.001) (Figure 1).



1000 T. Adraga?o et al.

Table 2. Vascular calcification and arterial stiffness (linear regression)

Dependent variable Independent variables B CI Significance R2

Age 0.055 0.032–0.079&amp;lt;0.001
Pulse wave velocity (all patients) Systolic pressure 0.021 0.007–0.035 0.004 0.424

SVCS &gt;3 0.845 0.074–1.615 0.032

Diabetes 10.102 0.926–19.278 0.031
Pulse pressure (all patients) Calcium carbonate (g/day) 3.281 0.844–5.719 0.009 0.268

SVCS &gt;3 10.103 2.315–17.890 0.012

SVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity.

Fig. 2. ROC curves of simple vascular calcification score, pulse wave
velocity and pulse pressure in relation with all-cause mortality.

Factors independently associated with PWV and with PP

In all patients, using linear regression with the enter method
and adjusting for multiple factors (Table 2), a higher vas-
cular calcification score was directly associated with PWV
(P = 0.032) and with PP (P = 0.012). Other factors ex-
plaining PWV were age (P &amp;lt;0.001) and systolic pressure
(P = 0.004). Diabetes (P = 0.031) and calcium carbonate
dose (P = 0.009) were directly associated with PP.

ROC curve analysis of mortality

During a 43-month observational period, 31 (30.7%) pa-
tients died. All-cause mortality was associated with a SVCS
&gt;3 (AUC = 0.701; 95% CI [0.602–0.788]; 84% sensitiv-
ity, 53% specificity, 88% negative predictive value and 1.78
positive likelihood ratio), with a PWV &gt;10.5 m/s (AUC =
0.738; 95% CI [0.641–0.820]; 71% sensitivity, 69% speci-
ficity, 85% negative predictive value and 2.26 positive like-
lihood ratio) and with a PP &gt;70 mmHg (AUC = 0.640;
95% CI [0.539–0.733]; 48% sensitivity, 81% specificity,
78% negative predictive value and 2.61 positive likelihood
ratio) (Figure 2). There was no difference in the AUC be-
tween ROC curves.

Cumulative survival and all-cause mortality risk

Lower cumulative survival (Figure 3) was observed in pa-
tients with a SVCS &gt;3 (32.7 versus 40.8 months; log

rank = 10.8; P = 0.001), with a PP &gt;70 mmHg (30.9
versus 38.8 months; log rank = 10.8; P = 0.001) and with
a PWV &gt;10.5 m/s (31.3 versus 39.3; log rank = 13.3;
P &amp;lt;0.001). In diabetic patients, higher PWV was not as-
sociated with higher mortality: 4 deaths in 6 patients with
PWV ?10.5 m/s (67%) versus 8 deaths in 13 patients with
PWV &gt;10.5 m/s (62%). In Cox regression analysis, using
the enter method (Table 3), the mortality-adjusted hazard
ratio was 3.308 (P = 0.032) for SVCS &gt;3, 3.227 (P =
0.031) for PP &gt; 70 mmHg in all patients and was 2.981
(P = 0.047) for PWV &gt;10.5 m/s in non-diabetic patients.
Entering vascular calcification score, PWV and PP in the
same model and using the enter method, SVCS &gt; 3 (HR =
4.247, P = 0.015), PP &gt; 70 mmHg (HR = 3.795, P =
0.031), lower BMI (HR = 0.856, P = 0.017) and vascular
disease at baseline (HR = 2.551, P = 0.047) were associ-
ated with mortality (Table 4).

Discussion

In general population, it was demonstrated that, in patients
older than 60 years of age, higher PP was associated with
higher cardiovascular risk [13]. In dialysis patients it was
demonstrated that a higher PP evaluated before or after HD
was associated with higher mortality in non-diabetic pa-
tients [14] or in all patients [15] and that higher aortic PWV
was associated with mortality [8]. Vascular calcifications,
evaluated by different methodologies [3–6,12], have been
associated with mortality in dialysis patients. In this study,
we tried to answer one of the research questions suggested
by the KDIGO Imaging Work Group: the evaluation of the
relationship between the radiological vascular calcification
assessment and the measurement of vascular stiffness by
PWV and by PP [7]. Vascular calcifications evaluated by ul-
trasonography have already been associated with increased
stiffness of large elastic-type arteries [10]. The Kauppila
score, [16] evaluating calcifications in the abdominal aorta,
which is an elastic artery, was the first plain X-ray calcifica-
tion score to be correlated with arterial stiffness, evaluated
by carotid-femoral PWV [11]. In this study, we used a SVCS
evaluated in plain X-ray of pelvis and hands that has been
previously associated with higher cardiovascular mortal-
ity, cardiovascular disease and cardiovascular hospitaliza-
tions [12]. We verified that this score, although evaluating
only muscular arteries, was associated both with carotid-
femoral PWV and with PP. In the same dialysis population,



Arterial stiffness and mortality in haemodialysis patients 1001

Table 3. Adjusted hazard ratio of all-cause mortality (Cox regression)

Independent variables B HR CI Significance

All patients SVCS &gt;3 1.196 3.308 1.109–9.863 0.032
All patients PP &gt;70 mmHg 1.171 3.227 1.114–9.347 0.031
Non-diabetic patients PWV &gt;10.5 m/s 1.092 2.981 1.013–8.775 0.047

SVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity; HR = adjusted hazard ratio.

Table 4. Predictors of all-cause mortality (Cox regression)

Dependent variable Independent variables B HR CI Significance

All-cause mortality (all patients) Age 0.004 1.004 0.966–1.044 0.824
HD duration (months) 0.000 0.999 0.992–1.006 0.805
Diabetes 0.348 1.416 0.508–3.948 0.506
Vascular disease at baseline 0.936 2.551 1.014–6.419 0.047
Systolic pressure (mmHg) ?0.022 0.978 0.955–1.002 0.077
Body mass index (kg/cm2) ?0.156 0.856 0.753–0.972 0.017
Calcium carbonate (g/day) ?0.100 0.905 0.651–1.259 0.554
Calcitriol (?g/week) ?0.161 0.851 0.455–1.594 0.615
SVCS &gt;3 1.446 4.247 1.319–13.673 0.015
PP &gt;70 mmHg 1.334 3.795 1.132–12.722 0.031
PWV &gt;10.5 m/s ?0.026 0.974 0.367–2.589 0.958

SVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity; HR = adjusted hazard ratio.

Fig. 3. A simple vascular calcification score &gt;3, a pulse wave velocity &gt;10.5 m/s and a pulse pressure &gt;70 mmHg were associated with lower survival.

higher vascular calcification score, higher PWV and higher
PP were associated with mortality with comparable hazard
ratios and with similar AUC in ROC curve analysis. In
our study, PWV was an independent predictor of mortality
only in non-diabetic patients, probably because, in diabetic
patients, mortality was equally high with higher or lower
PWV. In a study evaluating a large cohort of HD patients,
Tozawa et al. [14] observed that PP was also a predictor
of mortality only in non-diabetic patients. Covic et al. [9]
verified an opposite situation: in a group of young HD
patients with a low prevalence of cardiovascular disease,
arterial stiffness evaluated by the augmentation index was
not a predictor of mortality. PWV evaluation requires a spe-
cific device and is not widely available. In our study, simple
and inexpensive methods such as the evaluation of PP or
the assessment of the SVCS with plain X-ray were enough
to detect higher cardiovascular risk. Diagnosis of arterial
stiffness and vascular calcification has the advantage of
also providing important information that can be used for

guiding therapeutic intervention in dialysis patients. Identi-
fication of patients with higher PP may orientate the choice
of anti-hypertensive treatment with special indication for
inhibition of the renin–angiotensin axis and avoidance of
inappropriate reduction of diastolic blood pressure that may
threaten coronary reserve [17]. At the present time, it also
seems possible to interfere in some factors associated with
the development of vascular calcifications. Some studies
in dialysis patients have already demonstrated that vascular
calcifications may progress or remain stable depending on
the control of mineral metabolism alterations [5,18] and that
phosphate binder choice may have an impact on mortality
[5]. London et al. showed an association between vascular
calcifications and low bone turnover [19] and found a sig-
nificant interaction between calcium-containing phosphate
binders and aortic calcification and stiffness in the presence
of adynamic bone disease [20]. The presence or extension of
vascular calcifications may be an indication for an intensive
hyperphosphataemia control, for an adequate choice of



1002 T. Adraga?o et al.

phosphate binder and for avoidance of PTH oversuppres-
sion. In several studies, association of a calcium carbonate
dose with vascular calcifications [3–5,18,20,21] and with
PWV [8,20] has already been described and in our patients
we have also verified a correlation between the calcium
carbonate dose and PP. We have not verified any associ-
ation between calcium carbonate and calcitriol treatment
with survival.

Different methods can be used to evaluate vascular calci-
fications in dialysis patients. Electron beam computed to-
mography and multislice computed tomography are consid-
ered to be the gold standard for the evaluation of coronary
calcifications. They perform a quantitative assessment of
coronary calcification that permits the evaluation of calcifi-
cation progression but are very expensive. Screening vascu-
lar calcifications in dialysis patients may be performed by
different and inexpensive plain X-ray methods [4,11,12,22]
that have the advantage of being easily interpreted by the
attending physician. The SVCS and Kauppila score are
semi-quantitative scores with cut-off values associated with
higher cardiovascular risk. A cardiovascular calcification
index using the Kauppila score and valvular calcification
evaluated by echocardiography has been demonstrated to
be associated with coronary calcification in HD patients
[23]. Simpler methods to evaluate vascular calcifications
seem to be an attractive option but the final choice would
depend on the available tests and on the preference of the
nephrologist.

In summary, a SVCS evaluated in plain X-ray and PP
were associated with higher mortality in dialysis patients.
PWV was associated with higher mortality in non-diabetic
patients. In this study, we demonstrate that a SVCS evalu-
ated in plain X-ray of pelvis and hands is associated with the
arterial stiffness evaluated by PWV and PP. Identification of
vascular calcifications in dialysis patients is included in the
classification of CKD-MBD, and simple and inexpensive
plain X-ray methods are available for that purpose. Arterial
stiffness or the presence of vascular calcifications are an
alert sign for an increased mortality risk, and this informa-
tion may be relevant for guiding therapeutic intervention
in dialysis patients, such as selecting the most adequate
anti-hypertensive regimen or achieving an effective min-
eral metabolism management.

Conflict of interest statement. Teresa Adragao has received research grants
from Genzyme, has received lecture fees from Amgen, Genzyme, Abbot
and Novartis and consultancy fees from Genzyme and Abbot. The other
authors have no conflict of interest of any type (personal, commercial,
political, academic or financial) in the elaboration and presentation of this
work.

References

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardio-
vascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5
Suppl 3): S112–S119

2. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular
disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:
353–362

3. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial
stiffness, and cardiovascular risk in end-stage renal disease. Hyper-
tension 2001; 38: 938–942

4. London GM, Gue?rin AP, Marchais SJ et al. Arterial media calcifica-
tion in end-stage renal disease: impact on all-cause and cardiovascular
mortality. Nephrol Dial Transplant 2003; 18: 1731–1740

5. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary
calcification and phosphate binder choice in incident hemodialysis
patients. Kidney Int 2007; 71: 438–441

6. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high coronary
artery calcification score (CACS) on survival in patients on chronic
hemodialysis. Clin Exp Nephrol 2004; 8: 54–58

7. Moe S, Dru?eke T, Cunningham J et al. Kidney disease: improving
global outcomes (KDIGO). Definition, evaluation, and classification
of renal osteodystrophy: a position statement from kidney disease:
improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945–
1953

8. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness
on survival in end-stage renal disease. Circulation 1999; 99: 2434–
2439

9. Covic A, Mardare N, Gusbeth-Tatomir P et al. Arterial wave reflec-
tions and mortality in haemodialysis patients—only relevant in el-
derly, cardiovascularly compromised? Nephrol Dial Transplant 2006;
21: 2859–2866

10. Gue?rin AP, London GM, Marchais SJ et al. Arterial stiffening and
vascular calcifications in end-stage renal disease. Nephrol Dial Trans-
plant 2000; 15: 1014–1021

11. Raggi P, Bellasi A, Ferramosca E et al. Association of pulse wave
velocity with vascular and valvular calcification in hemodialysis pa-
tients. Kidney Int 2007; 71: 802–807

12. Adragao T, Pires A, Lucas C et al. A simple vascular calcification
score predicts cardiovascular risk in haemodialysis patients. Nephrol
Dial Transplant 2004; 19: 1480–1488

13. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood
pressure to coronary heart disease risk change with aging? The Fram-
ingham Heart Study. Circulation 2001; 103: 1245–1249

14. Tozawa M, Iseki K, Iseki C et al. Pulse pressure and risk of total mor-
tality and cardiovascular events in patients on chronic hemodialysis.
Kidney Int 2002; 61: 717–726

15. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse
pressure and mortality in patients undergoing maintenance hemodial-
ysis. JAMA 2002; 287: 1548–1555

16. Kauppila LI, Polak JF, Cupples LA et al. New indices to classify
location, severity and progression of calcific lesions in the abdominal
aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245–250

17. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal
patients: an update. Am J Kidney Dis 2005; 45: 965–977

18. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Seve-
lamer attenuates the progression of coronary and aortic calcification
in hemodialysis patients. Kidney Int 2002; 62: 245G–252G

19. London GM, Marty C, Marchais SJ et al. Arterial calcifications and
bone histomorphometry in end-stage renal disease. J Am Soc Nephrol
2004; 15: 1943–1951

20. London GM, Marchais SJ, Ge?rin AP et al. Association of bone activity,
calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc
Nephrol 2008; 19(9): 1827–1835

21. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcifica-
tion in young adults with end-stage renal disease who are undergoing
dialysis. N Engl J Med 2000; 342: 1478–1483

22. Okuno S, Maeno Y, Maekawa K et al. Presence of abdominal aortic
calcification is significantly associated with all-cause and cardiovas-
cular mortality in maintenance hemodialysis patients. Am J Kidney
Dis 2007; 49: 417–425

23. Muntner P, Ferramosca E, Bellasi A et al. Development of a cardiovas-
cular calcification index using simple imaging tools in haemodialysis
patients. Nephrol Dial Transplant 2007; 22: 508–514

Received for publication: 10.7.08
Accepted in revised form: 24.9.08



Revista Portuguesa de Nefrologia e Hipertensão 51

VASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS
IN HEMODIALYSIS PATIENTS

Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 51-56

INTRODUCTION

Intimal and medial calcification, the two main
types of arterial calcification, are associated,
respectively, with arteriosclerosis and medios-
clerosis. In non-dialysis patients, both intimal1
and medial calcification2 may be the result of an
active regulated process with different aetio-
logies, where local cells, such as macrophages
in the intima or vascular smooth cells in the
media, differentiate into osteoblasts3. In haemo-
dialysis patients it has also been demonstrated
that medial calcification is an active cellular pro-
cess, similar to bone formation4,5. Vascular
smooth muscle cells can differentiate into
osteoblasts due to different stimuli, some of
which may be hyperphosphatemia or hypercal-
cemia6. A passive calcification mechanism is,
however, not excluded. High calcium phospho-

Vascular calcification, cardiovascular risk and
arterial stiffness in hemodialysis patients

Teresa Adragão
Department of Nephrology. Hospital de Santa Cruz. Carnaxide. Portugal

Artigo Original

rus product may also contribute to the matrix
mineralization6. Reduction of calcification inhibi-
tors in dialysis patients, such as fetuin-A or
matrix-Gla protein, may be other factors asso-
ciated with the development of calcification7. It
has already been demonstrated that calcium
carbonate and calcium acetate are associated
with the progression of vascular calcification, a
phenomenon that can be attenuated or arrested
by sevelamer, a phosphorus binder that does
not increase calcium levels and also reduces
LDL-cholesterol8,9. In a rat model of hyperpa-
rathyroidism treatment with calcitriol or cina-
calcet reduced PTH but, unlike calcitriol,
cinacalcet did not produce hypercalcemia, in-
crease in calcium phosphorus product or aortic
calcification10.



Revista Portuguesa de Nefrologia e Hipertensão52

Teresa Adragão

VASCULAR CALCIFICATION AND
CARDIOVASCULAR RISK

Blacher et al.11 showed for the first time that
a vascular calcification score evaluated by B-
mode ultrasonography in large arteries was as-
sociated with an increased risk of mortality in
dialysis patients. Brawn et al.12 had previously
demonstrated that dialysis patients, when com-
pared with non-dialysis patients, presented a
higher coronary calcification score evaluated by
electron beam computed tomography (EBCT).
In general population this score, the Agatston
score, is mainly caused by intimal calcification
and is related with arteriosclerosis and coronary
stenosis13,14. The higher values of this score in
dialysis patients may be explained by the pre-
sence of both intimal and medial calcification.
Medial calcification is not occlusive but modi-
fies the properties of the arterial wall and may
also contribute to coronary ischemia. The quan-
titative significance of Agatston score may be
different from that described for the general
population where a score greater than 400 is
associated with a very high cardiovascular risk.
In a study evaluating 43 dialysis patients a mean
score of 559±255 was found in patients with
normal coronary angiographies while abnormal
coronary angiographies were associated with a
mean score of 2869±41715. In dialysis patients,
high values of Agatston score may occur in the
absence of occlusive coronary atherosclerosis16
but, like other calcification scores, Agatston
score was an independent predictor of death in
haemodialysis patients16. The discriminative sig-
nificance of Agatston score in dialysis patients
remains, however, to be identified.

Multislice computed tomography (MSCT)17
has already been employed for the diagnosis of
vascular calcifications in dialysis patients, but,
as well as EBCT, it is very expensive to be used
in a routine way. Evaluation of vascular calcifi-

cations in plain radiographs has been proposed
by KDOQI guidelines18. We have already veri-
fied that a simple vascular calcification score
based on plain radiographs of pelvis and hands
was a predictor of cardiovascular mortality, car-
diovascular hospitalizations and fatal and non-
fatal cardiovascular events19. Radial, iliac and
femoral arteries were the arteries evaluated for
the estimation of this score. This score may be
used as a simple and inexpensive tool for the
assessment of cardiovascular risk in haemodi-
alysis patients.

Development of a numeric cardiovascular
calcification index for cardiovascular risk evalua-
tion in dialysis patients has been recently sug-
gested20. The methodology recommended for
the assessment of this calcification index should
be non-invasive and low-cost, in order to be
widely accessible, such as conventional blood
pressure measurements for pulse pressure
evaluation, standard radiographs for vascular
calcifications assessment and echocardio-
graphy for valvular calcifications diagnosis.

Vascular11 and valvular21 calcification are de-
monstrated risk factors for cardiovascular death
in dialysis patients. Pulse pressure increase is
associated with vascular stiffness and has been
related with cardiovascular risk in general popu-
lation22 and in haemodialysis patients as well23.

We have developed, in a cohort of haemodi-
alysis patients, a combined cardiovascular
score based on pulse pressure and on vascu-
lar and valvular calcifications and compared it
with the previously described simple vascular
calcification score. This combined cardiovas-
cular score was a stronger predictor of cardio-
vascular risk than the simple vascular calcifica-
tion score24. We verified that the addition of a
valvular and of a pulse pressure score to the
simple vascular calcification score allowed a
more accurate prediction of cardiovascular risk
in this group of patients.



Revista Portuguesa de Nefrologia e Hipertensão 53

VASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS
IN HEMODIALYSIS PATIENTS

flection that finds the aortic valve still opened
and causes a systolic blood pressure increase
and a diastolic blood pressure decrease. In-
crease in systolic pressure provides an increase
in after load that can contribute to the develop-
ment left ventricular hypertrophy. Decrease in
diastolic pressure decreases coronary perfusion
which occurs during diastole and may aggra-
vate coronary ischemia.

Pulse pressure increase has already been
connected to cardiovascular risk in the general
population22 and in haemodialysis patients23.

Pulse wave velocity is also a marker of arte-
rial stiffness. The loss of elasticity of the arterial
wall increases the velocity of the blood flow
through the arterial system. Guérin et al de-
monstrated that, in haemodialysis patients, vas-
cular calcifications were associated with in-
creased stiffness of elastic type arteries like the
aorta and common carotid artery27. In this study
vascular calcifications were evaluated by ultra-
sonography. We have also verified in a cohort
of haemodialysis patients that the simple vas-
cular calcification score, assessed in plain ra-
diographs of hands and pelvis and evaluating
not elastic arteries but muscle arteries such as
radial, iliac and femoral arteries, was indepen-
dently and directly associated with pulse wave
velocity28. This study was another evidence of
the usefulness of this simple vascular calcifica-
tion score in this population.

PERIPHERAL ARTERY DISEASE
IN DIALYSIS PATIENTS

There is a remarkably high prevalence of
peripheral artery disease among patients with
renal insufficiency. Its prevalence may reach
24% of patients with creatinine clearance &amp;lt;60ml/
min versus 3.7% of persons with creatinine
clearance ³  60 ml/min29. Both moderate and

CLINICAL SIGNIFICANCE OF INTIMAL
AND MEDIAL CALCIFICATION IN
HAEMODIALYSIS PATIENTS

Intimal and medial calcifications are highly
prevalent in dialysis patients. Intimal calcifica-
tion corresponds to the type Vb of atheroscle-
rotic plaques (American Heart Association clas-
sification) and medial calcification is associated
with mediosclerosis. Standard radiographs can
be employed to differentiate these two different
types of arterial calcification25 since other more
sophisticated diagnostic techniques such as
ultrasonography, EBCT or MSCT can not dis-
criminate these calcification types. Using this
methodology, London et al. demonstrated that
intimal and medial calcification are independent
predictors of cardiovascular and all-cause death
in dialysis patients26. Intimal calcification was
associated with older age and lower survival
when compared with medial calcification. Me-
dial calcification was associated with haemo-
dialysis duration, diabetes, hyperphosphatemia
and with calcium carbonate dose treatment.

VASCULAR CALCIFICATION
CONTRIBUTES TO ARTERIAL STIFFNESS
IN HAEMODIALYSIS PATIENTS

Arterial stiffness is an alteration of the arte-
rial wall properties with multiple causes, some
of which are old age, diabetes, hypertension and
medial calcification. All these features are highly
prevalent in dialysis patients and arterial stiff-
ness is a common finding in this population.
Some of the manifestations of arterial stiffness
are isolated systolic hypertension, pulse pres-
sure increase and high pulse wave velocity.
Pulse pressure is the difference between
systolic and diastolic pressure. The arterial wall
stiffness creates an early aortic pulse wave re-



Revista Portuguesa de Nefrologia e Hipertensão54

Teresa Adragão

severe renal insufficiency are associated with
an increased risk of death in patients with pe-
ripheral artery disease30. In this study, the per-
centages of patients who presented with gan-
grene or ischemic ulceration rather than rest pain
increased with declining renal function. Lower
limb amputations are a major problem in dialy-
sis patients. Histological patterns found in 11
dialysis patients submitted to distal amputations
(figures 1 to 3) reflect the diversity of lesions
present in this population that may contribute to
the chronic distal artery disease31. Occlusive le-
sions consisted of luminal thrombi and choles-
terol emboli. Arteriosclerosis plaques and me-
dial calcification may be present in the same
patient and even in the same artery. In other
evaluation of 56 patients submitted to lower limb
amputations (non-published data) medial calci-
fication was present in 48% of the samples and
was associated with atherosclerotic plaques
type II or III (American Heart Association classi-
fication) in 50% of cases. In this group of pa-
tients submitted to lower limb amputations there
was no histological evidence of intimal calcifi-
cation in any sample. This data confirm the as-
sociation of medial calcification with distal ar-
tery disease. Dialysis vintage, diabetes, calcium

carbonate dose and hyperphosphatemia have
already been associated with medial calcifica-
tion26. In a registry study, hyperphosphatemia
was independently associated with future am-
putations32. These observations raise the hope
of modifying the evolution of peripheral artery
disease in dialysis patients by the correction of
some of these factors.

In summary, vascular calcifications are highly
prevalent in dialysis patients, and contribute to
cardiovascular mortality and morbidity. Plain

Fig. 1 – Muscular artery: cholesterol emboli. (Elastic van Giesen
x 100)

Fig. 2 – Exuberant medial calcification. (Hemotoxilin Eosin x
100)

Fig. 3 – Type II atherosclerosis lesion and medial calcification.
(Hemotoxilin Eosin x 100)



Revista Portuguesa de Nefrologia e Hipertensão 55

VASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS
IN HEMODIALYSIS PATIENTS

radiographs are a simple and inexpensive tool
for the assessment of cardiovascular risk. Ar-
teriosclerosis and mediosclerosis are the his-
tological setting for the development of vascu-
lar calcifications. Intimal calcification is asso-
ciated with arteriosclerosis and medial
calcification with mediosclerosis. In dialysis pa-
tients, medial calcification has been associated
with diabetes, dialysis vintage, hyperphos-
phatemia and treatment with calcium carbonate.
Decrease of calcification inhibitors facilitates this
process. Sevelamer can arrest vascular calci-
fication progression. In a rat model of hyperpa-
rathyroidism Cinacalcet, unlike calcitriol, was not
associated with vascular calcification develop-
ment. It is necessary to demonstrate that the
correction of those factors contributing to vas-
cular calcification is associated with a better car-
diovascular outcome in dialysis patients.

References

1. Shanahan CM, Cary NR, Metcalfe JC, Weissberg P. High
expression of genes for calcification-regulating proteins
in human atherosclerotic plaques. J Clin Invest 1994;
93:2393-40.

2. Parhami F, Bostrom K, Watson K, Demer LL. Role of mo-
lecular regulation in vascular calcification. J Atheroscler
Thromb 1996; 3:90-4

3. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds
M, Weissberg PL. Expression of mineralisation-regulating
proteins in association with human vascular calcification.
Z Kardiol 2000; 89 (Suppl 2) 63-8.

4. Jono S, McKee MD, Murry CE et al. Phosphate regulation of
vascular smooth muscle cell calcification. Circ Res 2000;
87:E10-7.

5. Moe SM, O’Neill KD, Duan D et al. Medial artery calcification
in ESRD patients is associated with deposition of bone
matrix proteins. Kidney Int 2002; 61:638-47.

6. Giachelli CM. Vascular calcification mechanisms. J Am Soc
Nephrol 15:2959-64.

7. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-
Dechent W, Floege J. Novel insights into uremic vascular
calcification: role of matrix Gla protein and alpha-2-
Heremans Schmid glycoprotein/fetuin. Blood Purif 2002;
20:473-6.

8. Chertow GM, Burke SK, Raggi P.Treat to Goal Working

Group. Sevelamer attenuates the progression of coro-
nary and aortic calcification in hemodialysis patients. Kid-
ney Int 2002; 62:245-52.

9. Chertow GM, Raggi P, McCarthy JT et al. The effects of
sevelamer and calcium acetate on proxies of atheroscle-
rotic and arteriosclerotic vascular disease in hemodialysis
patients. Am J Nephrol 2003; 23:307-14.

10 . Henley C, Colloton M, Cattley RC et al. 1,25-
Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar_/
Mimpara_) treatment mediates aortic calcification in a rat
model of secondary hyperparathyroidism. Nephrol Dial
Transplant 2005; 20: 1370-7

11. Blacher J, Guérin AP, Pannier B, Marchais SJ, London GM.
Arterial calcifications, arterial stiffness, and cardiovascu-
lar risk in end-stage renal disease. Hypertension 2001;
38: 938–942.

12. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft
FC. Electron beam computed tomography in the evaluation
of cardiac calcification in chronic dialysis patients. Am J
Kidney Dis 1996; 27:394-401.

13. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantifica-
tion of coronary artery calcium using ultrafast computed
tomography. J Am Coll Cardiol 1990; 15:827-32.

14. Bielak LF, Rumberger JA, Sheedy PF, et al. Probabilistic model
for prediction of angiographically defined obstructive coro-
nary artery disease using electron beam computed tomog-
raphy score strata. Circulation 2000; 102:380-85.

15. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M,
Goldsmith DJ. Coronary artery calcification is related to
coronary atherosclerosis in chronic renal disease patients:
a study comparing EBCT-generated coronary artery cal-
cium scores and coronary angiography. Nephrol Dial Trans-
plant 2004; 2307-12. Epub 2004 Jun 22.

16. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high
coronary artery calcification score (CACS) on survival in
patients on chronic hemodialysis. Clin Exp Nephrol 2004;
8:54-8.

17. Moe SM, O’Neill KD, Fineberg N et al. Assessment of vas-
cular calcification in ESRD patients using spiral CT. Nephrol
Dial Transplant 2003; 18:1152-8.

18. KDOQI Clinical Practice Guidelines for Bone Metabolism
and Disease in Chronic Kidney disease. Am J Kidney Dis
2003; 42 (Suppl 3).

19. Adragao T, Pires A, Lucas C et al. A simple vascular calci-
fication score predicts cardiovascular risk in hemodialysis
patients. Nephrol Dial Transplant 2004; 19: 1480-88.

20. Moe SM, Drueke TM. Special report: controversies in bone
and mineral metabolism in chronic kidney disease. Vascu-
lar calcification in chronic kidney disease. Am J Kidney
Dis 2004; 43:572-9.

21. Wang AY, Wang M, Woo J et al. Cardiac valve calcification
as an important predictor for all-cause mortality and car-
diovascular mortality in long-term peritoneal dialysis pa-
tients: a prospective study. J Am Soc Nephrol 2003; 14:
159-68.



Revista Portuguesa de Nefrologia e Hipertensão56

Teresa Adragão

22. Franklin S, Larson MG, Khan SA et al. Does the relation of
blood pressure to coronary heart disease risk change
with aging? The Framingham heart study. Circulation 2001;
103: 1245-9.

23. Klassen PS, Lowrie EG, Reddan DN et al. Association
between pulse pressure and mortality in patients under-
going maintenance hemodialysis. J Am Med Assoc 2002
287: 1548-55.

24. Adragao T, Pires A, Macedo A et al. A New Cardiovascu-
lar Calcification Index is an Independent Predictor of Car-
diovascular Risk In Hemodialysis Patients. J Am Soc
Nephrol 15: 2004 174A F-PO491(Abstract).

25. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M.
Medial artery calcification. A neglected harbinger of car-
diovascular complications in non-insulin-dependent dia-
betes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:
978-83.

26. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B,
Adda H. Arterial media calcification in end-stage renal dis-
ease: impact on all-cause and cardiovascular mortality.
Nephrol Dial Transplant 2003; 18:1731-40.

27. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial
stiffening and vascular calcificatins in end–stage renal
disease. Nephrol Dial Transplant 2000; 15: 1014-21

28. T Adragao, A Pires, C Lucas et al. Pulse wave velocity
correlates with simple vascular calcification score in
hemodialysis patients. Nephrol. Dial. Transplant 2003; 18
(suppl 4): 702 (Abstract  W487).

29. O’Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence
of peripheral arterial disease in persons with renal insuffi-
ciency: results from the National Health and Nutrition Exami-
nation Survey 1999-2000. Circulation 2004; 109:320-3.

30. O’Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM.
Impact of renal insufficiency on mortality in advanced lower
extremity peripheral arterial disease. J Am Soc Nephrol
2004;16:514-9

31. Gouveia R, Birne R, Adragao T, Pina A, Nogueira A, Pais M
J, Messias H, Martins AP. Histological vascular patterns in
lower limb amputations in hemodialysis patients. Nephrol
Dial Transplant EDTA 2004 abstract book, page 141
(SP370).

32. O’Hare AM, Bacchetti P, Segal M, Hsu CY, Johansen KL;
Dialysis Morbidity and Mortality Study Waves. Factors as-
sociated with future amputation among patients undergo-
ing hemodialysis: results from the Dialysis Morbidity and
Mortality Study Waves 3 and 4. Am J Kidney Dis 2003;
41:162-70



57

CAPÍTULO 5

CALCIFICAÇÃO VALVULAR CARDÍACA NOS DOENTES EM DIÁLISE

A calcifi cação valvular cardíaca foi durante muito tempo considerada um processo 
degenerativo passivo de lesão valvular. Contudo, nos últimos anos foram identifi cados 
mecanismos de calcifi cação valvular associados a um fenómeno de ativação osteoblástica. 
Vários fatores habitualmente expressos nos osteoblastos foram também identifi cados em 
válvulas cardíacas calcifi cadas, como osteopontina1, BMP (bone morphogenic protein) 2 e 
4,2 ou Runx2 (runt related transcription factor 2) e osterix3. Em alguns casos foram mesmo 
identifi cadas verdadeiras zonas ossifi cadas com formação de osso lamelar apresentando 
atividade osteoblástica e osteoclástica, traduzindo a existência de remodelação óssea2. 
Atualmente considera -se que a calcifi cação valvular cardíaca não é um processo passivo mas 
ativo que resulta da mutação fenotípica de células valvulares locais ainda não identifi cadas, 
provavelmente miofi broblastos ou pericitos que se transformam em osteoblastos2,3. Os 
mecanismos responsáveis por estas alterações ainda não são totalmente conhecidos, mas 
apresentam algumas semelhanças com o processo aterogénico vascular. Estas lesões valvulares, 
como as lesões ateroscleróticas, podem ser precedidas por ruptura da membrana basal, 
infi ltração por células infl amatórias, depósito de lípidos e podem estar associadas a diabetes, 
hipercolesterolemia, hipertensão arterial ou consumo de tabaco4. Esta formação de tecido 
ósseo descrito nas válvulas cardíacas calcifi cadas assemelha -se ao processo de calcifi cação 
ativa também descrito nas artérias e resultante da transformação das células musculares lisas 
em osteoblastos5.

A prevalência de calcifi cações valvulares é elevada nos doentes em diálise, variando entre 
32% e 47% em diferentes estudos6 -9. Na população geral10 e também nos doentes em diálise7 -9 
comprovou -se que as calcifi cações valvulares se associam a mortalidade mais elevada. Nos 
doentes em diálise já foi demonstrado que a presença de calcifi cações valvulares se associa a 
marcadores clássicos de aterosclerose como o aumento da espessura íntima -média carotídea, 
placas carotídeas e aumento da proteína C -reactiva11, mas as alterações do metabolismo 
fosfocálcico também parece estarem implicadas, como foi demonstrado por Ribeiro S, et al6.

Num grupo de 127 doentes em hemodiálise analisamos a prevalência das calcifi cações 
das válvulas aórtica e mitral, o risco de mortalidade destas calcifi cações valvulares e a sua 
relação com as calcifi cações arteriais diagnosticadas pelo score de calcifi cação vascular 



58

simples12. As calcifi cações valvulares cardíacas mitrais ou aórticas foram diagnosticadas por 
ecocardiografi a e estavam presentes, respectivamente, em 37 (29%) e em 19 doentes (15%); 
39 doentes (31%) apresentavam calcifi cações valvulares. A presença de calcifi cações valvulares 
associou -se a menor sobrevida, avaliada ao longo de 48 meses (Fig 5.1).

Fig. 5.1. A presença de calcifi cações valvulares (CV+) associou -se a maior mortalidade de causa global ou 
cardiovascular (Kaplan Meier)

As calcifi cações vasculares avaliadas pelo score de calcifi cação vascular simples estavam 
presentes em 72% dos doentes. O score de calcifi cação vascular foi um preditor independente 
de calcifi cação das válvulas aórtica ou mitral. Por cada aumento de 1 ponto no score de 
calcifi cação houve um aumento, respectivamente, de 46% e de 66% de risco de apresentar 
calcifi cação valvular aórtica ou mitral. Verifi cou -se também uma associação direta entre os 
valores da paratormona e a calcifi cação da válvula aórtica e os valores do fósforo sérico e a 
calcifi cação da válvula mitral.

Estes dados sugerem que a calcifi cação valvular possa partilhar mecanismos patogénicos 
semelhantes aos da calcifi cação vascular e que nos doentes em diálise a calcifi cação valvular 
faça parte de um processo sistémico de calcifi cação.

As guidelines KDIGO 200913 consideram que o rastreio das calcifi cações nos doentes 
renais crónicos possa ser feito através de RX simples ou através da avaliação das calcifi cações 
valvulares por ecocardiografi a. A presença de calcifi cações vasculares ou valvulares identifi cam 
os doentes com maior risco cardiovascular, e esta informação pode ser usada para orientar a 



59

terapêutica nestes doentes. Podemos tentar corrigir os mecanismos associados ao 
desenvolvimento e progressão das calcifi cações, nomeadamente tentar corrigir as alterações 
do metabolismo fosfocálcico, entre outros. Verifi cámos que nos nossos doentes a prevalência 
de calcifi cações valvulares é bastante inferior à prevalência de calcifi cações vasculares. Em 
análise por curvas ROC, avaliamos que a presença de calcifi cações valvulares apresenta um 
valor preditivo positivo de 87% e preditivo negativo de 34% para indicar presença de 
calcifi cações vasculares. Isto signifi ca que, no caso de haver calcifi cações valvulares, existe 
87% de probabilidades de também haver calcifi cações vasculares. No caso de não haver 
calcifi cações valvulares, a probabilidade de não haver calcifi cações vasculares é de apenas 
34%. Esta limitação deve ser tida em consideração se só usarmos o ecocardiograma para 
rastreio das calcifi cações nos doentes em diálise, pois podemos subavaliar o risco cardiovascular 
destes doentes. O ecocardiograma não substitui a utilização do RX simples para identifi car 
o risco cardiovascular associado às calcifi cações.

Em resumo, o score de calcifi cação vascular simples foi um preditor independente de 
calcifi cações valvulares, sugerindo que o processo de calcifi cação cardiovascular é 
sistémico, podendo partilhar fatores patogénicos comuns. É provável que a terapêutica 
utilizada no controlo da progressão das calcifi cações vasculares possa também afetar a 
progressão das calcifi cações valvulares. É necessário avaliar se o manejo das alterações 
do metabolismo mineral e ósseo pode ter um papel na evolução e no prognóstico da 
calcifi cação valvular destes doentes. O estudo ADVANCE, apresentado durante o XLVVII 
ERA -EDTA Congress 2010, em Munique, demonstrou que a terapêutica com Cinacalcet, 
agente calcimimético usado no tratamento do hiperparatiroidismo secundário, e baixas 
doses de vitamina D se associaram a uma redução significativa da progressão das 
calcifi cações na válvula aórtica.

Referências

  1. O’Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular 
lesions. Circulation 1995;92:2163 -2168.

  2. Mohler ER, Gannon F, Reynolds C, et al. Bone formation and infl ammation in cardiac valves. 
Circulation 2001;103:1522 -1528.

  3. Alexopoulos A, Bravou V, Peroukides S, et al. Bone regulatory factors NFATc1 and osterix in 
human calcifi c aortic valves. Int J Cardiol 2008; 17.

  4. Goldbarg SH, Elmariah S, Miller MA, et al. Insights into degenerative aortic valve disease. J Am 
Coll Cardiol 2007; 25,50(13): 1205 -1213.

  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2564.



60

  6. Ribeiro S, Ramos A, Brandão A, et al. Cardiac valve calcifi cation in haemodialysis patients: role 
of calcium -phosphate metabolism. Nephrol Dial Transplant 1998 (8):2037 -2040.

  7. Wang AY, Wang M, Woo J, et al. Cardiac valve calcifi cation as an important predictor for all -cause 
mortality and cardiovascular mortality in long -term peritoneal dialysis patients: a prospective 
study. J Am Soc Nephrol 2003; 14(1):159 -168.

  8. Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve 
calcium with coronary artery disease, atherosclerotic vascular disease, and all -cause mortality in 
137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 15;95(6):742-
-743.

  9. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcifi cation predicts mortality and coronary 
artery disease in end stage renal disease. Atherosclerosis 2007;191(2):348 -354.

10. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic -valve sclerosis 
with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142 -147.

11. Wang AY, Ho SS, Wang M, et al. Cardiac valvular calcifi cation as a marker of atherosclerosis and 
arterial calcifi cation in end -stage renal disease. Arch Intern Med 2005; 14;165(3):327 -332.

12. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. Vascular and 
valvular calcifi cations in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 
21(4): 293 -300.

13. KDIGO, Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global 
outcomes (KDIGO). Kidney Int 2009; 76 (Suppl):S113.



293

ABSTRACT

Osteoblastic bone formation has been described
in cardiac valves resembling the active calcification
process already demonstrated in arteries, in relation
to osteoblastic transformation of vascular smooth
muscle cells. The aim of our study was to evaluate
the mortality risk of cardiac valvular calcification in
haemodialysis patients and to analyse the associa-
tion of valvular calcification with arterial vascular cal-
cification. Valvular calcification (VC) was diagnosed
by B-Mode echocardiography. A simple vascular cal-
cification score (SVCS) was evaluated in plain X-ray
of hands and pelvis (0-8). We studied 127 prevalent
HD patients (75 males and 52 females) with a mean
HD duration of 48±53 months. Aortic VC (AVC) was
diagnosed in 19 patients (15%), mitral VC (MVC) in
37 patients (29%) and AVC or MVC in 39 patients
(31%); SVCS &gt; 0 was diagnosed in 91 patients (71%)
and SVCS ? 3 in 63 patients (50%). After 48 months
follow-up there were 43 all cause deaths and 21 car-
diovascular deaths. Vascular and all valvular calcifi-
cations were associated with lower cumulative sur-
vival. The adjusted risk of all cause death was 3.7
fold higher in AVC (p&lt;0.001). For each unit increment
of the SVCS there was 56% increase in cardiovascu-
lar death risk (p&lt;0.001). SVCS was associated with
aortic (p=0.002) and mitral (p&lt;0.001) valvular cal-
cification. In conclusion, in these patients valvular
and vascular calcifications were independent predic-
tors of mortality. Vascular calcification was independ-
ently associated with cardiac valvular calcification,

suggesting that these two types of calcification may
share common characteristics.

Key-Words:
Haemodialysis; mortality; valvular calcification; vas-
cular calcification.

INTRODUCTION

Vascular calcifications are highly prevalent in dial-
ysis patients and have been associated with an
increased risk of total and cardiovascular death1.
Some mechanisms linking vascular calcifications with
cardiovascular risk, such as the association between
vascular calcifications and arterial stiffness, have
already been recognised2. Loss of arterial distensi-
bility is associated with increased pulse pressure3,
left ventricular hypertrophy and decrease of coro-
nary perfusion during diastole. It has been demon-
strated that vascular calcification in dialysis and non-
dialysis patients is an active cellular process, similar
to bone formation4-6. Vascular smooth muscle cells
can differentiate into osteoblasts due to different
stimuli, which, in dialysis patients, may be hyper-
phosphataemia and hypercalcaemia7. Reduction of
calcification inhibitors, such as fetuin-A or matrix-
Gla protein, may be another factor associated with
the development of calcification8. Valvular calcifica-
tion is an independent predictor of cardiovascular
death in the general population9 and ectopic bone

Vascular and valvular calcifications
in dialysis patients: the same
pathogenesis?

Teresa Adragão, Ana Pires, Carlos Lucas, Rita Birne, Luís Magalhães, Margarida Gonçalves, Acácio Pita Negrão

Gambro-Healthcare, Nefroclinica. Estoril, Portugal

Port J Nephrol Hypert 2007; 21(4): 293-300

Received for publication: 31/05/2007

Accepted in revised form: 11/09/2007

ORIGINAL ARTICLE



294 Port J Nephrol Hypert 2007; 21(4): 293-300

formation has been also identified, most likely orig-
inating from differentiated myofibroblasts10, resem-
bling the active calcification process already demon-
strated in arteries. It has already been demonstrated
that valvular calcification is also a predictor of car-
diovascular mortality in peritoneal dialysis patients11.
The aim of this study was to evaluate in a group
of haemodialysis patients the risk of all cause death
and of cardiovascular death related to cardiac valvu-
lar calcification and to analyse the association of car-
diac valvular calcification with arterial vascular cal-
cification.

PATIENTS AND METHODS

Study design

An observational, prospective, single-centre study
of a cohort of prevalent haemodialysis patients was
used.

Population

One hundred and twenty seven patients, 75
males and 52 females, without previous parathy-
roidectomy were evaluated. Twenty six patients
(21%) were diabetic. At baseline, mean age was
62±15 years (24-91) and mean haemodialysis dura-
tion was 47±56 months (4-271). During an obser-
vational period of 48 months, 43 patients (34%)
died. The diagnosis of vascular disease at base-
line was based on previous clinical manifestations
and test results. Coronary artery disease was diag-
nosed if the patient had typical angina pectoris, a
positive stress test, suffered a myocardial infarc-
tion, or underwent a percutaneous coronary inter-
vention or coronary bypass surgery. Diagnosis of
cerebral vascular disease was based on the occur-
rence of stroke or transient ischaemic attack or the
detection of an old cerebral infarction in comput-
ed tomography. Peripheral arterial disease was diag-
nosed if there was claudication, ischaemic ulcers,
lower limbs amputation, revascularisation or diag-
nosis of obstruction by Doppler or angiography.
Coronary artery disease was diagnosed in 33
patients (25%). Peripheral artery disease was pres-
ent in 17 patients (13%) and 6 patients (5%) had
had a previous stroke. 

Vascular and valvular calcifications

Vascular calcifications were evaluated in plain X-ray
of pelvis and hands by a method previously described12.
Pelvis films were divided into four sections by two imag-
inary lines: a horizontal line over the upper limit of both
femoral heads and a median vertical line over the ver-
tebral column (Fig. 1). Hand films were divided for each

Teresa Adragão, Ana Pires, Carlos Lucas, Rita Birne, Luís Magalhães, Margarida Gonçalves, Acácio Pita Negrão

Figure 1

Ileo-femoral score evaluates the presence of vascular calcifications in iliac and

femoral arteries. Calcification score is the sum of the presence (1) or absence

(0) of vascular calcifications. In this example, pelvis score (1+1+1+1) = 4

Figure 2

Hand score evaluates the presence of vascular calcifications in radial and

digital arteries. In this example hand score (1+1+1+1) = 4. Total score is

the sum of pelvis and hand score (8)



Port J Nephrol Hypert 2007; 21(4): 293-300 295

hand by a horizontal line over the upper limit of the
metacarpal bones (Fig. 2). Pelvis films evaluated iliac
and femoral arteries (ileo-femoral score) and hand films
evaluated radial and digital arteries (hand score). Any
vascular calcification lining the vessel walls either in an
irregular pattern or in a linear pattern was considered.
The presence of vascular calcifications in each section
was rated as 1 and its absence as 0. Final score was
the sum of all sections and ranged from 0 to 8.

Valvular calcifications of mitral and aortic valve
were assessed with B-mode Echocardiography 

Biochemical analysis

Serum levels of the following biochemical param-
eters were evaluated and time averaged for the 6
months preceding the evaluation of vascular and
valvular calcifications: Ca, P, CaxP product, alkaline
phosphatase, albumin, total iPTH. Total iPTH was
evaluated every three months by immunochemilumi-
nescence using a second generation assay.

Statistical analysis

Data are expressed as frequencies for categorical
variables, mean values with SD for normally distrib-
uted variables. Comparison between groups was per-
formed by Mann-Whitney U and chi-square tests. Multi-
variate analysis was performed by Binary logistic
Regression Models. Survival evaluation was performed
with Cox regression models. Survival curves were per-
formed using Kaplan Meyer with evaluation of log rank.
Variables entered in multivariate analysis were age, gen-
der, haemodialysis duration, diabetes, CaxP, iPTH, albu-
min, cardiovascular disease at baseline and vascular
and valvular calcifications. Statistical analyses were per-
formed with the SPSS system 14.0 (SPSS Inc.,
Chicago,IL) and the Medcalc program version 6.0 (Med-
calc software; Mariakerke, Belgium). For all comparisons,
a P value&amp;lt;0.05 was considered statistically significant.

RESULTS

During an observational period of 48 months there
were 43 all-cause deaths (34%) and 21 (17%) car-
diovascular deaths and 34 patients (27%) needed 

cardiovascular hospitalisations. Demographic and bio-
chemical values of the whole group are shown in Table
1. Aortic and mitral valvular calcification were detect-
ed in 19 (15%) and in 37 (29%) patients respective-
ly. Aortic or mitral calcifications were detected in 39
patients (31%). Presence of vascular calcifications was
identified in 91 patients (72%). A simple vascular cal-
cification score (svcs) ? 3 was observed in 63 patients
(49.6%). Mean calcium carbonate dose was 2.1±1.01
g/day. Thirty three patients (26%) were treated with
calcitriol and the mean dose was 1.54±1.01 ?g / week.

Demographic, biochemical parameters and calci-
fications (Table I)

Haemodialysis duration was longer in patients with
aortic and mitral calcification (Table I). All cause death
and cardiovascular death were more frequent in
patients with valvular or vascular calcifications (Table
I). Other demographic or biochemical parameters were
not different in patients with or without valvular and
vascular calcifications.

Mean Survival and Cumulative Survival 

All cause death (Table II; Fig. 3) and cardiovascular
death (Table III; Fig. 4) were responsible for significant
lower mean survival and lower cumulative survival in
patients with valvular and vascular calcifications. 

Mortality risk of valvular and vascular calcifica-
tions (Table IV)

In separate Cox regression models, in all patients,
adjusting for age, gender, HD duration, diabetes,
iPTH, CaxP product, albumin and cardiovascular dis-
ease at baseline, the mortality risk for each type of
valvular calcification and for the vascular calcifica-
tion score was evaluated (Table IV). The adjusted risk
of all cause death and of cardiovascular death was,
respectively, 3.8 and 2.6 fold higher in patients with
aortic valvular calcification. The adjusted risk of all
cause death and of cardiovascular death was, respec-
tively, 2.4 and 2.9 fold higher in patients with mitral
valvular calcification. In non-diabetic patients, mitral
valvular calcification and mitral or aortic valvular cal-
cification were also associated with increase in all-
cause mortality (Table IV).

Vascular and valvular calcifications in dialysis patients: the same pathogenesis?



296 Port J Nephrol Hypert 2007; 21(4): 293-300

Table I

Valvular Calcifications

All Patients
Aortic Valve Mitral Valve Aortic or Mitral Valve

N=127
AVC=0 AVC&gt;0 MVC=0 MVC&gt;0 AMVC=0 AMVC&gt;0

N=108 N=19 N=89 N=38 N=87 N=40

Age 62±15 61±15 66±12 61±15 65±14 61±15 65±14

Male gender 75 (59%) 65 (60%) 10 (53%) 57 (63%) 18 (49%) 56 (64%) 19 (49%)

Diabetes 26 (21%) 23 (21%) 3 (16%) 18 (20%) 8 (22%) 18 (21%) 8 (21%)

HD duration (months) 48±53 44±52 65±49* 38±42 71±66** 38±42 69±66*

Ca (mg/dL) 9.9±0.7 9.9±0.8 10±0.6 9.9±0.8 10.0±0.6 9.9±0.8 10.0±0.6

P (mg/dL) 4.9±1.4 4.8±1.4 5.3±1.3 4.8±1.4 5.2±1.4 4.8±1.4 5.2±1.4

CaXP (mg2/dL2) 49.3±15.6 48.6±15.7 53.6±14.0 47.7±15.6 53.2±15.0 47.8±15.6 52.7±15.1

iPTH (pg/mL) 302±380 272±313 476±624 315±394 273±347 287±320 337±492

AP (ng/mL) 30.0±22.4 30.1±23.3 29.2±17.4 30.9±22.3 28.1±23.1 30.9±22.3 28.1±23.1

Albumin (g/L) 3.7±0.3 3.7±0.3 3.7±0.3 3.7±0.3 3.7±0.3 3.7±0.3 3.7±0.3

CaCO3 dose (g/day) 2.1±1.5 2.2±1.5 1.6±1.4 2.2±1.6 1.9±1.3 2.2±1.6 1.8±1.3

Ejection fraction (%) 38±7 38±6 38±7 37±6 38±7 38±6 38±7

LVPW (mm) 10.2±1.8 10.3±1.6 9.5±3.4 10.3±1.6 10±2.5 10.2±1.6 10.1±2.5

All cause death 43 (34%) 32 (30%) 11 (58%)* 24 (27%) 19 (51%)* 24 (27%) 19 (49%)*

Cardiovascular death 21 (17%) 15 (14%) 6 (32%) 10 (11%) 11 (30%)* 10 (11%) 11 (28%)*

Cardiovascular hospitalisation 34 (27%) 26 (24%) 8 (42%) 17 (19%) 17 (46%)** 17 (19%) 17 (44%)**

SVCS &gt; 0 91 (72%) 74 (69%) 17 (90%) 58 (64%) 33 (89%)** 57 (65%) 34 (87%)*

SVCS ? 3 63 (50%) 49 (45%) 14 (74%)* 37 (41%) 26 (70%)** 37 (42%) 26 (67%)*

*p&lt;0.05; **p&lt;0.01

Comparison between means: Mann-Whitney U; comparison between frequencies: chi-square. SVCS, simple vascular calcification score; AVC, aortic valve calcification; MVC, mitral

VC; AMVC, aortic or mitral VC; LVPW left ventricular posterior wall

Table II

All cause mortality (Kaplan Meier)

Aortic Valve Mitral Valve Aortic or Mitral Valve Plain X-ray score
AVC=0 AVC&gt;0 MVC=0 MVC&gt;0 AMVC=0 AMVC&gt;0 SVCS=0 SVCS&gt;0

N=108 N=19 N=90 N=37 N=88 N=39 N=36 N=91

Number of events 32 11 24 19 24 19 6 37

Mean survival (SE), months 40.0 (1.2) 34.5 (3.2) 41.1 (1.2) 34.5 (2.3) 40.9 (1.3) 35.2 (2.3) 42.4 (1.9) 37.9 (1.4)

Cum. survival (%) 70% 42% 73% 49% 73% 51% 83% 59%

Log Rank 5.78 7.75 5.94 5.48

Sig. 0.016 0.005 0.015 0.019

AVC, aortic valve calcification; MVC, mitral VC; AMVC, aortic or mitral VC; SVCS, simple vascular calcification score

Table III

Cardiovascular mortality (Kaplan Meier)

Aortic Valve Mitral Valve Aortic or Mitral Valve Plain X-ray score Plain X-ray score
AVC=0 AVC&gt;0 MVC=0 MVC&gt;0 AMVC=0 AMVC&gt;0 SVCS=0 SVCS&gt;0 SVCS&lt;3 SVCS?3

N=108 N=19 N=90 N=37 N=88 N=39 N=36 N=91 N=64 N=63

Number of events 15 6 10 11 10 11 20 1 4 17

Mean survival (SE), months 43.6 (0.8) 40.1 (2.8) 44.5 (0.8) 39.4 (2.1) 44.5 (0.8) 39.8 (2.0) 46.1 (0.8) 41.8 (1.1) 45.5 (0.8) 40.8 (1.5)

Cum. survival (%) 85% 61% 88% 65% 87% 68% 97% 75% 93% 71%

Log Rank 4.30 7.97 6.54 6.22 8.78

Sig. 0.038 0.005 0.011 0.010 0.003

AVC, aortic valve calcification; MVC, mitral VC; AMVC, aortic or mitral VC; SVCS, simple vascular calcification score

Teresa Adragão, Ana Pires, Carlos Lucas, Rita Birne, Luís Magalhães, Margarida Gonçalves, Acácio Pita Negrão



Port J Nephrol Hypert 2007; 21(4): 293-300 297

Factors independently associated with mortality
and morbidity (Table V)

In a Cox regression model adjusting also for all types
of valvular calcification and simple vascular calcification score,
factors associated with all cause mortality, cardiovascular

mortality and cardiovascular hospitalisations were
identified (Table V). Aortic valvular calcification was
directly associated with all cause mortality (HR = 3.72,
95% CI = 1.81 to 7.66, p&lt;0.001). The risk of all cause
death was 3.7 fold higher in patients with aortic valvu-
lar calcification. Simple vascular calcification score was

Figure 3

Lower survival in relation to all cause death in patients with valvular

calcification (VC)

Figure 4

Lower survival in relation to cardiovascular death in patients with valvu-

lar calcification (VC)

Table IV

Mortality risk of each valvular calcification and vascular calcification score (Cox Regression)

Dependent variable Independent variables B Sig. H.R. 95% CI
Aortic valvular calcification 1.32&amp;lt;0.001 3.8 1.83 to 7.76

All cause mortality
Mitral valvular calcification 0.89 0.004 2.4 1.32 to 4.50

Aortic or Mitral valvular calcification 0.93 0.003 2.5 1.36 to 4.67

All patients
Vascular calcification score 0.19 0.003 1.2 1.06 to 1.39

Aortic valvular calcification 0.96 0.047 2.6 1.01 to 6.77

Cardiovascular mortality
Mitral valvular calcification 1.17 0.008 3.2 1.36 to 7.58

Aortic or Mitral valvular calcification 1.07 0.015 2.9 1.23 to 6.84

Vascular calcification score 0.45&amp;lt;0.001 1.6 1.26 to 1.95

Non- diabetic All cause mortality
Mitral valvular calcification 0.92 0.009 2.5 1.22 to 5.04

patients
Aortic or Mitral valvular calcification 0.88 0.014 2.4 1.19 to 4.82

Cardiovascular mortality Vascular calcification score 0.64&amp;lt;0.001 1.89 1.38 to 2.58

Results are adjusted for age, HD duration, diabetes, iPTH, Ca x P product, albumin and vascular disease at baseline. Vascular calcification score and each valvular calcification

were evaluated in separate models.

Vascular and valvular calcifications in dialysis patients: the same pathogenesis?



298 Port J Nephrol Hypert 2007; 21(4): 293-300

directly associated with cardiovascular death (HR=1.56,
95% CI = 1.25 to 1.94, p&lt;0.001) and with cardiovascu-
lar hospitalizations (HR=1.34, 95% CI = 1.13 to 1.59,
p=0.001). For each unit increment of the simple vas-
cular calcification score there was a 56% increase of
cardiovascular death risk. PTH (p=0.04) was a nega-
tive predictor of all-cause mortality. Albumin was a neg-
ative predictor of all-cause mortality (p&lt;0.001) and of
cardiovascular hospitalisations (p=0.02). Diabetes (p=0.018)
and CaxP product (p=0.001) were directly associated
with cardiovascular hospitalisations.

Factors independently associated with valvular
or vascular calcifications (Table VI)

The simple vascular calcification score was an inde-
pendent predictor of aortic valvular calcification (p=0.002),
mitral valvular calcification (p&lt;0.001) or any valvular cal-
cification (p&lt;0.001). For each unit increase in vascular score

there was, respectively, a 46% and a 66% increase in aor-
tic and mitral valvular calcification risk (Table VI). PTH was
directly associated with aortic valvular calcification
(p=0.02). HD duration was directly associated with mitral
valvular calcification (p=0.003) or any valvular calcifica-
tion (p=0.01). Male gender was directly associated with
mitral valvular calcification (p=0.005) or any valvular cal-
cification (p=0.006). Phosphorus levels were directly asso-
ciated with mitral valvular calcification (p=0.04). Age
(p=0.001), diabetes (p=0.01) and HD duration (p=0.01)
were associated with simple vascular calcification score. 

DISCUSSION

The first study to demonstrate an association between
valvular calcification and mortality in dialysis patients
was Wang et al 11. In our group of haemodialysis patients
we have also verified that aortic and mitral valvular

Teresa Adragão, Ana Pires, Carlos Lucas, Rita Birne, Luís Magalhães, Margarida Gonçalves, Acácio Pita Negrão

Table VI

Factors independently associated with valvular or vascular calcification

Dependent variable Independent variables B Sig. O.R. 95% CI

Aortic valve calcification
PTH 0.001 0.020 1.00 1.000 to 1.002

vascular calcification score 0.380 0.002 1.46 1.145 to 1.866

male gender 1.565 0.005 4.78 1.599 to 14.316

Mitral valve calcification
HD duration (months) 0.012 0.003 1.01 1.004 to 1.020

Phosphorus 0.356 0.040 1.42 1.017 to 2.003
vascular calcification score 0.504&amp;lt;0.001 1.66 1.295 to 2.114

male gender 1.407 0.006 4.08 1.490 to 11.195

Aortic or Mitral valve calcification HD duration (months) 0.010 0.011 1.01 1.002 to 1.017
vascular calcification score 0.410&amp;lt;0.001 1.51 1.211 to 1.879

diabetes 1.730 0.012 5.64 1.467 to 21.708

Vascular calcification score age 0.049 0.001 1.05 1.020 to 1.027

HD duration (months) 0.015 0.011 1.015 1.004 to 1.027

Simple vascular calcification score is an independent predictor of aortic and mitral calcification

Table V

Factors independently associated with mortality and morbidity (Cox Regression)

Dependent variable Independent variables B Sig. H.R. 95% CI
PTH -0.001 0.043 0.99 0.99 t0 1.00

All cause mortality albumin -1.89&amp;lt;0.001 0.15 0.06 to 0.36
aortic valvular calcification 1.32&amp;lt;0.001 3.72 1.83 to 7.76

Cardiovascular mortality
male gender 1.26 0.005 3.54 1.46 to 8.58

simple vascular calcification score 0.45&amp;lt;0.001 1.56 1.25 to 1.94

diabetes 1.000 0.018 2.72 1.18 to 6.24

Cardiovascular hospitalisations
albumin -1.46 0.021 0.23 0.06 to 0.80

Ca x P product 0.05 0.001 1.05 1.02 to 1.08
simple vascular calcification score 0.09 0.001 1.34 1.13 to 1.59

Results are adjusted for age, HD duration, diabetes, iPTH, Ca x P product, albumin, vascular disease at baseline, vascular calcification score and all types of valvular calcifications.



Port J Nephrol Hypert 2007; 21(4): 293-300 299

calcifications and vascular calcifications were associat-
ed with all cause death and with cardiovascular death.
When valvular and vascular calcifications were evaluat-
ed in the same model, aortic valvular calcification was
an independent predictor of all cause death and the sim-
ple vascular calcification score was an independent pre-
dictor of cardiovascular death and cardiovascular hos-
pitalisations. Factors associated with valvular calcifications
were the simple vascular calcification score, male gen-
der, PTH and phosphorus levels. Ribeiro S et al 13 were
among the first authors to verify an association between
calcium phosphate product and valvular calcification,
pointing out the role of mineral metabolism in the patho-
genesis of valvular calcification in dialysis patients. 

Many factors may contribute to the development of
vascular and valvular calcifications in dialysis patients and
there is increasing evidence of a link between bone dis-
ease and vascular disease in these patients. Kidney Dis-
ease: Improving Global Outcomes (K/DIGO) has recom-
mended a new classification for mineral and bone disorder
of chronic kidney disease that includes the evaluation
of biochemical abnormalities (Ca, P, PTH and vitamin D
levels), diagnosis of renal osteodystrophy preferably by
bone biopsy and evaluation of vascular calcifications14.

The presence of hyperphosphataemia and increased
CaxP product has been considered a major pathogen-
ic factor leading to vascular and soft tissue calcifica-
tion in uraemic patients. Hyperphosphataemia can occur
either with hyperparathyroidism or with adynamic bone
disease and this may explain the lack of correlation
between vascular calcifications and PTH levels verified
in many studies. In this study we have found, as
described by Wang et al 11, a direct association between
PTH levels and valvular calcification. Other studies have
also verified an association between vascular calcifica-
tions and low PTH levels15 or an absence of associa-
tion between vascular calcifications and PTH levels2,16,17.
Giacheli CM7 has demonstrated, in an in vitro model
with vascular smooth muscle cells from human aorta,
that increase of phosphorus and calcium outside the
cell, in the culture media, leads to deposition of calcium
phosphate in the matrix. This happens via two different
mechanisms: an extracellular passive mechanism of direct
deposition but also by an active mechanism through
activation of an intracellular transcription factor, the core
binding factor ?-1 (Cbfa-1). This factor upregulates osteo-
genic genes and increases the synthesis of osteocalcin, alka-
line phosphatase, collagen-rich extracellular matrix and
creates the conditions for deposition of calcium-phosphate.

Under these conditions, the vascular smooth muscle cell
in the vessels acquires the phenotypic characteristics of an
osteoblast. Some studies have also associated vascular cal-
cification with oral calcium dose1,15,17,18. However, hyper-
calcaemia and hyperphosphataemia are not the only fac-
tors associated with vascular calcification in dialysis patients. 

A deficiency in inhibitor calcification factors such as fetu-
in-A or matrix-Gla protein have been also associated with
the development of vascular calcification8 and it is con-
sidered that vascular calcification is the final result of the
balance between calcification inhibitors and inducers. 

In our patients we have not verified any association
between calcium levels or calcium carbonate dose with
vascular or valvular calcifications but these parameters
were averaged for the six months preceding the eval-
uation of vascular and valvular calcifications and this
period of observation may not reflect the whole peri-
od of dialysis which really determines the exposure. Low
levels of 25-hydroxivitamin D have also been associat-
ed with vascular calcifications19 and treatment with
native or active vitamin D may have an impact on the
development of vascular calcifications20. We do not eval-
uate vitamin D levels routinely in our patients but it is
possible that this information, in the future, will be use-
ful in the management of bone disease in CKD patients.

In non renal patients with valvular calcification, ecto-
pic bone formation has been identified in the valves10.
This calcification, previously considered to be the result
of a passive degenerative mechanism, seems to be the
result of an active mechanism most likely originated
from differentiated myofibroblasts21. Osteoblastic bone
formation and osteoclastic bone resorption were iden-
tified in these calcified valves. Osteopontin, osteocal-
cin, BMP 2 and BMP 4, which are potent calcification
inducers, were also identified in these areas. This active
process of yet unclear origin resembles what has been
also described for active calcification of arterial walls
in dialysis7 and non dialysis patients4. 

In this study we have verified that a simple vascu-
lar calcification score evaluated in plain X-ray of pelvis
and hands was independently associated with valvu-
lar calcification. Wang AY et al 22 showed that valvu-
lar calcification was associated with an increase in
carotid media-thickness and carotid calcification.
These results suggest that calcification is a systemic
disorder in dialysis patients and that vascular and valvu-
lar calcification may share common characteristics. 

Vascular and valvular calcifications in dialysis patients: the same pathogenesis?



300 Port J Nephrol Hypert 2007; 21(4): 293-300

Computed tomography scans are more accurate for
the quantitative assessment of vascular calcifications
but may be inadequate for an initial screening of vas-
cular calcifications because of its price and its limit-
ed availability in some areas14. K/DOKI guidelines rec-
ommend the utilisation of plain X-ray for identification
of vascular calcifications in dialysis patients23. This
simple vascular calcification score evaluated in plain
X-ray was previously demonstrated to be associated
with coronary artery disease, peripheral artery disease
and to be a predictor of cardiovascular mortality and
cardiovascular hospitalisations in dialysis patients12.
This vascular calcification score is an inexpensive and
valuable tool that can be used for screening for the
presence of vascular calcifications in dialysis patients.

Limitations of this study

This is an observational study evaluating the asso-
ciation of valvular calcifications with mortality and
the association of vascular calcifications with valvu-
lar calcifications. It is not possible to demonstrate
a cause-effect relationship between these variables.

CONCLUSIONS

In summary, in these patients, male gender, HD
duration, PTH, phosphorus levels and vascular cal-
cifications were associated with cardiac valvular cal-
cification. Valvular and vascular calcifications were
independent predictors of all cause and cardiovas-
cular mortality. Vascular calcification was independ-
ently associated with cardiac valvular calcification,
suggesting that these two types of calcification may
be the result of the same pathogenic process.

Conflicts of interest. None declared.

References
1 Blacher J, Guérin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and car-

diovascular risk in end-stage renal disease. Hypertension 2001;38:938–942.

2 Guerin AP, London GM, Marchais SJ, Metivier F.Arterial stiffening and vascular calcifica-
tions in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.

3 Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mor-
tality in patients undergoing maintenance hemodialysis. J Am Med Assoc 2002;287:
1548–1555.

4 Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regu-
lating proteins in association with Monckeberg's sclerosis: evidence for smooth mus-
cle cell-mediated vascular calcification. Circulation 1999;100:2168–2176.

5 Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification and
inorganic phosphate. Am J Kidney Dis 2001;38(4 Suppl 1):S34-7.

6 Moe SM, O’Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is asso-
ciated with deposition of bone matrix proteins. Kidney Int 2002;61:638–647.

7 Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004:15:2959–2964.

8 Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcifica-
tion: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blo-
od Purif 2002;20:473–476.

9 Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis
with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-7.

10 Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone Forma-
tion and Inflammation in Cardiac Valves Circulation 2001;103:1522-1528.

11 Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification
as an important predictor for all-cause mortality and cardiovascular mortality in long-term
peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14: 159-68.

12 Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardio-
vascular risk in haemodialysis patients. Nephrol Dial Transplant 2004;19:1480–1488.

13 Ribeiro S, Ramos A, Brandão A, et al. Cardiac valve calcification in haemodialysis patients:
role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13: 2037-40.

14 Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal
osteodystrophy: A position statement from Kidney Disease: Improving Global Outco-
mes (KDIGO). Kidney Int 2006;69:1945–1953.

15 London GM, Marty C, Marchais SJ, et al. Arterial Calcifications and Bone Histomorpho-
metry in End-Stage Renal Disease. J Am Soc Nephrol 2004;15:1943–1951.

16 Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam compu-
ted tomography in the evaluation of cardiac calcification in chronic dialysis patients.
Am J Kidney Dis 1996;27:394–401.

17 Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with
end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–1483.

18 London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media cal-
cification in end-stage renal disease: Impact on all-cause and cardiovascular mortality.
Nephrol Dial Transplant 2003;18:1731–1740.

19 London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in
end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc
Nephrol. 2007 Feb;18(2):613-20

20 Fournier A, Harbouche L, Mansour J et al. Impact of calcium and vitamin D therapy on
arterial and cardiac disease in young adults with childhood-onset end-tage renal dise-
ase.. Nephrol Dial Transplant 2007;22:956-8.

21 Mohler ER, Chawla MK, Chang AW, et al. Identification and characteritization of calcif-
ying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-60.

22 Wang AY, HO SS, Wang M et al. Cardiac valvular calcification as a marker of atheros-
clerosis and arterial calcification in end stage renal disease. Arch Intern Med 2005;
165:327-32.

23 National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism
and Disease in Chronic Kidney disease. Am J Kidney Dis 2003;42 [Suppl 3].

Correspondence to:
Dr Teresa Adragão
Gambro-Healthcare, Nefroclinica-Estoril.
Rua Vale de S Rita, 19, 2765-293 Estoril, Portugal
tadragao@netcabo.pt

Teresa Adragão, Ana Pires, Carlos Lucas, Rita Birne, Luís Magalhães, Margarida Gonçalves, Acácio Pita Negrão



69

CAPÍTULO 6

EXISTE UM ELO DE LIGAÇÃO ENTRE O OSSO E O VASO 
NOS DOENTES EM DIÁLISE? (1.ª PARTE)

Calcifi cação vascular e análise histomorfométrica de biopsias ósseas

A insufi ciência renal crónica cria um cenário fi siopatológico no qual se verifi cam inúmeras 
alterações minerais e ósseas interligadas. A diminuição da excreção urinária de fósforo 
desencadeia uma cascata de acontecimentos que, se não tratados, conduzem ao 
hiperparatiroidismo secundário. Inicialmente, o aumento dos níveis do FGF -23 (fi broblast 
growth factor) e da paratormona mantém o controlo do metabolismo mineral, mas à medida 
que a doença renal progride perde -se este equilíbrio e os níveis elevados da paratormona 
tornam -se prejudicais, com repercussão a nível de vários órgãos -alvo, entre os quais o osso. 
A osteodistrofi a renal é uma entidade complexa que duma maneira simplista pode ser descrita 
como estando entre duas situações extremas de remodelação óssea: alta remodelação óssea, 
que corresponde ao hiperparatiroidismo secundário, e baixa remodelação óssea, que corresponde 
à doença óssea adinâmica. Entre estes dois extremos existe uma escala de alterações. Se às 
alterações de remodelação se associarem alterações de mineralização, surgem novas entidades: 
a osteomalacia, uma situação de baixa remodelação e défi ce de mineralização, e a osteodistrofi a 
urémica mista, uma situação de alta remodelação com défi ce de mineralização.

Nos anos 80, o principal diagnóstico feito por biopsia óssea era a osteodistrofi a urémica 
mista que resultava de hiperparatiroidismo secundário associado a um defeito de mineralização 
provavelmente em relação ao défi ce da vitamina D1. Outras alterações presentes eram a osteíte 
fi brosa, resultante de hiperparatiroidismo secundário predominante, e a osteomalacia em relação 
com a toxicidade óssea por alumínio. Nos últimos anos verifi cou -se um aumento da incidência 
de doença óssea adinâmica1 -3 que apresenta um padrão de baixa remodelação óssea. Esta nova 
patologia, mais frequente em doentes diabéticos e idosos, parece também associar -se a outros 
fatores, entre eles o uso de concentrações elevadas de cálcio no dialisante, o uso de doses 
elevadas de carbonato ou acetato de cálcio como quelante do fósforo e a supressão excessiva 
dos níveis de PTH após paratiroidectomia ou doses excessivas de vitamina D3. O aumento de 
doença adinâmica coincidiu com a modifi cação da terapêutica recomendada para a hiperfosfatemia 
nos doentes em diálise. No fi nal dos anos 80, o uso de hidróxido de alumínio como quelante 



70

do fósforo foi fortemente desaconselhado devido a estar associado ao desenvolvimento de 
osteomalacia, e foi substituído por doses elevadas de cálcio oral. No momento atual, os dois 
principais diagnósticos ósseos são a doença óssea adinâmica e o hiperparatiroidismo secundário1, 
sendo a frequência da doença adinâmica superior à do hiperparatiroidismo secundário, tal como 
se comprovou num grupo de doentes portugueses submetidos a biopsia óssea4.

A hiperfosfatemia e a hipercalcemia podem ocorrer, quer no hiperparatiroidismo secundário 
quer na doença adinâmica, embora por mecanismos diferentes. No hiperparatiroidismo, 
situação de elevada remodelação óssea, o próprio osso liberta cálcio e fósforo para a circulação. 
Na doença óssea adinâmica, o osso apresenta uma baixa remodelação óssea e é incapaz de 
incorporar cálcio e fósforo. O aumento de cálcio e de fósforo séricos não são totalmente 
removidos na diálise e depositam -se nos tecidos moles e nos vasos. Nas células musculares 
lisas das paredes das artérias identifi cou -se um processo ativo de diferenciação genética que 
conduz à transformação destas células em osteoblastos e é responsável pelo desenvolvimento 
das calcifi cações vasculares5. O aumento dos níves de fósforo e de cálcio são alguns dos 
fatores indutores desta transformação fenotípica5.

Por proposta da iniciativa KDIGO 20066, a doença mineral e óssea da doença renal crónica 
(CKD -MBD) é atualmente defi nida como uma desordem sistémica que se manifesta por um 
ou mais dos seguintes aspetos: anomalias bioquímicas, anomalias ósseas e calcifi cações 
vasculares e de tecidos moles. O logótipo da CKD -MBD mostra que a mortalidade, a doença 
cardiovascular e as fraturas ósseas resultam da interação de alterações laboratoriais, alterações 
ósseas e calcifi cações vasculares. Estas são as bases fi siopatológicas da atual hipótese da 
existência de um elo de ligação entre a doença óssea e a doença vascular nos doentes renais 
crónicos. É contudo necessário demonstrar ainda que a correção destas alterações minerais e 
ósseas conduz a uma redução da mortalidade e da morbilidade nestes doentes.

London et al7, em 2004, foram os primeiros a analisar a relação entre calcifi cações 
vasculares e dados de biopsias ósseas. Verifi caram, num grupo de 58 doentes, uma associação 
entre calcifi cações vasculares avaliadas por ecografi a e baixa remodelação óssea avaliada por 
biopsia óssea. Este estudo apresentava elevada percentagem de doentes submetidos a 
paratiroidectomia e doentes com depósitos de alumínio no osso.

Raggi et al demonstraram em 2005 que a terapêutica com cálcio, em comparação com a 
terapêutica de outro quelante do fósforo sem cálcio, o sevelamer, se associou a um efeito 
deletério no metabolismo ósseo e nos vasos8. Estes autores verifi caram um aumento das 
calcifi cações coronárias e, simultaneamente, uma diminuição dos valores da paratormona e 
da fosfatase alcalina. Verifi caram também que os doentes tratados com cálcio apresentaram 
uma diminuição da densidade mineral óssea, enquanto nos doentes tratados com sevelamer 
não houve alteração da densidade mineral óssea.



71

Num grupo de 38 doentes em hemodiálise9 analisamos a relação entre calcifi cações 
coronárias avaliadas pelo score de Agatston avaliado em TAC helicoidal multicorte com 
dados obtidos por análise histomorfométrica de biopsias ósseas. Este estudo constituiu uma 
análise alargada feita num grupo de doentes que tinham participado num ensaio clínico que 
comparou o efeito do sevelamer e do carbonato da cálcio4. Os diagnósticos obtidos na biopsia 
óssea neste grupo de doentes foram de baixa remodelação em 50% dos doentes e de alta 
remodelação em 39%; apenas 11% dos doentes apresentava remodelação óssea normal. Nos 
nossos doentes verifi camos a existência de associação entre calcifi cações vasculares e 
diminuição do volume ósseo. Em análise multivariada, verifi cou -se que esta associação 
persistia durante os primeiros anos após início de diálise, desaparecendo nos doentes deste 
estudo após 6 anos de diálise. Verifi cou -se pois uma interação entre o volume ósseo e a 
duração de hemodiálise. Por cada aumento de uma unidade no volume ósseo/volume total 
houve redução de risco de apresentar um score de Agatston superior a 400, de 24% nos 
doentes com 2 anos de diálise e de 16% nos doentes com 4 anos de diálise. Nos doentes 
com mais de 6 anos de diálise o aumento de volume ósseo não teve efeito benéfi co nas 
calcifi cações coronárias.

Fig. 6.1. Nos doentes com menos de 4 anos de diálise verifi cou -se uma redução de risco OR, odds ratio, de ter um 
score de Agatston &gt; 400 por cada aumento de 1% do volume ósseo (VO)

A principal conclusão do nosso estudo é de que a diminuição do volume ósseo é um fator 
de risco para a presença de calcifi cações coronárias. Os primeiros anos de tratamento dialítico 
e provavelmente o período pré -diálise podem ser momentos importantes para intervenção 



72

terapêutica. Na análise dos fatores de risco cardiovasculares tradicionais, idade, sexo, 
hipertensão arterial, níveis de colesterol e hábitos tabágicos, só a idade se associou às 
calcifi cações coronárias. Este artigo foi publicado na revista Clinical Journal of American 
Society of Nephrology e mereceu um comentário editorial de Gérard London10.

Neste nosso estudo, as calcifi cações coronárias foram avaliadas pelo score de Agatston 
em 38 doentes. Dispúnhamos, contudo, da análise do score de calcifi cação vascular simples, 
assim como da análise histomorfométrica de biopsias ósseas num grupo de 50 doentes. 
Os dados relacionados com as calcifi cações coronárias foram considerados os mais 
relevantes e originais e foi decidido serem os únicos admitidos para publicação. Na presente 
dissertação consideramos ser indispensável a apresentação da relação entre o score de 
calcifi cação vascular simples e as biopsias ósseas. Neste grupo de 50 doentes (27 homens 
e 23 mulheres), com a idade média de 53±15 anos e duração média de hemodiálise de 
63±54 meses, a presença de calcifi cações vasculares foi verifi cada em 30 doentes (60%), 
e um score de calcifi cação vascular &gt; 3 estava presente em 19 (38%). Apenas 5 doentes 
eram diabéticos. Em análise multivariada por regressão binária verifi camos que um score 
de calcifi cação vascular &gt; 3 se associou diretamente à idade, à duração de hemodiálise e 
aos níveis séricos de cálcio e, inversamente, aos níveis séricos de albumina e ao volume 
ósseo (Tabela 6.1). Por cada aumento de uma unidade do volume ósseo houve uma redução 
de risco de 15% de SCVS &gt; 3. Nos doentes com volume ósseo &amp;lt;17,6%, o risco de um 
SCVS &gt;3 foi 21 vezes superior, em comparação com os doentes com um SCVS ?3 (Tabela 
6.2). Este valor de corte do volume ósseo foi calculado por curvas ROC relacionando o 
volume ósseo com um SCVS &gt; 3. Um volume ósseo&amp;lt;16%, valor de corte defi nido nas 
KDOQI guidelines para diagnosticar baixo volume ósseo11 mas não ajustado à população 
portuguesa, associou -se a um risco 28 vezes superior de apresentar um SCVS&gt;3 (IC 95% 
2,1 a 366,7; p=0,011).

Fatores associados a um score de calcifi cação vascular simples &gt;3
Regressão binária: Modelo 1

Variável dependente: SCVS &gt; 3 B OR IC 95% Sig. R2
Idade 0,076 1,079 1,004 a 1,159 0,039

54%
Duração HD 0,023 1,023 1,005 a 1,042 0,013
Cálcio sérico 0,169 1,183 1,012 a 1,382 0,034
Albumina sérica  -0,42 0,643 0,440 a 0,938 0,022
Volume ósseo  -0,159 0,853 0,744 a 0,977 0,022

Tabela 6.1. Por cada diminuição de uma unidade de volume ósseo houve uma redução de risco de 15% de 
score de calcifi cação vascular simples SCVS &gt; 3



73

Factores associados a um score de calcifi cação vascular simples &gt;3
Regressão binária: Modelo 2

Variável dependente: SCVS &gt; 3 B OR IC 95% Sig. R2

Idade 0,087 1,091 1,003 a 1,187 0,043

59%
Duração HD 0,024 1,024 1,004 a 1,044 0,021
Cálcio sérico 0,152 1,165 1,002 a 1,353 0,046
Albumina sérica  -0,57 0,633 0,426 a 0,941 0,024
Volume ósseo &amp;lt;17.6% 3,050 21,115 2,518 a 177,096 0,005

Tabela 6.2. Nos doentes com volume ósseo &amp;lt;17,6%, o risco de ter um score de calcifi cação vascular simples &gt;3 
foi 21 vezes superior, em comparação com os doentes com um SCVS ?3

Os estudos de London5 mostram uma associação entre calcifi cações vasculares e baixa 
remodelação óssea. London demonstrou igualmente, noutro grupo de doentes, que a baixa 
remodelação óssea se associou a calcifi cações vasculares e a rigidez arterial na presença de 
tratamento com cálcio12. Outro estudo demonstrou que as calcifi cações vasculares não se 
desenvolvem exclusivamente em associação a baixa remodelação óssea. Barreto D, et al 
demonstraram que a progressão de calcifi cações coronárias se associa a doença óssea não 
controlada13. Neste estudo, num grupo de 38 doentes em diálise com calcifi cações coronárias 
na avaliação inicial, verifi cou -se em duas situações progressão das calcifi cações coronárias 
após um ano: nos doentes que evoluíram de uma situação de alta remodelação óssea para 
baixa remodelação, mas também na situação oposta, de baixa remodelação óssea para alta 
remodelação. Esta evolução foi independente do tipo de captador de fósforo usado, sugerindo 
que a alta ou a baixa remodelação óssea não controladas podem contribuir para a progressão 
das calcifi cações vasculares. Em resumo, todos estes estudos confi rmam a hipótese da existência 
de um elo de ligação entre doença óssea e doença vascular nos doentes em diálise. As 
calcifi cações vasculares podem surgir quer em associação a baixa quer a alta remodelação 
óssea. O nosso estudo foi o primeiro a demonstrar que o baixo volume ósseo é um fator de 
risco para a presença de calcifi cações coronárias.

Referências

  1. Malluche HH, Mawad H, Monier -Faugere MC. The importance of bone health in end -stage renal 
disease: out of the frying pan, into the fi re? Nephrol Dial Transplant 2004;19 (Suppl 1):i9 -i13.

  2. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end -stage renal failure -an 
evolving disorder. Kidney Int 1993;43(2):436 -442



74

  3. Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. 
J Bone Miner Res 1995;10(1):149 -156.

  4. Ferreira A, Frazão JM, Monier -Faugere MC, et al. Sevelamer study group effects of sevelamer 
hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc 
Nephrol 2008;19(2):405 -412.

  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.
  6. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of 

renal osteodystrophy: A position statement from Kidney disease: improving global outcomes 
(KDIGO). Kidney Int 2006; 69: 1945 -1953.

  7. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in 
end -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.

  8. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-
-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20(5):764 -772.

  9. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Dias Curto J, 
Malluche HH. Low bone volume – A risk factor for coronary calcifi cations in hemodialysis patients. 
Clin J Am Soc Nephrol 2009; 4(2): 450 -455.

10. London GM. Bone – vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol 
2009; 4: 254 -257.

11. KDOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. 
Am J Kidney Dis 2003; 42 (Suppl 3):S1 -S202

12. London GM, Marchais SJ, Guérin AP, et al. Association of bone activity, calcium load, aortic 
stiffness, and calcifi cations in ESRD. J Am Soc Nephrol 2008; 19: 1827 -1835.

13. Barreto DV, Barreto FC, Carvalho AB, et al. Association of changes in bone remodelling and 
coronary calcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 
52(6):1139 -1150.



Low Bone Volume—A Risk Factor for Coronary
Calcifications in Hemodialysis Patients

Teresa Adragao,* Johann Herberth,† Marie-Claude Monier-Faugere,† Adam J. Branscum,‡

Anibal Ferreira,§ Joao M. Frazao,? Jose Dias Curto,¶ and Hartmut H. Malluche†

*Nephrology Department, Santa Cruz Hospital, Lisbon, Portugal; †Division of Nephrology, Bone, and Mineral
Metabolism and ‡Department of Biostatistics, Statistics, and Epidemiology, University of Kentucky, Lexington,
Kentucky; §Nephrology Department, Curry Cabral Hospital, Lisbon, Portugal; ?Nephrology Department, Hospital de S.
Joa?o, Medical School and Nephrology Research and Development Unit, University of Porto, Porto, Portugal; and
¶ISCTE, Business School, Lisbon, Portugal

Background and objectives: There is increasing evidence that altered bone metabolism is associated with cardiovascular
calcifications in patients with stage 5 chronic kidney disease on hemodialysis (HD). This study was conducted to evaluate the
association between bone volume, turnover, and coronary calcifications in HD patients.

Design, setting, participants, &amp;amp; measurements: In a cross-sectional study, bone biopsies and multislice computed tomog-
raphy were performed in 38 HD patients. Bone volume/total volume, activation frequency, and bone formation rate/bone
surface were determined by histomorphometry and coronary calcifications were quantified by Agatston scores.

Results: Prevalence of low bone turnover was 50% and of low bone volume was 16%. Among the studied traditional cardio-
vascular risk factors, only age was found to be associated with coronary calcifications. Lower bone volume was a significant risk
factor for coronary calcifications during early years of HD, whereas this effect was not observed in patients with dialysis duration
&gt;6 yr. Histomorphometric parameters of bone turnover were not associated with coronary calcifications.

Conclusions: Low bone volume is associated with increased coronary calcifications in patients on HD.
Clin J Am Soc Nephrol 4: 450 – 455, 2009. doi: 10.2215/CJN.01870408

C
ardiovascular disease and stroke account for 60 to 70%
of all deaths in patients with chronic kidney disease
(CKD) on maintenance hemodialysis (HD) (1,2). In a

study utilizing electron beam computed tomography, dialysis
patients presented with higher coronary calcification scores
when compared with nondialysis patients (3). In HD patients,
vascular calcifications were shown to be associated with car-
diovascular morbidity and mortality (4). Conspicuously, how-
ever, two prospective trials on modification of traditional car-
diovascular risk factors in CKD patients could not demonstrate
significant differences in cardiovascular outcomes, including
death between an intensive “multiple traditional risk factor
intervention” group and the standard therapy group despite
significantly improved traditional risk factor control in the
former (5,6). Recent evidence shows that vascular calcifications
in CKD can occur early, and that deposition of calcium in the
vascular wall is a complex and tightly regulated process that is
akin to bone mineralization (7,8). In addition, abnormalities in
bone turnover and bone volume are associated with more
vascular calcifications in uremic patients (9,10).

Taking this evidence into consideration, the international initia-
tive, Kidney Disease: Improving Global Outcomes, recommends
the inclusion of evaluation for extraskeletal calcifications into a
new classification for “chronic kidney disease-mineral and bone
disorder” (11). Although an association between low bone turn-
over and increased vascular calcification (measured by a semi-
quantitative vascular calcification score) was reported previously
(9), the relationship between histomorphometric parameters of
bone formation and bone volume and quantitative determina-
tions of coronary calcifications by multislice computed tomog-
raphy (MSCT) while controlling for the traditional cardiovas-
cular risk factors of hypertension, gender, age, cholesterol, and
tobacco use has not been investigated in HD patients. The study
presented here aims at providing this information.

Materials and Methods
Study Design

This is an extension study in a cohort of patients who participated in
the Sevelamer Study Group randomized trial (12). Briefly, the Sevel-
amer Study Group study was a 54-wk randomized open-label study to
compare the effects of sevelamer hydrochloride and calcium carbonate
on bone histomorphometric parameters. This extension study investi-
gates the interaction between histologically determined parameters of
bone turnover/bone volume and coronary calcifications measured by
MSCT in a cross-sectional study design. The Institutional Review
Boards of all participating institutions approved the protocol. The
study has been conducted in adherence to the Declaration of Helsinki,
and all patients provided informed consent.

Received April 21, 2008. Accepted November 7, 2008.

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Hartmut H. Malluche, FACP, Division of Nephrology,
Bone, and Mineral Metabolism, Room MN 564, University of Kentucky Medical
Center, 800 Rose Street, Lexington, Kentucky, 40536-0084. Phone: 859-323-5048
ext. 221; Fax: 859-257-1052; E-mail: hhmall@uky.edu

Copyright © 2009 by the American Society of Nephrology ISSN: 1555-9041/402–0450



Population
Thirty-eight patients provided informed consent for performing his-

tomorphometric analysis of bone samples and MSCT for evaluation of
coronary calcifications and were enrolled in this extension study. In-
clusion criteria were ages 18 yr or older, dialysis duration of at least 3
mo, mental competence, and willingness to participate in the study. All
patients were required to have stable serum phosphorus of ?8.1 mg/dl
because higher levels were considered indicative of medication non-
compliance. The extension study called for providing consent to un-
dergo evaluation for coronary calcifications by MSCT, which was per-
formed on average 3.8 ? 1.9 mo after the bone biopsy. Exclusion criteria
were failed kidney transplant during the past 6 mo; pregnancy; uncon-
trolled systemic illnesses or organic diseases with potential influence on
bone metabolism such as diabetes mellitus, active or chronic liver
disease, malabsorption, malignancy, and thyroid dysfunction; history
of or present treatment with pharmacologic agents known to affect
bone metabolism such as bisphosphonates, fluoride, calcitonin, glu-
cocorticoids or other immunosuppressive agents, hormone replacement
therapy, and selective estrogen receptor modulators; chronic alcoholism
and/or drug addiction; and allergy to tetracycline compounds.

Hypertension was defined as blood pressure ?140/90 mmHg
and/or treatment with antihypertensive medications. Tobacco use was
defined as inhalative smoking of ?1 cigarette per day.

Bone Biopsies
Anterior iliac crest bone biopsies were done after tetracycline labeling

under local anesthesia and conscious sedation. The labeling schedule
consisted of a 2-d oral administration of tetracycline hydrochloride (250
mg twice daily) followed by a drug-free interval of 10 d, and subsequent
oral administration of demeclocycline hydrochloride (300 mg twice daily)
for 4 d. Bone biopsies were performed 3 to 4 d after completing the second
label. Bone samples were obtained with the one-step electrical drill tech-
nique (Straumann Medical, Waldenburg, Switzerland). Bone samples
were processed undecalcified and sections were stained with the modified
Masson–Goldner trichrome stain, the aurin tricarboxylic acid stain, and
solochrome azurin for assessment of stainable aluminum in bone (13).
Unstained sections were prepared for phase contrast and fluorescence
light microscopy. Histomorphometric analysis of bone was done at stan-
dardized sites in cancellous bone using the semiautomatic method (Os-
teoplan II, Kontron, Munich, Germany) at 200? magnification. Bone vol-
ume/total volume (BV/TV) was calculated for assessment of mineralized
bone volume, whereas activation frequency (Ac.f.) and bone formation
rate/bone surface (BFR/BS) were calculated for assessment of bone turn-
over. All bone samples were processed and analyzed without knowledge
of the clinical data. BV/TV classification was based on three categories
characterized by the distribution of our data (5th, 50th, and 95th percen-
tile). The classification of “low,” “normal,” and “high” bone turnover was
based on our normative database (14 –16). The outcome group for low
bone turnover was defined as Ac.f. ?0.49 yr?1 and/or BFR/BS ?1.8
mm3/cm2/yr. The outcome group for normal bone turnover was defined
as Ac.f. 0.49 to 0.72 yr?1 and/or BFR/BS 1.8 to 3.9 mm3/cm2/yr. The
outcome group for hig bone turnover was defined as Ac.f. ?0.72 yr?1

and/or BFR/BS ?3.9 mm3/cm2/yr.

Assessment of Coronary Calcifications
Vascular calcifications were assessed by a quantitative score using

MSCT. MSCT scans were performed with the four-slice technique on
the model Somatom Volume Zoom (Siemens AG, Erlangen, Germany).
Slices of 2.5-mm thickness were acquired under the following condi-
tions: 120 kVp, 130 mAs, and 0.5 gantry rotation time. All images were
transferred to a workstation and analyzed with calcium scoring soft-

ware (HeartView CT, Siemens AG, Erlangen, Germany). Quantification
of coronary calcification was performed by calculating the Agatston
(Agt.) score on the basis of the maximum x-ray attenuation coefficient
(measured in Hounsfield units).

Biochemical Analyses
Blood was drawn at the time of the bone biopsy after an overnight

fast. The following biochemical parameters were measured: serum
calcium and phosphorus by an autoanalyzer (Hitachi 747, Globe Sci-
entific Inc.), immunoreactive parathyroid hormoneby DPC IMMULITE
PTH IRMA (Diagnostics Products Corporation, Los Angeles, Califor-
nia; normal range 16 to 87 pg/ml; intra- and interassay coefficients of
variation ?7 and ?9%, respectively); 25-(OH)-vitamin D by LIAISON
25-OH Vitamin D assay (Diasorin, Saluggia, Italy; normal range 25 to
100 ng/ml; intra- and interassay coefficients of variation 4.1 and 7%,
respectively); and total cholesterol was measured by the Synchron LX
system (Beckman Coulter, Fullerton, California; desirable range ?200
mg/dl; intra- and interassay coefficients of variation both ?3%).

Statistical Analyses
Descriptive statistics are presented as means, medians, minimums,

maximums, and SD stratified according to Agt. score groups of ?100,
100 to 400, and ?400. The variables Ac.f., BFR/BS, and HD duration
had right-skewed distributions and were log transformed for analysis.
Boxplots were used to characterize the distributions of BV/TV, log
Ac.f., and log BFR/BS for each Agt. score group. Bivariate associations
were assessed using the nonparametric Kruskal–Wallis test for continuous
variables and Fisher’s exact test for categorical variables. Multivariable
associations were assessed using separate ordinal (proportional odds)
logistic regression analyses to evaluate the effects of BV/TV, log Ac.f., and
log BFR/BS on Agt. score, adjusted for measured demographic and
biologic factors. All calculations were performed using the R statistical
package (R Foundation for Statistical Computing, Vienna, Austria) and
SAS version 9.1 (SAS Institute Inc., Cary, North Carolina, USA).

Results
Demographic characteristics of the study population are pre-

sented in Table 1. There were no statistically significant differ-
ences between the coronary Agt. score groups except for age.
The study included only nondiabetic patients.

BV/TV was low in 6 (16%), normal in 9 (24%), and high in 23
(60%) patients. Low bone turnover was diagnosed in 19 pa-
tients (50%), normal turnover in 4 patients (11%), and high
turnover in 15 patients (39%) on the basis of Ac.f. and BFR/BS.
There were no disagreements regarding classification of bone
turnover between Ac.f. and BFR/BS. None of the biopsies
showed positive staining for aluminum or iron. In unadjusted
analyses, there were no statistically significant differences be-
tween the three Agt. score groups regarding the bone histomor-
phometric parameters BV/TV, Ac.f., and BFR/BS (Figure 1).

Ordinal logistic regression revealed that, among the studied
traditional cardiovascular risk factors, age was the only vari-
able that predicted Agt. score groups (P ? 0.02). Our data
showed that Agt. score groups were also predicted by BV/TV
(P ? 0.02); one unit (%) increase in BV/TV in patients with the
same age and on HD for ?2 yr decreases the odds of being in
the high Agt. score group (Agt. ?400) by 24% [odds ratio: 0.76;
95% confidence interval: 0.61 to 0.94]. In addition, the interac-
tion term between BV/TV and HD duration was associated

Clin J Am Soc Nephrol 4: 450 – 455, 2009 Bone Volume and Coronary Calcifications 451



with Agt. score groups (P ? 0.05); the effect of BV/TV on the
odds of being in a specific Agt. score group decreased with
increasing HD duration (Figure 2) and was no longer statisti-
cally significant in patients on HD for ?6 yr (odds ratio: 0.90;
95% confidence interval: 0.80 to 1.02).

To better study the interactions between BV/TV, age, and
HD duration for predicting Agt. score groups, we divided these

independent variables into three categories characterized by
the distribution of our data (5th, 50th, and 95th percentiles).
Classification according to these percentiles corresponded to
BV/TV values of 15, 24, and 37%; ages of 30, 50, and 75 yr; and
HD durations of 2, 4, and 17 yr. Because ordinal logistic regres-
sion revealed that the associations between bone volume (BV/
TV) and coronary calcifications were no longer statistically

Table 1. Demographic characteristics of the study population

Characteristic
Agatston Score

?100 100 to 400 ?400 P

Age (yr) 0.03a

N 19 8 11
mean (SD) 45.2 (15.2) 59.8 (14.9) 57.2 (15.1)
median (min, max) 45 (21, 74) 59 (39, 76) 57 (37, 78)

Cholesterol (g/L) 0.44a

N 19 8 11
mean (SD) 1.70 (0.3) 1.6 (0.2) 1.5 (0.2)
median (min, max) 1.7 (1.2, 2.4) 1.6 (1.2, 2.0) 1.5 (1.2, 2.0)

Calcium (mg/dl) 0.35a

N 19 8 11
mean (SD) 96 (6.6) 94 (6.2) 98 (5.7)
median (min, max) 95.4 (87, 111) 93.6 (85, 104) 100 (87, 105)

Phosphorus (mg/dl) 0.08a

N 19 8 11
mean (SD) 5.4 (0.9) 4.6 (0.8) 5.0 (0.7)
median (min, max) 5.5 (3.9, 7.2) 4.8 (3.2, 5.3) 5.0 (3.8, 6.3)

iPTHc (pg/ml) 0.47a

N 19 8 11
mean (SD) 620 (614) 293 (167) 570 (700)
median (min, max) 353.4 (50, 2164) 259 (155, 679) 301 (100, 2572)

25-(OH)-vitamin D (ng/ml) 0.78a

N 19 8 11
mean (SD) 21.2 (7.8) 19.5 (6.2) 20.2 (10.0)
median (min, max) 21.5 (7.8, 37.6) 17.5 (13.5, 27.8) 14.6 (11.0, 41.4)

Dialysis duration (mo) 0.48a

N 19 8 11
mean (SD) 73.1 (56.6) 44.9 (23) 87.2 (77.2)
median (min, max) 48.3 (21, 206) 39.5 (19, 77) 45 (23, 242)

Gender 0.27b

N 19 8 11
male (N, %) 9 (47.3) 3 (37.5) 8 (72.7)
female (N, %) 10 (52.6) 5 (62.5) 3 (27.3)

Tobacco use 0.88b

N 19 8 11
yes (N, %) 4 (21.0) 1 (12.5) 3 (27.3)
no (N, %) 15 (79.0) 7 (87.5) 8 (72.7)

Hypertension 0.63b

N 19 8 11
yes (N, %) 11 (57.9) 4 (50.0) 8 (72.7)
no (N, %) 8 (42.1) 4 (50.0) 3 (27.3)

aP value computed from Kruskal–Wallis test.
bP value computed from Fisher’s exact test.
ciPTH, immunoreactive parathyroid hormone.

452 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 450 – 455, 2009



significant after a HD duration of 6 yr, the sixth-year HD
duration time point was also examined. Accordingly, Figure 3
depicts changes in the probabilities for the Agt. score group
?100 (Figure 3, A through D) and for the Agt. score group ?400
(Figure 3, E through H) for the three different BV/TV values
(depicted on the x-axis) and three different ages (depicted by
different lines) on the basis of the four different HD durations
(Figure 3, A and E ? 2 yr; Figure 3 B and F ? 4 yr; Figure 3, C
and G ? 6 yr; and Figure 3, D and H ? 17 yr). Irrespective of
HD duration, increasing age carries a higher likelihood of hav-
ing an Agt. score of ?400 and accordingly a lower likelihood of
having an Agt. score ?100. This age effect was observed in each
BV/TV class. However, the magnitude of this bone volume
effect is conditional on HD duration; in the HD duration classes
of 2 and 4 yr, lower BV/TV bears a higher likelihood of having
an Agt. score ?400 and, accordingly, lower likelihood of having

an Agt. score ?100 irrespective of the age group (Figure 3).
However, in long HD duration classes (17 yr), higher BV/TV is
associated with lower likelihood of an Agt. score ?100 and
higher likelihood of an Agt. score ?400 irrespective of age.

In the case of shorter HD duration (?6 yr), the incremental
increase in the likelihood of having an Agt. score ?100 is the
largest for increasing BV/TV from the 5th to the 50th percentile
for younger patients (30 yr), whereas older patients (75 yr)
derive the highest benefit from increasing BV/TV from the 50th
to the 95th percentile. It is of note that, after 2 yr of HD
duration, a 30-yr-old patient with a low BV/TV has about the
same probability of having an Agt. score ?100 (P ? 0.39) than
a 75-yr-old patient with normal BV/TV (P ? 0.36). Figure 3 also
shows that the likelihood of having an Agt. score ?100 is lower
at the lowest BV/TV at the shortest HD duration than at normal
or high BV/TV at the longest HD duration irrespective of age.

Ordinal logistic regression conducted with Ac.f. and BFR/BS
revealed that only age was predictive of the Agt. score class of
coronary arteries (P ? 0.03). No specific interactions were
found between variables of bone turnover and the studied
traditional risk factors (P ? 0.05).

Discussion
Our data confirm previous studies reporting on the effect of

age on vascular calcifications in HD patients (17,18). We also
confirm previous observations reporting lack of predictive
value of the traditional cardiovascular risk factors of hyperten-
sion, smoking, gender, and cholesterol for cardiovascular out-
comes in HD patients (5,6,18,19).

The novel aspect of our study is the investigation of the
interaction between the bone volume and the bone turnover
components of renal osteodystrophy (determined by histomor-
phometry) and coronary calcifications (determined by MSCT)

Figure 1. Distribution of values for bone volume/tissue volume
(BV/TV), activation frequency (Ac.f.), and bone formation
rate/bone surface (BFR/BS) among the Agatston (Agt.) score
classes ?100, 100 to 400, and ?400. Box ? median, 25 to 75%;
T-bars ? minimum and maximum values.

Figure 2. Effect of the interaction between BV/TV volume and
hemodialysis (HD) duration on the odds of an Agt. score of
?400. Odds ratio represents the change in the odds for an Agt.
score ?400 for each 1% increase in BV/TV. Vertical bars ? 95%
confidence interval.

Figure 3. Changes in the probabilities for (A through D) the Agt.
score group ?100 and (E through H) the Agt. score group ?400
for different BV/TV values and ages on the basis of four different
HD durations (A and E ? 2 yr, B and F ? 4 yr, C and G ? 6 yr,
D and H ? 17 yr). Solid line ? 30-yr-old patient; long dashed
line ? 50-yr-old patient; short dashed line ? 75-yr-old patient.

Clin J Am Soc Nephrol 4: 450 – 455, 2009 Bone Volume and Coronary Calcifications 453



in prevalent HD patients. Low bone volume and bone loss are
common findings in patients on renal replacement therapy
(20,21). Our study demonstrates the importance of bone vol-
ume for predicting coronary calcifications. Specifically, it ap-
pears that lower bone volume is predictive of higher Agt.
scores, reflecting higher risk of cardiovascular events (Agt.
?100) irrespective of age. Although correlations between bone
loss and progressive arterial calcifications were described in the
general population, (22,23) there is little information available
on their possible interaction in HD patients. Peripheral arterial
calcifications assessed by plain radiographs and low bone vol-
ume were observed in an early study by Zuchelli and col-
leagues, but the authors did not examine a possible interrela-
tion between bone volume and vascular calcifications and did
not report on the contribution of traditional risk factors for
cardiovascular calcifications (24). Similarly, assessment of bone
mineral density by quantitative computed tomography in HD
patients showed less coronary calcifications with higher verte-
bral bone mineral density (25). Although several serum mark-
ers of bone metabolism such as bone morphogenic proteins (26)
and osteoprotegerin (27) were implicated in the pathogenesis of
vascular calcifications, to our knowledge this is the first popu-
lation-based study that describes the predictive value of histo-
logically measured bone volume for coronary calcifications in
HD patients.

An interesting finding in our study is that the effect of bone
volume on Agt. scores is conditional on HD duration; if HD
duration is ?6 yr, the bone volume effect seems to be overrid-
den by other risk and/or protective factors that determine
coronary calcifications. In light of a 5-yr mortality rate of ?75%
for patients on dialysis (1), it appears that the bone volume
effect is of great importance for most HD patients. The impli-
cations of lower bone volume for higher Agt. scores is further
highlighted by our finding that 30-yr-old patients who exhibit
low bone volume early in the course of HD have probabilities
for low Agt. scores comparable to 75-yr-old patients with nor-
mal bone volume.

London and colleagues previously reported on the associa-
tion between histologically diagnosed low bone turnover and
arterial calcifications detected on plain radiographs and evalu-
ated by semiquantitative calcifications scores in HD patients
(9). Our study presented here did not find an association be-
tween bone turnover parameters and coronary calcifications
measured by MSCT, although a relationship was demonstrated
between histologically determined bone turnover and thoracic
aorta and iliac artery calcifications in a previous publication
(10). Discordance between predictors of aortic and coronary
calcifications has been described in a series of publications from
the large, population-based Multi-Ethnic Study of Atheroscle-
rosis (MESA) (28 –30). Accordingly, our findings supplement
rather than contradict the findings of London and colleagues
and highlight that studies aiming at predicting vascular calci-
fications have to take into account the site examined within the
vascular tree, the morphology of the vascular tissue, and the
localization of calcification within the vascular wall.

Limitations of our study are that patients were recruited from
dialysis centers in Portugal and diabetic patients were not

included. Accordingly, we cannot generalize our findings to
other populations and draw inferences on a possible effect of
diabetes mellitus on the observed interaction between bone
volume and coronary calcifications. We are currently in the
process of designing larger studies that focus on the contribu-
tion of renal osteodystrophy to coronary calcifications in dif-
ferent HD patient populations. On the basis of recent improve-
ments in the sensitivity of MSCT scanners for detecting
coronary calcifications, it is conceivable that the magnitude of
the bone volume effect will be greater than observed in our
presented here. More sensitive detection methods for coronary
calcifications might also contribute to a more precise estimation
of the contribution of bone turnover to coronary calcification.

In summary, our data implicate that low bone volume is a
significant risk factor for coronary calcifications in HD patients,
and that this risk is dependent on the patient’s age and HD
duration. Although statistical associations do not necessarily im-
ply cause and effect relationships, our findings suggest that early
prevention of bone loss in CKD patients might carry important
implications for reducing coronary calcifications, especially be-
cause age and HD duration are not modifiable risk factors.

Acknowledgments
The following colleagues have participated in the study: Ce?lia Gil,

Carlos Oliveira, Jose? Galva?o, Anto?nio Morais Sarmento, Silvia Ribeiro,
Jorge Dickson, Berta Carvalho, Ilídio Rodrigues, Jorge Baldaia, and
Odete Pereira.

This study was supported by grant NIH RO1 DK51530 (H.H.M.); by
the Kentucky Nephrology Research Trust (M-C.M-F.); by the Dean’s
Clinical Research Scholar Program, University of Kentucky, no
1012112710 (J.H.); and by a grant from Genzyme.

The authors thank ISNI, Instituto Nefrolo?gico de Investigac?a?o, for
assistance in the organization of this study, and Ms. Julia Van Willigen
and Richard Wheeler for their technical assistance.

Disclosures
None.

References
1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of

cardiovascular disease in chronic renal disease. Am J Kid-
ney Dis 32[5 Suppl 3]: S112–S119, 1998

2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco
MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular
disease risks in chronic hemodialysis patients. Kidney Int
58: 353–362, 2000

3. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,
Luft FC: Electron beam computed tomography in the eval-
uation of cardiac calcification in chronic dialysis patients.
Am J Kidney Dis 27: 394 – 401, 1996

4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM:
Arterial calcifications, arterial stiffness, and cardiovascular
risk in end-stage renal disease. Hypertension 38: 938 –942, 2001

5. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW,
Leano R, Isbel NM: Effect of aggressive risk factor modi-
fication on cardiac events and myocardial ischemia in pa-
tients with chronic kidney disease. Heart 92: 1402–1408,
2006

454 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 450 – 455, 2009



6. Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C,
Marwick TH: Increased targeting of cardiovascular risk
factors in patients with chronic kidney disease does not
improve atheroma burden or cardiovascular function. Am
Heart J 151: 745–753, 2006

7. Moe SM: Vascular calcification and renal osteodystrophy
relationship in chronic kidney disease. Eur J Clin Invest
36[Suppl 2]: 51– 62, 2006

8. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B,
Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff
RM, Salusky IB: Coronary-artery calcification in young
adults with end-stage renal disease who are undergoing
dialysis. N Engl J Med 342: 1478 –1483, 2000

9. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F,
de Vernejoul MC: Arterial calcifications and bone histo-
morphometry in end-stage renal disease. J Am Soc Nephrol
15: 1943–1951, 2004

10. Adragao T, Ferreira A, Frazao J, Gil C, Oliveira C, Sar-
mento J, Ribeiro S, Dickson J, Carvalho B, Rodrigues I,
Baldaia J, Faugere M, Malluche H: Vascular calcifications
and bone turnover in hemodialysis patients. Nephrol Dial
Transplant 21 [Suppl 4]: 292, 2006

11. Moe S, Drueke T, Cunningham J, Goodman W, Martin K,
Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G:
Definition, evaluation, and classification of renal osteodys-
trophy: A position statement from Kidney Disease: Im-
proving Global Outcomes (KDIGO). Kidney Int 69: 1945–
1953, 2006

12. Ferreira A, Frazao J, Faugere M, Mueller R, Malluche H:
Effects of sevelamer hydrochloride and calcium carbonate
on bone mineralisation and turnover in haemodialysis pa-
tients: A one-year randomised, open-label bone biopsy
study [Abstract]. Nephrol Dial Transplant 21: 293, 2006

13. Malluche HH, Faugere MC: Atlas of Mineralized Bone His-
tology, New York, Karger, 1986

14. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ,
Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N,
McCary LC, Turner SA, Goodman WG: An assessment of
cinacalcet HCl effects on bone histology in dialysis patients
with secondary hyperparathyroidism. Clin Nephrol 69:
269 –278, 2008

15. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler
R, Fanti P, Monier-Faugere MC, Malluche HH: Differences
in bone turnover and intact PTH levels between African
American and Caucasian patients with end-stage renal
disease. Kidney Int 64: 737–742, 2003

16. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao
J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S,
Hoenger RM, Duggal A, Malluche HH: Effects of sevel-
amer hydrochloride and calcium carbonate on renal os-
teodystrophy in hemodialysis patients. J Am Soc Nephrol 19:
405– 412, 2008

17. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek
M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M,
Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC,
Drueke TB, Sulowicz W: Factors involved in vascular cal-
cification and atherosclerosis in maintenance haemodialy-
sis patients. Nephrol Dial Transplant 22: 515–521, 2007

18. Fabbian F, Catalano C, Orlandi V, Conte MM, Lupo A,
Catizone L: Evaluation of aortic arch calcification in hemo-
dialysis patients. J Nephrol 18: 289 –293, 2005

19. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB,
Fonarow GC: Racial and survival paradoxes in chronic
kidney disease. Nat Clin Pract Nephrol 3: 493–506, 2007

20. Ishani A, Paudel M, Taylor BC, Barrett-Connor E, Jamal S,
Canales M, Steffes M, Fink HA, Orwoll E, Cummings SR,
Ensrud KE: Renal function and rate of hip bone loss in
older men: The Osteoporotic Fractures in Men Study. Os-
teoporos Int 19: 1529 –1556, 2008

21. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis
PK, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R,
Vlachojannis JG, Dombros AN, Utas C, Akpolat T,
Bozfakioglu S, Wu G, Karayaylali I, Arinsoy T, Stathakis
PC, Yavuz M, Tsakiris JD, Dimitriades CA, Yilmaz ME,
Gultekin M, Karayalcin B, Yardimsever M, Oreopoulos
DG: Bone mineral density and its correlation with clinical
and laboratory factors in chronic peritoneal dialysis pa-
tients. J Bone Miner Metab 24: 79 – 86, 2006

22. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-
Alonso C, Cannata-Andia JB: Progression of vascular cal-
cifications is associated with greater bone loss and in-
creased bone fractures. Osteoporos Int 19: 1161–1166, 2008

23. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcifi-
cation and the risk of osteoporosis and fractures. J Clin
Endocrinol Metab 89: 4246 – 4253, 2004

24. Zucchelli P, Catizone L, Casanova S, Fusaroli M, Fabbri L,
Ferrari G: Renal osteodystrophy in CAPD patients. Miner
Electrolyte Metab 10: 326 –332, 1984

25. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H,
Schulz W, Neumayer HH, Raggi P, Bommer J: Two year
comparison of sevelamer and calcium carbonate effects on
cardiovascular calcification and bone density. Nephrol Dial
Transplant 20: 1653–1661, 2005

26. Nguyen KQ, Olesen P, Ledet T, Rasmussen LM: Bone
morphogenetic proteins regulate osteoprotegerin and its
ligands in human vascular smooth muscle cells. Endocrine
32: 52–58, 2007

27. Mazzaferro S, Pasquali M, Pugliese F, Barresi G, Carbone I,
Francone M, Sardella D, Taggi F: Serum levels of calcifica-
tion inhibition proteins and coronary artery calcium score:
Comparison between transplantation and dialysis. Am J
Nephrol 27: 75– 83, 2007

28. Takasu J, Katz R, Nasir K, Carr JJ, Wong N, Detrano R,
Budoff MJ: Relationships of thoracic aortic wall calcifica-
tion to cardiovascular risk factors: The Multi-Ethnic Study
of Atherosclerosis (MESA). Am Heart J 155: 765–771, 2008

29. Nasir K, Katz R, Takasu J, Shavelle DM, Detrano R, Lima
JA, Blumenthal RS, O’Brien K, Budoff MJ: Ethnic differ-
ences between extra-coronary measures on cardiac com-
puted tomography: Multi-Ethnic Study of Atherosclerosis
(MESA). Atherosclerosis 198: 104 –114, 2008

30. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E,
Ouyang P, Jackson S, Saad MF: Ethnic differences in cor-
onary calcification: The Multi-Ethnic Study of Atheroscle-
rosis (MESA). Circulation 111: 1313–1320, 2005

See related editorial, “Bone–Vascular Axis in Chronic Kidney Disease: A Reality?” on pages 254 –257.

Clin J Am Soc Nephrol 4: 450 – 455, 2009 Bone Volume and Coronary Calcifications 455



Editorial

Bone–Vascular Axis in Chronic Kidney Disease: A Reality?
Ge?rard M. London
Service de Ne?phrologie, Centre Hospitalier Manhe?s, Fleury Me?rogis, France; INSERM U970, Paris, France

Clin J Am Soc Nephrol 4: 254 –257, 2009. doi: 10.2215/CJN.06661208

C
hronic kidney disease (CKD) is characterized by
changes in mineral metabolism associated with alter-
ations of its hormonal regulation and various forms of

bone disease. In the past, these associations focused attention
on the kidney– bone axis. The last decade has seen renewed
interest on interactions among mineral metabolism disorders
and extraosseous and cardiovascular calcifications observed in
CKD or end-stage renal disease (ESRD). Vascular calcification
is an active process similar to bone formation that implicates a
variety of proteins involved in bone and mineral metabolism
(1,2) and is considered part of a systemic dysfunction defined
as CKD–mineral and bone disorder (3). Growing evidence link-
ing bone with different functional and structural characteristics
of the arterial tree has contributed to developing the concept of
the bone–vascular axis (4).

The first observations suggesting the existence of the bone–
vascular axis were the frequent associations of osteoporosis and
atherosclerotic vascular calcifications observed in postmeno-
pausal women (5–7). Longitudinal population-based studies
revealed a relationship between the progression of vascular
calcifications and bone demineralization, and others were iden-
tified between bone mineral density (BMD) and aortic or cen-
tral artery calcifications (6), or coronary arteries in type 2 dia-
betes (8). The osteopenia– osteoporosis association was also
linked with arterial functional indexes, such as aortic stiffness
and interactions independent of calcifications, suggesting
broader biologic interplay (9,10).

Relationships between bone and vascular modifications were
also observed in CKD and ESRD patients. In dialysis patients,
coronary artery calcification score was found to be inversely
correlated with vertebral bone mass (11,12). In addition, a high
systemic arterial calcification score combined with bone histo-
morphometry suggestive of low bone activity was observed in
hemodialysis patients (13,14). Arterial stiffening and low spine
BMD or calcaneal osteopenia were significantly associated in
CKD and hemodialysis patients (15–17).

In the present issue of the Journal, Adragao et al. (18) provide
new evidence linking altered bone metabolism to coronary
calcifications in patients with stage-5 CKD on hemodialysis. In
their cross-sectional study performed on 38 hemodialyzed pa-
tients, they analyzed the relationships between bone biopsy

parameters (bone volume/total volume, bone formation rate/
bone surface, and activation frequency) and coronary calcifica-
tions determined by multislide computer tomography. Their
principal conclusion was that low bone volume is associated
with more coronary calcifications, whereas histomorphometric
parameters of bone turnover were independent of coronary
calcifications.

Their results complete those of Barreto et al. (12), who found
a negative correlation between coronary calcifications and tra-
becular bone volume or its thickness. The absence of correla-
tions between histomorphometric indexes of bone turnover and
coronary calcifications differ from reports by London et al.
(13,14), who found an association between systemic arterial
calcifications (aorta and the main peripheral arteries) and in-
dexes of low bone turnover, but not trabecular volume. One
important difference between these publications resides in the
arterial territories analyzed and the relationships of the differ-
ent bone changes (bone volume, osteoblasts number, or tetra-
cycline labeling), which do not necessarily reflect the same
mechanisms. Adragao et al. (18) studied coronary artery calci-
fications, whereas London et al. (13,14) examined the aorta and
systemic arteries.

Researchers investigating the arterial system should keep in
mind the marked heterogeneity of the arterial tree (19). Blood
vessel formation recruits cells of different origins whose com-
ponents are derived from vascular smooth muscle cells (VSMC)
and pericytes. VSMC is a tissue generated by at least seven
unique and nonoverlapping sources, and different vessels or
even segments of the same vessel, are composed of VSMC
arising from distinct progenitors that respond in origin-specific
ways to different common stimuli. The observations linking
arterial calcifications to bone usually concern the aorta or large
conduit arteries and coronary arteries. Whereas the coronary
arteries are derived from proepicardium, the aorta’s origin
even more complex. The ascending aorta and aortic arch orig-
inate from neural crest, the thoracic aorta (athero-resistant) is
derived from somites, and splanchnic mesoderm gives rise to
the abdominal aorta (athero-susceptible). The boundaries of
these different segments are sharp and are associated with
quite different responses to common risk factors. Arterial bed-
specific susceptibilities were documented in human studies
showing that despite common risk factors, each analyzed vas-
cular segment (coronary arteries, ascending aorta and its major
arteries, thoracic aorta at the renal artery level, and terminal
aorta and femoral arteries) mounted its own distinct response
to atherogenesis (20).

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Ge?rard London, Centre Hospitalier Manhe?s, 8, rue Roger
Clavier, 91712 Fleury-Me?rogis Cedex, France. Phone: 33 1 69256485; Fax: 33 1
69256525; E-mail: glondon@club-internet.fr

Copyright © 2009 by the American Society of Nephrology ISSN: 1555-9041/402–0254



The eventual biologic link between vascular calcifications
and bone changes is certainly part of the aging process, but in
many studies, these bone–vascular associations remained sig-
nificant after adjustment for age, which suggests an age-inde-
pendent causal relationship (5–7). The mechanisms responsible
for bone–vascular interactions are not well understood.

The results of increasing numbers of experimental studies led
to the recognition of similarities between bone development
and mineralization and the process of arterial calcifications. The
calcification process involves VSMC differentiation into osteo-
blast-like cells, with subsequent mineralization. This process is
induced and regulated by equilibrium between factors promot-
ing or inhibiting calcification, involving a variety of proteins
that are important for bone metabolism but are also expressed
in arteries (1–3). Clinical data on humans indicate that osteo-
porosis and vascular calcifications are influenced by several
common risk factors, such as diabetes, inflammation, dyslipi-
demia, oxidative stress, estrogen deficiency, vitamin D and K
deficiencies, and others (21–24). The roles of dyslipidemia, ox-
idative stress, and inflammation seem to be of importance.
Oxidized lipids can paradoxically induce atherosclerosis and
the differentiation of osteoblasts, with subsequent arterial wall
mineralization having the opposite effect, that is, inhibiting
osteoblastic differentiation into bone osteoblasts (25). Oxidized
lipids are also a substrate for peroxisome proliferator-activator
receptor-? (PPAR?), which redirects the differentiation of mes-
enchymal progenitors from preosteoblasts to adipocytes and
Cbfa1/Runx2 expression essential for osteoblastogenesis.

In osteoporosis, it is osteoprotegerin (OPG), the receptor
activator of the nuclear factor-kappa B (NF-?B) ligand
(RANKL) system, that has attracted the most attention (26,27).
OPG-deficient mice develop osteoporosis with severe cortical
and trabecular bone porosity and high fractures rates. In par-
allel with these bone lesions, these mice develop medial calci-
fication of the aorta and large arteries (28). By binding RANKL,
OPG inhibits osteoclastogenesis and bone resorption. OPG and
RANKL are also involved in immune-induced inflammatory
responses. OPG can limit local inflammatory responses, and in
vitro OPG, produced by smooth muscle and endothelial cells,
acts as an antiapoptotic factor prolonging endothelial cell sur-
vival (27). Changes of the RANKL/OPG ratio are critical to the
evaluation of clinical impact, and high OPG-associated cardio-
vascular risk probably represents an inadequate response of
OPG to increased RANKL activity (29).

Although osteoporosis–arterial calcification interactions
could be observed in general populations in the absence of
overt mineral metabolism disorders, in CKD/ESRD patients,
the associations between vascular calcifications and bone dis-
orders are linked to deterioration of mineral and bone metab-
olism caused by serum phosphate and calcium changes, and
disruption of endocrine and humoral pathways, including
parathyroid hormone (PTH), calcitriol, fibroblast growth fac-
tor-23 (FGF-23)/Klotho, and others (1–3). Experimental and
clinical data indicate that hyperphosphatemia plays a direct
role in the osteoblast-like transformation of VSMC by upregu-
lating Cbfa1/Runx2 and osterix transcription factors (1,2,30,31).
The calcification could be enhanced by the imbalance between

inducers and local or systemic inhibitors of calcification, such as
low fetuin-A, pyrophosphate, or osteopontin (31–33). In CKD
and ESRD patients, the relationship between bone and vascular
calcifications concerns several aspects of bone disorders, such
as high bone turnover (secondary hyperparathyroidism), and
low bone activity (adynamic bone disease), and low bone vol-
ume. In secondary hyperparathyroidism, the increased bone
resorption associated with the endogenous release of phos-
phate and calcium could play a critical role in the induction of
vascular calcification. Chronic PTH elevation upregulates
RANKL, downregulates OPG gene expression, and raises the
RANKL/OPG ratio (34). The high prevalence and extent of
arterial calcification is also observed in ESRD patients with
bone demineralization or low bone activity (11–14,18), a clinical
situation closer to the osteoporosis–vascular calcification asso-
ciation seen in general populations.

In general populations and ESRD patients, relationships be-
tween bone disorders and vascular dysfunction were observed
independently of calcifications, age, BP, and other confounding
factors, thereby suggesting direct bone–vascular cross-talk.
Bone is an active “endocrine” organ, as demonstrated by fibro-
blast growth factor 23 (FGF-23) regulation of the phosphate
balance. FGF-23 is synthesized and released by osteocytes,
which are terminally differentiated osteoblasts. Osteoblast
function could be an important player in the bone–vascular
axis. Lee et al. (35) showed that osteoblasts exert endocrine
regulation of energy metabolism, with osteocalcin (OCN) play-
ing an important role. OCN can regulate the expression of
insulin genes, ?-cell proliferation, and adiponectin (ADPN)
release and its expression adipocytes (36). In general popula-
tions, serum OCN was positively associated with ADPN
(37,38). ADPN protects arteries against hypertension, slows
atherosclerosis, and activates osteoblastogenesis (39,40). An in-
verse relationship was found between ADPN and OCN and
arterial stiffness (38). Plasma ADPN levels are low in metabolic
syndrome and type 2 diabetes patients. Whether this low
ADPN could account for decreased osteoblastogenesis and fre-
quently observed adynamic bone disease in diabetic patients
remains a hypothesis.

Multiple hormones involved in the endocrine regulation of
adipose tissue and energy metabolism could affect bone struc-
ture, including leptin. Leptin is a powerful inhibitor of in vivo
bone formation (41) and facilitates vascular calcification (42). In
ESRD, serum leptin is elevated and is associated with low PTH
(43), suggesting that leptin might diminish bone activity and
promote arterial calcifications in this setting.

Bone loss may also occur as a secondary consequence of
ischemia related to vascular disease. Arteries and arterioles
within the bone are also subject to arteriosclerosis, and a link
between compromised intraosseous circulation and consequent
osteoporosis may exist (44). Intraosseous angiogenesis and
bone remodeling are regulated by similar cytokines and growth
factors, and interactions between bone formation–resorption
and blood supply are known to occur (45). A recent study
showed that in otherwise healthy women, bone-perfusion in-
dices were lower in women with osteoporosis compared with
women with osteopenia or normal BMD (46).

Clin J Am Soc Nephrol 4: 254 –257, 2009 Bone–Vascular Axis 255



In conclusion, increasing numbers of articles on general pop-
ulations and CKD and ESRD patients have reported significant
associations among arterial pathology (atherosclerosis and ar-
terial calcifications) and bone disorders, including osteoporosis,
and high or low bone activity. The pathophysiology and bio-
logic links between bone and arterial abnormalities suggest the
existence of bone–vascular cross-talk. The nature of this com-
munication is not well understood. It could be a consequence of
(1) the action of common factors on bone remodeling and
atherosclerosis/calcification, (2) the direct action of bone cells
(osteoblasts and/or osteocytes) on vascular biology and struc-
ture, and/or (3) the compromised bone blood supply resulting
from arteriosclerosis of bone vessels and reduced perfusion.

Disclosures
None.

References
1. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Ex-

ploring the biology of vascular calcification in chronic kid-
ney disease: What’s circulating? Kidney Int 73: 384 –390,
2008

2. Demer LL, Tintut Y: Vascular calcification: Pathobiology of
multifaceted disease. Circulation 117: 2938 –2948, 2008

3. Moe S, Dru?eke T, Cunningham J, Goodman W, Martin K,
Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G:
Definition, evaluation, and classification of renal osteodys-
trophy: A position statement from Kidney Disease: Im-
proving Global Outcomes (KDIGO). Kidney Int 69: 1945–
1953, 2006

4. Hamerman D: Osteoporosis and atherosclerosis: Biological
linkage and the emergence of dual-purpose therapies. Q
J Med 98: 467– 484, 2005

5. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman
JC: Progression of aortic calcification is associated with
metacarpal bone loss during menopause: A population-
based longitudinal study. Arterioscler Thromb Vasc Biol 20:
1926 –1931, 2000

6. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcifi-
cation and the risk of osteoporosis and fractures. J Clin
Endocrin Metab 89: 4246 – 4253, 2004

7. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb
MA, Cummings SR: Relationship between osteoporosis
and cardiovascular disease in postmenopausal women.
J Bone Mineral Res 20: 1912–1920, 2005

8. Carr JJ, Register TC, Hsu F-Ch, Lohman K, Lenchik L,
Bowden DW, Langefeld CD, Xu J, Rich SS, Wagenknecht
LE, Freedman BI: Calcified atherosclerotic plaque and bone
mineral density in type 2 diabetes: The diabetes heart
study. Bone 42: 43–52, 2008

9. Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto
H, Kumakura H, Takayama Y, Kanda T, Murakami M,
Kurabayashi M: Elevated arterial stiffness in postmeno-
pausal women with osteoporosis. Maturitas 55: 212–218,
2006

10. Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto
H, Kumakura H, Takayama Y, Kanda T, Murakami M,
Kurabayashi M: Relationship between brachial arterial en-

dothelial function and lumbar spine bone mineral density
in postmenopausal women. Circ J 71: 1555–1559, 2007

11. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,
Luft FC: Electron-beam computed tomography in the eval-
uation of cardiac calcifications in chronic dialysis patients.
Am J Kidney Dis 27: 394 – 401, 1996

12. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cen-
doroglo M, Draibe SA, Moyses RM, Neves KR, Jorgetti V,
Blair A, Guiberteau R, Fernandes Canziani ME: Coronary
calcification in hemodialysis patients: The contribution of
traditional and uremia-related risk factors. Kidney Int 67:
1576 –1582, 2005

13. London GM, Marty C, Marchais SJ, Gue?rin AP, Me?tivier F,
de Vernejoul MC: Arterial calcifications and bone histo-
morphometry in end-stage renal disease. J Am Soc Nephrol
15: 1943–1951, 2004

14. London GM, Marchais SJ, Gue?rin AP, Boutouyrie P, Me?-
tivier F, de Vernejoul MC: Association of bone activity,
calcium load, aortic stiffness, and calcifications in ESRD.
J Am Soc Nephrol 19: 1827–1835, 2008

15. Joki N, Hase H, Shiratake M, Kishi N, Tochigi S, Imamura
Y: Calcaneal osteopenia is a new marker for arterial stiff-
ness in chronic hemodialysis patients. Am J Nephrol 25:
196 –202, 2005

16. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P:
Pulse wave velocity is inversely related to vertebral bone
density in hemodialysis patients. Hypertension 49: 1278 –
1284, 2007

17. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr
PG: Association between vascular calcification, arterial
stiffness and bone mineral density in chronic kidney dis-
ease. Nephrol Dial Transplant 23: 586 –593, 2008

18. Adragao T, Herberth J, Monier-Faugere M-C, Branscum
AJ, Ferreira A, Frazao JM, Curto JD, Malluche HH: Low
bone volume—a risk factor for coronary calcifications in
hemodialysis patients. Clin J Am Soc Nephrol 4: 450 – 455,
2009

19. Majesky MW: Developmental basis of vascular smooth
muscle diversity. Atheroscler Thromb Vasc Biol 27: 1248 –
1258, 2007

20. DeBackey M, Glaser D: Patterns of atherosclerosis: Effect of
risk factors on recurrence and survival – Analysis of 11,890
cases with more than 25-years follow-up. Am J Cardiol 85:
1045–1053, 2000

21. Parhami F, Garfinkel A, Demer LL: Role of lipids in osteo-
porosis. Arterioscler Thromb Vasc Biol 20: 2346 –2348, 2000

22. Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE,
Kim GS: Higher circulating hsCRP levels are associated
with lower bone mineral density in healthy pre- and post-
menopausal women: Evidence for a link between systemic
inflammation and osteoporosis. Osteoporos Int 16: 1263–
1271, 2005

23. Braam LA, Hoeks APG, Brouns F, Hamulya?k K, Gerich-
hausen MJ, Vermeer C: Beneficial effects of vitamins D and
K on the elastic properties of the vessel wall in postmeno-
pausal women: A follow-up study. Thromb Haemost 91:
373–380, 2004

24. Gerdhem P, Obrant KJ: Effects of cigarette smoking on
bone mass as assessed by dual-energy X-ray absorptiom-
etry and ultrasound. Osteoporos Int 13: 932–936, 2002

25. Mody N, Parhami F, Sarafian TA, Demer LL: Oxidative

256 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 254 –257, 2009



stress modulates osteoblastic differentiation of vascular
and bone cells. Free Radic Biol Med 31: 509 –519, 2001

26. Hofbauer LC, Schoppet M: Clinical implications of the
osteoprotegerin/RANKL/RANK system for bone and vas-
cular diseases. JAMA 292: 490 – 495, 2004

27. Collin-Osdoby P: Regulation of vascular calcification by
osteoclast regulatory factors RANKL and osteoprotegerin.
Circ Res 95: 1046 –1057, 2004

28. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Cap-
parelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ,
Simonet WS: Osteoprotegerin-deficient mice develop early
onset osteoporosis and arterial calcification. Genes Dev 12:
1260 –1268, 1998

29. Flore CE, Pennisi P, Ferro G, Ximenes B, Privitelli L, Mang-
iafico RA, Santoro F, Parisi N, Lombardo T: Altered osteo-
protegerin/RANKL ratio and low bone mineral density in
celiac patients on long-term treatment with gluten-free
diet. Horm Metab Res 38: 417– 422, 2006

30. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurg-
ers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL,
Shanahan CM: Human vascular smooth muscle cells un-
dergo vesicle-mediated calcification in response to changes
in extracellular calcium and phosphate concentrations: A
potential mechanism for accelerated vascular calcification
in ESRD. J Am Soc Nephrol 15: 2857–2867, 2004

31. Scatena M, Liaw L, Ghiachelli CM: Osteopontin: A multi-
functional molecule regulating chronic inflammation and
vascular disease. Arterioscler Thromb Vasc Biol 27: 2304 –
2309, 2007

32. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI,
O’Neill WC: Phosphate-induced vascular calcification:
Role of pyrophosphate and osteopontin. J Am Soc Nephrol
15: 1392–1401, 2004

33. Hermans MM, Brandenburg V, Ketteler M, Kooman JP,
van der Sande FM, Gladziwa U, Rensma PL, Bartelet K,
Konings CJ, Hoeks AP, Floege J, Leunissen KM: Study on
the relationship of serum fetuin-A concentration with aor-
tic stiffness in patients on dialysis. Nephrol Dial Transplant
21: 1293–1299, 2006

34. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP,
Bikle DD, Nissenson RA: PTH differentially regulates ex-
pression of RANKL and OPG. J Bone Miner Res 19: 234 –244,
2004

35. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux
C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim

JK, Mauvais-Jarvis F, Ducy P, Karsenty G: Endocrine reg-
ulation of energy metabolism by the skeleton. Cell 130:
456 – 469, 2007

36. Ferron M, Hinoi E, Karsenty G, Ducy P: Osteocalcin dif-
ferentially regulates ?-cells and adipocyte gene expression
and affects the development of metabolic disease in wild-
type mice. Proc Natl Acad Sci U S A 105: 5266 –5270, 2008

37. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD:
Serum adiponectin and bone mineral density in women.
J Clin Endocrin Metab 92: 1517–1523, 2007

38. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M,
Kurioka S, Yano S, Sugimoto T. Serum osteocalcin is asso-
ciated with glucose metabolism and atherosclerosis param-
eters in type 2 diabetes mellitus. J Clin Endocrin Metab.
2008; (ahead of print)

39. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A,
Hashimoto J, Yoshikawa H, Shimomura I: Adiponectin
increases bone mass by suppressing osteoclasts and acti-
vating osteoblasts. Biochem Biophys Res Commun 331: 520 –
526, 2005

40. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao
EY: Adiponectin stimulates human osteoblast proliferation
and differentiation via the MAPK signaling pathway. Exp
Cell Res 309: 99 –109, 2005

41. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim
CA, Ogawa Y, Liu X, Ware SM, Craigen WJ, Robert JJ,
Vinson C, Nakao K, Capeau J, Karsenty G: Serum leptin
level is a regulator of bone mass. PNAS 101: 3258 –3263,
2004

42. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL:
Leptin enhances the calcification of vascular cells: Artery
wall as a target of leptin. Circ Res 88: 954 –960, 2001

43. Coen G, Ballanti P, Fischer MS, Balducci A, Calabria S,
Colamarco L, Di Zazzo G, Lifrieri F, Manni M, Sardella D,
Nofroni I, Bonucci E: Serum leptin in dialysis renal os-
teodystrophy. Am J Kidney Dis 42: 1036 –1042, 2003

44. Laroche M: Intraosseous circulation from physiology to
disease. Joint Bone Spine 69: 262–269, 2002

45. Alagiakrishnan K, Juby A, Hanley D, Tymchak W, Sclater
A: Role of vascular factors in osteoporosis. J Gerontol 4:
362–366, 2008

46. Griffith JF, Yeung DK, Tsang PH, Choi KC, Kwok TC,
Ahuja AT, Leung KS, Leung PC: Compromised bone mar-
row perfusion in osteoporosis. J Bone Miner Res 23: 1068 –
1075, 2008

See related article, “Low Bone Volume—A Risk Factor for Coronary Calcifications in Hemodialysis Patients,” on pages
450 – 455.

Clin J Am Soc Nephrol 4: 254 –257, 2009 Bone–Vascular Axis 257



    157

 INTRODUCTION

Haemodialysis patients are at a very high cardio-
vascular risk not explained by traditional risk fac-
tors1,2. Conventional treatment which reduces car-
diovascular risk in the general population may not 
be effective in dialysis patients, as shown in the 4D 
trial which compared atorvastatin with placebo in a 
group of diabetic patients on haemodialysis3. Ator-
vastatin as compared with placebo did not reduce 
the primary composite endpoint which included 
cardiovascular death or non fatal acute myocardial 
infarction or stroke.

These results may be partially explained by the 
characteristics of cardiovascular death observed in 
dialysis patients. Cardiovascular death is the main 
cause of death in dialysis patients and accounts 
for 48% of all deaths in dialysis patients in the 
USA, as shown by USRDS annual report4. This 
report states that sudden death is the main cause 
of cardiovascular death, responsible for 27% of all 
deaths, while atherosclerosis and acute myocar-
dial infarction, situations in which statin adminis-
tration is recommended, accounts for only 11% of 
all deaths4. 

Another possible explanation for the ineffective-
ness of statins observed in the 4D trial is the type 
of vascular calcification that haemodialysis patients 
develop. Vascular calcification is another factor 
associated with cardiovascular mortality in dialysis 
patients and can onset in two different clinical situ-
ations with different treatment options5. There are 
two types of vascular calcifications: intimal and 
medial calcification. Intimal calcification is associ-
ated with atherosclerosis and is related to altered 

lipid metabolism. Medial calcification is associated 
with arteriolosclerosis and in chronic kidney disease 
(CKD) patients is associated with altered mineral 
metabolism6, in a clinical setting where statins are 
probably not operative. 

The main manifestations of intimal calcification 
are the result of the formation of atherosclerotic 
plaques with stenotic lesions and ischaemia. Medial 
calcification does not cause obstructive lesions but 
modifies the properties of the arterial wall and 
increases arterial stiffness. Arterial stiffness causes 
an increase in pulse pressure and pulse wave veloc-
ity, alterations associated with the development of 
left ventricular hypertrophy and decrease in coronary 
perfusion during diastole and which may cause myo-
cardial ischaemia, even in the absence of stenotic 
lesions. 

It has been demonstrated that vascular calcifica-
tion in dialysis and non-dialysis patients is an 
active cellular process, similar to bone formation7-9. 
Vascular smooth muscle cells can differentiate into 
osteoblasts with different stimuli, which, in dialysis 
patients, may be hyperphosphataemia and hyper-
calcaemia8. Reduction of calcification inhibitors, 
such as fetuin-A or matrix-Gla protein, may be 
another factor associated with the development of 
calcification10. CKD patients experience two distinct 
situations associated with an increase in Ca and P 
levels: hyperparathyroidism, with high bone turn-
over where the bone itself is the source of the high 
levels of Ca and P and adynamic bone disease with 
low bone turnover. Here the bone behaves as a 
“frozen bone” and it is not able to capture the Ca 
and P that the patient receives in food or with 
treatment. 

Is there a link between bone 
and vessel in dialysis patients?
Teresa Adragão

Department of Nephrology, Hospital de Santa Cruz. Carnaxide, Portugal.

Port J Nephrol Hypert 2008; 22(2): 157-163

Received for publication: 01/02/2008

Accepted: 28/02/2008

REVIEW ARTICLE

Nefro - 22-2.indd   157 17-04-2008   11:00:51



158    Port J Nephrol Hypert 2008; 22(2): 157-163

Teresa Adragão

  EVALUATION OF VASCULAR 
CALCIFICATIONS

KDIGO has recommended a new classification for 
chronic kidney disease mineral and bone disorder 
(CKD MBD) which for the first time includes evalua-
tion of vascular calcifications11. In haemodialysis 
patients vascular calcifications can be evaluated by 
different techniques: electron beam computed 
tomography (EBCT)12, multislice computed tomogra-
phy (MSCT)13, ultrasonography5 and plain X-ray6,14,15. 
EBCT and MSCT allow a quantitative measurement 
and are considered the gold standard for evaluating 
vascular calcification but are very expensive. The use 
of plain X-ray for screening vascular calcifications 
has been suggested by KDOQI16 and KDIGO11. We 
have developed a vascular calcification score evalu-
ated by plain X-ray of hands and pelvis which is a 
predictor of cardiovascular death and cardiovascular 
morbidity in dialysis patients14 (Fig. 1). This simple 
vascular calcification score has also been correlated 
with valvular calcifications17 and arterial stiffness18. 

Plain X-ray and ultrasonography are semi-quan-
titative, less expensive and useful for screening for 

vascular calcifications. They can be used to identify 
patients at higher risk of a cardiovascular event. 
EBCT and MSCT are useful for evaluating the pro-
gression of vascular calcification and the effect of 
different treatments on vascular calcification pro-
gression. These two techniques do not differentiate 
intimal from medial calcification and the explanation 
for the very high scores evaluated in dialysis 
patients is the presence of both intimal and medial 
calcification.

  VASCULAR CALCIFICATIONS 
AND HISTOMORPHOMETRIC 
ANALYSIS OF BONE BIOPSIES

London et al.19 demonstrated an association 
between vascular calcifications and low bone turn-
over in a study evaluating 58 haemodialysis 
patients. 23 of these had undergone parathyroidec-
tomy and 33 had aluminium deposits in bone. 
Vascular calcifications were evaluated by ultra-
sonography. More calcifications were associated 
with lower osteoblasts surface and with other 

Figure 1

Results after 3 years’  follow-up*

*Adragao T, Pires A, Lucas C. et al. Nephrol Dial Transplant 2004;19:1480–8

Nefro - 22-2.indd   158 17-04-2008   11:00:52



Port J Nephrol Hypert 2008; 22(2): 157-163    159

Is there a link between bone and vessel in dialysis patients?

markers of low bone turnover, with lower PTH 
levels and with higher calcium dose. In a group of 
42 Portuguese haemodialysis patients who under-
went bone biopsy20 we verified that low bone 
volume was associated with vascular calcifications 
evaluated by MSCT (Fig. 2) or by plain X-ray and 
with higher pulse wave velocity. Adynamic bone 
disease was present in 50% of patients. There were 
no cases of osteomalacia and no aluminium depos-
its in bone.

Gulay et al. demonstrated in a group of 224 
patients that vascular calcifications evaluated by 
MSCT were associated with lower activation fre-
quency evaluated in bone biopsies21. These stud-
ies show an association between vascular calcifi-
cations with low bone volume and with low bone 
turnover in dialysis patients, suggesting that 
patients whose bone is not able to retain calcium 
or phosphorus have higher vascular calcification 
scores. One added risk factor for the development 
of vascular calcifications in the setting of low 
bone turnover could be the administration of 
higher calcium doses, as verified in the London 
study. 

  VASCULAR CALCIFICATIONS 
AND BONE MINERAL DENSITY

An association between low bone mineral den-
sity and vascular calcifications has already been 
described in the general population. In post-meno-
pausal women it was demonstrated that low bone 
mineral density is associated with increase in aortic 
calcifications22. 

Few studies correlating bone mineral density with 
vascular calcifications have been performed in 
dialysis patients. Taal et al.23 verified that osteope-
nia and osteoporosis evaluated by DEXA were asso-
ciated with decreased survival in dialysis patients. 
Raggi et al.24 showed that lower bone mineral den-
sity evaluated in lumbar spine by quantitative com-
puted tomography was associated with higher pulse 
wave velocity. In a group of 70 Portuguese perito-
neal dialysis patients we verified that low bone 
mineral density evaluated by DEXA at the femoral 
neck, but not at the lumbar spine, was associated 
with more vascular calcifications evaluated by plain 
X-ray, with higher pulse wave velocity and with 
peripheral artery disease25 (Fig. 3). 

Figure 2

Vascular Calcifications and Bone Biopsies*

*Adragao T, Ferreira A, Frazao J, et al. Nephrol Dial Transplant  2006; 21(4), iv 292 (abstract)

Nefro - 22-2.indd   159 17-04-2008   11:00:52



160    Port J Nephrol Hypert 2008; 22(2): 157-163

Teresa Adragão

Patients with osteopenia or osteoporosis had 
higher prevalence of peripheral artery disease 
(37%) than patients with normal bone mineral 
density (7%). These associations were adjusted for 
age, gender, diabetes, haemodialysis duration, 
systolic pressure and CaxP product. The absence 
of correlation of bone mineral density evaluated at 
the lumbar spine with vascular calcifications and 
arterial stiffness is probably explained by the pres-
ence of vascular calcifications in the aorta which 
may affect the correct measurement of bone min-
eral density. 

The pathogenesis of the association between low 
bone mineral density parameters and vascular cal-
cifications is not yet known and may be explained 
by a cause-effect relationship or by a common 
aetiological factor affecting both the bone and the 
vessel. Increase in calcium and phosphorus are some 
of the factors that induce vascular calcification8. 
Either hyperparathyroidism or adynamic bone dis-
ease may be associated with osteoporosis26 and 
may be the cause of hyperphosphataemia and hyper-
calcaemia. Oestrogen deficiency is associated with 
osteoporosis27 and oestrogen receptors have been 
identified in vascular smooth muscle cells28 and in 
osteoblasts29.

  CARDIOVASCULAR RISK FACTORS 
AND VITAMIN D DEFICIENCY

In several observational studies, treatment with 
active vitamin D has been associated with reduced 
mortality30-32. This effect was independent of PTH, 
Ca and P levels31, suggesting a pleiotropic effect of 
vitamin D, beyond the control of hyperparathyroid-
ism. London et al. demonstrated that vitamin D 
deficiency in dialysis patients was associated with 
vascular calcification and arterial stiffness33. Vitamin 
D deficiency may also be associated with develop-
ment of cardiac ventricular hypertrophy, as demon-
strated in Vitamin D receptor knock-out mice34. 

One possible explanation for this hypothetical 
beneficial effect of vitamin D is given by the discov-
ery that 1,25-vitD suppresses renin gene expression35 
and by the association between vitamin D deficiency 
and activation of the renin angiotensin system34. 
Activation of vitamin D receptor has also been asso-
ciated with reduction of vascular calcifications36. In 
a group of 48 Portuguese haemodialysis patients we 
verified that vitamin D deficiency was independently 
associated with vascular calcifications evaluated 
either by plain X-ray or by MSCT. Vitamin D defi-
ciency was also associated with aortic augmentation 

Figure 3

Vascular Calcifications, Arterial Stiffness and Bone Mineral Density*

*Adragao T, Branco P, Birne R. J Am Soc Nephrol 2006;17:272A TH-PO779 (abstract) 

Nefro - 22-2.indd   160 17-04-2008   11:00:52



Port J Nephrol Hypert 2008; 22(2): 157-163    161

Is there a link between bone and vessel in dialysis patients?

index, a marker of arterial stiffness and with left 
ventricular mass index (LVMI) evaluated by M Mode 
echocardiography37 (Fig. 4). This association was 
adjusted for age, mean arterial pressure, haemoglo-
bin and cholesterol levels. 

The association of 25-vitD deficiency with LVMI 
increase that we verified in our patients is an impor-
tant finding that goes towards explaining the reduc-
tion of mortality associated with treatment with 
active vitamin D. Left ventricular hypertrophy is 
associated with arrhythmic risk and with sudden 
death38,39 and sudden death is the main cause of 
cardiovascular death in the dialysis population4. 

  WILL TREATMENT OF BONE 
DISEASE REDUCE CARDIOVASCULAR 
RISK IN DIALYSIS PATIENTS?

If it is true that there is a link between bone 
disease and cardiovascular disease, it is necessary 
to demonstrate that the management of mineral and 
bone disorder is associated with a reduction in 
cardiovascular risk. There is already some evidence 
demonstrating this effect. The TTG40 and RIND41 

trials have evaluated the progression of coronary 
calcifications in patients with hyperphosphataemia 
treated with sevelamer or calcium salts. The TTG 
evaluated prevalent patients and the RIND evalu-
ated incident patients. The TTG showed that 
patients treated with calcium showed a 25% 
increase in the coronary Agatston score while coro-
nary calcification did not increase in patients 
treated with sevelamer. In the RIND trial patients 
treated with calcium had an 11-fold increase in 
median coronary calcification score as compared 
with patients treated with sevelamer. 

Both studies also demonstrated that calcium and 
sevelamer had a similar effect on the reduction of 
phosphorus levels, showing that it is not enough to 
reduce phosphorus levels to avoid progression of 
vascular calcifications. In terms of biochemical 
parameters, the main difference was that in patients 
treated with calcium there was also an increase in 
Ca levels and a decrease in PTH levels.

Raggi et al.42 evaluated the effect of phosphate 
binders on bone mineral density in a group of 200 
haemodialysis patients. Vascular calcifications and 
bone mineral density were assessed at baseline and 
at the end of treatment by either sevelamer or 

Figure 4

Vitamin D deficiency and cardiovascular risk factors*

*AdragaoT, Ferreira A, Frazão J. Port J Nephrol Hypert 2008;22:66 (abstract)

Nefro - 22-2.indd   161 17-04-2008   11:00:53



162    Port J Nephrol Hypert 2008; 22(2): 157-163

Teresa Adragão

calcium salts. Patients treated with calcium salts 
showed an increase in coronary calcifications and a 
decrease in trabecular bone density, in association 
with higher Ca levels, lower PTH levels and lower 
total and bone-specific alkaline-phosphatase levels. 
This effect of calcium treatment on bone density was 
confirmed in the Asmus et al.43 study, showing that 
treatment of 72 haemodialysis patients with calcium 
carbonate was associated with a decrease in bone 
density as compared with sevelamer. 

The follow-up study of the RIND trial44 showed 
that in incident patients treatment with calcium was 
associated with lower survival than sevelamer. The 
DCOR trial45, a multicentre, open-label study, com-
pared the effect on mortality of sevelamer versus 
calcium salts in 2100 prevalent haemodialysis 
patients. All-cause and cardiovascular mortality were 
not statistically different between the two treatment 
groups. This study could only demonstrate that 
treatment with sevelamer reduced mortality in 
patients over 65 years of age, and in patients 
treated for more than 2 years. 

There are many reasons which could explain the 
different outcomes of the DCOR and RIND trials. 
The former evaluated prevalent patients while the 
latter was performed in patients new to dialysis. The 
mean follow-up was shorter in the DCOR trial: 20 
months in DCOR versus 44 months in RIND. In the 
DCOR trial, the number of previewed cardiovascular 
events necessary to demonstrate a difference 
between the two treatment groups was not reached. 
Annual mortality rate in the DCOR trial was lower 
than the annual mortality rate reported in USRDS4: 
15.02% in the sevelamer group and 16.15% in the 
calcium binders group. Vascular calcification was not 
evaluated in DCOR but prevalent patients may have 
a higher vascular calcification score than incident 
patients. For instance, baseline coronary calcification 
score was higher in prevalent patients in the TTG 
trial, where median score was 641 Hounsfield units, 
than in incident patients in the RIND trial with a 
median score of 473 Hounsfield units. These results 
underline the need to begin treatment at an earlier 
phase in haemodialysis patients.

In non-randomised studies, treatment with active 
vitamin D has been associated with a reduction of 
mortality in dialysis patients. In a small cohort of hae-
modialysis patients with secondary hyperparathyroidism, 

treatment with calcitriol was associated with regression 
of left ventricular hypertrophy46. This result may be the 
consequence of a cardioprotective effect of vitamin D 
or could be associated with control of hyperparathyroid-
ism. It is necessary to demonstrate if correction of 
25-vitD deficiency with or without treatment with active 
vitamin D contributes to a reduced cardiovascular risk 
in dialysis patients.

  CONCLUSIONS

Vascular calcifications are the result of a complex 
balance between calcification inducers and inhibitors 
and are associated with cardiovascular risk in dialy-
sis patients.

Vascular calcifications are associated with low 
bone turnover, low bone volume and low bone 
density. Management of bone and mineral disorders 
in chronic kidney disease may be associated with 
cardiovascular risk reduction. Plain X-ray can be used 
for screening vascular calcifications in dialysis 
patients and the evaluation of the simple vascular 
calcification score identifies patients at higher car-
diovascular risk. This information is an important 
aid in choosing the most suitable treatment for these 
patients.

Presence of vascular calcifications, old age, dia-
betes mellitus, haemodialysis vintage, previous 
parathyroidectomy and adynamic bone disease are 
the most frequent factors associated with develop-
ment or progression of vascular calcifications. In 
these patients it is important to avoid positive cal-
cium balance, hyperphosphataemia and oversup-
pression of PTH. Vitamin D deficiency has also been 
associated with vascular calcifications, arterial stiff-
ness and left ventricular hypertrophy and it is neces-
sary to demonstrate if treatment with vitamin D is 
associated with a reduced cardiovascular risk.

Understanding the mechanisms linking bone dis-
ease to cardiovascular disease is opening up a new 
treatment field that might reduce the high cardio-
vascular risk of dialysis patients.

Conflict of interest statement. Dr Adragão has received research 

grants from Amgen and Genzyme and has received lecture fees 

from Amgen, Genzyme and Abbott.

Nefro - 22-2.indd   162 17-04-2008   11:00:53



Port J Nephrol Hypert 2008; 22(2): 157-163    163

Is there a link between bone and vessel in dialysis patients?

References

 1 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic 
renal disease. J Am Soc Nephrol 1998;9:(12):S16-23

 2 Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors 
in dialysis patients compared with the general population: the CHOICE Study. J Am 
Soc Nephrol 2002;13:1918-27

 3 Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mel-
litus undergoing  hemodialysis. N Engl Med 2005;353:238-48

 4 U.S. Renal Data System, USRDS 2005 Annual Data Report; National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005

 5 Blacher J, Guérin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and 
cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938–942

 6 London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage 
renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 
2003;18:1731-40

 7 Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regu-
lating proteins in association with Monckeberg’s sclerosis: evidence for smooth 
muscle cell-mediated vascular calcification. Circulation 1999;100:2168–2176

 8 Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004:15:2959–296

 9 Moe SM, O’Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is 
associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-647

 10 Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcification: 
role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood 
Purif 2002;20:473–476

 11 Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal 
osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes 
(KDIGO). Kidney Int 2006;69:1945–1953

 12 Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam com-
puted tomography in the evaluation of cardiac calcification in chronic dialysis patients. 
Am J Kidney Dis 1996;27:394–401

 13 Moe SM, O’Neill KD, Fineberg N et al. Assessment of vascular calcification in ESRD 
patients using spiral CT. Nephrol Dial Transplant 2003;18:1152-8

 14 Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardio-
vascular risk in haemodialysis patients. Nephrol Dial Transplant 2004;19:1480-1488.

15  Belasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging tests and 
coronary artery calcium measured by computed tomography in hemodalysis patients. 
Kidney Int 2006;70:16

 16 National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism 
and Disease in Chronic Kidney disease. Am J Kidney Dis 2003;42 [Suppl 3]

 17 Adragao T, Pires A, Lucas C et al. Vascular and valvular calcifications in dialysis patients: 
the same pathogenesis? Port J Nephrol Hypert 2007;21:281-285

 18 T.Adragao, A.Pires, C.Lucas et al. A simple vascular calcification score is a predictor of 
pulse wave velocity in hemodialysis patients. J Am Soc Nephrol 2005 16:473A (PO638).

 19 London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphom-
etry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943–1951

 20 Adragao T, Ferreira A, Frazão JM, et al. Vascular Calcifications and bone turnover in 
hemodialysis patients. Nephrol Dial Transplant 2006;21(suppl 4) iv 292 (MO014)

 21 Gulay A, Mehmet O, Soner D et al. The Link Between Cardiovascular And Bone Disease 
In Hemodialysis Patients. SaO012. XLIV ERA-EDTA Congress 2007

 22 Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and 
fractures. J Clin Endocrinol Metab 2004;89:4246-53

 23 Taal MW, Roe S, Masud T, et al. Total hip bone mass predicts survival in chronic 
hemodialysis patients. Kidney Int 2003;63:1116-20

 24 Raggi P, Bellasi A, Ferramosca E et al. Pulse wave velocity is inversely related to 
vertebral bone density in hemodialysis patients. Hypertension 2007;49:1278-84

 25 Adragao T, Branco P, Birne R, et al. Bone Mineral Density, Arterial Calcifications and 
Arterial Stiffness in PD patients. J Am Soc Nephrol 17:2006, 272A TH-PO779 (abstract)

 26 Malluche HH, Monier-Faugere MC. Renal osteodystrophy: What’s in a name? Presenta-
tion of a clinically useful new model to interpret bone histologic findings. Clin Neph-
rol 2006;65:235-242

 27 Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: 
estrogen deficiency causes both type I and type II osteoporosis in postmenopausal 
women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73

 28 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular 
system. N Engl J Med 1999;340:1801–1811

 29 Eriksen EF, Colvard DS, Berg NJ et al. Evidence of estrogen receptors in normal human 
osteoblast-like cells. Science 1988;241:84-86

 30 Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with 
paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56

 31 Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis 
survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-25

 32 Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients 
receiving different vitamin D analogs. Kidney Int 2006;70:1858-65

 33 London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions 
in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc 
Nephrol 2007;18:613-20

 34 Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout 
mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endo-
crinol Metab 2005;288:E125-32

 35 Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regula-
tor of the renin-angiotensin system. J Clin Invest 2002;110:229-238

 36 Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin 
D receptor activation. Kidney Int 2006:69:33-43

 37 Adragao T, Ferreira A, Frazao J, et al. Déficit de 25-Hidroxivitamina D: um novo factor 
de risco cardiovascular? Port J Nephrol Hypert 2008;22(1):66 CO SE 1005 (abstract).

 38 Oikarinen L, Nieminen MS, Viitasalo M, et al. Relation of QT interval and QT dispersion 
to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive 
patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 
2001;10:1883-91

 39 Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy 
is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year 
survey. Nephrol Dial Transplant 2004;19:1829-34

 40 Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coro-
nary and aortic calcification in dialysis patients. Kidney Int 2002;62:245-52

 41 Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary 
artery calcification in patients new to dialysis. Kidney Int 2005;68:1815-24

 42 Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with 
calcium based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-72

 43 Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium 
carbonate effects on cardiovascular calcification and bone density. Nephrol Dial 
Transplant 2005;20:1653-61

 44 Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and 
binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41

 45 Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based 
phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7

 46 Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion 
in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006;102:21-29

Nefro - 22-2.indd   163 17-04-2008   11:00:54





Treatment of hyperphosphatemia with sevelamer
hydrochloride in dialysis patients: effects on vascular
calcification, bone and a close look into the
survival data
Joa?o M. Fraza?o

1
and Teresa Adraga?o

2

1
Nephrology Department, Hospital de S. Joa?o, Medical School and Nephrology Research and Development Unit, University of Porto,
Porto, Portugal and 2Department of Nephrology, Hospital de Santa Cruz, Carnaxide, Portugal

In chronic kidney disease patients, bone and mineral

abnormalities have a major impact on morbidity and

mortality. Hyperphosphatemia has been associated with

increased mortality and with the development of

cardiovascular calcification, an independent predictor of

mortality. Vascular calcifications have been associated with

low bone turnover, low bone volume and lower activation

frequency. In dialysis patients, the treatment of

hyperphospathemia with calcium based compounds, when

compared with sevelamer, is associated with more frequent

episodes of hypercalcemia, suppression of intact parathyroid

hormone and with progression of coronary calcifications. In

the presence of adynamic bone disease, calcium load has a

significantly higher impact on aortic calcifications and

stiffening. A randomized, prospective, open label study,

evaluated patients with bone biopsies at the beginning and

after 1 year treatment period with sevelamer hydrochloride

or calcium carbonate. Sevelamer treatment resulted in no

statistically significant changes in bone turnover or

mineralization compared with calcium carbonate, but bone

formation rate increased and trabecular architecture

improved only with sevelamer. In incident dialysis patients,

treatment with sevelamer has been associated with better

survival, while in prevalent patients a clear benefit could only

be demonstrated in older patients and in patients treated for

more than 2 years. In conclusion, the treatment of

hyperphosphatemia with sevelamer hydrochloride, a non-

calcium and non-metal containing phosphate binder, is

associated with a beneficial effect on vascular calcification

progression, bone disease and most likely with a survival

benefit in some hemodialysis patients populations.

Kidney International (2008) 74 (Suppl 111), S38–S43; doi:10.1038/ki.2008.544

KEYWORDS: hyperphosphatemia; severelamer hydrochloride; vascular

calcification; survival

The last few years have seen major developments in the
management of bone and mineral disorders associated with
chronic kidney disease (CKD). Acknowledgment of the fact
that these bone and mineral abnormalities in CKD patients
have a major impact on morbidity and mortality drove
nephrologists’ attention to the importance of controlling these
alterations. In addition, new compounds have been developed
for the control of hyperphosphatemia and for the treatment of
secondary hyperparathyroidism, raising many questions to-
ward the use of non-calcium-containing phosphate binders.

Until recently, the only phosphate binders available were
aluminum or calcium-based compounds. These compounds
were efficacious but were also associated with significant side
effects. The use of aluminum-containing phosphate binders is
associated with bone disease as well as hematologic and central
nervous system toxicity, whereas the use of calcium-containing
phosphate binders is associated with increased risk of
hypercalcemia and cardiovascular calcification.

1–4
It is now

known that serum calcium levels are not accurate in predicting
the calcium balance and burden. The excessive amount of
calcium ingested from diet and calcium-containing binders has
been associated with cardiovascular calcifications, even in the
presence of normal calcium serum levels.1–4 The non-calcium,
non-metal-containing, and non-absorbed phosphate binder,
sevelamer hydrochloride, has provided an effective way to bind
phosphorus in the gut without the risks of hypercalcemia, soft
tissue or vascular calcifications, or heavy metal accumulation.

EFFECTS ON VASCULAR CALCIFICATION

In recent years, it has become clear that the presence of
elevated serum phosphorus levels in CKD stage 5 patients is
positively associated with increased mortality.5,6 Hyperpho-
sphatemia and elevated calcium-phosphorus product
(Ca X P) are associated with cardiovascular calcification.1,2

Cardiovascular calcification is an independent predictor of
mortality. Several authors have now reported a strong
positive association between the presence and extent of
vascular calcification and both cardiovascular and all-cause
mortality.3,7,8 Raggi et al.9 reported that previous myocardial

review http://www.kidney-international.org

&amp;amp; 2008 International Society of Nephrology

Correspondence: Joa?o M. Fraza?o, Hospital de S. Joa?o, Servic?o de

Nefrologia, Alameda Herna?ni Monteiro, 4200 Porto, Portugal.

E-mail: jmmdfrazao@netcabo.pt

S38 Kidney International (2008) 74 (Suppl 111), S38–S43



infarction, angina, and known coronary artery disease were
all more common in CKD stage 5 patients with extensive
calcification.

Most stage 5 CKD patients present with hyperpho-
sphatemia. The clinical outcomes of this mineral abnormality
include secondary hyperparathyroidism with consequent
renal bone disease, extra-osseous calcification, and increased
mortality.

Therapeutic strategies to control phosphorus levels
include dietary restrictions, dialysis, and the use of
phosphate-binding agents. Reduction of phosphate intake
in the diet is often difficult and is also limited by the
associated protein restriction, as all proteins contain
phosphate. Phosphate is also difficult to remove by dialysis.
Increased dialysis time or frequency may be effective, but it is
often difficult to implement because of logistic problems and
poor patient acceptance.

Sevelamer hydrochloride has been widely studied and
shown to be effective in reducing phosphorus levels and
Ca X P without causing hypercalcemia and soft tissue
calcification in stage 5 CKD population on hemodialysis,
with the added benefit of cholesterol reduction (total and
low-density lipoprotein cholesterol). This compound is well
tolerated with few side effects, the more frequently reported
ones being diarrhea, constipation, dyspepsia, nausea, and
vomiting.

Chertow et al.4 reported the results of a randomized
parallel design clinical trial comparing sevelamer with
calcium-based phosphorus binders in 200 hemodialysis
patients. Sevelamer and calcium-based compounds provided
similar control of serum phosphorus and Ca X P. Adherence
to the prescribed dose of binder in the sevelamer and
calcium-containing binder groups was similar: 86 vs 80%,
respectively. The group treated with sevelamer received an
average binder dose of 6.5±2.9 g per day and the group
treated with calcium-based binders, 4.3±1.9 g per day (4.6
and 3.9 g per day of calcium acetate or calcium carbonate,
respectively). The calcium-based group had more frequent
episodes of hypercalcemia when compared with the sevela-
mer group: 43 and 17%, respectively. Suppression of intact
parathyroid hormone secretion below the 150–300 pg/ml
range was more common at the end of the study in the
calcium-based binders group, 57 vs 30%, despite the
protocol-specified reduction or cessation of vitamin D for
intact parathyroid hormone below 150 pg/ml. Twelve percent
of patients in the calcium group required rescue therapy with
aluminum-containing binders for a calcium-phosphorus
product above 72 mg

2
/100ml

2
, compared with 4% of patients

in the sevelamer group. Total and low-density lipoprotein
cholesterol decreased significantly in the sevelamer-treated
group compared with a non-change in the calcium binders
group. It is relevant that, the electron beam computed
tomography (EBCT) performed at the beginning of the study
detected a prevalence of coronary artery calcification of 83%
and aortic calcification of 80% of the study patients. There
was significant progression of the coronary artery and aortic

calcification EBCT score, at weeks 26 and 52, in the calcium-
containing binders-treated group, despite the use of an
average dose of calcium-containing binders of only 4.3±1.9 g
per day, which corresponds to values of elemental calcium
under the Kidney Disease Outcomes Quality Initiative
recommendations. There was no significant progression in
the sevelamer-treated group.

The high prevalence of vascular calcification seen in the
dialysis population in the Chertow study4 has been
confirmed by other reports and is of major concern because
of the positive association between the presence and severity
of calcification and mortality in this population. There is also
some evidence that most of the patients develop vascular
calcifications while on hemodialysis treatment. In fact, a
report from Spiegel et al.10 revealed that only 34% of patients
with advanced CKD starting dialysis had coronary artery
calcifications scores that placed them above the 90th
percentile for age and sex. In the same patient population
initiating dialysis, 109 patients underwent baseline and at
least one additional measurement of coronary artery
calcification.11 At baseline, 37% of the patients who under-
went treatment with sevelamer and 31% of the patients who
underwent treatment with calcium-based binders had no
evidence of calcification. The authors report that no patients
with a zero coronary calcium score progressed to a coronary
artery calcium score 430, using EBCT, in an 18-month
period of time. Patients already having a coronary artery
calcium score 430 at baseline progressed during the time of
the study in both arms. The patients treated with calcium-
based binders showed a more rapid and severe progression
when compared with those receiving sevelamer. It can be
noted that, during this study, all the patients were maintained
on dialysis with a calcium dialysate concentration of
2.5 mEq/l. The authors conclude that patients new to dialysis,
with no evidence of coronary calcification, showed little
evidence of disease development over a period of 18 months
independent of the phosphate binder used. Patients with even
little evidence of coronary calcification progress with both
binders; however, the group treated with calcium-based
binders have a much more severe progression when
compared with the patients treated with sevelamer.11 With-
out any doubt, this study confirms the importance of the
Kidney Disease Outcomes Quality Initiative clinical practice
guidelines for bone metabolism and disease in CKD,
recommending that calcium-based binders should be avoided
in patients with evidence of severe calcification.12

‘Kidney Disease: Improving Global Outcomes’ has re-
commended a new classification for CKD mineral and bone
disorder that includes for the first time the evaluation of
vascular calcifications.13 In hemodialysis patients, vascular
calcifications may be evaluated by different techniques:
EBCT,14 multislice computed tomography (MSCT),15 ultra-
sonography,7 and plain X-ray.3,8,16 EBCT and MSCT allow a
quantitative measurement and are considered the gold
standard for evaluating vascular calcification, but are very
expensive. The utilization of plain X-ray for screening

Kidney International (2008) 74 (Suppl 111), S38–S43 S39

JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review



vascular calcifications has been suggested by Kidney Disease
Outcomes Quality Initiative12 and ‘Kidney Disease: Improv-
ing Global Outcomes’.13 We have developed a vascular
calcification score evaluated in plain X-ray of hands and
pelvis (Figure 1), which was a predictor of cardiovascular
death and cardiovascular morbidity in dialysis patients
(Figure 2).8 This simple vascular calcification score has been
also correlated with valvular calcifications

17
and with arterial

stiffness.18

Plain X-ray and ultrasonography are semiquantitative, less
expensive, and useful for screening the presence of vascular
calcifications. They can be used to identify patients at higher
risk of a cardiovascular event. EBCT and MSCT are useful for
evaluating the progression of vascular calcification and the
effect of different treatments on progression of vascular
calcification. These two techniques do not differentiate
intimal from medial calcification, and the explanation for
the very high scores evaluated in dialysis patients is the
presence of both types of calcification.

EFFECTS ON BONE

In a randomized prospective, open label study, 119
hemodialysis patients were evaluated with bone biopsies
performed at the beginning and after a 1-year treatment
period, to compare the effects of sevelamer hydrochloride
and calcium carbonate on bone.19 Biopsy-proven adynamic
bone disease was the most frequent bone abnormality at
baseline (59%). The serum phosphorus levels were similarly
controlled in both groups, although the serum calcium level
was consistently lower and intact parathyroid hormone
higher in patients treated with sevelamer. Compared with
baseline values, there were no changes in mineralization lag
time or measures of bone turnover after 1 year of treatment
with both sevelamer and calcium carbonate. Bone formation
rate per bone surface increased significantly from baseline
only in the sevelamer-treated patients. In addition, of those
with abnormal microarchitecture at baseline (that is,
trabecular separation), 7 of 10 in the sevelamer group
normalized after 1 year compared with 0 of 3 in the calcium
group. In summary, this study showed that sevelamer
treatment resulted in no statistically significant changes in
bone turnover or mineralization compared with calcium
carbonate, but bone formation rate increased and trabecular
architecture improved only with sevelamer.

In a group of 42 hemodialysis patients submitted to bone
biopsies,20 we have verified that low bone volume was
associated with vascular calcifications evaluated by MSCT or
by plain X-ray and with higher pulse wave velocity. Adynamic
bone disease was present in 50% of patients. There were no
cases of osteomalacia and no aluminum deposits in bone.

London et al.21 showed the existence of an association
between vascular calcifications and low bone turnover. In this
study, 58 hemodialysis patients were evaluated; 23 patients
had been submitted to parathyroidectomy and 33 patients
had aluminum deposits in bone. Vascular calcifications were
evaluated by ultrasonography. More calcifications were
associated with lower osteoblast surface and with other

Figure 1 | Pelvis score evaluates the presence of vascular
calcifications in iliac and femoral arteries. Hands score
evaluates the presence of vascular calcification in the radial and
digital arteries. Calcification score is the sum of the presence (1) or
absence (0) of vascular calcifications in each section. In this
example pelvis score (1 þ 1 þ 1 þ 1) ¼ 4 and hands score
(1 þ 1 þ 1 þ 1) ¼ 4. Total score is 8.

C
V

 M
o

rt
a

lit
y

403020100

n = 58

3 deaths
5%

14 deaths
23%Log rank  =  5.7

P = 0.01

n = 65

sc&amp;lt;3

Follow-up (months)

Kaplan–Meier
n = 123

COX regression

CV hospitalizations

0.01 100

Peripheral artery disease

Vascular disease

CV death

9.3

3.8

3.9

4.4

P = 0.001

P = 0.001

P = 0.02

P = 0.02

1010.1

0.2

0.1

0

sc &gt; 3

Vascular score &gt; 3 and CV death Vascular score &gt; 3 and CV risk 

Figure 2 | Calcification score from plain X-ray of hands and pelvis was a predictor of cardiovascular death and cardiovascular
morbidity in dialysis patients. After 3 years of follow-up vascular score X3 was associated with higher cardiovascular mortality and
morbidity.8

S40 Kidney International (2008) 74 (Suppl 111), S38–S43

review JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival



markers of low bone turnover, with lower parathyroid
hormone levels and with higher calcium dose. Asci et al.22

showed, in a group of 224 patients, that vascular calcifica-
tions evaluated by MSCT were associated with lower
activation frequency evaluated in bone biopsies.

A recent study was performed to assess the impact of bone
activity on the relationships between the dosage of calcium-
containing binders and aortic stiffness or abdominal aorta
calcification score.23 A significant interaction was found
between the dosage of calcium-containing phosphate binders
and bone activity such that the calcium load had a
significantly higher impact on aortic calcifications and
stiffening in the presence of adynamic bone disease.

The data presented suggest that sevelamer treatment has a
beneficial effect on bone, with an increase in the bone
formation rate and an improvement in the trabecular
architecture. There is an association between vascular
calcifications and low bone volume and with low bone
turnover in dialysis patients. Finally, in dialysis patients with
adynamic bone, calcium load has a greater influence on
aortic calcifications and stiffening. Patients whose bone is not
able to retain calcium or phosphorus have higher vascular
calcification scores. One added risk factor for the develop-
ment of vascular calcifications in the setting of low bone
turnover is the administration of calcium-containing phos-
phate binders.

A CLOSE LOOK INTO THE SURVIVAL DATA

The promise of a survival benefit with the use of sevelamer
hydrochloride has been evaluated in two randomized
prospective, controlled studies with interesting results that
generate some controversy and certainly have not completely
solved the issue.

The first was the ‘Dialysis Clinical Outcomes Revisited
(DCOR)’ study.

24
This 3-year trial involving more than 2100

patients compared the difference in mortality and morbidity
outcomes for patients receiving sevelamer hydrochloride and
those receiving calcium-containing phosphate binders. This
was the largest outcomes study ever conducted in the
hemodialysis population. This study showed that the patients
treated with sevelamer hydrochloride experienced a reduction
of 7% in the risk of death from all causes when compared
with the patients treated with calcium-based phosphate
binders, which was statistically not significant (P ¼ 0.3). The
patients aged 65 years or more (a predefined analysis) were
23% less likely to die when treated with sevelamer
hydrochloride, as compared with treatment with calcium-
based binders. In addition, patients treated with sevelamer
hydrochloride for more than 2 years had a 34% reduction of
the mortality risk for all causes compared with those treated
with the calcium-containing binders.

The second study was the ‘Renagel in New to Dialysis
Patients.’25 This was a randomized controlled, prospective,
open label study with 127 patients incident to dialysis,
assigned to 18 months treatment with sevelamer hydro-
chloride or calcium-containing phosphate binders, to assess

coronary artery calcification progression. Mortality was a
predetermined secondary end point.25 Twenty-three deaths in
the calcium-containing phosphate binders group and 11
deaths in the sevelamer hydrochloride-assigned patients
occurred during the median 44 months of follow-up time
after randomization, a significantly lower mortality for
patients treated with sevelamer hydrochloride. The survival
benefit observed with sevelamer hydrochloride treatment
persisted after full multivariate adjustment.

It is very important to analyze the reasons for the
differences observed in the outcomes of these two trials. The
DCOR trial evaluated prevalent patients probably with a
more important burden of calcification, whereas ‘Renagel in
New to Dialysis Patients’ trial was performed in patients new
to dialysis. It is probably very difficult to reverse already
existing vascular calcifications. The DCOR trial has been
criticized for the short follow-up time of less than 2 years.
The median follow-up was shorter in the DCOR trial
compared with the ‘Renagel in New to Dialysis Patients’
trial, 19 vs 44 months, respectively. The short follow-up time
in the DCOR trial did not allow the differences in mortality
to appear. In fact, for the patients followed for more than 2
years, the difference in mortality became significant. In the
DCOR trial, the number of previewed cardiovascular events
necessary to demonstrate a difference between the two
treatment groups was not reached. The annual mortality rate
in the DCOR trial was inferior to the annual mortality rate
reported in United States Renal Data System.26

The results of these two studies strongly suggest that the
use of sevelamer as a phosphate binder decreases mortality in
incident and in elderly hemodialysis patients and reinforces
the importance of earlier initiation of treatment with
sevelamer hydrochloride in hemodialysis patients.

A final comment is on the systematic review of the clinical
efficacy and safety of sevelamer hydrochloride in dialysis
patients published by Tonelli et al.27 In the mortality analysis,
the authors included five studies (Table 1), with only one of
them having mortality as the primary end point.25 The other
three studies included (Table 1) in the mortality analysis
involved a small number of patients, had a short follow-up,
and mortality was not an end point. These studies4,28,29 were
not powered in terms of follow-up time, number of patients,
and end points to evaluate mortality. In our view, it is
impossible to withdraw any mortality information in studies
with 42 patients and a 5-month follow-up, or a crossover
study with 20 patients and a total follow-up of 18 weeks. The
Chertow study’s4 primary end point was vascular calcifica-
tion; mortality was not even an end point and received 24%
weight in the analysis. Regarding the ‘Renagel in New to
Dialysis Patients’ study, with a long follow-up for the
secondary end point mortality and evidence of survival
benefit in the sevelamer-treated group, the weight attributed
was only 4.26%.

In our opinion, the available data on mortality benefit
with sevelamer hydrochloride treatment from two rando-
mized prospective controlled trials constitute a very positive

Kidney International (2008) 74 (Suppl 111), S38–S43 S41

JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review



fact that is certainly innovative in the nephrology field. We
are not aware of any other pharmacological intervention in
dialysis patients with such ground in terms of hard outcome
data.

In a recent editorial,
30
the authors state that ‘to cultivate a

balanced approach to understanding results generated by
meta-analysis of data from small trials it is important to
accept the limitations implicit in this method.’ Meta-analysis
only generates hypotheses and certainly should be carefully
interpreted. One should always keep in mind that well-
designed, randomized controlled trials are the strong bases
for evidence-based medicine.

There is mounting evidence from basic science,
31

observational studies,32 and randomized trials with surrogate
end points such as cardiovascular calcification4,11 and
mortality25 that calcium can be toxic for dialysis patients.
With this level of information, the nephrology community
should be asking what level of scientific evidence is needed to
convince us to discontinue, or at least to be extremely
cautious with the use of calcium-containing phosphate
binders, a potentially harmful therapy.

DISCLOSURE
Joa?o M Fraza?o has received consulting and lecture fees from
Amgen and Genzyme. Teresa Adraga?o has declared no financial
interests.

REFERENCES
1. Guerin A, London G, Marchais S et al. Arterial stiffening and vascular

calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:
1014–1021.

2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in
young adults with end-stage renal disease who are undergoing dialysis.
N Engl J Med 2000; 342: 1478–1483.

3. London GM, Gue?rin AP, Marchais SJ et al. Arterial media calcification in
end-stage renal disease: impact on all-cause and cardiovascular mortality.
Nephol Dial Transplant 2003; 18: 1731–1740.

4. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer
attenuates the progression of coronary and aortic calcification in
hemodialysis patients. Kidney Int 2002; 62: 245–252.

5. Block G, Hulbert-Shearon T, Levin N et al. Association of serum
phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:
607–617.

6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and
morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:
2208–2218.

7. Blacher J, Gue?rin AP, Pannier B et al. Arterial calcifications, arterial
stiffness, and cardiovascular risk in end-stage renal disease. Hypertension
2001; 38: 938–942.

8. Adraga?o T, Pires A, Lucas C et al. A simple vascular calcification score
predicts cardiovascular risk in haemodialysis patients. Nephrol Dial
Transplant 2004; 19: 1480–1488.

9. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in
adult hemodialysis patients. A link between end-stage renal
disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:
695–701.

10. Spiegel DM, Raggi P, Metha R et al. Coronary and aortic calcification in
patients new to dialysis. Hemodialysis Int 2004; 8: 265–272.

11. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on
coronary artery calcification in patients new to hemodialysis. Kidney Int
2005; 68: 1815–1824.

12. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney disease. Am J Kidney Dis 2003;
42(Suppl 3): S1–S201.

13. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and
classification of renal osteodystrophy: a position statement from Kidney
Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:
1945–1953.

14. Braun J, Oldendorf M, Moshage W et al. Electron beam computed
tomography in the evaluation of cardiac calcification in chronic dialysis
patients. Am J Kidney Dis 1996; 27: 394–401.

15. Moe SM, O’Neill KD, Fineberg N et al. Assessment of vascular calcification
in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18:
1152–1158.

16. Belasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging
tests and coronary artery calcium measured by computed tomography in
hemodalysis patients. Kidney Int 2006; 70: 16.

17. Adragao T, Pires A, Lucas C et al. Vascular and valvular calcifications in
dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 21:
281–285.

18. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score is a
predictor of pulse wave velocity in hemodialysis patients. J Am Soc
Nephrol 2005; 16: 473A (PO638).

19. Ferreira A, Fraza?o JM, Monier-Faugere MC et al. Effects of sevelamer
hydrochloride and calcium carbonate on renal osteodystrophy in
hemodialysis patients. J Am Soc Nephrol 2008; 19: 405–412.

20. Adragao T, Ferreira A, Fraza?o JM et al. Vascular Calcifications and bone
turnover in hemodialysis patients. Nephrol Dial Transp 2006; 21(Suppl 4):
iv 292 (MO014).

21. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone
histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15:
1943–1951.

22. Asci G, Ozkahya M, Duman S et al. The link between cardiovascular and
bone disease in hemodialysis patients. Nephrol Dial Transp 2007;
22(Suppl 6): vi 217 (MO014).

23. London GM, Marchais SJ, Ge?rin AP et al. Association of bone activity,
calcium load, aortic sitfness, and calcifications in ESRD. J Am Soc Nephrol
2008; 19: 1827–1835.

24. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-
based phosphate binders on mortality in hemodialysis patients. Kidney Int
2007; 72: 1130–1137.

25. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification
and phosphate binder choice in incident hemodialysis patients. Kidney Int
2007; 71: 438–441.

26. U.S. Renal Data System, USRDS 2005 Annual Data Report National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2005.

27. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical
efficacy and safety of sevelamer in dialysis patients. Nephrol Dial
Transplant 2007; 22: 2856–2866.

Table 1 | Summary of the studies used for mortality analysis

Author Number of patients Follow-up Primary end points

Block et al.25 127 18 months for the primary end point (calcifications)
and 44 months for the secondary end point (mortality)

Progression of calcifications

Chertow et al.4 200 52 weeks Progression of calcifications
Sadek et al.28 42 5 months Biochemical parameters
Shaheen et al.

29
20 Crossover study 18 weeks Biochemical parameters

Suki et al.
24

2103 22 months Mortality

S42 Kidney International (2008) 74 (Suppl 111), S38–S43

review JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival



28. Sadek T, Mazouz H, Bahloul H et al. Sevelamer hydrochloride with or
without alphacalcidol or higher dialysate calcium vs calcium carbonate in
dialysis patients: an open-label, randomized study. Nephrol Dial
Transplant 2003; 18: 582–589.

29. Shaheen FA, Akeel NM, Badawi LS et al. Efficacy and safety of sevelamer.
Comparison with calcium carbonate in the treatment of hyperphosphatemia
in hemodialysis patients. Saudi Med J 2004; 25: 785–791.

30. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution.
Nat Clin Pract nephrol 2008; 4: 115.

31. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;
15: 2959–2961.

32. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of
time-varying indicators of bone disease in maintenance hemodialysis
patients. Kidney Int 2006; 70: 771–780.

Kidney International (2008) 74 (Suppl 111), S38–S43 S43

JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review



99

CAPÍTULO 7

EXISTE UM ELO DE LIGAÇÃO ENTRE O OSSO E O VASO 
NOS DOENTES EM DIÁLISE? (2.ª PARTE)

Densidade mineral óssea, histomorfometria óssea e calcifi cações vasculares

RELAÇÃO ENTRE DENSIDADE MINERAL ÓSSEA E HISTOMORFOMETRIA ÓSSEA

Em 2001, a osteoporose foi defi nida pelo National Institute of Health (NIH) como uma 
patologia óssea caracterizada pela redução da força óssea predispondo para um aumento 
do risco de fraturas1. A força óssea depende fundamentalmente de dois fatores: da densidade 
mineral óssea e da qualidade óssea1. Por sua vez, a qualidade óssea resulta da remodelação, 
da mineralização e da arquitetura ósseas. Nos indivíduos da população geral, a densidade 
mineral óssea contribui em 70% para a força óssea1 e a baixa densidade mineral óssea 
relaciona -se com o risco de fraturas. A Organização Mundial de Saúde defi ne osteoporose 
baseando -se em valores de densidade mineral óssea inferiores a 2,5 desvio -padrão do valor 
médio de mulheres jovens caucasianas (T -score ?  -2,5 DP) e defi ne osteopenia para valores 
de T -score inferiores ou iguais a  -1,5 DP2. Os indivíduos da população geral com osteopenia 
ou osteoporose têm um risco de fraturas ósseas, respectivamente, de 4 e de 8 vezes superior 
ao risco de fraturas dos indivíduos com densidade mineral óssea normal3. Os doentes em 
diálise apresentam um risco de fraturas 4,4 vezes superior ao da população geral4. Pela 
compreensão dos diferentes fatores que contribuem para a força óssea, e conhecendo as 
diversas alterações ósseas que se desenvolvem no doente renal crónico, é fácil compreender 
que as alterações da densidade mineral óssea não podem ser as únicas a explicar o risco 
de fraturas destes doentes. Ao contrário do que se verifi ca nos indivíduos da população 
geral5, já foi demonstrado que a densidade mineral óssea, nos doentes renais em diálise, 
não permite identifi car o risco de fraturas6,7. Diferentes estudos têm apresentado resultados 
contraditórios na análise da relação entre os dados de biopsias ósseas e os resultados da 
avaliação da densidade mineral óssea por DXA (dual energy X -ray absorptiometry), 
mostrando que a baixa densidade mineral óssea pode associar -se tanto a baixa remodelação 
como a alta remodelação óssea. Gerakis et al8 mostraram, num grupo de 62 doentes em 
diálise, que a baixa densidade mineral óssea se associou a marcadores bioquímicos e 



100

histológicos de hiperparatiroidismo secundário. Lobão R et al9 verifi caram, num grupo de 
40 doentes renais crónicos nos estadios 3 e 4, e com baixa densidade mineral óssea, que 
o diagnóstico histológico predominante foi a doença óssea adinâmica e a osteomalacia. 
Estes autores não encontraram qualquer relação entre volume ósseo e densidade mineral 
óssea. As guidelines KDIGO 200910 não aconselham a avaliação da densidade mineral 
óssea nos doentes em diálise por este método não predizer nem o risco de fraturas nem o 
tipo de osteodistrofi a renal nesta população. Foi contudo encontrada uma associação entre 
a densidade mineral óssea avaliada no antebraço com o risco de fraturas11 e os valores de 
paratormona12. Os resultados medidos nos corpos vertebrais refl etem a avaliação do osso 
trabecular, enquanto os resultados medidos no colo do fémur ou no antebraço avaliam 
fundamentalmente o osso cortical. A biopsia óssea usada no diagnóstico de osteodistrofi a 
renal avalia geralmente apenas o osso trabecular, mas é possível também avaliar o osso 
cortical. Num grupo de 46 doentes portugueses em diálise, avaliados simultaneamente por 
DXA e por análise histomorfométrica de biopsias ósseas, encontramos uma relação inversa 
entre os valores de densidade mineral óssea obtidos por DXA e os marcadores bioquímicos 
e histológicos de hiperparatiroidismo secundário13 (fosfatase alcalina óssea, PTH intacta, 
número osteoblastos/cm, taxa de formação óssea e frequência de ativação óssea). Não 
encontramos qualquer relação entre volume ósseo trabecular e densidade mineral óssea. 
Numa análise posterior a este mesmo grupo de doentes, avaliamos a associação entra a 
densidade mineral óssea avaliada por DXA e o volume ósseo cortical e trabecular avaliados 
por biopsia óssea. Ajustando para a idade e duração de hemodiálise, verifi cámos que a 
densidade mineral óssea avaliada no colo do fémur, mas não na coluna lombar, se 
correlacionava de forma muito signifi cativa com a porosidade cortical mas não com o 
volume ósseo trabecular (Tabela 7.1). Fomos os primeiros a descrever esta associação e 
este estudo foi publicado na Osteoporosis International14. Este achado inovador do nosso 
estudo foi mencionado pela ERBP (European Renal Best Practice) no comentário feito à 
posição da KDIGO que considera ser reduzida a utilidade da densidade mineral óssea nos 
doentes em diálise15

Variáveis preditoras de porosidade cortical (regessão linear)

Variável dependente: porosidade cortical B SE Sig.
DMO femoral  -157,49 52,36 0,005
Idade &gt; 50 anos  -8,7 2,18&amp;lt;0,001
Duração de HD  -25,44 8,40 0,005

Tabela 7.1. A densidade mineral óssea (DMO) femoral, a idade superior a 50 anos e a duração da hemodiálise 
(HD) correlacionaram -se negativamente com a porosidade cortical avaliada nas biopsias ósseas



101

Já foi demonstrado que o hiperparatiroidismo secundário pode ter efeitos opostos no osso 
trabecular e no osso cortical16,17, e este dado pode explicar os diferentes resultados obtidos 
pela DXA consoante o local estudado e a ausência de correlação entre os dados da densidade 
mineral óssea obtida por DXA e o risco de fraturas. Nos indivíduos do sexo masculino da 
população geral, não existe correlação entre as fraturas osteoporóticas vertebrais e os resultados 
da densidade mineral óssea. Ostertag A et al mostraram que as fraturas vertebrais no sexo 
masculino se associaram à porosidade cortical avaliada em biopsia óssea18.

A utilidade diagnóstica da DXA nos doentes renais crónicos ainda não está demonstrada. 
Na nossa opinião, o termo “osteoporose” deve ser usado com cuidado nos doentes renais 
crónicos, pois não existe uniformidade neste diagnóstico utilizando estes dois métodos de 
diagnóstico: a biopsia óssea e a DXA. É mais correto falar de baixa densidade mineral óssea 
quando se utiliza a DXA e de baixo volume ósseo trabecular, porosidade, ou menor espessura 
cortical quando se utiliza a biopsia óssea. O nosso estudo atribui pela primeira vez à DXA 
um papel no diagnóstico de porosidade cortical nos doentes em diálise. A utilidade da avaliação 
diferencial da densidade mineral óssea cortical e trabecular necessita de ser confi rmada em 
estudos prospetivos. É necessário avaliar se a baixa densidade mineral óssea femoral avaliada 
em doentes renais crónicos, que no nosso estudo se associou à porosidade cortical, se associa 
a maior risco de fraturas nesta população.

RELAÇÃO ENTRE DENSIDADE MINERAL ÓSSEA E CALCIFICAÇÕES VASCULARES

A associação entre baixa densidade mineral óssea e calcifi cações vasculares já foi 
demonstrada em inúmeros estudos na população geral19 -22. Os mecanismos responsáveis por 
esta associação não estão bem esclarecidos, podendo ser explicados por um fator comum ou 
por uma relação causal entre a doença óssea e a doença vascular. A dislipidemia pode contribuir 
simultaneamente para a formação de placas ateroscleróticas e para a osteoporose23. Já foi 
demonstrado in vitro que os produtos de oxidação dos lípidos são capazes de promover uma 
diferenciação osteogénica de células musculares lisas humanas24 mas também têm um efeito 
inibitório na diferenciação de pré -osteoblastos25. Esta dupla ação da dislipidemia poderia 
explicar a associação, inicialmente considerada paradoxal, entre calcifi cações arteriais e 
osteoporose. Contradizendo estes achados in vitro, o estudo observacional PERF26, que avaliou 
1176 mulheres dos 60 aos 85 anos, demonstrou a existência de uma associação entre doença 
arterial periférica e osteoporose, mas não conseguiu evidenciar uma relação independente 
entre a dislipidemia e as alterações da densidade mineral óssea. Uma das hipóteses destes 
autores é a de que a dislipidemia não tem um efeito modulador direto mas indireto na densidade 
mineral óssea, através das lesões que provoca nos vasos nutritivos do osso.



102

A associação entre densidade mineral óssea e calcifi cações vasculares, amplamente 
estudada nos indivíduos idosos da população geral, tem sido pouco investigada nos doentes 
em diálise. O grupo de trabalho de imagiologia das KDIGO, International Controversies 
Conference em 200627 propôs o estudo da relação entre densidade mineral óssea e calcifi cações 
vasculares nos doentes em diálise. Até ao momento, poucos estudos tinham avaliado esta 
associação. Taal et al mostraram que a osteoporose e a osteopenia, num grupo de 88 doentes 
em diálise, se associaram a maior mortalidade28. Braun et al mostraram a existência de uma 
relação inversa entre calcificações cardíacas e massa óssea avaliadas por tomografia 
computorizada de feixes de eletrões29. Num grupo de 110 doentes em diálise, Raggi P et al30 
demonstraram a existência de uma relação inversa entre a velocidade de onda de pulso 
carotidofemoral e a densidade mineral óssea vertebral avaliada por tomografi a computorizada 
quantitativa. Não encontraram relação entre a velocidade de onda de pulso e a densidade 
mineral óssea avaliada por DXA na coluna lombar. Nos doentes sem calcifi cações vasculares, 
verifi caram a existência de uma correlação entre os resultados obtidos por DXA e por tomografi a 
computorizada. Na presença de calcifi cações vasculares, esta correlação desaparecia, e a 
hipótese apresentada por estes autores foi a de que a presença de calcifi cações vasculares na 
aorta, muito prevalentes nos doentes em diálise, falsearia os resultados da DXA. Num grupo 
de 70 doentes portugueses em diálise peritoneal31, demonstramos a existência de uma associação 

Densidade Mineral Óssea no Colo do Fémur

Fig. 7.1. A velocidade de onda de pulso (VOP) 
correlacionou -se inversamente com a densidade 
mineral óssea avaliada no colo do fémur

Fig. 7.2. Um score de calcifi cação vascular simples 
(SCVS) &gt; 3 associou -se a menor densidade mineral 
óssea avaliada no colo do fémur, em comparação com 
um SCVS&lt;3 (teste T de Student)



103

inversa entre a densidade mineral óssea avaliada por DXA no colo do fémur e a velocidade 
de onda de pulso carotidofemoral avaliada através do Complior (Artech Medical, Pantin, 
France) (Fig.7.1), com calcifi cações vasculares avaliadas pelo score simples de calcifi cação 
(Fig 7.2) e com a presença de doença coronária e doença arterial periférica (Fig.7.3).

Estas correlações não se verifi caram com a densidade mineral óssea avaliada na coluna 
lombar. Em análise multivariada confi rmou -se a associação independente e inversa entre a 
densidade mineral óssea avaliada no colo do fémur e a velocidade de onda de pulso, com um 
SCVS &gt;3 e com a presença de doença arterial periférica31. Verifi camos que os doentes com 
calcifi cações vasculares apresentavam um T -score lombar superior quando comparados com 
os doentes sem calcifi cações vasculares, enquanto o T -score femoral era semelhante nos 
doentes com e sem calcifi cações vasculares. Este dado sugere que as calcifi cações vasculares 
contribuem para os valores mais elevados do T -score lombar e está de acordo com os achados 
de Raggi et al30. O nosso estudo foi o primeiro a demonstrar, numa população de doentes no 
estadio 5D, uma associação independente e inversa entre a densidade mineral óssea e as 
calcifi cações vasculares avaliadas por RX simples e com doença arterial periférica. Em 
conclusão, demonstramos com este estudo a existência de uma associação entre valores mais 
baixos de densidade mineral óssea femoral e calcifi cações vasculares avaliadas por RX 
simples, com rigidez arterial e com doença arterial periférica. Os mecanismos para esta 
associação não estão ainda identifi cados, mas estes dados reforçam a hipótese da existência 
de um elo de ligação entre a doença óssea e a doença vascular nos doentes em diálise.

Densidade Mineral Óssea no Colo do Fémur

Fig.7.3. Associação inversa entre a densidade mineral óssea avaliada no colo do fémur e a presença de doença 
coronária (CAD+) e doença arterial periférica (DAP+) (teste T de Student)



104

Referências

  1. Malluche HH, Mawad H, Monier -Faugere MC. The importance of bone health in end -stage renal 
disease: out of the frying pan, into the fi re? Nephrol Dial Transplant 2004;19 Suppl (1):i9 -i13.

  2. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end -stage renal failure -an 
evolving disorder. Kidney Int 1993;43(2):436 -442.

  3. Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. 
J Bone Miner Res 1995;10(1):149 -156.

  4. Ferreira A, Frazão JM, Monier -Faugere MC, et al. Sevelamer study group effects of sevelamer 
hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc 
Nephrol 2008;19(2):405 -412.

  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.
  6. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of 

renal osteodystrophy: A position statement from kidney disease: improving global outcomes 
(KDIGO). Kidney Int 2006; 69: 1945 -1953.

  7. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in 
end -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.

  8. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-
-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20(5):764 -772.

  9. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Dias Curto J, 
Malluche HH. Low bone volume – A risk factor for coronary calcifi cations in hemodialysis patients. 
Clin J Am Soc Nephrol 2009; 4(2): 450 -455.

10. London GM. Bone -vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol 
2009; 4: 254 -257.

11. London GM, Marchais SJ, Guérin AP, et al. Association of bone activity, calcium load, aortic 
stiffness, and calcifi cations in ESRD. J Am Soc Nephrol 2008; 19: 1827 -1835.

12. Barreto DV, Barreto FC, Carvalho AB, et al. Association of changes in bone remodelling and coronary 
calcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52(6):1139 -1150.

13. Adragão T, Ferreira A, Frazão J, et al. Bone mineral density, bone histomorphometric analysis 
and vascular calcifi cations in hemodialysis patients. Nephrol Dial Transplant 2007; 22 (Suppl 6): 
vi 172 -vi 173. [Abstract FP456.]

14. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Malluche HH. 
Femoral bone mineral density reflects histologically determined cortical bone volume in 
hemodialysis patients. Osteoporos Int 2010; 21(4):619 -625.

15. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali 
C, London GM, Vanholder R. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) 
Chronic Kidney Disease -Mineral and Bone Disorder (CKD -MBD). Guidelines: a European Renal Best 
Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 9. [Epub ahead of print.]



105

16. Miller MA, Chin J, Miller SC, Fox J. Disparate effects of mild, moderate, and severe secondary 
hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insuffi ciency. Bone 
1998;23(3): 257 -266.

17. Yunbo D, Luca V, Seeman E. Parathyroid hormone defi ciency and excess: similar effects on trabecular 
bone but differing effects on cortical bone. J Clin Endocrinol Metab 1999; 84(2): 718 -722.

18. Ostertag A, Cohen -Solal M, Audran M, et al. Vertebral fractures are associated with increased cortical 
porosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone 2009; 44: 413-417.

19. Hak AE, Pols HA, van Hemert AM, et al. Progression of aortic calcifi cation is associated with 
metacarpal bone loss during menopause: a population -based longitudinal study. Arterioscler 
Thromb Vasc Biol 2000; 20(8):1926 -1931.

20. Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the progression of abdominal aortic calcifi cation 
over a 25 year period: the Framingham heart study. Calcif Tissue Int 2001; 68(5):271 -276.

21. Schulz E, Arfai K, Liu X, et al. Aortic calcifi cation and the risk of osteoporosis and fratures. J 
Clin Endocrinol Metab 2004; 89(9): 4246 -4253.

22. Tanko LB, Christiansen C, Cox DA et al. Relationship between osteoporosis and cardiovascular 
disease in postmenopausal women. J Bone Miner Res 2005; 20(11):1912 -1920.

23. Parhami F, Garfi nkel A, Demer LL. Role of lipids in osteoporosis. Arterioscl Thromb Vasc Biol 
2000; 20: 2346 -2348.

24. Proudfoot D, Davies JD, Skepper JN, et al. Acetylated low density lipoprotein stimulates human 
vascular smooth muscle cell calcifi cation by promoting osteoblastic differentiation and inhibiting 
phagocytosis. Circulation 2002; 106: 3044 -3050.

25. Parhami F, Morow ADS, Ballucan J, et al. Lipid oxidation products have opposite effects on 
calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of 
arterial calcifi cation in osteoporotic patients. Arterioscl Thromb Vasc Biol 1997; 17 (4): 680 -687.

26. Bagger YZ, Rasmussen HB, Alexandersen P, et al. The PERF study group links between 
cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis 
per se? Osteoporos Int 2007; 18: 505 -512.

27. Moe S, Drueke T, Cunningham J, et al. Defi nition, evaluation, and classifi cation of renal 
osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). 
Kidney Int 2006; 69: 1945 -1953.

28. Taal MW, Roe S, Masud T, Green D, et al. Total hip bone mass predicts survival in chronic 
hemodialysis patients. Kidney Int 2003; 63(3):1116 -1120.

29. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation 
of cardiac calcifi cation in chronic dialysis patients. Am J Kidney Dis 1996; 27:394 -401.

30. Raggi P, Bellasi A, Ferramosca E, et al. Pulse wave velocity is inversely related to vertebral bone 
density in hemodialysis patients. Hypertension 2007; 49:1278 -1284.

31. Adragão T, Branco P, Birne R, Curto JD, Almeida E, Prata MM, Pais MJ. Bone mineral density, vascular 
calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; 28 (6): 668 -672.





668

SHORT REPORTS NOVEMBER 2008 – VOL. 28, NO. 6 PDI

lation in medulla of cats. Neurosci Res 1998; 30:287–93.
6. Porzio G, Aielli F, Narducci F, Varrassi G, Ricevuto E,

Ficorella C, et al. Hiccup in patients with advanced cancer
successfully treated with gabapentin: report of three
cases. N Z Med J 2003; 116(1182):U605.

7. Petroianu G, Hein G, Stegmeier-Petroianu A, Bergler W,
Rufer R. Gabapentin “add-on therapy” for idiopathic
chronic hiccup (ICH). J Clin Gastroenterol 2000; 30:321–4.

8. Hernandez JL, Pajaron M, Garcia-Regata O, Jimenez V,
Gonzalez-Macias J, Ramos-Estebanez C. Gabapentin for
intractable hiccup. Am J Med 2004; 117:279–81.

9. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker
H. Gabapentin therapy for pruritis in haemodialysis pa-
tients: a randomized, placebo-controlled, double-blind
trial. Nephrol Dial Transplant 2004; 19:3137–9.

10. Molnar MZ, Novak M, Mucsi I. Management of restless leg
syndrome in patients on dialysis. Drugs 2006; 66:607–24.

Bone Mineral Density, Vascular
Calcifications, and Arterial Stiffness in

Peritoneal Dialysis Patients

The objective of this study was to evaluate the correla-
tion of bone mineral density (BMD), evaluated by DXA, with
vascular calcifications, arterial stiffness, and vascular dis-
ease in patients on peritoneal dialysis. Vascular calcifica-
tions were evaluated by vascular calcification score on plain
x ray, and arterial stiffness was measured by pulse wave
velocity using the Complior device (Artech Medical, Pantin,
France). Adjusting for multiple factors, lower BMD at the
femoral neck, but not at the lumbar spine, was associated
with higher pulse wave velocity (p = 0.037), higher vascu-
lar calcification score (p = 0.013), and peripheral artery
disease (p = 0.006). These data reinforce the hypothesis of
the existence of a link between bone disease and cardio-
vascular disease in dialysis patients.

Perit Dial Int 2008; 28:668–672 www.PDIConnect.com

KEY WORDS: Bone mineral density; vascular calcif ica-
tions; arterial stif fness.

In dialysis patients there is increasing evidence of theexistence of a link between bone disease and cardio-
vascular disease. Low bone mineral density (BMD) in the
general population is associated with atherosclerotic
calcifications (1). The relationship between BMD values
and vascular calcif ications is one of the issues recom-
mended for clinical research by the imaging work group
of the KDIGO International Controversies Conference (2).
The objective of this study was to evaluate, in a group of

brain and cerebrospinal fluid of ESRF patients (3,4).
Guanidine is a competitive gamma-amino butyric acid
(GABA) receptor antagonist and may counteract GABA
inhibition of respiratory muscles (4). In this particular
case, gabapentin, a novel amino acid derived by the ad-
dition of a cyclohexyl group to the chemical backbone of
GABA, may have been effective in treating hiccups for
two reasons: it increased endogenous GABA-mediated
inhibition of inspiratory muscles (3,4), or it reduced cal-
cium influx via inhibition of voltage-operated calcium
channels in presynaptic terminals of respiratory muscles.
Furthermore, gabapentin also increases the levels of se-
rotonin, an important neurotransmitter for the raphe
magnus nucleus in the medulla, the most likely source
of GABAergic inhibitory inputs to the hiccup reflex arc
(5). Indeed, there are several reports of gabapentin
being used for the treatment of intractable hiccups in
the setting of cancer or gastrointestinal disorders, but
not in ESRF (6–8).

Dizziness, somnolence, and peripheral edema are the
most frequent side effects of gabapentin. However, in
trials where gabapentin was used for treating hiccups
(6–8), no side effects were reported. Gabapentin is also
advantageous in that it is effective for restless leg syn-
drome, neuropathic pain, and pruritis in patients with
renal failure (9,10). Thus, gabapentin may be useful for
ESRF patients with intractable idiopathic hiccups.

Andrew M.L. Ong*
Chieh Suai Tan

Marjorie W.Y. Foo
Terence Y.S. Kee

Renal Medicine
Singapore General Hospital

Singapore

*e-mail: andrew.mingliang@gmail.com

REFERENCES

1. Alonso-Navarro H, Rubio L, Jimenez-Jimenez FJ. Refrac-
tory hiccups: successful treatment with gabapentin. Clin
Neuropharmacol 2007; 30:186–7.

2. Hansen BJ, Rosenberg J. Persistent postoperative hic-
cups: a review. Acta Anaesthesiol Scand 1993; 37:643–6.

3. Fraser CL, Arieff AI. Nervous system complications in ure-
mia. Ann Intern Med 1988; 109:143–53.

4. De Deyn PP, D’Hooge R, Van Bogaert PP, Marescau B. En-
dogenous guanidino compounds as uremic neurotoxins.
Kidney Int Suppl 2001; 78:S77–83.

5. Oshima T, Sakamoto M, Tatsuta H, Arita H. GABAergic in-
hibition of hiccup-like reflex induced by electrical stimu-



669

PDI NOVEMBER 2008 – VOL. 28, NO. 6 SHORT REPORTS

peritoneal dialysis patients, the relationship of BMD with
vascular calcifications, pulse pressure, pulse wave veloc-
ity (PWV), and cardiovascular disease.

PATIENTS

This study was a cross-sectional analysis of a cohort
of per it oneal dialy sis patients. Seventy patients
(37 males, 33 females) without previous parathyroidec-
tomy were evaluated after signing an informed consent
form. Mean age was 52 ± 14 years and mean dialysis du-
ration was 46 ± 28 months; 17 patients were diabetic.
During the 6 months preceding BMD evaluation, 29 and
33 patients were treated, respectively, with calcium car-
bonate (1.2 ± 0.45 g/day) and calcitriol (1.6 ± 1.2 ?g/
week). During this period, dialysate calcium concentra-
tions of 1.25 and 1.75 mmol/L were used, respectively,
in 40 and 30 patients. No patient had been previously
treated with bisphosphonates or cinacalcet. Coronary
artery disease, peripheral artery disease (PAD), and ce-
rebral vascular disease were diagnosed, respectively, in
20, 18, and 8 patients, based on clinical manifestations
and diagnostic tests.

METHODS

Bone mineral density was evaluated by dual-energy
x-ray absorptiometry (DXA) using the Hologic QDR Dis-
covery scanner (Hologic, Bedford, Massachusetts, USA)
in the lumbar spine and the femoral neck, using NHANES
III as the database reference (3). DXA parameters are
not standardized for dialysis patients and we used the
WHO cutoff of a T-score &gt; –1 SD, which def ines normal
BMD. According to the Osteoporosis Work Group (4), a
Z-score ? –1 SD, which is adjusted to age, could be more
appropriate to diagnose low BMD in dialysis patients.
During the first month af ter BMD evaluation, vascular
calcifications were evaluated on plain x rays of pelvis and
hands using a method previously described (5), with the
f inal score ranging from 0 to 8. Arterial stiffness was
evaluated by pulse pressure (pulse pressure = systolic
blood pressure – diastolic blood pressure) and by ca-
rotid–femoral PWV using a noninvasive automated de-
vice (Complior; Artech Medical, Pantin, France). Serum
levels of the following biochemical parameters were
evaluated ever y month and time averaged for the
6 months preceding the DXA evaluation: calcium, phos-
phorus, calcium–phosphate product, albumin, alkaline
phosphatase, and C-reactive protein. Total intact par-
athyroid hormone was evaluated ever y 3 months by
immunochemiluminescence using a second-generation
assay.

Statistical Analysis: Data are presented as frequencies
for categorical variables and as mean values with SD for
continuous variables. Univariate analysis was performed
by independent samples t-test, chi-square, Fisher’s exact
test, paired-samples t-tests, and Pearson correlation
coeff icient. The association of DXA parameters with car-
diovascular factors was evaluated by linear and logistic
regression models adjusting for age, gender, diabetes,
and body mass index. Absence of colinearity was checked
in all models. Vascular calcif ication score (VCS) was
evaluated as a categorical dependent variable (VCS ? 3)
based on our previous studies showing an association
between VCS ? 3 and higher cardiovascular mortality (5).
Statistical analyses were performed using the SPSS sys-
tem 14.0 (SPSS Inc., Chicago, Illinois, USA). A p value&amp;lt;
0.05 was considered statistically signif icant.

RESULTS

Vascular calcif ications were present in 43 patients. A
T-score ? –1 SD was obser ved at the lumbar spine in
39 patients and at the femoral neck in 43 patients. A
Z-score ? –1 SD was present at the lumbar spine in 21 pa-
tients and at the femoral neck in 24 patients.

In univariate analysis, lower femoral T-score (Table 1)
was associated with higher pulse pressure, higher PWV,
higher prevalence of vascular calcification, and higher
prevalence of PAD. Lower femoral BMD was associated
with higher VCS and higher PWV (Figure 1). Lower femo-
ral BMD was also associated with presence of coronary
artery disease (0.66 ± 0.15 vs 0.74 ± 0.13 g/cm2, p = 0.03)
and PAD (0.64 ± 0.14 vs 0.75 ± 0.13 g/cm2, p = 0.006)
(Figure 1). Patients with vascular calcif ications had a
higher lumbar T-score than patients without calcifica-
tions (–1.1 ± 1.5 vs –1.7 ± 1.6 SD, p = 0.02). In multi-
variate analysis, BMD evaluated at the femoral neck was
negatively associated with VCS ? 3, PAD (Table 2), and
PWV (Table 3), adjusting for age, gender, diabetes, and
body mass index. In similar models, a lower femoral
Z-score, but not T-score, was associated with VCS ? 3
[odds ratio (OR) = 0.5, p = 0.030] and PAD (OR = 0.44,
p = 0.016).

DISCUSSION

In this group of peritoneal dialysis patients, we have
verified that low BMD at the femoral neck, but not at the
lumbar spine, is independently associated with VCS on
plain x ray and with arterial stif fness. The association of
lower bone mineral mass or density with vascular calci-
f ications or PWV has already been demonstrated in
nonrenal and dialysis patients (1,6,7) but, for the first



670

SHORT REPORTS NOVEMBER 2008 – VOL. 28, NO. 6 PDI

TABLE 1
Cardiovascular Characteristics According to T-Score

All patients  T-score in lumbar spine T-score in femoral neck
(n=70)  &gt; –1 SD (n=31)  ? –1 SD (n=39)  &gt; –1 SD (n=27)  ? –1 SD (n=43)

PP (mmHg) 57.9±16.8 55.8±14.4 59.5±18.5 52.8±13.2 61.0±18.2a

PWV (m/s) 7.8±1.6 7.6±1.6 8.1±1.6 7.4±1.5 8.2±1.6a

VCS?3 29 (41%) 12 (39%) 17 (44%) 7 (26%) 22 (51%)b
PAD 18 (26%) 5 (16%) 13 (3%) 2 (7%) 16 (37%)c

PP = pulse pressure; PWV = pulse wave velocity; VCS = vascular calcification score; PAD = peripheral artery disease; SD = standard
deviation.
a p &amp;lt;0.05: comparison between groups by t-test.
b p &amp;lt;0.05: comparison between groups by chi-square.
c p &amp;lt;0.01: comparison between groups by Fisher’s exact test.

Figure 1 — Lower bone mineral density (BMD) at femoral neck is associated with higher pulse wave velocity, with more calcifica-
tions, and with peripheral artery disease (PAD).

time, an association between low BMD and plain x-ray
vascular calcif ications and vascular disease is shown in
dialysis patients. Evaluation of vascular calcif ications is
now required to classify the mineral and bone disorder
seen in chronic kidney disease (2), and plain x ray may
be a simple and inexpensive method to do so. One ex-
planation for the association of lower BMD with PWV or
vascular disease is their common relationship with vas-
cular calcifications (6,8). The absence of association be-
tween lumbar BMD and ar ter ial stif fness or vascular
calcifications present in our study has already been de-
scribed in dialysis patients (7) and may be explained by
the presence of vascular calcifications in the aorta pos-
sibly contributing to a higher BMD value (7). This can
also explain why, in our study, patients with calcifica-
tions had a higher lumbar T-score compared with patients
without calcifications. The pathogenesis of the associa-

tion between low BMD parameters and vascular calcif i-
cations is not known yet and might be explained by a
common etiologic factor. Both hyperparathyroidism and
adynamic bone disease may be associated with low bone
volume (9) and may also be associated with hyperphos-
phatemia and hypercalcemia, which are inducers of vas-
cular calcifications (10). Low bone turnover has also been
associated with vascular calcif ications (11). This study
presents, however, some limitations: Vascular score has
the advantage of simplicity and low cost but it is a
semiquantitative evaluation, and the cross-sectional
analysis allows only identif ication of associations be-
tween the variables.

In conclusion, in this group of patients, lower values
of bone mineral density, evaluated by DXA, at the femo-
ral neck but not at the lumbar spine were associated with
more calcif ications, arter ial stif fness, and peripheral



671

PDI NOVEMBER 2008 – VOL. 28, NO. 6 SHORT REPORTS

artery disease. The mechanisms for this association are
not yet identif ied but these findings reinforce the hy-
pothesis of the existence of a link between bone disease
and vascular disease in dialysis patients.

Teresa Adragao1*
Patrícia Branco2

Rita Birne1

José Dias Curto3

Edgar de Almeida2

Mateus Martins Prata2

Maria Joao Pais1

Nephrology Department1

Santa Cruz Hospital, Carnaxide
Nephrology Department2

Santa Maria Hospital
ISCTE Business School3

Lisbon, Portugal

*e-mail: tadragao@netcabo.pt

TABLE 3
Factors Associated with Pulse Wave Velocity (PWV)

Dependent variable Independent variable B 95% CI p Value R 2

PWVa 0.58
Age 0.07 0.05 to 0.09&amp;lt;0.001
SBP 0.02 0.00 to 0.03 0.020
Ca×P 0.03 0.00 to 0.05 0.028
BMD (femoral neck) –2.52 –4.87 to –0.16 0.037

SBP = systolic blood pressure; Ca×P = calcium–phosphate product; BMD = bone mineral density; CI = confidence interval.
a Adjusted for gender, diabetes, and body mass index.

REFERENCES

1. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O’Donnel CJ,
Wilson PW, et al. Bone loss and the progression of abdomi-
nal aortic calcification over a 25 year period: the Framing-
ham Heart Study. Calcif Tissue Int 2001; 68:271–6.

2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K,
Olgaard K, et al. Definition, evaluation, and classification
of renal osteodystrophy: a position statement from Kid-
ney Disease: Improving Global Outcomes (KDIGO). Kidney
Int 2006; 69:1945–53.

3. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,
Borgstrom F, et al. European guidance for the diagnosis
and management of osteoporosis in postmenopausal
women [Published erratum appears in Osteoporos Int
2008; 19:1103–4]. Osteoporos Int 2008; 19:399–428.

4. Cunningham J, Sprague SM, Cannata-Andia J, Coco M,
Cohen-Solal M, Fitzpatrick L, et al. Osteoporosis Work
Group. Osteoporosis in chronic kidney disease. Am J Kid-
ney Dis 2004; 43:566–71.

5. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L,
Gonçalves M, et al. A simple vascular calcification score
predicts cardiovascular risk in haemodialysis patients.

TABLE 2
Factors Associated with Vascular Calcifications and Peripheral Artery Disease (PAD)

Dependent variable Independent variable B OR 95% CI p Value R 2

VCS?3a 0.45
Age 0.11 1.12 1.05 to 1.20 0.001
Diabetes 2.58 13.13 1.96 to 87.73 0.008
Phosphorus 0.76 2.13 1.16 to 3.93 0.015
BMD (femoral neck) –8.83 0.00 0.00 to 0.15 0.013

PADb 0.29
Diabetes 2.11 8.24 1.65 to 41.14 0.010
Phosphorus 0.74 2.09 1.07 to 4.10 0.031
BMD (femoral neck) –8.82 0.00 0.00 to 0.08 0.006

VCS = vascular calcification score; BMD = bone mineral density; OR = odds ratio; CI = confidence interval.
a Adjusted for gender and body mass index.
b Adjusted for age, gender, and body mass index.



672

SHORT REPORTS NOVEMBER 2008 – VOL. 28, NO. 6 PDI

Nephrol Dial Transplant 2004; 19:1480–8.
6. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,

Luft FC. Electron beam computed tomography in the evalu-
ation of cardiac calcification in chronic dialysis patients.
Am J Kidney Dis 1996; 27:394–401.

7. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P.
Pulse wave velocity is inversely related to vertebral bone
density in hemodialysis patients. Hypertension 2007; 49:
1278–84.

8. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial
stiffening and vascular calcifications in end-stage renal

disease. Nephrol Dial Transplant 2000; 15:1014–21
9. Malluche HH, Monier-Faugere MC. Renal osteodystrophy:

what’s in a name? Presentation of a clinically useful new
model to interpret bone histologic findings. Clin Nephrol
2006; 65:235–42.

10. Giachelli CM. Vascular calcification mechanisms. J Am Soc
Nephrol 2004; 15:2959–64.

11. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F,
de Vernejoul MC. Ar ter ial calcif ications and bone
histomorphometry in end-stage renal disease. J Am Soc
Nephrol 2004; 15:1943–51.





ORIGINAL ARTICLE

Femoral bone mineral density reflects histologically
determined cortical bone volume in hemodialysis patients

T. Adragao &amp;amp; J. Herberth &amp;amp; M.-C. Monier-Faugere &amp;amp; A. J. Branscum &amp;amp; A. Ferreira &amp;amp;
J. M. Frazao &amp;amp; H. H. Malluche

Received: 6 January 2009 /Accepted: 22 May 2009
# International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Abstract
Summary We evaluated the associations between dual
energy X-ray absorptiometry (DXA) and histologically
determined cancellous and cortical bone volume by control-
ling for vascular calcifications and demographic variables in
hemodialysis (HD) patients. Femoral bone mineral density
(f-BMD) was associated with cortical porosity.
Introduction Assessment of bone mass in chronic kidney
disease patients is of clinical importance because of the
association between low bone volume, fractures, and vascular

calcifications. DXA is used for noninvasive assessment of
bone mass whereby vertebral results reflect mainly cancellous
bone and femoral results reflect mainly cortical bone. Bone
histology allows direct measurements of cancellous and
cortical bone volume. The present study evaluates the
association between DXA and histologically determined
cancellous and cortical bone volumes in HD patients.
Methods In 38 HD patients, DXA was performed for
assessment of bone mass, anterior iliac crest bone biopsies
for bone volume, and multislice computed tomography for
vascular calcifications.
Results While lumbar bone mineral density (l-BMD) by DXA
was not associated with histologically measured cancellous
bone volume, coronary Agatson score showed a borderline
statistically significant association (P=0.055). When controlled
for age and dialysis duration, f-BMD by DXA was associated
with cortical porosity determined by histology (P=0.005).
Conclusions The usefulness of l-BMD for predicting bone
volume is limited most probably because of interference by
soft tissue calcifications. In contrast, f-BMD shows signif-
icant association with cortical porosity.

Keywords Bone biopsy. Bone mineral density.

Bone volume . Chronic kidney disease . Cortical porosity.

Vascular calcifications

Introduction

Low bone mass is a common complication of chronic
kidney disease (CKD), and the most prominent clinical
complications of low bone mass are fractures. Compared to
the general population, the incidence of fractures was
reported to be 3.6–9.8 times higher for stage 5 CKD
patients on dialysis (CKD-5 patients) [1]. In the Dialysis

Osteoporos Int
DOI 10.1007/s00198-009-0988-9

T. Adragao
Nephrology Department, Santa Cruz Hospital,
Lisbon, Portugal

J. Herberth : M.-C. Monier-Faugere : H. H. Malluche
Division of Nephrology, Bone and Mineral Metabolism,
University of Kentucky,
Lexington, KY, USA

A. J. Branscum
Departments of Biostatistics, Statistics, and Epidemiology,
University of Kentucky,
Lexington, KY, USA

A. Ferreira
Nephrology Department, Curry Cabral Hospital,
Lisbon, Portugal

J. M. Frazao
Nephrology Department, Hospital de S. João, Medical School and
Nephrology Research and Development Unit, University of Porto,
Porto, Portugal

H. H. Malluche (*)
Division of Nephrology, Bone &amp;amp; Mineral Metabolism,
UK Medical Center,
Room MN 564, 800 Rose Street,
Lexington 40536-0084 KY, USA
e-mail: hhmall@uky.edu



Outcomes and Practice Patterns Study, the authors found a 7%
increased risk of hip fracture per year of dialysis treatment [2].
Most recently, low bone mass has also been shown to be
associated with increased cardiovascular calcifications in
non-CKD and CKD patients [3, 4]. In light of the high
mortality associated with fractures and cardiovascular disease
in CKD [5, 6], noninvasive methods for assessing bone mass
in this patient population is of great clinical importance.

Dual energy X-ray absorptiometry (DXA) is the most
widely used tool for assessment of bone mass in the general
population [7, 8]. However, DXA measures not only the
mineral content of bone but also of the surrounding soft
tissue [9, 10] limiting the interpretation of results [11].
CKD-5 patients represent a unique population particularly
prone to developing soft tissue and vascular calcifications
[12, 13]. Therefore, overestimation of bone mineral density
(BMD) by anterioposterior (AP) lumbar DXA represents a
great problem in these patients; this limitation should be
less pronounced but not excluded in femoral DXA
measurements [14]. Overall, studies evaluating the role of
BMD determination by DXA for assessment of fracture risk
in CKD-5 patients report conflicting results [15–18].

In order to guide appropriate therapeutic interventions,
characterization of the relationship between DXA measure-
ments and histologically determined bone volume in CKD-5
patients is desirable. In an early study, Lindergard and
colleagues could not find a correlation between BMD
measured at the radius (consisting primarily of cortical bone)
and histologically determined bone volume at the iliac crest of
CKD-5 patients (cancellous bone) [19]. In contrast, a more
recent study in CKD-5 patients reported that hip and spine T-
scores were associated with histologically determined bone
volume at the iliac crest [20]. In light of these conflicting
results, we evaluated the associations between BMD
measured by DXA at the spine and femur and histologically
determined bone volume in cancellous bone (bone volume/
tissue volume) and in cortical bone (cortical width and
cortical porosity) in CKD-5 patients. Moreover, vascular
calcifications were assessed by multislice computed tomog-
raphy (MSCT) and adjusted for in statistical analyses.

Materials and methods

Study design

This study investigates the association between BMD
measured by DXA at the hip and spine and histologically
determined parameters of bone volume in cancellous and
cortical bone in a cross-sectional study design. In addition,
vascular calcifications were measured by multislice com-
puted tomography at the thoracic aorta and the coronary
and iliac arteries and were adjusted for in the analyses. The

protocol was approved by the Institutional Review Boards
of participating institutions. The study has been conducted
in adherence to the Declaration of Helsinki, and all patients
provided informed consent.

Patients

Thirty-eight white stage 5 CKD patients on hemodialysis were
recruited from 11 medical centers in Portugal. All patients
provided informed consent for performing DXA measure-
ments, bone biopsies, and multislice computed tomography.
DXA measurements were performed at time of bone biopsy
and patients underwent multislice computed tomography on
average 3.8±1.9 months after the bone biopsy.

Inclusion criteria These are age 18 years or older, dialysis
duration of at least 3 months, mental competence, and
willingness to participate in the study.

Exclusion criteria These are kidney transplant; pregnancy;
uncontrolled systemic illnesses or organic diseases with
potential influence on bone metabolism such as diabetes
mellitus, active or chronic liver disease, malabsorption,
malignancy, and thyroid dysfunction; history of or present
treatment with bisphosphonates, fluoride, calcitonin, gluco-
corticoids, or other immunosuppressive agents, hormone
replacement therapy, and selective estrogen receptor mod-
ulators; and chronic alcoholism and/or drug addiction.

Bone biopsies

Anterior iliac crest bone biopsies were performed under
local anesthesia and conscious sedation. Bone samples were
obtained with the one-step electrical drill technique (Strau-
mann Medical, Waldenburg, Switzerland). Bone samples
were processed undecalcified and cut avoiding cracks or
overlaps of bone tissue. Sections were stained with the
modified Masson–Goldner trichrome stain [21], the aurin
tricarboxylic acid stain [22], and solochrome azurin [23],
assessment of stainable aluminum, and modified Gomori
stain for detection of iron [24]. Unstained sections were
prepared for phase contrast and fluorescent light microsco-
py. Histomorphometric analysis of bone was done at
standardized sites in cancellous (×200 magnification) and
cortical bone (×80 magnification) using the semi-automatic
method (Osteoplan II, Kontron, Munich, Germany). For
cancellous bone, the volume of bone trabecules (BV) and
total tissue volume (TV) were traced and bone volume/total
volume (BV/TV) was calculated for assessment of miner-
alized trabecular bone volume. For cortical bone, cortical
width was measured; cortical porosity was determined by
tracing the total cortex and all Haversian canals and

Osteoporos Int



computing the ratio between canal area over total cortical
tissue area.

Results were compared to our normative database
consisting of histomorphometric results of age- and gender-
matched healthy individuals [25, 26]. “Low” cancellous bone
volume was defined as BV/TV&amp;lt;16.8%, “normal” as BV/TV
between 16.8% and 22.9%, and “high” as BV/TV &gt;22.9%.
Cortical width was considered “low” for values&amp;lt;0.52 mm,
“normal” for values between 0.52 and 1.65 mm, and “high”
for values &gt;1.65 mm. Cortical porosity was classified “low”
for values&amp;lt;1.9%, “normal” for values between 1.9% and
12%, and “high” for values &gt;12%. All bone samples were
processed and analyzed without knowledge of the clinical
data at the Bone Diagnostic and Research Laboratory,
University of Kentucky, Lexington, KY, USA.

Bone mineral density

DXA was performed by the same operator on the same
Hologic QDR Discovery scanner according to the manu-
facturer’s recommendations for patient positioning, scan
protocols, and scan analysis. Measurements of the spine
and hip were obtained from the AP projection. For AP
lumbar spine, lumbar vertebrae 1 to 4 were measured and
BMD results were analyzed for mean measurements of L1–
L4. For proximal femur scans, BMD was measured at the
femoral neck. The coefficients of variation for these BMD
measurements are AP spine 1.2% and femur 0.9%.

Assessment of vascular calcifications

Vascular calcifications were assessed at the thoracic aorta
and coronary and iliac arteries by a quantitative score using
MSCT. MSCT scans were performed on the model
Somatom Volume Zoom (Siemens AG, Erlangen, Ger-
many). Slices of 2.5 mm thickness were acquired under the
following conditions: 120 kVp, 130 mAs, and 0.5 gantry
rotation time. All images were transferred to a workstation
and analyzed with calcium scoring software (HeartView
CT, Siemens AG, Erlangen, Germany). Quantification of
vascular calcifications was performed by calculating the
Agatston score based on the maximum X-ray attenuation
coefficient (measured in Hounsfield units) [27].

Biochemical measurements

Blood was drawn at the time of the bone biopsy after an
overnight fast. The following biochemical parameters were
measured: serum calcium and phosphorus by an autoan-
alyzer (Hitachi 747, Globe Scientific Inc, USA), intact
parathyroid hormone (iPTH) by DPC IMMULITE® PTH
IRMA from Diagnostics Products Corporation (Los
Angeles, CA, USA; normal range 16–87 pg/ml; intra- and

interassay coefficients of variation&amp;lt;7% and&amp;lt;9%), and 25-
(OH)-vitamin D by LIAISON® 25-OH Vitamin D assay
(Diasorin, Saluggia, Italy; normal range 25–100 ng/ml;
intra- and interassay coefficients of variation 4.1% and 7%).

Statistical analysis

Descriptive statistics are presented as means, medians,
minimums, maximums, and standard deviations (SDs). The
variables iPTH and hemodialysis (HD) duration were log-
transformed for analysis. Boxplots were used to characterize
the distributions of BV/TV, cortical width, and cortical
porosity. Bivariate associations were assessed using scatter
plots, nonparametric Spearman rank correlations, locally
weighted regression, and generalized additive models to
characterize the associations between femoral/lumbar BMD
and cortical porosity, cortical width, and BV/TV. Linear
regression analyses were performed to evaluate possible
relationships while controlling for relevant measured corre-
lates. All calculations were performed using the R statistical
package (R Foundation for Statistical Computing, Vienna,
Austria) and SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA).

Results

Characteristics of the study population are presented in
Table 1. All patients were receiving phosphate binder
therapy (58% sevelamer hydrochloride, 42% calcium
acetate) and 19 patients (50%) were treated with active
vitamin D analogs. None of the patients were treated with a
calcimimetic agent. There were no clinically symptomatic
fractures prior and during the study.

In cancellous bone, BV/TV was low in 16%, normal in
24%, and high in 60% patients. In cortical bone, cortical
porosity was low in 3%, normal 40%, and high in 57%, and
cortical width was low in 8%, normal 89%, and high in 3%.
None of the biopsies showed positive staining for alumi-
num or iron.

DXA results are reported as “measured bone mineral
density” (in grams per centimeter squared). The correlation
between lumbar and femoral BMD measurements was r=
0.49 (P=0.01).

Femoral bone mineral density

Unadjusted analysis of the association between femoral
BMD and cortical porosity revealed a correlation coeffi-
cient r=?0.20 (P=0.24). When adjusted for different
Agatston score groups, no statistically significant effects
of the different vascular calcifications sites were found. In
the final model, a forward predictor selection routine

Osteoporos Int



identified femoral BMD (point estimate ?157.49; P=
0.005), age &gt;50 years (point estimate ?8.37; P=0.001),
and HD duration (point estimate ?25.44; P=0.005) as being
associated with cortical porosity (Table 2). Further statisti-
cal analysis recognized a statistically significant interaction
between femoral BMD and HD duration (point estimate
32.48; P=0.01): independent of age group, cortical porosity
increased as femoral BMD decreased, and this increase in
cortical porosity was more rapid for patients with shorter
HD duration (Fig. 1).

Unadjusted correlation analysis of femoral BMD and
cancellous bone volume (BV/TV) yielded r=?0.06 (P=
0.73). While age, gender, and HD duration were not
predictive of cancellous bone volume (BV/TV), the model
containing femoral BMD and coronary Agatston score
&gt;100 revealed a statistically significant negative association
(point estimate ?4.93; P=0.03); this association was,
however, lost when the model was adjusted for age and
gender.

When examining a possible association between femoral
BMD and cortical width, unadjusted (r=0.004; P=0.98)
and adjusted analyses (models containing age, gender, HD
duration, and vascular calcifications) did not yield any
significant predictors.

Lumbar bone mineral density

In unadjusted analysis, the correlation between lumbar
BMD and cancellous bone volume (BV/TV) was not
statistically significant (r=?0.1; P=0.53) and remained
statistically nonsignificant when the model was adjusted
for gender, age, and HD duration (P&gt;0.05 for all variables).
Similar results were found for the correlations between
lumbar DXA and cortical width/porosity (r=?0.09, P=
0.60; r=?0.15, P=0.39, respectively) and adjusted models
(gender, age, HD duration, all variables P&gt;0.05).

In the next analytical step, the model was adjusted for
Agatston scores measured at the thoracic aorta, coronary
artery, or iliac artery. For this purpose, patients were
classified according to an Agatston score cutoff of 100
(?100 versus &gt;100). Regression modeling revealed that

Table 2 Predictor variables of cortical porosity (from linear regression
analysis)

Estimate Standard error P value

fBMD ?157.49 52.36 0.005
Age &gt;50 years ?8.37 2.18 0.0005
HD ?25.44 8.40 0.005
fBMD/HD 32.48 12.09 0.01

fBMD femoral bone mineral density, HD hemodialysis duration,
fBMD/HD interaction term between femoral bone mineral density
and hemodialysis duration

Fig. 1 Estimated mean cortical porosity based on age group and HD
duration. The three lines in each plot correspond to patients with
dialysis durations equal to the 25th (solid line), 50th (dashed line), and
75th (dotted line) empirical percentiles

Mean (SD) Median (min–max)

Age (years) 45.2 (15.2) 45 (21–74)

Gender

Male (N, %) 20 (52.6)
Female (N, %) 18 (47.4)

Dialysis duration (months) 73.1 (56.6) 48.3 (21–206)

Calcium (mg/dl) 96 (6.6) 95.4 (87–111)

Phosphorus (mg/dl) 5.4 (0.9) 5.5 (3.9–7.2)

iPTH (pg/ml) 620 (614) 353.4 (50–2,164)

VIT D25 (ng/ml) 21.2 (7.8) 21.5 (7.8–37.6)

Agatston scores

Coronary arteries 958.3 (1,888.4) 99.25 (0.0–6,726.0)

Thoracic aorta 1,391.0 (3,026.9) 3.2 (0.0–12,576.2)

Iliac arteries 2,916.0 (5,430.6) 848.2 (0.0–28,670.0)

Table 1 Characteristics of the
study population

iPTH intact parathyroid hor-
mone, vit D25 25(OH)-hydroxy
vitamin D

Osteoporos Int



only coronary Agatston score &gt;100 showed borderline
significant negative association with lower cancellous bone
volume (BV/TV) (point estimate ?4.14; P=0.055) but this
association was lost when the model was also adjusted for
gender and age.

Conclusions

The National Institutes of Health consensus conference on
“Osteoporosis prevention, diagnosis and therapy” defines
osteoporosis as a systemic disease of impaired bone
strength [28]. Clinically and in specific populations, the
diagnosis “osteoporosis” is defined on the basis of
standardized BMD levels (T-score??2.5 SD) determined
by DXA at the spine, hip, or forearm [29]. In the case of
patients suffering from CKD, the use of this traditional
approach to diagnose osteoporosis is problematic since all
forms of renal bone disease may be accompanied by low
BMD [30, 31], and erroneously high BMD measurements
due to vascular/soft tissue calcifications—which are com-
monly encountered pathologic findings in CKD patients—
are known problems of anterioposterior DXA projections
[32]. Accordingly, it has been proposed that, currently, the
only way to establish the diagnosis of osteoporosis in
patients with stage 5 CKD is the histomorphometrical
finding of low bone volume [33]. Based on these
observations, we selected not to classify our patients
according to specific scores but to evaluate the association
between measured bone mineral density (expressed in
grams per centimeter squared) at the lumbar and femoral
sites and histomorphometric determinants of cancellous
bone volume (BV/TV) and cortical bone volume (cortical
width and cortical porosity). Furthermore, we adjusted our
models for Agatston scores measured by multislice com-
puted tomography.

Our study results corroborate previous observations
regarding lack of associations between histologically
determined cancellous bone volume (BV/TV) and BMD
measurements reported in CKD patients (creatinine clear-
ance 10–78 ml/min) [34] and expand those findings to stage
5 CKD patients on hemodialysis. The usefulness of iliac
crest bone biopsies for assessment of bone changes in the
femur has been reported in patients requiring total hip
replacement [35]. Although there is paucity of data
regarding the association between cortical bone and
fractures in CKD patients, the role of increased cortical
porosity and decreased cortical thickness in femoral neck
fractures has been described in the general population [36–
38]. A novel finding of our study is the statistically highly
significant association between cortical porosity and fem-
oral BMD in stage 5 CKD patients that persisted after
statistical adjustments. Since cortical changes of the

femoral neck contribute to the risk of hip fractures [38]
and fractures of the axial skeleton are highly prevalent in
stage 5 CKD patients [39], our findings suggest a possible
clinical role of femoral DXA measurements for identifying
stage 5 CKD patients on hemodialysis at risk for fracture.
The stronger association between femoral BMD and
cortical porosity at shorter HD durations implies that
additional factors present after longer HD vintage such as
more extensive soft tissue calcifications will limit the value
of femoral BMD for assessing cortical porosity as dialysis
vintage progresses.

We would like to acknowledge the following limitations
of our study: Goal of our study was not the comprehensive
evaluation of all risk factors for hip fractures in stage 5
CKD patients but to investigate the role of DXA measure-
ments for assessing histological parameters of cancellous
(BV/TV) and cortical bone volume (cortical porosity and
cortical width). In order to limit the influence of potentially
confounding variables of bone metabolism and vascular
calcifications, we imposed strict inclusion and exclusion
criteria for study participation; accordingly, our findings
call for larger population-based studies to validate a
possible role of femoral BMD measurements by DXA
including hip structural analysis for assessing bone fracture
risk not only in stage 5 CKD patients on different dialysis
modalities but also to include patients suffering from
different levels of CKD as well as CKD patients with
previous fractures. Future large age-matched population-
based studies will also need to answer the question on
differences in bone volume between healthy and CKD
patients.

In summary, our data suggest a role for femoral DXA
measurements to assess cortical porosity in stage 5 CKD
patients on hemodialysis. Anterioposterior lumbar measure-
ments by DXA do not yield information useful for
assessment of cancellous bone volume (BV/TV) that has
been shown to be associated with coronary calcifications
[4]. In light of the high morbidity and mortality of stage 5
CKD patients, future prospective clinical studies will need
to further characterize the role of this relatively inexpensive
and widely available clinical tool (DXA) for assessment of
clinical outcomes such as fractures.

Acknowledgments The following colleagues have participated in
the study: Célia Gil, Carlos Oliveira, José Galvão, António Morais
Sarmento, Silvia Ribeiro, Jorge Dickson, Berta Carvalho, Ilídio
Rodrigues, Jorge Baldaia, and Odete Pereira. This study was
supported by grants National Institutes of Health NIH RO1
DK51530 (H.H.M.), by the Kentucky Nephrology Research Trust
(M-C.M-F., H.H.M.), by the Dean’s Clinical Research Scholar
Program, University of Kentucky, no 1012112710 (J.H.), and by a
grant from Genzyme. The authors would like to thank ISNI, Instituto
Nefrológico de Investigação, for the assistance in the organization of
this study and Ms. Juliana Van Willigen and Richard Wheaton for
their technical assistance.

Osteoporos Int



Conflicts of interest None.

References

1. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA,
Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of
hip fracture among patients with end-stage renal disease. Kidney
Int 58:396–399

2. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-
Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006)
Incidence and risk factors for hip or other bone fractures among
hemodialysis patients in the dialysis outcomes and practice
patterns study. Kidney Int 70:1358–1366

3. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic
calcification and the risk of osteoporosis and fractures. J Clin
Endocrinol Metab 89:4246–4253

4. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ,
Ferreira A, Frazao JM, Dias Curto J, Malluche HH (2009) Low
bone volume—a risk factor for coronary calcifications in
hemodialysis patients. Clin J Am Soc Nephrol 4:450–455

5. Coco M, Rush H (2000) Increased incidence of hip fractures in
dialysis patients with low serum parathyroid hormone. Am J
Kidney Dis 36:1115–1121

6. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM
(2006) PTH and the risks for hip, vertebral, and pelvic fractures
among patients on dialysis. Am J Kidney Dis 47:149–156

7. Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM,
Fordham JN, Fuerst T, Hadji P, Itabashi A, Krieg MA, Lewiecki
EM (2008) Peripheral dual-energy X-ray absorptiometry in the
management of osteoporosis: the 2007 ISCD Official Positions. J
Clin Densitom 11:188–206

8. Writing Group for the ISCD Position Development Conference
(2004) Indications and reporting for dual-energy X-ray absorpti-
ometry. J Clin Densitom 7:37–44

9. Hangartner TN, Johnston CC (1990) Influence of fat on bone
measurements with dual-energy absorptiometry. Bone Miner
9:71–81

10. Formica C, Loro ML, Gilsanz V, Seeman E (1995) Inhomogeneity
in body fat distribution may result in inaccuracy in the
measurement of vertebral bone mass. J Bone Miner Res
10:1504–1511

11. Wren TA, Kim PS, Janicka A, Sanchez M, Gilsanz V (2007)
Timing of peak bone mass: discrepancies between CT and DXA. J
Clin Endocrinol Metab 92:938–941

12. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV,
Teehan BP, Levey AS (2000) Atherosclerotic cardiovascular
disease risks in chronic hemodialysis patients. Kidney Int
58:353–362

13. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of
cardiovascular disease in chronic renal disease. Am J Kidney Dis
32:S112–S119

14. Taal MW, Masud T, Green D, Cassidy MJ (1999) Risk factors for
reduced bone density in haemodialysis patients. Nephrol Dial
Transplant 14:1922–1928

15. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA (2002)
Bone density and heel ultrasound testing do not identify patients
with dialysis-dependent renal failure who have had fractures. Am
J Kidney Dis 39:843–849

16. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988)
Fractures and vertebral bone mineral density in patients with renal
osteodystrophy. Clin Nephrol 30:57–62

17. Urena P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal
M, Cantor T, de Vernejoul MC (2003) Bone mineral density,
biochemical markers and skeletal fractures in haemodialysis
patients. Nephrol Dial Transplant 18:2325–2331

18. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E,
Nishizawa Y (2005) Increased incidence of vertebral fracture in
older female hemodialyzed patients with type 2 diabetes mellitus.
Calcif Tissue Int 76:256–260

19. Lindergard B, Johnell O, Nilsson BE, Wiklund PE (1985) Studies
of bone morphology, bone densitometry and laboratory data in
patients on maintenance hemodialysis treatment. Nephron
39:122–129

20. Van Eps CL, Jeffries JK, Anderson JA, Bergin PT, Johnson DW,
Campbell SB, Carpenter SM, Isbel NM, Mudge DW, Hawley CM
(2007) Mineral metabolism, bone histomorphometry and vascular
calcification in alternate night nocturnal haemodialysis. Nephrol-
ogy (Carlton) 12:224–233

21. Goldner J (1938) A modification of the Masson trichrome
technique for routine laboratory purposes. Am J Pathol 14:237–
243

22. Lillie PD, Fullmer HM (1976) Histopathologic technique and
practical histochemistry. McGraw Hill, New York

23. Denton J, Freemont AJ, Ball J (1984) Detection of distribution of
aluminum in bone. J Clin Pathol 37:136–142

24. Gomori G (1936) Microtechnical demonstration: a criticism of its
methods. Am J Pathol 12:655–663

25. Malluche HH, Meyer W, Sherman D, Massry SG (1982)
Quantitative bone histology in 84 normal American subjects.
Micromorphometric analysis and evaluation of variance in iliac
bone. Calcif Tissue Int 34:449–455

26. Malluche HH, Faugere MC (1986) Atlas of mineralized bone
histology. Karger, New York

27. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M
Jr, Detrano R (1990) Quantification of coronary artery calcium
using ultrafast computed tomography. J Am Coll Cardiol 15:827–
832

28. NIH Consensus Development Panel (2001) Osteoporosis preven-
tion, diagnosis, and therapy. JAMA 285:785–795

29. Miller PD, Bonnick SL, Rosen CJ (1996) Consensus of an
international panel on the clinical utility of bone mass measure-
ments in the detection of low bone mass in the adult population.
Calcif Tissue Int 58:207–214

30. Lindberg JS, Moe SM (1999) Osteoporosis in end-state renal
disease. Semin Nephrol 19:115–122

31. Hruska KA, Teitelbaum SL (1995) Renal osteodystrophy. N Engl
J Med 33:166–174

32. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-
Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard
M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J
(2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis
43:566–571

33. Miller PD (2005) Treatment of osteoporosis in chronic kidney
disease and end-stage renal disease. Curr Osteoporos Rep 3:5–
12

34. Lobao R, Carvalho AB, Cuppari L, Ventura R, Lazaretti-Castro
M, Jorgetti V, Vieira JG, Cendoroglo M, Draibe SA (2004) High
prevalence of low bone mineral density in pre-dialysis chronic
kidney disease patients: bone histomorphometric analysis. Clin
Nephrol 62:432–439

35. Dorr LD, Arnala I, Faugere MC, Malluche HH (1990) Five-year
postoperative results of cemented femoral arthroplasty in patients
with systemic bone disease. Clin Orthop Relat Res 259:114–
121

Osteoporos Int



36. Boyce TM, Bloebaum RD (1993) Cortical aging differences and
fracture implications for the human femoral neck. Bone 14:769–778

37. Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J
(1999) Regional differences in cortical porosity in the fractured
femoral neck. Bone 24:57–64

38. Mayhew PM, Thomas CD, Clement JG, Loveridge N, Beck TJ,
Bonfield W, Burgoyne CJ, Reeve J (2005) Relation between age, fem-
oral neck cortical stability, and hip fracture risk. Lancet 366:129–135

39. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis PK,
Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis
JG, Dombros AN, Utas C, Akpolat T, Bozfakioglu S, Wu G,
Karayaylali I, Arinsoy T, Stathakis PC, Yavuz M, Tsakiris JD,
Dimitriades CA, Yilmaz ME, Gultekin M, Karayalcin B, Yard-
imsever M, Oreopoulos DG (2006) Bone mineral density and its
correlation with clinical and laboratory factors in chronic
peritoneal dialysis patients. J Bone Miner Metab 24:79–86

Osteoporos Int





121

CAPÍTULO 8

QUE MÉTODOS UTILIZAR PARA AVALIAR 
A CALCIFICAÇÃO VASCULAR?1 -3

Diversos estudos em doentes renais crónicos têm utilizado diferentes métodos para 
diagnosticar calcifi cações vasculares. Braun et al4, em 1996, foram os primeiros a mostrar que 
os doentes em diálise apresentam um score de Agatston muito superior ao da população geral. 
Blacher et al5, em 2001, demonstraram que calcifi cações vasculares avaliadas por ecografi a 
em grandes vasos são preditoras de mortalidade nos doentes em diálise. Em 2003, Moe S et 
al6 verifi caram que a tomografi a axial computorizada multicorte pode ser utilizada em vez da 
tomografi a de feixe de eletrões para medir o score de Agatston nos doentes em diálise. Em 
2003, London et al7 usaram, pela primeira vez, um RX simples do abdómen para avaliar 
calcifi cações vasculares e demonstraram que calcifi cações vasculares avaliadas por este método 
se associavam a maior risco de mortalidade nos doentes em diálise. Em Fevereiro de 2004 foi 
aceite para publicação e em Março de 2004 foi publicado on -line o nosso estudo8, que descrevia 
um método original e semiquantitativo para avaliação de calcifi cações vasculares nos doentes 
em diálise usando RX simples da bacia e das mãos. Demonstramos nesse estudo que este 
score, de utilização muito simples, é preditor de mortalidade cardiovascular, de internamentos 
cardiovasculares e de doença coronária e arterial periférica nos doentes em diálise.

Avaliação quantitativa das calcifi cações vasculares: score de Agatston

O score de Agatston permite a avaliação quantitativa das calcifi cações vasculares. Este 
método baseia -se no coefi ciente de atenuação máximo dos raios X, medido por unidades 
hounsfi eld. Braun et al4 demonstraram que o valor médio do score de calcifi cação nos doentes 
em diálise era 10 vezes superior a doentes da população geral com doença coronária provável 
ou documentada. O signifi cado clínico do score de Agatston é, contudo, diferente nos doentes 
com ou sem doença renal crónica. Na população geral está bem demonstrado que o score de 
calcifi cação de Agatston se relaciona com a carga aterosclerótica e que um valor superior a 
400 é preditor de eventos cardiovasculares ou de necessidade de procedimentos coronários 
nos 2 a 5 anos após a determinação deste score. A localização ou o grau de calcifi cação podem 



122

não se relacionar com o local da estenose, mas, quanto maior o score, maior a probabilidade 
de estenose em qualquer local, nas artérias coronárias 9.

Os doentes em diálise podem, contudo, ter scores de Agatston muito elevados sem se verifi car 
estenose coronária, e isso foi demonstrado por Haydar et al, que compararam coronariografi as 
com a avaliação de calcifi cações coronárias pelo score de Agatston num grupo de 46 doentes em 
diálise10. Esta discrepância entre os dados da angiografi a e os dados da quantifi cação da calcifi cação 
coronária que se verifi ca nos doentes em diálise pode ser explicada pela existência simultânea de 
calcifi cações da íntima e de calcifi cações não estenosantes da média. Numa análise anatomopatológica 
das artérias coronárias, comparando indivíduos com e sem doença renal, demonstrou -se de forma 
inequívoca que os doentes renais crónicos apresentam uma maior quantidade de cálcio, quer na 
íntima quer na média, e maior intensidade de marcadores infl amatórios quando comparados com 
doentes não renais11. Por outro lado, nos doentes em diálise, valores de score de Agatston superiores 
ou iguais a 40012 ou a 20013 relacionam -se com a mortalidade cardiovascular, sendo esta associação 
consistente com todos os restantes estudos que demonstram que as calcifi cações vasculares, 
qualquer que seja o local, se associam a aumento de mortalidade.

Atualmente, a avaliação do score de Agatston é feita geralmente por tomografi a axial 
computorizada multicorte, pois esta tecnologia tem múltiplas utilizações e está amplamente 
distribuída, bastando uma especifi cação do seu software para poder medir este score.

Ecografi a e ecocardiografi a

Blacher et al5 usaram a ecografi a de grandes artérias para avaliar as calcifi cações vasculares 
em quatro territórios vasculares: aorta, carótidas, artérias ilíacas e femorais. Este estudo, 
realizado em 2001, foi o primeiro a demonstrar que as calcifi cações vasculares se associam 
a maior risco de morte. As calcifi cações valvulares avaliadas por ecocardiografi a são preditoras 
de mortalidade nos doentes em diálise14 -16 e a iniciativa KDIGO 200917 reconhece que a 
ecocardiografi a pode ser utilizada para o diagnóstico de calcifi cações valvulares, de modo a 
identifi car os doentes com maior risco cardiovascular. Num grupo de 123 doentes em diálise, 
verifi camos, como previamente demonstrado, que a calcifi cação valvular aórtica ou mitral se 
associa a um risco aumentado de morte de causa global ou cardiovascular. Verifi camos que 
as calcifi cações vasculares avaliadas por RX simples são preditoras de calcifi cações valvulares 
diagnosticadas por ecocardiografi a18. Por cada aumento de uma unidade no score de calcifi cação 
vascular simples, verifi cou -se um aumento de 46% de risco de ter simultaneamente calcifi cação 
da válvula aórtica e de 66% de ter calcifi cação da válvula mitral. A presença de calcifi cações 
valvulares apresenta um alto valor preditivo positivo e um baixo valor preditivo negativo para 



123

indicar presença de calcifi cações vasculares. Isto signifi ca que, no caso de haver calcifi cações 
valvulares, existe elevada probabilidades de também haver calcifi cações vasculares. No caso 
de não haver calcifi cações valvulares, a probabilidade de não haver calcifi cações vasculares 
é baixa. O ecocardiograma não substitui a utilização do RX simples para identifi car o risco 
cardiovascular associado às calcifi cações.

RX simples

London G et al foram os primeiros a demonstrar que calcifi cações vasculares avaliadas 
em RX simples são preditoras de mortalidade nos doentes em diálise7. Baseando -se numa 
metodologia previamente descrita por Letho19, diferenciaram calcifi cação da camada média 
e da íntima pelas imagens radiológicas. A calcifi cação da média é linear e regular e apresenta 
frequentemente um traçado duplo em linha de comboio. A calcifi cação da íntima é irregular 
e descontínua. Este importante estudo demonstrou que as calcifi cações da camada média não 
são achados radiológicos, mas têm signifi cado clínico. Neste estudo, os autores demonstraram 
que as calcifi cações da média e da íntima foram preditores independentes de mortalidade. O 
nosso estudo8 foi publicado alguns meses após o estudo de London e foi o primeiro a usar 
um score semiquantitativo para avaliar as calcifi cações vasculares. As calcifi cações são 
avaliadas em setores defi nidos nos RX das mãos ou da bacia. Os limites do score são de 0 e 
8. Posteriormente, mais estudos foram publicados mostrando a associação entre calcifi cações 
vasculares avaliadas por RX simples e mortalidade. A presença de calcifi cações na aorta 
abdominal20 ou a presença de calcifi cações no acesso vascular 21 associaram -se a maior risco 
de morte, O score da calcifi cação aortoabdominal descrito por Kauppila L22, que avalia as 
calcifi cações na aorta abdominal de L1 a L4, usando um RX simples de perfi l, é preditor de 
mortalidade na população geral23 e, nos doentes em diálise, apresenta uma boa correlação 
com o score coronário de Agatston24. Os resultados preliminares do estudo CORD25 mostram 
que o score de Kauppila se associa à idade, à duração da diálise e à doença vascular prévia. 
Em comunicação apresentada no Congresso da EDTA, em 2008, Honkanen E et al mostraram 
que um score de Kauppila superior ou igual a 7 se associa a maior risco de mortalidade.

Comparamos o score simples de calcifi cação com o score de calcifi cação na aorta abdominal, 
ou score de Kauppila, na avaliação do índice tornozelo -braço num grupo de 219 doentes em 
hemodiálise26. Os valores preditivos positivo e negativo de um score vascular simples superior 
a 3 identifi car um score de Kauppila superior ou igual a 6 foram, respectivamente, 79% e 85%. 
Ambos os métodos se associaram a maior risco de doença arterial obliterativa, defi nida por índice 
tornozelo -braço, inferior a 0,9, apresentando uma área semelhante sob a curva. Só as calcifi cações 



124

detetadas no RX das mãos e nas artérias colaterais da bacia se associaram a maior risco de índice 
tornozelo -braço superior a 1,3. O padrão radiológico mais comum das calcifi cações vasculares 
destas artérias colaterais ou distais é linear. Esta associação sugere uma eventual contribuição 
de calcifi cações da camada média arterial para o aumento do índice tornozelo -braço.

Várias técnicas não invasivas permitem fazer o rastreio de calcifi cações vasculares: 
técnicas de tomografi a axial computorizada para avaliação do score de calcifi cação coronário, 
ecografi a de grandes vasos, ecocardiografi a para avaliação das calcifi cações valvulares aórtica 
e mitral e RX simples para avaliar diferentes territórios arteriais. A tomografia axial 
computorizada multicorte ou a tomografi a computorizada de feixe de eletrões são consideradas 
técnicas gold -standard para avaliação das calcifi cações coronárias ou aórticas. São técnicas 
quantitativas dispendiosas que têm sido usadas em vários ensaios clínicos para avaliação da 
progressão das calcifi cações coronárias. Estas técnicas não distinguem a calcifi cação da íntima 
da da média e apresentam valores muito elevados nos doentes renais crónicos, devido à elevada 
prevalência de calcifi cações da média nestes doentes11. Os elevados scores de calcifi cação 
diagnosticados por estes métodos associam -se a maior risco cardiovascular, mas podem não 
se relacionar com doença coronária obstrutiva. O RX simples, a ecografi a dos grandes vasos 
e a ecocardiografi a são métodos simples e baratos mais indicados para o rastreio das calcifi cações 
vasculares nos doentes em diálise. A iniciativa KDIGO 200917 reconhece a utilidade do RX 
simples e da ecocardiografi a para fazer o rastreio das calcifi cações vasculares. Na escolha do 
melhor método a usar nos nossos doentes para este fi m devemos, contudo, ter em conta que 
o ecocardiograma subavalia o risco cardiovascular relacionado com as calcifi cações.

Qual a utilidade de avaliar as calcifi cações vasculares 
nos doentes renais crónicos?

A mortalidade cardiovascular é a principal causa de morte nos doentes em diálise. Até 
ao momento atual, muito poucas intervenções terapêuticas se associaram a uma redução da 
mortalidade, e isto verificou -se apenas em ensaios clínicos com reduzido número de 
participantes. O candesartan associou -se à redução de eventos cardiovasculares27, o carvedilol 
reduziu a mortalidade em doentes com cardiomiopatia28 e o sevelamer reduziu a mortalidade 
num grupo de 127 doentes em diálise com hiperfosfatemia12.

A presença de calcifi cações vasculares é um sinal de alerta para um elevado risco 
cardiovascular nos doentes renais crónicos. Nestes doentes justifi ca -se a intervenção terapêutica 
em todos os fatores associados ao desenvolvimento e progressão das calcifi cações vasculares, 
sendo a correção das alterações do metabolismo fosfocálcico um dos campos de atuação. 



125

Esperamos que o progressivo conhecimento dos múltiplos mecanismos fi siopatológicos na 
base do desenvolvimento das calcifi cações vasculares permitam alargar o campo de intervenção 
terapêutica nos nossos doentes. Será sempre necessário confi rmar se este tipo de intervenção 
terapêutica se associa à redução da morbilidade e da mortalidade nestes doentes.

Referências

  1. Adragão T, Frazão JM. Cardiovascular risk in dialysis patients: an X -ray vision on vascular 
calcifi cations. Kidney Int 2008; 74(12):1505 -1507.

  2. Adragão T. Evaluation of vascular calcifi cations in CKD patients. Int J Artif Organs 2009;32(2):81-
-86.

  3. Adragão T, Ferreira A, Frazão J. Evaluación no invasiva de la calcifi cación vascular en pacientes 
con ERC. (Aceite para publicação no livro “Alteraciones del metabolismo óseo -mineral en la 
enfermedad renal crónica”, editado pelo Prof. Jorge Cannata).

  4. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation 
of cardiac calcifi cation in chronic dialysis patients. Am J Kidney Dis 1996; 27:394 -401.

  5. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular 
risk in end -stage renal disease. Hypertension 2001;38:938 -942.

  6. Moe SM, O’Neill KD, Fineberg N, et al. Assessment of vascular calcifi cation in ESRD patients 
using spiral CT. Nephrol Dial Transplant 2003; 18: 1152 -1158.

  7. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: 
impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-
-1740.

  8. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004;19(6):1480 -1488.

  9. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcifi cation: Patophysiology, epidemiology, 
imaging methods and clinical implications. A statement for health professionals from the American 
Heart Association. Circulation 1996; 94: 1175 -1192.

10. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcifi cation is related to coronary 
atherosclerosis in chronic renal disease patients: a study comparing EBCT -generated coronary 
artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307 -2312.

11. Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: 
immunohistochemistry, backscatter imaging, and x -ray analysis in renal and nonrenal patients. 
Clin J Am Soc Nephrol 2007;2(1):121 -134.

12. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and phosphate binder 
choice in incident hemodialysis patients. Kidney Int 2007;71(5):438 -441.

13. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcifi cation score 
(CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8(1):54 -58.



126

14. Wang AY, Wang M, Woo J, et al. Cardiac valve calcifi cation as an important predictor for all -cause 
mortality and cardiovascular mortality in long -term peritoneal dialysis patients: a prospective 
study. J Am Soc Nephrol 2003;14(1):159 -168.

15. Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve 
calcium with coronary artery disease, atherosclerotic vascular disease, and all -cause mortality in 137 
patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 15;95(6):742 -743.

16. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcifi cation predicts mortality and coronary 
artery disease in end stage renal disease. Atherosclerosis 2007;191(2):348 -354.

17. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global 
outcomes (KDIGO). Kidney Int 2009; 76 (Suppl): S113.

18. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP.Vascular and 
valvular calcifi cations in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 
21(4): 293 -300.

19. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of 
cardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb 
Vasc Biol 1996; 16: 978 -983.

20. Okuno S, Maeno Y, Maekawa K, et al. Presence of abdominal aortic calcifi cation is signifi cantly 
associated with all -cause and cardiovascular mortality in maintenance hemodialysis patients. Am 
J Kidney Dis; 2007: 49: 417 -425.

21. Schlieper G, Krüger T, Djuric Z, et al. Calcifi cation of the arteriovenous fi stula predicts mortality 
in haemodialysis patients. Kidney Int 2008; 74: 1582 -1587.

22. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression 
of calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-
-250.

23. Wilson PWF, Kauppila LI, O’Donnell CJ, et al. Abdominal aortic calcifi c deposits are an important 
predictor of vascular morbidity and mortality. Circulation 2001;103: 1529 -1534.

24. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium 
measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623 -1628.

25. Honkanen E, Kauppila L, Wikström B, et al; CORD study group. Abdominal aortic calcifi cation 
in dialysis patients: results of the CORD study. Nephrol Dial Transplant 2008; 23: 4009 -4015.

26. Adragão T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle 
brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3 
(Suppl 3): iii492. [Abstract Su545.]

27. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type -1 receptor blocker, 
reduces cardiovascular events in patients on chronic haemodialysis – a randomized study. Nephrol 
Dial Transplant 2006; 21: 2507 -2512.

28. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two -year survival in dialysis patients 
with dilated cardiomyopathy: a prospective, placebo -controlled trial. J Am Coll Cardiol 2003; 41: 
1438 -1444.



Kidney International (2008) 74          1505

c o m m e n t a r yhttp://www.kidney-international.org
© 2008 International Society of Nephrology

see original article on page 1582

Cardiovascular risk in dialysis 
patients: an X-ray vision on 
vascular calcifications
Teresa Adragão1 and João M. Frazão2

In dialysis patients, there is an association between vascular 
calcifications and mortality. Hyperphosphatemia and calcium overload 
are associated with development of vascular calcifications, especially 
in the presence of low bone turnover. Different plain X-ray methods are 
now available to evaluate vascular calcifications in dialysis patients. 
The presence of vascular calcifications is an alert sign for increased 
cardiovascular risk, and this information is important for choosing the 
most suitable treatment for dialysis patients.
Kidney International (2008) 74, 1505–1507. doi:10.1038/ki.2008.503 

Introduction
In recent years, observational studies in 
dialysis patients have verified the exist-
ence of an association between vascu-
lar calcifications and mortality.1–5 The 
abnormal mineral metabolism, a conse-
quence of chronic kidney disease (CKD), 
has been associated with development 
of vascular calcifications. In an in vitro 
model using smooth muscle cells from 
the human aorta, it was demonstrated 
that high levels of phosphorus, calcium, 
or both induce vascular calcification6 
by an active intracellular process that 
transforms vascular smooth muscle cells 
into osteoblast-like cells. Vascular cal-
cifications are associated with low bone 
turnover,7 and the hypothesis of the exist-
ence of a link between bone disease and 
cardiovascular disease has been raised. 
Kidney Disease: Improving Global Out-
comes (KDIGO) has recommended a new 
classification for chronic kidney disease 

mineral and bone disorder (CKD-MBD) 
that includes the presence of vascular 
calcifications.

Methods to evaluate  
vascular calcifications
Braun et al.,8 in 1996, used electron 
beam computed tomography to evaluate 
coronary calcifications and showed that 
hemodialysis patients had a very high 
coronary Agatston score when compared 
with nonrenal patients. Blacher et al.,1 
in 2001, demonstrated for the first time 
that the presence of vascular calcifica-
tions in hemodialysis patients, evaluated 
by ultrasonography in large arteries, was 
associated with increased mortality. In 
2003, London et al.2 showed that vascu-
lar calcifications evaluated in plain X-ray 
were associated with all-cause and cardi-
ovascular mortality in dialysis patients. 
After these initial observations, other 
studies3,5 confirmed the association 
between vascular calcifications, evalu-
ated with plain X-ray, and mortality in 
the CKD stage 5 hemodialysis popula-
tion. We developed a simple vascular 
calcification score, using the presence of 
vascular calcification, in a plain X-ray 
of the pelvis and hands3 (Figure 1). This 
simple score was an independent pre-
dictor of cardiovascular death, cardio-
vascular hospitalizations, and vascular 

disease in dialysis patients. The Kauppila 
score, using the presence of vascular cal-
cification in a plain X-ray of the lateral 
abdominal aorta, previously associated 
with cardiovascular death in the general 
population, has been recently validated 
for evaluating mortality risk in hemo-
dialysis patients (E. Honkanen et al., 
2008; EDTA Congress; Stockholm, Swe-
den; abstr.). Even a simpler evaluation of 
vascular calcifications in the abdominal 
aorta, identifying only the presence or 
absence of calcifications,5 was also a pre-
dictor of mortality in dialysis patients. 
Schlieper et al.9 (this issue) now publish 
an interesting observation showing that 
the presence of vascular calcification 
of the hemodialysis vascular access, 
evaluated by plain X-ray, is also an 
independent predictor of mortality.

Electron beam computed tomo graphy 
and multislice computed tomo graphy 
are considered the gold standard for 
quantitative evaluation of vascular cal-
cifications, but they are expensive and 
not widely available. In the setting of 
clinical trials performed with CKD 
patients, these quantitative techniques 
have been useful to evaluate the effect 
of different treatment options on vascu-
lar calcification progression. However, 
the meaning of the coronary Agatston 
score is different in dialysis patients as 
compared with the general population. 
In the general population, the coronary 
Agatston score is correlated with the 
atherosclerotic calcium load and is a 
predictor of cardiovascular events. In 
dialysis patients, there is no precise 
correlation between calcium score and 
coronary angiography. The Agatston 
score does not differentiate intimal from 
medial calcification, and hemodialysis 
patients can have a very high coronary 
Agatston score, because both intimal and 
medial calcifications may be present in 
coronary arteries. Medial calcifications 
contribute to aortic stiffness and to 
decreased coronar y perfusion dur-
ing diastole without causing coronary 
stenotic lesions. For that reason, a high 
coronary Agatston score cannot be used 
to identify dialysis patients who will 
benefit from a coronary angioplasty.

1Nephrology Department, Hospital de Santa 
Cruz, Carnaxide, Portugal; and 2Nephrology 
Department, Hospital de São João, School 
of Medicine and Nephrology Research and 
Development Unit, Porto University, Porto, 
Portugal
Correspondence: Teresa Adragão, Nephrology 
Department, Hospital de Santa Cruz, Av Prof 
Reinaldo Santos, 2795-523, Carnaxide, Portugal.  
E-mail: tadragao@netcabo.pt



1506   Kidney International (2008) 74   

c o m m e n t a r y

Vascular calcification evaluated  
in the vascular access
Schlieper et al.9 evaluated calcification of 
arteriovenous fistulas or synthetic grafts 
with plain X-ray and verified that cal-
cification of the vascular access was an 
independent predictor of mortality. The 
authors conclude that this is a cost-effective 
and easy-to-perform method to identify 
dialysis patients at increased mortality 
risk. Calcification of the vascular access 
was present in 23% of patients and was 
associated with male gender, diabetes, and 
dialysis vintage. The authors have verified 
that the presence of calcifications in the 
vascular access was highly correlated with 
the presence of vascular calcifications of 
iliac and femoral arteries, suggesting that 
there is a common pathogenic process 
affecting these different sites of the vascu-
lature. This common pathogenic process 
could explain why vascular calcifications, 
independently of their localization, are 
associated with mortality risk. The pres-
ence of calcification in the vascular access 
may have, however, a different mean-
ing from that observed in other arteries. 
Intimal calcification is associated with 
atherosclerotic plaques, and medial calci-
fication is associated with arteriolosclero-
sis. In hemodialysis patients it has already 
been demonstrated2 that these two types 
of vascular calcifications may coexist in 
the same patient and in the same vessel 
and that they are independent predictors 
of cardiovascular and all-cause mortality. 
Calcification of the vascular access seems 
to be predominantly composed of medial 
calcification.10 Most probably, a method 

to evaluate vascular calcifications that 
includes these two types of vascular cal-
cification, intimal and medial calcifica-
tion2,3,5 (E. Honkanen et al., 2008; EDTA 
Congress; Stockholm, Sweden; abstr.), 
should be more appropriate for evaluating 
the global mortality risk. In our opinion, 
there are other limitations in the choice 
of this method to evaluate vascular calci-
fications. One limitation is the exclusion 
of all patients who do not have a vascular 
access, such as peritoneal dialysis patients 
and patients without vascular conditions 
to receive an access. Also, local hemody-
namic factors, unrelated to cardiovascular 
risk, may be associated with development 
of calcifications of the vascular access. The 
presence of calcification in the vascular 
access might have an interesting advantage 
of identifying calcium deposition occur-
ring after initiation of dialysis. However, 
the identification of this phenomenon at 
such a late stage might not be so helpful 
to guide a therapeutic intervention. An 
earlier identification of vascular calcifica-
tions, in predialysis or in incident patients, 
is probably a more intelligent and useful 
approach. Such patients constitute a popu-
lation with elevated risk of rapid calcifica-
tion progression and certainly deserve a 
more aggressive therapeutic approach.

What is the preferable vascular  
calcification screening method?
A method adequate for screening vascu-
lar calcifications should be inexpensive 
and simple to interpret. Any of the plain 
X-ray methods mentioned here for evalu-
ation of vascular calcifications can be easily 

interpreted by the attending physician. 
Another important quality for choosing 
a screening method is a correct balance 
between sensitivity and specificity. Which 
of the methods using plain X-ray for evalu-
ation of vascular calcification is the best? 
For a definitive answer to this question, 
comparative studies in the same population 
will be required and certainly welcome.

In our opinion, all of the methods 
described here that recognize the presence 
of vascular calcification with plain X-ray 
of different vascular territories have been 
demonstrated to be very useful in the eval-
uation of CKD population mortality risk. 
Certainly, the final choice of the method to 
be used in a specific institution should be 
based on the experience and preference of 
the nephrology attending physicians.

What is the importance of screening  
vascular calcifications in dialysis patients?
The identification of dialysis patients with 
calcified vessels and the evaluation of vas-
cular calcification extension could be very 
useful for cardiovascular risk stratification 
and therapeutic guidance. Vascular calci-
fications most likely are multifactorial and 
result from a complex balance between 
inducers and inhibitors. However, at this 
stage of knowledge, we can only interfere 
in a very small number of those factors 
— mainly, alterations of mineral metabo-
lism. Several studies have already dem-
onstrated that vascular calcifications in 
dialysis patients may progress or remain 
stable depending on the control of the 
mineral metabolism alterations, such as 
hyperphosphatemia. Another important 
aspect besides the control of hyperphos-
phatemia per se is the choice of the phos-
phate-binding agent. One should avoid 
the use of calcium-containing phosphate 
binders in patients with calcified vessels.

London et al. demonstrated an associa-
tion between vascular calcifications and 
low bone turnover.7 The same group11 
found a significant interaction between 
dosage of calcium-containing phos-
phate binders and bone activity such 
that calcium load had a significantly 
higher impact on aortic calcifications 
and stiffening in the presence of ady-
namic bone disease. Low-bone-turnover 
status should b e prevented, when 
possible, avoiding para thyroid hormone 

Figure 1 | Simple vascular calcification score evaluation. Calcification score is the sum 
of the presence (1) or absence (0) of vascular calcifications in each section. Pelvis score 
(1+1+1+1) = 4 and hands score (1+1+1+1) = 4. Total score is 8.



Kidney International (2008) 74          1507

c o m m e n t a r y

oversuppression, and calcium-containing 
binders should be avoided in patients with 
such a condition.11

In summary, vascular calcifications are 
associated with increased mortality in dial-
ysis patients. Different methods can be used 
to identify vascular calcifications in these 
patients. Plain X-ray evaluation of vascular 
calcifications is inexpensive and simple to 
interpret and should be used for the screen-
ing of vascular calcifications. Nephrologists 
have now at their disposal different plain 
X-ray methods to evaluate vascular calcifi-
cations in their CKD patients. The presence 
of vascular calcifications in CKD patients 
constitutes an important alert sign for an 
increased cardiovascular risk. This infor-
mation is important and should serve to 
guide nephrologists in the design of more 
appropriate and aggressive therapeutic 
strategies to control mineral metabolism 
in their patients.
DISCLOSURE
Teresa Adragão has received research grants 
from Amgen and Genzyme and has received 
lecture fees from Amgen, Genzyme, Abbott, 
and Novartis. João M. Frazão has received 
consultancy and lecture fees from Amgen 
and Genzyme. He is also an advisory board 
member for Amgen and Genzyme.

REFERENCES
1. Blacher J, Guérin AP, Pannier B et al. 

Arterial calcifications, arterial stiffness, and 
cardiovascular risk in end-stage renal disease. 
Hypertension 2001; 38: 938–942.

2. London GM, Guerin AP, Marchais SJ et al. Arterial 
media calcification in end-stage renal disease: 
impact on all-cause and cardiovascular mortality. 
Nephrol Dial Transplant 2003; 18: 1731–1740.

3. Adragao T, Pires A, Lucas C et al. A simple vascular 
calcification score predicts cardiovascular risk in 
haemodialysis patients. Nephrol Dial Transplant 
2004; 19: 1480–1488.

4. Block GA, Raggi P, Bellasi A et al. Mortality effect 
of coronary calcification and binder choice in 
incident hemodialysis patients. Kidney Int 2007; 
71: 438–441.

5. Okuno S, Maeno Y, Maekawa K et al. Presence 
of abdominal aortic calcification is significantly 
associated with all-cause and cardiovascular 
mortality in maintenance hemodialysis patients. 
Am J Kidney Dis 2007; 49: 417–425.

6. Yang H, Curinga G, Giachelli CM. Elevated 
extracellular calcium levels induce smooth 
muscle cell matrix mineralization in vitro. Kidney 
Int 2004; 66: 2467–2468.

7. London GM, Marty C, Marchais SJ et al. Arterial 
calcifications and bone histomorphometry in 
end-stage renal disease. J Am Soc Nephrol 2004; 
15: 1943–1951.

8. Braun J, Oldendorf M, Moshage W et al. Electron 
beam computed tomography in the evaluation 
of cardiac calcification in chronic dialysis 
patients. Am J Kidney Dis 1996; 27: 394–401.

9. Schlieper G, Krüger T, Djuric Z et al. Vascular 
access calcification predicts mortality in 

hemodialysis patients. Kidney Int 2008; 74: 1582–1587. 
10. Wang N, Yang J, Yu X et al. Radial artery calcification 

in end-stage renal disease patients is associated 
with deposition of osteopontin and diminished 
expression of alpha-smooth muscle actin. 

Nephrology (Carlton) 2008; 13: 367–375.
11. London GM, Marchais SJ, Guérin AP et al. 

Association of bone activity, calcium load, aortic 
stiffness, and calcifications in ESRD. J Am Soc 
Nephrol 2008; 19: 1827–1835.

see original article on page 1588 

DRIVE it home:  
making the case for prospective 
economic data collection  
in randomized clinical trials
Eric L. Eisenstein1

Although the results of Pizzi et al. point to the potential economic 
attractiveness of a ferric gluconate treatment strategy, they may not be 
sufficient to change public policy and reimbursement practices. What is 
required is a large, simple trial that will replicate the results of the DRIVE trial 
in a broader population with longer follow-up and a prospectively defined 
economic and quality-of-life study conducted from the societal perspective.
Kidney International (2008) 74, 1507–1509. doi:10.1038/ki.2008.553 

In 1972, Archie Cochrane put forth three 
tests that all medical technologies must 
pass.1 The first test, of efficacy, assesses 
whether the new technology can work 
under ideal circumstances, such as those 
found in a randomized clinical trial. The 
second test, of effectiveness, evaluates 
whether the technology works under usual 
circumstances, such as those found in actual 
practice. And the third test, of efficiency, 
determines whether the new technology is 
worth it—put differently, whether there is 
a proper relationship between the benefits 
derived through the use of the technol-
ogy and the resources it consumes (Figure 
1). While the renal research community 
has demonstrated increasing success in 
answering Cochrane’s first two questions 
with respect to important clinical and pol-
icy issues, it has exhibited less interest in his 
third question. In few areas is the disparity 

between clinical and economic research 
greater than in the appropriate use of epo-
etin alfa for anemia correction in patients 
with kidney disease.

In recent years, our understanding of 
the efficacy and effectiveness of epoetin 
alfa in patients with kidney disease has 
increased substantially. The Cardiovascu-
lar Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta (CREATE) study 
reported that complete correction of ane-
mia in patients with chronic kidney disease 
does not reduce the risk of cardiovascular 
events.2 This message was amplified by the 
Correction of Hemoglobin and Outcomes 
in Renal Insufficiency (CHOIR) study, 
which reported that the use of higher ver-
sus lower target hemoglobin levels is asso-
ciated with increased cardiovascular risk 
with no improvement in quality of life.3 
Subsequently, a secondary analysis from the 
CHOIR study refocused the discussion by 
reporting that patients who achieved their 
hemoglobin targets (whether lower- or 
higher-level) had better cardiovascular out-
comes than those who did not.4 The under-
lying issue was that a greater proportion of 

1Duke Clinical Research Institute, Durham, North 
Carolina, USA
Correspondence: Eric Eisenstein, Duke Clinical 
Research Institute, P.O. Box 17969, Durham, North 
Carolina 27715, USA.  
E-mail: Eric.Eisenstein@duke.edu





0391-3988/081-06 $25.00/0

The International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 81-86

Evaluation of vascular calcifications in CKD patients
TERESA ADRAGÃO

Nephrology Department, Santa Cruz Hospital, Carnaxide - Portugal

© Wichtig Editore, 2009

ABSTRACT: In observational studies on dialysis patients, there has been a consistent association
between vascular calcifications and mortality. Hyperphosphatemia and calcium treatment are some
of the factors associated with development of vascular calcifications, especially in the presence of
low bone turnover disease. Several non-invasive imaging techniques have been used to screen for
the presence of vascular calcifications: plain X-Ray, echocardiography, ultrasonography, and com-
puted tomography. Presence of vascular calcifications is a warning sign for increased cardiovascular
risk and this information may be relevant for choosing the most suitable treatment for dialysis pa-
tients. (Int J Artif Organs 2009; 32: 81-6)

KEY WORDS: Vascular calcifications, Imagiology, Chronic kidney disease

INTRODUCTION

High cardiovascular risk in chronic kidney disease pa-
tients is not fully explained by traditional risk factors. The
Framingham risk score, based on age, gender, diabetes,
hypertension, lipid profile and smoking habits, fails to
predict cardiovascular events in dialysis (1) and pre-dialy-
sis (2) patients and several non-traditional risk factors are
commonly considered to contribute to the high cardio-
vascular risk in this population.

In the last few years a new explanation has been added
to the list of the already numerous cardiovascular risk
factors of chronic kidney disease patients. The associa-
tion of cardiovascular calcifications with mortality, veri-
fied in multiple observational studies, is considered to be
a consistent finding and has been classified as grade B
evidence in recent KDIGO recommendations. In experi-
mental studies, it is demonstrated that an altered mineral
metabolism has a direct causal effect on vascular calcifi-
cations. In a model using vascular smooth muscle cells
from the human aorta, Giachelli (3) demonstrated that hy-
perphosphatemia and hypercalcemia were inducers of
vascular calcification by activation of intracellular Cbfa1,
which led to the transformation of the vascular smooth
muscle cell into an osteoblast. 

Hypercalcemia and hyperphosphatemia are commonly
seen in dialysis patients under two opposing conditions.
In secondary hyperparathyroidism, a situation with high

bone turnover, the bone itself contributes to the high lev-
els of phosphorus and calcium. In adynamic bone dis-
ease, a condition with low bone turnover, the bone be-
haves as if it were “frozen” and is unable to capture ex-
traosseus calcium and phosphorus derived mainly from
food and, in the case of calcium, from treatment as well.

These observations have led to the hypothesis that a
link exists between bone disease and vascular disease in
dialysis patients. In the KDIGO position paper published
in 2006 , the presence of soft tissue and of vascular cal-
cifications have been included in the definition of chronic
kidney disease mineral and bone disorder (CKD-MBD)
(4).

Types of vascular calcification

Vascular calcifications present two different histological
types: intimal and medial calcification. Thus far, intimal
and medial calcifications have been considered to be two
distinct entities, with different clinical presentations and
prognoses. The possibility that these two entities may
constitute a continuum of vascular pathology in CKD pa-
tients has been hypothesized (5). However, the fact that
media calcification is detected earlier in the course of
CKD, and in the absence of lipid and cholesterol deposi-
tion, challenges this hypothesis (6). Intimal calcification is
related to dyslipidemia and accompanies the progression

Review



82

Non-invasive diagnosis of vascular calcifications in CKD patients

of atherosclerotic plaque. Medial calcification is associat-
ed with arteriolosclerosis, and develops mainly in diabet-
ic, chronic kidney disease, and elderly patients. Clinical
manifestations of intimal calcification are related to the
presence of atherosclerotic plaques that obstruct the ar-
teries by rupture and /or thrombosis. Medial calcification
does not cause arterial obstruction and was once consid-
ered a radiological finding with no clinical consequences.
Today we know that medial calcification modifies the
properties of the arterial wall and is one of the factors
that contributes to arterial stiffness. Arterial stiffness in
manifested by an increase in pulse wave velocity and in
pulse pressure. Due to the loss of distensibility in the aor-
ta, there is an earlier reflection of the aortic wave that
finds the aortic valve still opened. The consequence is an
increase in the systolic and a decrease in the diastolic
pressure. Systolic pressure increase contributes to the
development of left ventricular hypertrophy. Decrease in
diastolic pressure may compromise the coronary perfu-
sion that is mainly performed during diastole. Medial cal-
cification may then be associated with symptomatic
coronary disease in the absence of obstructive coronary
artery disease. 

Methods to diagnose vascular calcifications:
quantitative evaluation of coronary 
calcifications

Electron Beam Computed Tomography (EBCT) and
Multislice Computed Tomography (MSCT)

Braun et al (7) in 1996 used Electron Beam Computed
Tomography (EBCT) to evaluate coronary calcifications in
dialysis patients. Quantification of calcification is per-
formed by calculating the Agatston score. This method is
based on the maximum X-ray attenuation coefficient,
measured in Hounsfield units, and the area of calcifica-
tion is multiplied by the density scores. Analysis of 49 he-
modialysis patients demonstrated that the mean cardiac
calcification score was more than 10-fold higher in he-
modialysis patients than in 102 non-dialysis control pa-
tients with documented or suspected cardiovascular dis-
ease. The meaning of the Agatston score may be differ-
ent in renal and non-renal patients. In non-renal patients
the amount of coronary calcium is related to the overall
atherosclerotic plaque burden and is an effective predic-

tor of coronary artery disease. It is well established that
individuals with Agatston scores above 400 have an in-
creased occurrence of coronary procedures (bypass,
stent placement and angioplasty) and of cardiac events
(myocardial infarction and cardiac death) within the 2 to 5
years after the test. The extent and site of calcification
may not correspond to the site of stenosis but the greater
the amount of calcification, the greater the likelihood of
obstructive disease somewhere in the coronary arteries.
In general population, several studies have shown a good
correlation between calcium scores and coronary steno-
sis (8). 

Dialysis patients, however, can have very high coronary
Agatston scores without coronary stenosis. Haydar et al
(9) compared coronary angiographies with coronary
Agatston scores obtained by EBCT in a group of 46 he-
modialysis patients. A higher coronary Agatston score
was associated with a higher number of diseased ves-
sels, however, eleven patients with no occlusive coronary
disease in the angiography had a median coronary Agat-
ston score of 619, which, in the general population, is as-
sociated with coronary stenosis. Three- or four-vessel
disease in twenty dialysis patients was associated with a
median coronary Agatston score of 3748, a score rarely
seen in the general population. Since this method does
not discriminate intimal from medial calcification, these
very high calcification scores in dialysis patients may be
explained by the probable occurrence of both types of
vascular calcification in coronary arteries. 

The existence of a different morphology of coronary le-
sions in CKD and non-CKD patients has been demon-
strated in an autopsy study (10). CKD patients show
heavy calcification of the media, with higher calcium con-
tent in the media and in the intima and with more fre-
quent presence and greater intensity of inflammation
markers. In dialysis patients, there is, however, a good
correlation between coronary calcifications and cardio-
vascular risk. Coronary calcifications have been related
with cardiovascular events (11) and with mortality (12,
13). Nevertheless, the clinical significance of Agatston
score cut-off values in the general population for the di-
agnosis of occlusive coronary disease cannot be applied
to dialysis patients. Likewise, coronary calcification has
also been a predictor of mortality in dialysis patients but
in association with lower coronary Agatston score values
than those described in association with coronary occlu-
sive disease (9). In prevalent patients a coronary Agat-
ston score greater than 200 was associated with all-



Adragao 

83

cause death (12), and in incident patients, a coronary
Agatston score greater than 400 was associated with
lower survival (13). Therefore, the association of coronary
calcifications with mortality is consistent with all the other
observational studies showing that the presence of vas-
cular calcifications, independently of their location, is
predictive of mortality. 

Currently, evaluation of coronary calcifications with
EBCT has been substituted by multislice computed to-
mography (MSCT). Application of EBCT is limited to the
assessment of coronary calcification, while MSCT has
multiple uses and with software adjustments may also
evaluate coronary calcification. This technique is widely
available and is now an alternative for quantitative evalu-
ation of coronary calcification. It has been demonstrated
that MSCT is a viable technique for the evaluation of
coronary arteries and aortic vascular calcification in CKD
patients (14).

Ultrasonography and echocardiography

Ultrasonography was the method used by Blacher (15)
to evaluate vascular calcifications in four arterial territo-
ries in dialysis patients: the carotid, aorta, iliac and
femoral arteries. This study, performed in 2001, was the
first to demonstrate that vascular calcifications were as-
sociated with increased mortality in dialysis patients and
it showed that the higher the number of territories affect-
ed, the lower the survival. 

Calcification of heart valves can be evaluated by
echocardiography; this type of calcification was associat-
ed with lower survival in peritoneal dialysis patients (16).
In a group of 127 hemodialysis patients we have also ver-

ified that valvular calcification is a predictor of all-cause
and cardiovascular death. The simple vascular calcifica-
tion score evaluated in plain X-ray of pelvis and hands
(17), described in the next section, was associated with
valvular calcification, raising the hypothesis of a common
pathogenesis for valvular and vascular calcification in this
population (18). 

Plain X-ray

In 2003 London et al (19) were the first to demonstrate
that vascular calcifications evaluated by plain X-ray were
associated with all-cause and cardiovascular mortality.
These authors differentiated medial from intimal calcifica-
tion in plain X-ray films. Medial calcification is linear and
regular, presenting a railroad track type, while intimal cal-
cification is patchy and irregular. This study demonstrat-
ed that medial calcification is not a radiological finding
but has an important clinical signification. These two
types of calcification were sometimes found in the same
patient and in the same vessel and were independent
predictors of mortality. Intimal calcification was associat-
ed with older age and higher LDL-cholesterol levels. Me-
dial calcification was associated with hemodialysis vin-
tage and diabetes. Calcium carbonate dose and phos-
phorus levels were associated with both types of calcifi-
cation. 

Other studies (17, 20) have confirmed the association
between vascular calcifications, evaluated with plain X-
ray, and mortality in the CKD stage-5 hemodialysis popu-
lation. We developed a simple vascular calcification
score, evaluated in a plain X-ray of the pelvis and hands
(17) (Fig. 1). This simple score was an independent pre-

Fig. 1 - Simple va-
scular calcification
s core  e valu at ion .
Calcification score
is  the  su m of  t he
presence (1) or ab-
sence (0) of vascu-
lar calcifications in
each section. Pelvis
score (1+1+1+1) =
4 and hands score
(1+1+1+1) = 4. To-
tal score is 8.



84

Non-invasive diagnosis of vascular calcifications in CKD patients

dictor of cardiovascular death, cardiovascular hospital-
izations and vascular disease in dialysis patients and was
an independent predictor of arterial stiffness evaluated by
pulse wave velocity and pulse pressure (21). 

The Kauppila score evaluates the presence of vascular
calcifications in the anterior and posterior wall of the ab-
dominal aorta using a lateral plain X-ray of the lumbar
vertebral segments from L1 to L4. This score has been
associated with cardiovascular death in a subgroup of
participants of the Framingham Heart Study (22). This
score has also been tested in dialysis patients. It pre-
sents a good correlation with the coronary Agatston
score and demonstrates high sensitivity and specificity in
predicting a high coronary Agatston score (23). The pre-
liminary results of the CORD study, evaluating outcomes
in relation with the Kauppila score, have shown that ab-
dominal aortic calcification is associated with age, dialy-
sis duration and previous cardiovascular disease (24).
The plain X-ray score and Kauppila scores are semi-
quantitative evaluations of vascular calcifications. Simpler
evaluations of vascular calcifications, assessing only the
presence or absence of vascular calcifications have also
been associated with mortality, such as the identification
by plain X-ray of vascular calcifications in the abdominal
aorta (20) or in the hemodialysis vascular access (25). 

CONCLUSIONS

What is the best non-invasive method to diagnose
vascular calcifications?

Several non-invasive imaging techniques have been
used to screen for the presence of vascular calcifications:
plain X-ray to evaluate different arterial territories,
echocardiography for assessment of valvular calcifica-
tion; two-dimensional ultrasound for calcification of
carotid arteries, femoral arteries and aorta; and comput-
ed tomography technologies.

Existing studies demonstrate that vascular calcifica-
tions, independently of their location, are predictors of
mortality in CKD patients. EBCT and MSCT are consid-
ered to be the gold standard for evaluating coronary cal-
cifications. They allow a quantitative assessment of vas-
cular calcifications and have been used in several ran-
domized clinical trials for evaluating progression of calci-
fication. These methods do not differentiate intimal from
medial calcification, and high coronary scores in dialysis

patients, though related with higher cardiovascular risk,
may not be related with coronary obstructive disease.
The clinical implications of this score in dialysis patients
are not identical to those for the general population. 

Plain X-Ray, ultrasonography and echocardiography
are less expensive and, for that reason, more convenient
for screening vascular calcifications. Plain X-ray methods
have the advantage of greater simplicity and the possibil-
ity of being easily interpreted by the attending physician.
The simple vascular calcification score and Kauppila
score perform a semi-quantitative evaluation of vascular
calcification with cut-off values that allow the identifica-
tion of patients with a higher cardiovascular risk. A car-
diovascular calcification index using the Kauppila score
and valvular calcification evaluated by echocardiography
have been demonstrated to be associated with coronary
calcification in hemodialysis patients evaluated by EBCT
(26). Simpler methods to evaluate vascular calcifications
seem to be an attractive option but the final choice of the
method to employ would depend on the available tests
and on the preference of the nephrologist.

Is it useful to screen vascular calcifications in dialysis
patients?

Cardiovascular death is the main cause of mortality in
CKD patients and, at present, very few therapeutic inter-
ventions have shown success in the reduction of all-
cause or cardiovascular mortality in this population. Can-
desartan (27), which has been associated with reduction
of cardiovascular events in dialysis patients, carvedilol
(28) in patients with dilated cardiomyopathy, and seve-
lamer (29), used to control phosphorus levels in incident
patients, are some of the few treatments that have been
associated with increased survival in dialysis patients. In
CKD patients, the presence of vascular calcifications is a
marker of increased cardiovascular risk and this associa-
tion, based on observational studies, is classified as
grade B evidence by the recent KDIGO recommenda-
tions. Vascular calcifications are multifactorial and result
from a complex balance between inducers and inhibitors.
At the present stage of knowledge we can only intervene
in a very small number of these factors, mainly, in the
correction of the mineral metabolism. Several studies
have already demonstrated that vascular calcifications in
dialysis patients may progress or remain stable depend-
ing on the control of the mineral metabolism and on the
type of phosphate binder (30-32). London et al demon-



Adragao 

85

strated an association between vascular calcifications
and low bone turnover (33) and found a significant inter-
action between calcium-containing phosphate binders
and aortic calcification and stiffness in the presence of
adynamic bone disease (34). 

Identification of vascular calcifications in CKD patients
is included in the classification of CKD-MBD. This infor-
mation may be used for selecting the most suitable con-
trol of the mineral metabolism, such as intensive control
of hyperphosphatemia, suitable choice of phosphate
binder and prevention of low bone turnover status, for 
instance, by avoidance of calcium-containing binders or
of PTH oversupression. In predialysis (35) and dialysis
patients it has been demonstrated that, vascular calcifi-
cations are progressive and for this reason it seems logi-
cal to begin evaluation of vascular calcifications at an
early stage, possibly in predialysis patients.

In conclusion, different methods can be used for
screening vascular calcifications. Plain-X-ray is a simple

and inexpensive method to perform this evaluation. Con-
sidering the poor results of therapeutic interventions on
cardiovascular mortality in CKD patients, the available
evidence justifies the more frequent use of this simple
evaluation in these patients. This information may be
used to detect cardiovascular risk and to guide therapeu-
tic intervention in chronic kidney disease patients.

Conflict of interest statement 
Teresa Adragao has received research grants from Genzyme; lectu-
re fees from Amgen, Genzyme, Abbot and Novartis; and consul-
tancy fees from Genzyme and Abbot.

Address for correspondence: 
Teresa Adragão, MD
Nephrology Department
Hospital de Santa Cruz
Av Prof Reinaldo Santos 
2795-523, Carnaxide, Portugal
e-mail: tadragao@netcabo.pt

REFERENCES

1. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic car-
diovascular disease risks in chronic hemodialysis patients.
Kidney Int 2000; 58: 353-62.

2. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffith JL. The
Framingham predictive instrument in chronic kidney disea-
se. J Am Coll Cardiol 2007; 50: 217-24.

3. Giachelli CM. Vascular calcification mechanisms. J Am Soc
Nephrol 2004: 15: 2959-64.

4. Moe S, Drueke T, Cunningham J, et al. Definition, evalua-
tion, and classification of renal osteodystrophy: A position
statement from Kidney Disease: Improving Global Outco-
mes (KDIGO). Kidney Int 2006; 69: 1945-53.

5. McCullough PA, Agrawal V, Danielewicz E, et al. Accelera-
ted atherosclerotic calcification and Monckeberg’s sclero-
sis: A continuum of advanced vascular pathology in chronic
kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585- 98.

6. Amann K. Media calcification and intima calcification are di-
stinct entities in chronic kidney disease. Clin J Am Soc
Nephrol 2008; 3: 1599-1605. 

7. Braun J, Oldendorf M, Moshage W, et al. Electron beam
computed tomography in the evaluation of cardiac calcifica-
tion in chronic dialysis patients. Am J Kidney Dis 1996; 27:
394-401.

8. Wexler L, Brundage B, Crouse J, et al. Coronary artery cal-
cification: Patophysiology, epidemiology, imaging methods
and clinical implications. A statement for health professio-

nals from the American Heart Association. Circulation 1996;
94: 1175-92.

9. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery cal-
cification is related to coronary atherosclerosis in chronic
renal disease patients: a study comparing EBCT-generated
coronary artery calcium scores and coronary angiography.
Nephrol Dial Transplant 2004; 19: 2307-12.

10. Gross ML, Meyer HP, Ziebart H, et al. Calcification of Coro-
nary Intima and Media: Immunohistochemistry, Backscatter
Imaging, and X-Ray Analysis in Renal and Nonrenal Pa-
tients. Clin J Am Soc Nephrol 2007; 2: 121-34.

11. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcifica-
tion in adult hemodialysis patients. A link between end-sta-
ge renaldisease and cardiovascular disease? J Am Coll Car-
diol 2002; 39: 695-701.

12. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coro-
nary artery calcification score (CACS) on survival in patients
on chronic hemodialysis. Clin Exp Nephrol 2004; 8: 54-8.

13. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coro-
nary calcification and phosphate binder choice in incident
hemodialysis patients. Kidney Int 2007; 71:438-41.

14. Moe SM, O’Neill KD, Fineberg N, et al. Assessment of va-
scular calcification in ESRD patients using spiral CT. Neph-
rol Dial Transplant 2003; 18: 1152-8.

15. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications,
arterial stiffness, and cardiovascular risk in end-stage renal
disease. Hypertension 2001; 38: 938-42.

16. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification



86

Non-invasive diagnosis of vascular calcifications in CKD patients

as an important predictor for all-cause mortality and cardio-
vascular mortality in long-term peritoneal dialysis patients: a
prospective study. J Am Soc Nephrol 2003; 14: 159-68.

17. Adragao T, Pires A, Lucas C, et al. A simple vascular calcifi-
cation score predicts cardiovascular risk in haemodialysis
patients. Nephrol Dial Transplant 2004;19: 1480-8.

18. Adragao T, Pires A, Lucas C, et al. Vascular and valvular
calcifications in dialysis patients: the same pathogenesis?
Port J Nephrol Hypertens 2007; 21: 281-5.

19. London GM, Guerin AP, Marchais SJ, et al. Arterial media
calcification in end-stage renal disease: impact on all-cause
and cardiovascular mortality. Nephrol Dial Transplant 2003;
18: 1731-40.

20. Okuno S, Maeno Y, Maekawa K, et al. Presence of Abdomi-
nal Aortic Calcification Is Significantly Associated With All-
Cause and Cardiovascular Mortality in Maintenance Hemo-
dialysis Patients. Am J Kidney Dis; 2007: 49: 417-25.

21. Adragão T, Pires A, Birne R, et al. A plain X-ray vascular cal-
cification score is associated with arterial stiffness and mor-
tality in dialysis patients. Nephrol Dial Transplant 2009; 24:
997-1002. 

22. Wilson PWF, Kauppila LI, O’Donnell CJ, et al. Abdominal
Aortic Calcific Deposits Are an Important Predictor of Va-
scular Morbidity and Mortality. Circulation 2001; 103: 1529.

23. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of
simple imaging tests and coronary artery calcium measured
by computed tomography in hemodialysis patients. Kidney
Int 2006; 70: 1623-8.

24. Honkanen E, Kauppila L, Wikström B, et al; CORD study
group. Abdominal aortic calcification in dialysis patients: re-
sults of the CORD study. Nephrol Dial Transplant 2008; 23:
4009-15. 

25. Schlieper G, Krüger T, Djuric Z, et al. Calcification of the ar-
teriovenous fistula predicts mortality in haemodialysis pa-

tients. Kidney Int 2008; 74: 1582-7. 
26. Muntner P, Ferramosca E, Bellasi A, et al. Development of a

cardiovascular calcification index using simple imaging
tools in haemodialysis patients. Nephrol Dial Transplant
2007; 22: 508-14.

27. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an
angiotensin II type-1 receptor blocker, reduces cardiova-
scular events in patients on chronic haemodialysis – a ran-
domized study. Nephrol Dial Transplant 2006; 21: 2507-12.

28. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases
two-year survival in dialysis patients with dilated cardiomyo-
pathy: a prospective, placebo-controlled trial. J Am Coll
Cardiol 2003: 41: 1438-44.

29. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coro-
nary calcification and binder choice in incident hemodialysis
patients. Kidney Int 2007; 71: 438-41.

30. Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenua-
tes the progression of coronary and aortic calcification in
dialysis patients. Kidney Int 2002; 62: 245-52.

31. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer
and calcium on coronary artery calcification in patients new
to dialysis. Kidney Int 2005; 68: 1815-24.

32. Russo D, Miranda I, Ruocco C, et al. The progression of co-
ronary artery calcification in predialysis patients on calcium
carbonate or sevelamer. Kidney Int  2007; 72: 1255-61.

33. London GM, Marty C, Marchais SJ, et al. Arterial calcifica-
tions and bone histomorphometry in end-stage renal disea-
se. J Am Soc Nephrol 2004; 15: 1943-51.

34. London GM, Marchais SJ, Guérin AP, et al. Association of
bone activity, calcium load, aortic stiffness, and calcifica-
tions in ESRD. J Am Soc Nephrol 2008; 19: 1827-35.

35. Russo D, Corrao S, Miranda I, et al. Progression of coronary
artery calcification in predialysis patients.  Am J Nephrol
2007; 27: 152-8.



137

CAPÍTULO 9

COMENTÁRIOS FINAIS

O score de calcifi cação vascular simples avaliado em RX simples da bacia e das mãos 
revelou -se, como fi cou demonstrado com os estudos descritos, um método simples para 
identifi cação do risco cardiovascular. Este método de avaliação das calcifi cações vasculares 
também foi usado por outros grupos nacionais e internacionais, o que permitiu confi rmar a 
facilidade e a reprodutibilidade da sua aplicação.

Utilização do score de calcifi cação vascular simples em estudos 
publicados por outros grupos.

1. Matias P et al1 demonstraram, num grupo de 223 doentes em hemodiálise, que os níveis 
de 25 -hidroxvitamina D3 se correlacionaram inversamente com a presença de diabetes 
mellitus, com os níveis séricos de albumina e de BNP (brain natriuretic peptide) e com 
um score de calcifi cação vascular simples superior a 3 (Tabela. 9.1).

Dependent 
variable 

Independent 
variables

? 95% CI P R2

[25(OH)D3]

Diabetes mellitus -0.44 -0.23 to -0.01&amp;lt;0.001

0.532
Albumin 0.41 1.24 to 2.68 0.003
Log10 BNP -0.37 -0.24 to -0.02 0.005
PP &gt; 65 mmHg -0.36 -0.41 to -0.05 0.006
SVCS ?3 -0.39 -0.28 to -0.04 0.002

BNP. brain natriuretic peptide: PP. pulse pressure: SVCS. simple vascular calcifi cation score.

Tabela 9.1. Preditores dos níveis séricos de 25(OH) vitamina D por regressão linear. O score de 
calcifi cação vascular simples ? 3 (SVCS, simple vascular calcifi cation score) apresentou uma associação 
inversa com os níveis séricos de 25(OH) vitamina D

Referência: Matias PJ et al. 25 -hydroxyvitamin D3, arterial calcifi cations and cardiovascular risk markers in 

haemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.



138

2. Este mesmo grupo demonstrou noutro estudo2 que os doentes submetidos a amputação 
apresentavam um score de calcifi cação vascular mais elevado (Fig. 9.1). As calcifi cações 
vasculares foram avaliadas pelo score de calcifi cação vascular simples, e um score de 
calcifi cação mais elevado foi um preditor independente de amputação (OR 2,01; IC 
1,41 -3.01; p=0,01).

Fig. 9.1. O score de calcifi cação vascular foi mais elevado nos doentes submetidos a amputação

Referência: Matias P, et al. Factors associated with lower -extremity amputations in haemodialysis 
patients. Port J Nephrol Hypert 2008; 22(1): 31 -36.

3. Wei T et al avaliaram, num grupo de 47 doentes em hemodiálise, a relação entre o 
sRANKL (soluble receptor activator of nuclear factor kB ligand) e os eventos 
cardiovasculares3. Neste estudo, os preditores de eventos cardiovasculares foram os níveis 

Factors of cardiovascular events determined by multivariate regression analysis

Factors
Standardized 
coeffi cients, ?

t p value 95% CI

sRANKL, pmol/l -0.322 -2.215 0.035 -2.948 ~ -0.115
Calcifi cation score 0.584 4.087 0.000 0.051 ~0.152
Phosphate, mmol/l 0.732 2.935 0.007 0.105 ~0.588
Ca × P, mmol2 /l2 -0.658 -2.818 0.009 - 0.284 ~0.045

Tabela 9.2. O score de calcifi cação constituído pelo SCVS (0 -8) + calcifi cações na aorta abdominal 
(0 -2) foi um dos preditores de eventos cardiovasculares

Referência: Wei T et al. Relationship of sRANKL level and vascular calcifi cation score to cardiovascular 
events in maintenance hemodialysis patients. Blood Purif 2009; 28:342 -345.



139

de sRANKL, os níveis de fósforo sérico e as calcifi cações vasculares (Tabela 9.2). As  
calcifi cações vasculares foram avaliadas por um score composto pelo score de calcifi cação 
vascular simples (de 0 a 8), ao qual foi somado um score de calcifi cação aórtico (0 a 2), 
sendo o score fi nal 0 a 10. Wei T et al foram o primeiro grupo internacional a incluir o 
score de calcifi cação vascular simples na avaliação de calcifi cações vasculares.

4. Schlieper G et al4 avaliaram os fatores associados à presença de calcifi cações vasculares 
usando o score de calcifi cação vascular simples avaliado no RX simples da bacia e das 
mãos e um score de calcifi cação que associava as calcifi cações vasculares da bacia e 
das mãos às calcifi cações das fístulas arteriovenosas, calcifi cações valvulares cardíacas 
e calcifi cações carotídeas (Tabelas 9.3 e 9.4).

 Estes autores verifi caram que a idade, o sexo masculino, a duração da diálise, um valor 
mais baixo de Kt/V, o produto fosfocálcico, os hábitos tabágicos e a proteína C reactiva 
de alta sensibilidade foram preditores independentes das calcifi cações vasculares. Ambos 
os scores se relacionaram com o aumento da velocidade de onda de pulso e foram ambos 
preditores de mortalidade. Segundo estes autores, a avaliação do score combinado não 
mostrou vantagens em relação ao score de calcifi cação vascular simples e, sob um ponto 
de vista prático, o score de calcifi cação vascular simples que utiliza apenas um RX da 
bacia e das mãos pode representar um método mais fácil para avaliação dos doentes.

Multivariate analysis of risk factors for vascular calcifi cations 
(ordinal logistic regression, Adragão score)

Score 0
(n=89)

Score 1-2
(n=45)

Score 3-8
(n=54)

OR 95% CI P

Age years 57 ± 10 61 ± 10 61 ± 11 1.08 1.04-1.11&amp;lt;0.001
Male gender 36 (40%) 24 (53%) 40 (74%) 2.75 1.41-5.38 0.003
Smoking 17 (19%) 22 (42%) 22 (42%) 2.32 1.16-4.65 0.017
Dialysis vintage, years 5.74 ± 4.43 7.54 ± 4.41 7.69 ± 4.83 1.13 1.03-1.23 0.006
Ca × PO4  product, mmol

2/l2 3.55 ± 1.02 3.76 ±1.02 3.96 ± 1.14 1.75 1.29-2.37 0.0003
Kt/V 1.33 ± 0.18 1.25 ± 0.13 1.23 ± 0.18 0.095 0.01-0.64 0.015
Anti-HCV antibody 16 (18%) 17 (38%) 18 (33%) 1.39 0.59-3.31 0.454
hsCRP, mg/l 7.71 ±18.9 7.88 ± 10.68 14.31 ± 20.43 1.01 1.00-1.03 0.096
Total cholesterol, mmol/l 5.35 ± 1.27 4.94 ± 1.04 5.01 ± 0.98 0.99 0.75-1.30 0.930

Tabela 9.3. Preditores do score de calcifi cação vascular simples

Referência: Schlieper et al. Risk factors for cardiovascular calcifi cations in non -diabetic Caucasian 
haemodialysis patients. Kidney Blood Pres Res 2009;32(3):161 -168.



140

Multivariate analysis of risk factors for cardiovascular calcifi cations 
(ordinal logistic regression, composite score)

Score 0-2
(n = 84)

Score 3-5
(n = 42)

Score 6-15
(n = 48) 

OR 95% CI p

Age years 56.75 ± 10.03 61.07 ± 9.90 60.81 ± 11.23 1.06 1.02-1.09 0.002
Male gender 35 (42%) 19 (45%) 37 (77%) 2.32 1.19-4.52 0.014
Dialysis vintage, years 5.84 ± 4.13 7.36 ± 5.29 7.66 ± 4.55 1.13 1.04-1.24 0.005
hsCRP, mg/l 6.18 ± 8.16 6.21 ± 9.79 12.85 ± 17.23 1.04 1.01-1.07 0.012
Kt/V 1.34 ± 0.18 1.27 ± 0.16 1.23 ± 0.19 0.11 0.02-0.70 0.019
Smoking 20 (24%) 12 (29%) 20 (43%) 1.84 0.89-3.83 0.097
Anti-HCV antibody 16 (19%) 15 (36%) 15 (31%) 1.25 0.52-3.02 0.614

Tabela 9.4. Preditores de um score composto de calcifi cação vascular (SCVS+calcifi cação da fístula 
AV + calcifi cação valvular cardíaca + calcifi cações carotídeas)

Referência: Schlieper et al. Risk factors for cardiovascular calcifi cations in non -diabetic Caucasian 
haemodialysis patients. Kidney Blood Pres Res 2009;32(3):161 -168.

5. As calcifi cações da córnea e da conjuntiva são calcifi cações extravasculares relativamente 
frequentes nos doentes em diálise. Seyahi N et al5 foram os primeiros a mostrar uma associação 
entre este tipo de calcifi cação extravascular e as calcifi cações vasculares. O SCVS foi o método 
escolhido para avaliar as calcifi cações vasculares. No grupo de doentes com mais calcifi cações 
conjuntivais e corneanas (CCC) verifica -se maior percentagem de doentes com 
calcifi cações vasculares avaliadas no RX simples da bacia e das mãos (Tabela 9.5).

Clinical and biochemical data. BMD results, 
and vascular calcifi cation frequency of patients

All Patients
(N = 63)

Low CCC 
Score

(n = 17)

High CCC 
Score

(n = 16)
p

Men/women 30/33 7/10 8/8 NS
Age (y) 43.5 ± 11.7 37.9 ± 14.8 46.31 ± 14.3 NS
Peritoneal dialysis/hemodialysis 44/19 10/7 12/4 NS
RRT duration (mo) 54.5 ± 39.9 21.1 ± 5.1 42.2 ± 10.6 0.003
Parathyroidectomy 5 (7.9) 1 (5.9) 1 (6.3) NS
Calcium (mg/dL) 9.22 ± 0.56 9.08 ± 0.38 9.39 ± 0.6 NS
Phosphorus (mg/dL) 5.38 ± 1.30 5.17 ± 1.04 5.96 ± 1.58 NS
Ca × P (mg2/dL2) 48.47 ± 12.41 44.76 ± 10.36 56.11 ± 17.44 0.021
ALP (U/L) 161.0 ± 116.7 133.1 ± 65.7 156.5 ± 96.5 NS
PTH (pg/mL) 310.8 ± 257.4 292.2 ± 272.5 320.6 ± 243.4 NS

(Continua)



141

All Patients
(N = 63)

Low CCC 
Score

(n = 17)

High CCC 
Score

(n = 16)
p

Albumin (g/dL) 3.75 ± 0.46 3.62 ± 0.61 3.88 ± 0.36 NS
CRP (mg/dL) 14.31 ± 22.40 13.09 ± 17.95 13.14 ± 22.71 NS
Lumbar BMD (g/cm2) 1.01 ± 0.19 1.02 ± 0.19 1.02 ± 0.23 NS
Femoral BMD (g/cm2) 0.78 ± 0.13 0.81 ± 0.16 0.79 ± 0.09 NS
Active vitamin D (?g/d) 0.36 ± 0.34 0.37 ± 0.32 0.28 ± 0.20 NS
Elemental calcium (g/d) 0.84 ± 0.41 0.71 ±0.42 0.82 ± 0.39 NS
Elemental aluminium (g/d) 0.42 ± 0.32 0.52 ± 0.41 0.47 ± 0.28 NS
Presence of vascular calcifi cation
 Pelvis
 Hands

21 (33.3)
16 (27.0)
9 (14.3)

1 (5.6 ) 
1 (5.6)
0 (0.0)

9 (56.3)
7 (43.8)
3 (18.8)

002
017
NS

Tabela 9.5. Associação de calcifi cações conjuntivais corneanas (CCC) às calcifi cações vasculares

Referência: Seyahi N et al. Association of conjunctival and corneal calcifi cation with vascular calcifi cation 
in dialysis patients. Am J Kidney Dis 2005 45(3):550 -556

6. Jung JY et al 6, num grupo de 69 doentes submetidos a diálise peritoneal, analisaram 
os fatores associados à rigidez arterial. Verifi caram que a fetuína -A e a PTH se 
correlacionaram inversamente e que a pressão arterial média se correlacionou diretamente 
com a velocidade de onda de pulso. A fetuína -A é um inibidor da calcifi cação vascular 
e estes autores demonstraram que um score de calcifi cação vascular simples superior 

Fig. 9.2. Um score de calcifi cação vascular simples ? 2 (SVCS, simples vascular calcifi cation score) 
associou -se a valores mais baixos de fetuína -A e mais elevados de velocidade de onda de pulso

Referência: Jung JY et al. Factors associated with aortic stiffness and its change over time in peritoneal 
dialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]

(Continuação)



142

a 2 se associou a valores mais baixos de fetuína -A e a valores mais elevados de velocidade 
de onda de pulso (Fig. 9.2).

7. Este mesmo grupo7 verifi cou a constância desta associação inversa entre o score de 
calcifi cação vascular simples e os níveis de fetuína -A num grupo de 249 doentes 
em diálise peritoneal (Tabela 9.6).

Parameter r P

Dependent variable : Fetuin – A
SVCS - 0.468&amp;lt;0.001
hfPWV - 0.338&amp;lt;0.001
Age - 0.327&amp;lt;0.001
Albumin 0.284 0.001

Mean ± SD P

Diabetes Yes 0.32 ± 0.08 0.002
No 0.35 ± 0.07

ASVD history Yes 0.30 ± 0.08 0.007
No 0.35 ± 0.07

SVCS: Simple vascular calcifi cation score. r : Pearson´s correlation coeffi cient. hfPWV: heart-to-femoral 
pulse wave velocity.SD: standard deviation ASVD: Atherosclerotic vascular disease

Tabela 9.6. O score de calcifi cação vascular simples (SVCS, simple vascular calcifi cation score) foi 
um dos fatores que apresentou uma correlação negativa com os níveis séricos de fetuína -A

Referência: Jung JY et al. Association of AHSG gene polymorphisms and aortic stiffness in peritoneal 
dialysis patients. Am J Nephrol 2010;31(6):510 -517.

8. Kim SC et al 8 analisaram, num grupo de 93 doentes em diálise peritoneal, as 
relações entre os níveis de PTH, as calcificações vasculares avaliadas pelo score 
de calcificação vascular simples e pelo score coronário de Agatston e a rigidez 
arterial avaliada pela velocidade de onda de pulso. Verificaram que os doentes 
com valores mais baixos de PTH (&lt;150 pg/mL) apresentavam mais calcificações 
(SCVS ? 3). A presença de diabetes mellitus e os valores mais baixos de PTH 
foram preditores independentes de calcificações vasculares (Tabela 9.7). Este 
grupo mostrou ainda que um SCVS &gt; 1 foi preditor de um score de calcificação 
coronário de Agatston &gt; 400 (Tabela 9.8).



143

Binary logistic regression analysis of risk factors associated 
with vascular calcifi cation score of ? 3 (forward method)

Variable OR 95% CI p value

DM 31.3 6.3 -155.8&amp;lt;0.001
PTH group (inter) 1.00  –  –
PTH group (low) 5.75 1.27 -25.9 0.023
PTH group (high) 4.19 0.85 -20.7 0.078

OR, Odds ratio; CI, confi dence interval; DM, diabetes mellitus; PTII, parathyroid hormone. Excluded: 
age, cholesterol, HbAlc, and albumin 

Tabela 9.7. A presença de diabetes mellitus e valores mais baixos de PTH foram preditores de um SCVS ? 3

Referência: Kim SC et al. Low iPTH can predict vascular and coronary calcifi cations in patients 
undergoing peritoneal dialysis. Nephron Clin Pract 2010 6,117(2):c113 -c119. [Epub ahead of print.]

Binary logistic regression analysis of factors associated 
with a CAC score of ? 400 (forward method)

Variables OR 95% CI p value

SVCS ? 1 76.0 6.00 -962.3 0.001

OR, Odds ratio; SVCS, simple vascular calcifi cation score. Excludes variables; diabetes mellitus, age, body 
mass index, HbAlc, and diastolic blood pressure.

Tabela 9.8. Um score de calcifi cação vascular simples &gt; 1 (SVCS, simple vascular calcifi cation score) foi 
um preditor de um score de calcifi cação coronária de Agatston &gt; 400 (CAC, coronary artery calcifi cation)

Referência: Kim SC et al. Low iPTH can predict vascular and coronary calcifi cations in patients undergoing 
peritoneal dialysis. Nephron Clin Pract 2010; 6,117(2):c113 -c119. [Epub ahead of print.]

9. Garcia -Cantón et al9 avaliaram as calcifi cações vasculares num grupo de 210 doentes 
renais crónicos não em diálise (estadios 4 e 5), utilizando o score de calcifi cação vascular 

25-Hydroxyvitamin D SVCS (Adragão) Kauppila

Defi ciency (&lt;15 ng/mL) Mean 4.8 ± 2 / median 6 Mean 12 ± 7 / median 13
Insuffi ciency (15-30 ng/mL) Mean 3.7 ± 3 / median 4 Mean 9.6 ± 7 / median 9
Normal (&gt;30 ng/mL) Mean 2.3 ± 2 / median 2 Mean 6.3 ± 6 / median 3

SVCS, simple vascular calcifi cation score.

Referência: García -Cantón C, Bosch E, Ramírez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin 
D levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 
2010; 18. [Epub ahead of print].

Tabela 9.9. Níveis séricos de 25 -hidroxi -vitamina D e calcifi cações vasculares em doentes não em diálise



144

simples descrito por nós e o score de Kauppila10 avaliado na aorta abdominal; 120 
doentes (57%) apresentaram um SCVS&gt;3; 114 doentes (54%) apresentaram um score 
de Kauppila &gt;7. Só 18,5% desta população apresentava níveis séricos adequados de 
25 -hidroxivitamina D. Os níveis séricos baixos de 25 -hidroxivitamina D foram preditores 
independentes de calcifi cações vasculares avaliadas pelos dois métodos.

Binary logistic regression with SVCS

Variables entering the equation

OR 95% CI Signifi cance

Age 1.058 1.021-1.096 0.002
Diabetes 5.229 2.290-11.940 0.0001
CVD 2.957 1.343-6.511 0.007
25(OH)D 0.954 0.917-0.993 0.020

SVCS, simple vascular calcifi cation score; CVD, cardiovascular disease.

Tabela 9.10. Preditores do score de calcifi cação vascular simples

Referência: García -Cantón C, Bosch E, Ramírez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin 
D levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. 
2010; 18. [Epub ahead of print.]

Binary logistic regression with Kauppila

Variables entering the equation

OR 95% CI Signifi cance

Age 1.103 1.061-1.146 0.0001
CVD 2.609 1.249-5.450 0.011
25(OH)D 0.953 0.918-0.992 0.017

CVD, cardiovascular disease.

Tabela 9.11. Preditores de score de calcifi cação de Kauppila.

Referência: García -Cantón C, Bosch E, Ramírez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin 
D levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. 
2010; 18. [Epub ahead of print.]

Este estudo reveste -se de particular importância, pois é o primeiro a avaliar as calcifi cações 
vasculares utilizando RX simples num grupo de doentes renais crónicos não em diálise, 
revelando, nesta população, que a prevalência das calcifi cações vasculares é elevada. Tal 



145

como foi demonstrado numa população em diálise1, também nesta população se verifi cou 
uma associação inversa entre o score de calcifi cação vascular simples e os níveis de 
hidroxivitamina D. O score de calcifi cação vascular simples mostrou ser um instrumento útil 
com resultados semelhantes aos obtidos com o score de Kauppila.

A utilização do score de calcifi cação vascular simples para avaliação das calcifi cações 
vasculares nos doentes em diálise foi já sugerida por duas sociedades internacionais de 
nefrologia: pela Sociedade Espanhola de Nefrologia em SEN guidelines. Recommendations 
of the Spanish society of nephrology for managing bone -mineral metabolic alterations in 
chronic renal disease patients11 e pelo grupo de Estudos do Metabolismo Mineral e Ósseo 
da Sociedade Uruguaia de Nefrologia, em Recomendaciones para el manejo de las alteraciones 
del metabolismo mineral y oseo de la enfermedad renal crónica en estadio 512. O estudo 
OSERCE II observacional, de iniciativa da Sociedade Espanhola de Nefrologia, com início 
em 2009, pretende avaliar nos doentes renais crónicos nos estadios 3 a 5 alterações do 
metabolismo mineral e ósseo, entre outras. Prevê a inclusão de 1500 doentes. Um dos 
parâmetros a analisar neste estudo é a prevalência de calcifi cações vasculares. Os métodos 
escolhidos para diagnóstico das calcifi cações vasculares foram dois scores avaliados em RX 
simples: o score de calcifi cação da aorta abdominal descrito por Kauppila L10 e o score de 
calcifi cação vascular simples descrito por nós13.

Nos diferentes estudos efectuados por nós, verifi camos que as calcifi cações vasculares 
avaliadas por este método nos doentes renais crónicos foram preditoras de maior risco de 
mortalidade cardiovascular13, de mortalidade de causa global14, de maior risco de doença 
coronária13 e de doença arterial periférica13. O score de calcifi cação vascular simples foi ainda 
um preditor independente de rigidez arterial 14 avaliada por velocidade de onda de pulso ou por 
pressão de pulso. Este score de calcifi cação associou -se inversamente à densidade mineral óssea 
do colo do fémur, avaliada por dual energy X -ray absorptiometry (DXA)15. Em estudos efetuados 
por outros grupos foi demonstrado que as calcifi cações vasculares avaliadas por este método são 
preditoras de maior risco de eventos cardiovasculares3, de amputações dos membros inferiores2, 
de velocidade de onda de pulso4,6, de calcifi cações corneanas e conjuntivais5 e de calcifi cações 
coronárias8. Também foi demonstrada uma associação inversa entre o score de calcifi cação 
vascular simples e os níveis de PTH 8, com os níveis de 25(OH)vitamina D1,9 e com os níveis 
de fetuína A6,7. O score de calcifi cação vascular simples mostrou ser um instrumento útil para 
a avaliação das calcifi cações vasculares também em doentes renais crónicos não em diálise9.

Todos estes estudos realizados por diferentes grupos, que utilizaram o score de calcifi cação 
vascular simples na sua metodologia, comprovam a facilidade de utilização deste score, e a 
concordância de resultados comprova a sua reprodutibilidade e utilidade na avaliação dos 
doentes renais crónicos.



146

Comparação entre o score de calcifi cação vascular simples 
e o score de Kauppila.

As guidelines KDIGO 2009 sugerem que o conhecimento da presença de calcifi cações 
vasculares pode ser usado para orientar o tratamento da doença mineral e óssea nos 
doentes renais crónicos e sugerem a avaliação de calcifi cações vasculares na aorta 
abdominal10. Este score da aorta abdominal avaliado em RX simples foi comparado com 
o score coronário de Agatston. Bellasi et al16 demonstraram que um score Kauppila 
superior ou igual a 7 apresentava uma elevada sensibilidade e especifi cidade para 
diagnosticar um score de Agatston superior a 400 ou 1000. O score coronário de Agatston 
é considerada a técnica gold -standard para a avaliação das calcifi cações coronárias e 
aórticas17. Esta será provavelmente a razão pela qual as guidelines KDIGO 2009 sugerem 
a utilização do score de calcifi cação na aorta abdominal avaliado em RX simples como 
alternativa ao score de Agatston. É contudo necessário demonstrar que as calcifi cações 
coronárias nos doentes renais crónicos são o paradigma do fenómeno de calcifi cação 
vascular sistémica nesta população.

Tivemos já a oportunidade de comparar o score de calcifi cação vascular simples com o 
score de calcifi cação na aorta abdominal, ao estudarmos a doença arterial periférica num 
grupo de 219 doentes em hemodiálise18. Verifi camos que ambos os scores de calcifi cação 
são preditores de um índice tornozelo -braço&amp;lt;0,9, apresentando uma semelhante área sob a 
curva. O score de calcifi cação vascular simples superior a 3 teve uma sensibilidade de 73% 
e uma especifi cidade de 86% para identifi car um score de calcifi cação aorticoabdominal 
superior a 6. O score de calcifi cação vascular simples permite ainda identifi car calcifi cações 
em artérias colaterais e distais, sendo este tipo de calcifi cações preditoras de um índice 
tornozelo -braço &gt;1,3. O padrão típico da calcifi cação vascular neste território arterial (artérias 
colaterais e distais) é linear, correspondendo à calcifi cação da camada média da parede 
arterial descrita por London19. A calcifi cação da íntima e da média são preditores independentes 
de mortalidade nos doentes em diálise19. Ao contrário do score de calcifi cação vascular 
simples, o score de calcifi cação aorticoabdominal não identifi ca este tipo de calcifi cação da 
média. Futuros estudos poderão avaliar a vantagem clínica de distinguir os dois tipos de 
calcifi cação vascular nestes doentes.

García -Cantón et al também utilizaram os dois métodos, o score de calcifi cação vascular 
simples e o score Kauppila, na avaliação das calcifi cações vasculares na mesma população9. 
Os resultados obtidos pelos dois métodos foram muito semelhantes. Kim et al verifi caram 
que um score de calcifi cação vascular simples foi um preditor independente de um score 
coronário de Agatston &gt; 4008.



147

Calcifi cações vasculares em doentes renais crónicos: 
questões ainda em avaliação

Tal como outros, defendemos a hipótese da existência de um elo de ligação entre as 
alterações do metabolismo mineral e ósseo e a doença cardiovascular na doença renal crónica. 
As calcifi cações vasculares são um dos elementos desta associação e resultam da transformação 
fenotípica das células musculares lisas da parede dos vasos. A hipercalcemia e a hiperfosfatemia 
são alguns dos fatores responsáveis por este processo celular ativo20, estabelecendo o elo de 
ligação entre as alterações minerais e as calcifi cações vasculares. Barreto D et al demonstraram 
que a progressão das calcifi cações vasculares se associam as alterações do metabolismo 
ósseo21. Em situações de baixa ou de alta remodelação óssea, o osso é incapaz de exercer a 
sua função de tampão que permite a manutenção do cálcio sérico nos limites adequados e, 
no caso de se verifi car hipercalcemia, o depósito extraósseo de cálcio é obrigatório22,23. London 
et al foram os primeiros a demonstrar, num grupo de doentes em hemodiálise, associação 
entre calcifi cações vasculares e baixa remodelação óssea diagnosticada por biopsia óssea24.O 
nosso grupo foi o primeiro a demonstrar, também em doentes em hemodiálise, uma associação 
entre calcifi cações vasculares e baixo volume ósseo diagnosticado por biopsia óssea25. Fomos 
igualmente os primeiros a verifi car, num grupo de doentes em diálise peritoneal, uma associação 
entre calcifi cações vasculares e a baixa densidade mineral óssea avaliada no colo do fémur15. 
A importância deste achado foi demonstrada pela associação, descrita por nós, também pela 
primeira vez, entre a densidade mineral óssea avaliada no colo do fémur e a porosidade cortical 
medida em biopsia óssea26. Os nossos diferentes trabalhos reforçam assim esta hipótese da 
existência de um elo de ligação entre o osso e o vaso na doença renal crónica.

Existem ainda algumas questões sem resposta defi nitiva. Serão as calcifi cações da camada 
média e da íntima da parede arterial duas entidades diferentes ou uma diferente manifestação 
da mesma patologia? No doente renal crónico, as calcifi cações podem surgir em diversos 
tipos de artérias, desde as artérias elásticas às artérias musculares, mas nem todas as artérias 
desenvolvem aterosclerose. A aorta torácica e as artérias dos membros superiores, por exemplo, 
parecem resistentes ao processo aterosclerótico. Haimovici H demonstrou, com estudos de 
transposição de artérias em cães, que a aorta torácica, independentemente do local para onde 
era transposta, se mantinha resistente à aterosclerose, enquanto o inverso se verifi cava com 
a aorta abdominal 27.

McCullough PA et al defendem a hipótese de que a calcifi cação aterosclerótica e a 
calcifi cação da média são um contínuo da patologia vascular na doença renal crónica e que 
a esclerose de Monckberg, que corresponde à calcifi cação da média, corresponde a um processo 
de aterosclerose avançada28. Esta hipótese foi revogada por Amann K, demonstrando que 



148

estes dois tipos de calcifi cação são distintos sob os pontos de vista histológico, fi siopatológico 
e clínico, e que a calcifi cação da média pode preceder a calcifi cação da íntima29. A calcifi laxis 
é um tipo muito particular de calcifi cação da camada média que afeta as arteríolas da pele e 
é um processo independente da aterosclerose.

A possibilidade de estabilização ou regressão das calcifi cações vasculares é outra questão 
amplamente debatida. Já se demonstrou que um captador de fósforo à base de cálcio pode 
aumentar a progressão das calcifi cações coronárias30 -32, mas este achado não foi universal33,34. 
A patologia óssea, impedindo o osso de se comportar como tampão para o cálcio, é uma das 
explicações para a progressão das calcificações vasculares22,23. O cinacalcet, agente 
calcimimético usado no tratamento do hiperparatiroidismo secundário, também pode afetar 
a progressão das calcifi cações. Os resultados do estudo ADVANCE foram apresentados na 
sessão “Late Breaking Trials” durante o XLVVII ERA -EDTA Congress 2010, em Munique. 
Este estudo comparou, num grupo de doentes em hemodiálise, o efeito da terapêutica conjunta 
de cinacalcet e dose baixa de vitamina D com a terapêutica com doses fl exíveis de vitamina 
D e demonstrou uma redução signifi cativa da progressão das calcifi cações na válvula aórtica 
no grupo tratado com cinacalcet. A progressão das calcifi cações coronárias, o parâmetro de 
efi cácia primário, não atingiu diferença com signifi cado estatístico entre os dois grupos.

A semelhança entre a remodelação óssea e a calcifi cação vascular está na base de inúmeros 
estudos que avaliaram o efeito dos bifosfonatos na progressão das calcifi cações vasculares35. 
Os bifosfonatos inibem a calcifi cação vascular em modelos animais de insufi ciência renal 
crónica. Este efeito também se verificou em quatro estudos envolvendo doentes em 
hemodiálise36 -39, mas o número de doentes avaliados nestes estudos foi pequeno e só dois 
deles randomizados. A normalização da função renal obtida com a transplantação renal é 
outro fator que pode infl uenciar a progressão das calcifi cações vasculares. Até agora, o efeito 
da transplantação renal na progressão das calcifi cações vasculares foi analisado apenas em 
alguns estudos que envolveram um pequeno número de doentes. Verifi cou -se uma estabilização 
das calcifi cações coronárias em dois destes estudos40,41 e a progressão das calcifi cações 
noutro42. Em doentes renais crónicos não em diálise já foi demonstrado que existe progressão 
acelerada das calcifi cações coronárias, em comparação com indivíduos com função renal 
normal43, e a alteração da função renal após a transplantação renal pode explicar essa 
progressão. O tiossulfato de sódio, antídoto do cianeto e usado em casos de toxicidade da 
cisplatina, tem sido também aplicado com sucesso no tratamento de casos de arteriolopatia 
urémica cálcica, também denominada calcifi laxis. Esta patologia traduz -se histologicamente 
por calcifi cação da camada média de arteríolas do tecido celular subcutâneo com fi brose 
endovascular e trombose. Este agente antioxidante consegue sequestrar iões cálcio e formar 
compostos de cálcio muito solúveis, impedindo a sua precipitação44.



149

Em resumo, o desenvolvimento e a progressão das calcificações vasculares nos 
doentes renais crónicos são processos complexos para os quais contribuem inúmeros 
fatores indutores e inibidores, muito provavelmente em associação com o estado da 
remodelação óssea e da capacidade ou incapacidade de o osso se comportar como tampão 
para o cálcio. O diagnóstico das calcificações vasculares pode ser um instrumento útil 
na orientação terapêutica destes doentes. Várias técnicas não invasivas permitem fazer 
o rastreio de calcificações vasculares, mas, independentemente do método usado, pensamos 
que o importante é que as calcificações vasculares sejam diagnosticadas nos doentes 
renais crónicos.

Congratulamo -nos com o facto de dois dos nossos estudos13,14 terem sido incluídos nas 
referências das guidelines KDIGO 2009 nas tabelas da prevalência das calcifi cações 
vasculares (KDIGO 2009: Tabela suplementar 10, Fig. 3.6) e da associação entre calcifi cações 
vasculares e mortalidade (KDIGO 2009: Tabela suplementar 12, Fig. 3.7). A inclusão destes 
nossos dois estudos nas referências destas guidelines que utilizaram o exigente sistema 
GRADE (grades of recommendation, assessment, development, and evaluation) na 
classifi cação e seleção dos estudos valida o interesse científi co destes dois trabalhos.

A presença de calcifi cações vasculares identifi ca os doentes com mais elevado risco 
cardiovascular. Concordamos com a sugestão das guidelines KDIGO 2009, que considera 
que a presença de calcifi cações vasculares nos doentes renais crónicos nos estádios 3 a 5 é 
uma informação que pode ser usada para orientar o tratamento da doença mineral e óssea 
nestes doentes. É necessário contudo ainda analisar se a ausência de desenvolvimento ou 
de progressão das calcifi cações vasculares se associa a uma redução da morbilidade ou da 
mortalidade nestes doentes. É necessário também avaliar se uma atuação diagnóstica e 
terapêutica nos estadios mais precoces da doença renal crónica poderá ter efeito na redução 
da progressão da doença óssea e do risco cardiovascular nestes doentes.

Referências

  1. Matias PJ, Ferreira C, Jorge C, et al. 25 -hydroxyvitamin D3, arterial calcifi cations and cardiovascular 
risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.

  2. Matias P, Aires I, Jorge C, Factors associated with lower -extremity amputations in haemodialysis 
patients. Port J Nephrol Hypert 2008; 22(1): 31 -36.

  3. Wei T, Wang M, Wang Mi, et al. Relationship of sRANKL level and vascular calcifi cation score 
to cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009;28:34 -345.

  4. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, Krüger T, 
Westenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dimkovic N. Risk 



150

factors for cardiovascular calcifi cations in non -diabetic Caucasian haemodialysis patients. Kidney 
Blood Pres Res 2009;32(3):161 -168.

  5. Seyahi N, Altiparmak MR, Kahveci A, Yetik H, Kanberoglu K, Serdengecti K, Ataman R, Erek 
E. Association of conjunctival and corneal calcifi cation with vascular calcifi cation in dialysis 
patients. Am J Kidney Dis 2005;45(3):550 -556.

  6. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over 
time in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]

  7. Jung JY, Hwang YH, Lee H, et al. Association of AHSG gene polymorphisms and aortic stiffness 
in peritoneal dialysis patients. Am J Nephrol 2010;31(6):510 -517.[ Epub 2010 May 7.]

  8. Kim SC, Kim HW, Oh SW, Yang HN, Kim MG, Jo SK, Cho WY, Kim HK. Low iPTH can predict 
vascular and coronary calcifi cations in patients undergoing peritoneal dialysis. Nephron Clin Pract 
2010; (6)117(2):c113 -c119. [Epub ahead of print.]

  9. García -Canton C, Bosch E, Ramírez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin D 
levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 
2010; 18. [Epub ahead of print.]

10. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression 
of calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-
-250.

11. Torregrosa JV, Cannata Andia J, Bover J, Caravaca F, Lorenzo V, Martín de Francisco AL, Martín-
-Malo A, Martínez I, González Parra E, Fernández Giráldez E, Rodríguez Portillo M, Sociedad 
Española de Nefrologia. SEN guidelines. Recommendations of the Spanish Society of Nephrology 
for managing bone -mineral metabolic alterations in chronic renal disease patients. Nefrologia 
2008;28 (Suppl 1):1 -22.

12. Grupo de Estudio de Alteraciones del Metabolismo Mineral y Óseo, Fajardo L, Olaizola I, Alvarez 
A, Petraglia A, Mimbacas C, Caorsi H, Ambrosoni P. Recomendaciones para el manejo de las 
alteraciones del metabolismo mineral y oseo de la enfermedad renal crónica en 2008. de nefrología, 
c de nefrologia,2008. nefrouruguay.com

13. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004;19(6):1480 -1488.

14. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP. A plain X -ray vascular 
calcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol 
Dial Transplant 2009;24(3):997 -1002.

15. Adragão T, Branco P, Birne R, Curto JD, Almeida E, Prata MM, Pais MJ.Bone mineral density, 
vascular calcifications, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 
2008;28(6):668 -672.

16. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium 
measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623 -1628.



151

17. Bellasi A, Raggi P. Techniques and technologies to assess vascular calcifi cation. Semin Dial 2007; 
20(2):129 -133.

18. Adragão T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Joaquim Bordalo J, Prata MM. 
Ankle brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 
2010; 3: (Suppl 3): iii492 (Abstract Su545).

19. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: 
impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731 -1740.

20. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.
21. Barreto DV, Barreto F C, Carvalho AB, et al. Association of changes in bone remodelling and 

coronary calcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 6: 
1139 -1150.

22. Braun J. Extraosseous calcifi cation in patients with chronic renal failure – no escape? Nephrol 
Dial Transplant 2005; 20: 2054 -2059.

23. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fl uid calcium 
content. Clin J Am Soc Nephrol 2010; 5: S12 -S22.

24. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in 
end -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.

25. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Dias Curto J, 
Malluche HH. Low bone volume – A risk factor for coronary calcifi cations in hemodialysis patients. 
Clin J Am Soc Nephrol 2009; 4(2): 450 -455.

26. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Malluche HH. 
Femoral bone mineral density reflects histologically determined cortical bone volume in 
hemodialysis patients. Osteoporos Int 2010; 4: 619 -625.

27. Haimovici H. The role of arterial tissue suceptibility in atherogenesis. Tex Heart Inst 1991; 18: 
81 -83.

28. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcifi cation and 
Monckeberg’s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. 
Clin J Am Soc Nephrol 2008; 3:1585 -1598.

29. Amann K. Media calcifi cation and intima calcifi cation are distinct entities in chronic kidney 
disease. Clin J Am Soc Nephrol 2008; 3: 1599 -1605.

30. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic 
calcifi cation in hemodialysis patients. Kidney Int 2002; 62: 245 -252.

31. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery 
calcifi cation in patients new to hemodialysis. Kidney Int 2005; 68: 1815 -1824.

32. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcifi cation in predialysis 
patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255 -1261.

33. Qunibi W, Moustafa M, Muenz LR, et al. A 1 -year randomized trial of calcium acetate versus 
sevelamer on progression of coronary artery calcifi cation in hemodialysis patients with comparable 



152

lipid control: the calcium acetate renagel evaluation -2 (CARE -2) study. Am J Kidney Dis 2008; 
51: 952 -965.

34. Barreto DV, Barreto F, Carvalho AB, et al. Phosphate binder impact on bone remodeling and 
coronary calcifi cation -results from the BRiC study. Nephron 2008; 110: 273 -283.

35. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential 
benefi ts and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4: 221 -233.

36. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary 
artery calcifi cation in patients receiving long -term hemodialysis. Am J Kidney Dis 2004; 44: 680-
-688.

37. Hashiba H, Aizawa S, Tamura K, et al: Inhibitory effects of etidronate on the progression of 
vascular calcifi cation in hemodialysis patients. Ther Apher Dial 2004; 8 (3): 241 -247.

38. Hashiba H, Aizawa S, Tamura K, et al: Inhibition of the progression of aortic calcifi cation by 
etidronate treatment in hemodialysis patients: Long -term effects. Ther Apher Dial 2006; 10: 59-
-64.

39. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect of etidronic acid on arterial 
calcifi cation in dialysis patients. Clin Drug Investig 2006; 26: 215 -222.

40. Moe, SM, O’Neill, KD, Resterova, M, et al. Natural history of vascular calcifi cation in dialysis 
and transplant patients. Nephrol Dial Transplant 2004; 19:2387 -2393.

41. Oschatz, E, Benesch, T, Kodras, K, et al. Changes of coronary calcifi cation after kidney 
transplantation. Am J Kidney Dis 2006; 48:307.

42. Schankel, K, Robinson, J, Bloom, RD, et al. Determinants of coronary artery calcifi cation 
progression in renal transplant recipients. Am J Transplant 2007; 7:2158 -2164.

43. Russo D, Corrao S, Miranda I, et al. Progression of coronary artery calcifi cation in predialysis 
patients. Am J Nephrol 2007;27(2):152 -158.

44. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcifi c 
uremic arteriolopathy. Nat Rev Nephrol 2009; 5(9):539 -543.



153

CAPÍTULO 10

RESUMO DA DISSERTAÇÃO

A presente dissertação para tese de doutoramento apresenta o desenvolvimento e a 
validação de um método simples e original para o diagnóstico de calcifi cações vasculares em 
doentes em diálise, utilizando um score semiquantitativo criado por nós e obtido em RX 
simples da bacia e das mãos, denominado score de calcifi cação vascular simples. Demonstramos 
que este score vascular simples é preditor de risco cardiovascular nos doentes em diálise. O 
score de calcifi cação vascular simples associou -se ainda à baixa densidade mineral óssea 
avaliada por dual energy X -ray absortiometry (DXA) no colo do fémur. Verifi camos igualmente 
que, em doentes em diálise, as calcifi cações coronárias quantifi cadas pelo score de Agatston 
e o score de calcifi cação vascular simples se associaram a um menor volume ósseo avaliado 
em biopsias ósseas. Estes trabalhos corroboram a hipótese da existência de um elo de ligação 
entre a doença óssea e a doença vascular nos doentes em diálise, e um dos elementos que 
contribuem para este elo de ligação podem ser as calcifi cações vasculares.

Este score de calcifi cação vascular simples avalia calcifi cações em artérias de grande, 
médio e pequeno calibre, e inclui os dois padrões radiológicos de calcifi cação: calcifi cação 
linear, associada à calcifi cação da camada média da parede arterial, e calcifi cação irregular, 
associada à calcifi cação da camada íntima arterial1. Nos diferentes trabalhos por nós publicados 
demonstramos que as calcifi cações vasculares avaliadas por este método simples e barato 
permitem a identifi cação de indivíduos com elevado risco cardiovascular. Este score vascular 
associa -se a maior risco de mortalidade cardiovascular2, de mortalidade de causa global3, de 
internamentos cardiovasculares2, de doença cardiovascular2, de doença arterial periférica2,4, 
de calcifi cações valvulares5 e de rigidez arterial3.

As guidelines KDIGO (Kidney disease: improving global outcomes), publicadas em 2009, 
sugerem que os doentes renais crónicos nos estadios 3 a 5, com calcifi cações vasculares e 
valvulares, devem ser considerados como apresentando o mais elevado risco cardiovascular6. 
A elevada mortalidade dos doentes renais crónicos não é totalmente explicada pelos fatores 
de risco tradicionais7. A organização KDIGO defende, desde 2006, a hipótese da existência de 
um elo de ligação entre a doença óssea e a doença vascular8. Esta ligação pode ser explicada 
pelas alterações do metabolismo mineral e ósseo e pela sua interação com as calcifi cações 
vasculares. Verifi camos, nos nossos trabalhos, uma associação entre calcifi cações vasculares 



154

e doença óssea. O baixo volume ósseo diagnosticado por análise histomorfométrica de biopsias 
ósseas foi preditor de maior risco de calcifi cações vasculares avaliadas pelo score de calcifi cação 
vascular simples (dados apresentados nesta dissertação, no capítulo 6) e pelo score coronário 
de Agatston num grupo de doentes em diálise9. A contribuição original deste artigo9 foi 
considerada merecedora de um editorial feito pelo Dr. Gérard London10, investigador líder na 
área da calcifi cação vascular dos doentes renais crónicos e actual Presidente da EDTA (European 
Dialysis and Transplantation Association). Fomos também os primeiros a descrever uma 
associação independente e inversa entre a densidade mineral avaliada no colo do fémur por 
DXA (dual energy X -ray absortiometry) com calcifi cações vasculares avaliadas pelo score de 
calcifi cação vascular simples, com rigidez arterial avaliada por velocidade de onda de pulso 
carotidofemoral e com doença arterial periférica diagnosticada por critérios clínicos11. Fomos 
igualmente os primeiros a mostrar uma correlação signifi cativa entre a densidade mineral óssea 
avaliada por DXA no colo do fémur, mas não na coluna lombar, com a espessura cortical 
avaliada por análise histomorfométrica em biopsia óssea12. O nosso estudo atribui pela primeira 
vez à DXA um papel no diagnóstico de porosidade cortical nos doentes em diálise. A utilidade 
da avaliação diferencial da densidade mineral óssea cortical e trabecular necessita ainda de ser 
confi rmada em estudos prospectivos. Este achado inovador do nosso estudo foi mencionado 
pela ERBP (European Renal Best Practice) no comentário feito à posição da KDIGO que 
considera ser reduzida a utilidade da densidade mineral óssea nos doentes em diálise13.

Dois dos trabalhos incluídos nesta dissertação foram referenciados nas guidelines KDIGO 
2009 para avaliar a prevalência das calcifi cações vasculares (KDIGO 2009: Tabela suplementar 
10, Fig. 3.6) e para validar a associação entre calcifi cações vasculares e mortalidade 
cardiovascular (KDIGO 2009: Tabela suplementar 12, Fig. 3.7)6. A inclusão destes nossos 
dois estudos nas referências destas guidelines, que utilizaram o exigente sistema GRADE 
(Grades of recommendation, assessment, development, and evaluation) na classifi cação e 
selecção dos estudos, valida o interesse científi co dos nossos trabalhos.

O diagnóstico de calcifi cações vasculares tem um interesse prático para os doentes renais 
crónicos. A presença de calcifi cações vasculares é um sinal de alerta para a existência de um 
elevado risco cardiovascular, e esta informação pode ser utilizada para modifi car a terapêutica 
nestes doentes6. Diferentes métodos podem ser usados para diagnosticar calcifi cações vasculares 
nos doentes em diálise14,15. O score de calcifi cação vascular simples tem a vantagem da 
simplicidade e de poder ser facilmente interpretado pelo nefrologista, sem necessidade de um 
radiologista. A reprodutibilidade deste score já foi demonstrada por diferentes grupos em estudos 
nacionais e internacionais16 -24. Nestes estudos foi demonstrado que as calcifi cações vasculares 
avaliadas pelo método criado por nós são preditoras de maior risco de eventos cardiovasculares16, 
de amputações dos membros inferiores17, de velocidade de onda de pulso18,19, de calcifi cações 



155

corneanas e conjuntivais20 e de calcifi cações coronárias21. Também foi demonstrada uma 
associação inversa entre o score de calcifi cação vascular simples com os níveis séricos de 
PTH21, com os níveis de 25(OH)vitamina D 22,23 e com os níveis de fetuína A19,24.

Todos estes estudos, realizados por diferentes grupos, que utilizaram o score de calcifi cação 
vascular simples na sua metodologia, comprovam a facilidade de utilização deste score e a 
concordância de resultados atestam a sua reprodutibilidade e a utilidade na avaliação dos 
doentes renais crónicos.

Abstract

This thesis presents the development and validation of a simple and original method to 
identify vascular calcifi cations in dialysis patients, using a semi -quantitative score that we 
have created and that is obtained in plain X -ray of pelvis and hands. This score was named 
in different publications as “simple vascular calcifi cation score”.

We have demonstrated that this score is a predictor of higher cardiovascular risk in dialysis 
patients. The simple vascular calcifi cation score was also associated with lower mineral bone 
density evaluated by DXA in femoral neck. In hemodialysis patients coronary calcifi cations 
evaluated by the coronary Agatston score and by the simple vascular calcifi cation score were 
associated with lower bone volume analysed in bone biopsies. These studies corroborate the 
hypothesis of the existence of a link between bone disease and vascular disease in dialysis 
patients and one of the elements of this link may be vascular calcifi cations.

This simple vascular calcifi cation score identifi es calcifi cations in large, medium and small 
calibre arteries and includes the two radiological patterns of arterial calcifi cation: linear calcifi cation 
which has been associated with the calcifi cation of the media layer of the arterial wall and irregular 
and patchy calcifi cation which has been associated with the calcifi cation of the intima layer of 
the arterial wall1. In the several studies that we have published we have demonstrated that vascular 
calcifi cations evaluated by this simple and inexpensive method allow the identifi cation of patients 
with high cardiovascular risk. This simple vascular calcifi cation score is an independent predictor 
of cardiovascular mortality2, all -cause mortality3, cardiovascular hospitalizations2, cardiovascular 
disease2, peripheral artery disease2,4, valvular calcifi cations5 and arterial stiffness3.

KDIGO (Kidney Disease: Improving Global Outcomes) guidelines published in 2009 suggest 
that chronic kidney disease patients in stages 3 to 5, with vascular and valvular calcifi cations should 
be considered to be at the highest cardiovascular risk6. The high mortality of chronic kidney disease 
patients is not completely explained by the traditional risk factors7 and KDIGO group supports, 
since 2006, the hypothesis of the existence of a link between bone disease and vascular disease8. 



156

This link may be explained by the alterations of the bone and mineral metabolism and their interaction 
with development and progression of vascular calcifi cations. We have also verifi ed in our studies 
the existence of an association between vascular calcifi cations and bone disease. Low bone volume 
diagnosed by histomorphometric analysis of bone biopsies, in a group of dialysis patients, was 
independently associated with the simple vascular calcifi cation score (data presented in this thesis, 
chapter 6) and with coronary calcifi cations evaluated by the Agatston score9. The original contribution 
of this article published in CJASN9 deserved a commentary in an Editorial written by Prof. Gérard 
London10 leader investigator in this area and current EDTA (European Dialysis and Transplantation 
Association) President. We were also the fi rst group to describe an independent and inverse 
association between bone mineral density evaluated in the femoral neck by DXA (dual energy 
X -ray absortiometry) with vascular calcifi cations evaluated by the simple vascular calcifi cation 
score, with arterial stiffness evaluated by carotid -femoral pulse wave velocity and with peripheral 
artery disease diagnosed by clinical criteria11. We were also the fi rst group to demonstrate a signifi cant 
correlation between bone mineral density evaluated by DXA in femoral neck but not in lumbar 
spine, with cortical thickness evaluated by histomorphometric analysis of bone biopsy12. Our study 
has attributed to DXA, for the fi rst time, a role in the diagnosis of cortical porosity in dialysis 
patients. The clinical utility of the differential evaluation of bone mineral density in cortical or 
trabecular bone needs, however, to be confi rmed in prospective studies. This original fi nding of our 
study was mentioned by ERBP (European Renal Best Practice) commenting the KDIGO position 
in relation with the reduced utility of bone mineral density evaluation in dialysis patients13.

Two of the studies included in this thesis have been integrated in a group of studies 
selected as references by the KDIGO guidelines published in 2009 to evaluate the prevalence 
of vascular calcifi cations in CKD patients (KDIGO 2009: Supplementary Table 10, Fig. 3.6) 
and to corroborate the association between vascular calcifi cations and cardiovascular mortality 
(KDIGO 2009: Supplementary Table 12, Fig. 3.7)6. The inclusion of both studies as references 
in the KDIGO guidelines that have used the exigent GRADE system (Grades of Recommendation, 
Assessment, Development, and Evaluation) in the classifi cation and selection of studies, 
validates the scientifi c value of our studies.

The diagnosis of vascular calcifi cations has a practical interest for chronic kidney disease 
patients. The presence of vascular calcifi cations is an alert sign to the existence of a high 
cardiovascular risk and this information may be used to modify the treatment of these patients6. 
Different methods may be used to detect the presence of vascular calcifi cations in dialysis 
patients14,15. The simple vascular calcifi cation score has the advantage of being simple, 
inexpensive and easily evaluated by the Nephrologist without the need for a Radiologist 
interpretation. The reproducibility of this method has already been demonstrated by other 
groups in national and international studies16 -24. It was demonstrated in those studies that 



157

vascular calcifi cations evaluated by the method created by us, predict higher risk of cardiovascular 
events16, higher risk of lower limbs amputations17, higher pulse wave velocity18,19, corneal 
and conjuntival calcifi cations 20 and coronary calcifi cations21. A negative association between 
the simple vascular calcifi cation score and PTH levels21, 25(OH) vitamin D levels22,23 and 
Fetuin A levels19,24 has also been demonstrated. All these studies performed by different groups 
that have used the simple vascular calcifi cation score in their methods demonstrate that this 
score is simple, useful and reproducible in the evaluation of chronic kidney disease patients.

Referências

  1. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: 
impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731 -1740.

  2. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular 
calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 
2004;19(6):1480 -1488.

  3. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP A plain X -ray vascular 
calcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol 
Dial Transplant 2009;24(3):997 -1002.

  4. Adragão T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle 
brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3: 
(Suppl3): iii492 (Abstract Su545).

  5. Adragão T. Vascular calcifi cation, cardiovascular risk and arterial stiffness in hemodialysis patients. 
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 51 -56.

  6. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney Disease: Improving 
Global Outcomes (KDIGO). Kidney Int 2009; (76) (Suppl): S113.

  7. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffi th JL. The Framingham predictive instrument 
in chronic kidney disease J Am Coll Cardiol 2007; 50: 217 -224.

  8. Smoe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation 
of renal osteodystrophy: A position statement from kidney disease: improving global outcomes 
(KDIGO). Kidney Int 2006; 69: 1945 -1953.

  9. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Dias Curto J, 
Malluche HH. Low bone volume – A risk factor for coronary calcifi cations in hemodialysis patients. 
Clin J Am Soc Nephrol 2009; 4(2): 450 -455.

10. London GM. Bone  – vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol 
2009; 4: 254 -257.



158

11. Adragão T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ.Bone mineral density, 
vascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; 
28(6):668 -672.

12. Adragão T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Frazão JM, Malluche HH. 
Femoral bone mineral density reflects histologically determined cortical bone volume in 
hemodialysis patients. Osteoporos Int 2010; 21(4):619 -625.

13. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, 
Zoccali C, London GM, Vanholder R. Endorsement of the Kidney Disease Improving Global 
Outcomes (KDIGO) Chronic Kidney Disease -Mineral and Bone Disorder (CKD -MBD) Guidelines: 
a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 9. 
[Epub ahead of print.]

14. Adragão T. Evaluation of vascular calcifi cations in CKD patients. Int J Artif Organs 2009;32(2):81-
-86.

15. Adragão T, Frazão JM. Cardiovascular risk in dialysis patients: an X -ray vision on vascular 
calcifi cations. Kidney Int 2008;74(12):1505 -1507.

16. Wei T, Wang M, Wang Mi, et al. Relationship of sRANKL level and vascular calcifi cation score 
to cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009;28:34 -345

17. Matias P, Aires I, Jorge C, associated with lower -extremity amputations in haemodialysis patients. 
Port J Nephrol Hypert 2008; 22(1): 31 -36.

18. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, Krüger T, 
Westenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dimkovic N. Risk 
factors for cardiovascular calcifi cations in non -diabetic Caucasian haemodialysis patients. Kidney 
Blood Pres Res 2009; 32(3):161 -168.

19. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over 
time in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]

20. Seyahi N, Altiparmak MR, Kahveci A, Yetik H, Kanberoglu K, Serdengecti K, Ataman R, Erek 
E. Association of conjunctival and corneal calcifi cation with vascular calcifi cation in dialysis 
patients. Am J Kidney Dis 2005;45(3):550 -556.

21. Kim SC, Kim HW, Oh SW, Yang HN, Kim MG, Jo SK, Cho WY, Kim HK. Low iPTH can predict 
vascular and coronary calcifi cations in patients undergoing peritoneal dialysis. Nephron Clin Pract 
2010; (6) 117(2):c113 -c119. [Epub ahead of print.]

22. Matias PJ, Ferreira C, Jorge C et al. 25 -Hydroxyvitamin D3, arterial calcifi cations and cardiovascular 
risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.

23. García -Canton C, Bosch E, Ramírez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin D 
levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 
2010; 18. [Epub ahead of print.]

24. Jung JY, Hwang YH, Lee H, et al. Association of AHSG gene polymorphisms and aortic stiffness 
in peritoneal dialysis patients. Am J Nephrol 2010;31(6):510 -517.





CALCIFICAÇÕES VASCULARES 
NOS DOENTES EM DIÁLISE: 

ELO DE LIGAÇÃO ENTRE DOENÇA ÓSSEA 
E DOENÇA VASCULAR

TERESA ADRAGÃO

2011


	Tese Teresa Adragão - CAPA
	Tese Teresa Adragão - 3ª PROVA.pdf
	Tese Teresa Adragão - CONTRACAPA

&lt;&lt;
  /ASCII85EncodePages false
  /AllowTransparency false
  /AutoPositionEPSFiles true
  /AutoRotatePages /None
  /Binding /Left
  /CalGrayProfile (Dot Gain 20%)
  /CalRGBProfile (sRGB IEC61966-2.1)
  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)
  /sRGBProfile (sRGB IEC61966-2.1)
  /CannotEmbedFontPolicy /Error
  /CompatibilityLevel 1.4
  /CompressObjects /Tags
  /CompressPages true
  /ConvertImagesToIndexed true
  /PassThroughJPEGImages true
  /CreateJobTicket false
  /DefaultRenderingIntent /Default
  /DetectBlends false
  /DetectCurves 0.0000
  /ColorConversionStrategy /CMYK
  /DoThumbnails false
  /EmbedAllFonts true
  /EmbedOpenType false
  /ParseICCProfilesInComments true
  /EmbedJobOptions true
  /DSCReportingLevel 0
  /EmitDSCWarnings false
  /EndPage -1
  /ImageMemory 1048576
  /LockDistillerParams false
  /MaxSubsetPct 100
  /Optimize false
  /OPM 1
  /ParseDSCComments true
  /ParseDSCCommentsForDocInfo true
  /PreserveCopyPage true
  /PreserveDICMYKValues true
  /PreserveEPSInfo true
  /PreserveFlatness true
  /PreserveHalftoneInfo false
  /PreserveOPIComments true
  /PreserveOverprintSettings true
  /StartPage 1
  /SubsetFonts true
  /TransferFunctionInfo /Apply
  /UCRandBGInfo /Preserve
  /UsePrologue false
  /ColorSettingsFile ()
  /AlwaysEmbed [ true
  ]
  /NeverEmbed [ true
  ]
  /AntiAliasColorImages false
  /CropColorImages true
  /ColorImageMinResolution 300
  /ColorImageMinResolutionPolicy /OK
  /DownsampleColorImages true
  /ColorImageDownsampleType /Bicubic
  /ColorImageResolution 300
  /ColorImageDepth -1
  /ColorImageMinDownsampleDepth 1
  /ColorImageDownsampleThreshold 1.00333
  /EncodeColorImages true
  /ColorImageFilter /DCTEncode
  /AutoFilterColorImages true
  /ColorImageAutoFilterStrategy /JPEG
  /ColorACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /ColorImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000ColorACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000ColorImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasGrayImages false
  /CropGrayImages true
  /GrayImageMinResolution 300
  /GrayImageMinResolutionPolicy /OK
  /DownsampleGrayImages true
  /GrayImageDownsampleType /Bicubic
  /GrayImageResolution 300
  /GrayImageDepth -1
  /GrayImageMinDownsampleDepth 2
  /GrayImageDownsampleThreshold 1.00333
  /EncodeGrayImages true
  /GrayImageFilter /DCTEncode
  /AutoFilterGrayImages true
  /GrayImageAutoFilterStrategy /JPEG
  /GrayACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /GrayImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000GrayACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000GrayImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasMonoImages false
  /CropMonoImages true
  /MonoImageMinResolution 1200
  /MonoImageMinResolutionPolicy /OK
  /DownsampleMonoImages true
  /MonoImageDownsampleType /Bicubic
  /MonoImageResolution 1200
  /MonoImageDepth -1
  /MonoImageDownsampleThreshold 1.00833
  /EncodeMonoImages true
  /MonoImageFilter /CCITTFaxEncode
  /MonoImageDict&amp;lt;&lt;
    /K -1
  &gt;&gt;
  /AllowPSXObjects false
  /CheckCompliance [
    /None
  ]
  /PDFX1aCheck false
  /PDFX3Check false
  /PDFXCompliantPDFOnly false
  /PDFXNoTrimBoxError true
  /PDFXTrimBoxToMediaBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXSetBleedBoxToMediaBox true
  /PDFXBleedBoxToTrimBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXOutputIntentProfile (None)
  /PDFXOutputConditionIdentifier ()
  /PDFXOutputCondition ()
  /PDFXRegistryName ()
  /PDFXTrapped /False

  /CreateJDFFile false
  /Description&amp;lt;&lt;
    /ARA&amp;lt;FEFF06270633062A062E062F0645002006470630064700200627064406250639062F0627062F0627062A002006440625064606340627062100200648062B062706260642002000410064006F00620065002000500044004600200645062A064806270641064206290020064406440637062806270639062900200641064A00200627064406450637062706280639002006300627062A0020062F0631062C0627062A002006270644062C0648062F0629002006270644063906270644064A0629061B0020064A06450643064600200641062A062D00200648062B0627062606420020005000440046002006270644064506460634062306290020062806270633062A062E062F062706450020004100630072006F0062006100740020064800410064006F006200650020005200650061006400650072002006250635062F0627063100200035002E0030002006480627064406250635062F062706310627062A0020062706440623062D062F062B002E0635062F0627063100200035002E0030002006480627064406250635062F062706310627062A0020062706440623062D062F062B002E&gt;
    /BGR&amp;lt;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&gt;
    /CHS&amp;lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002&gt;
    /CHT&amp;lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002&gt;
    /CZE&amp;lt;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&gt;
    /DAN&amp;lt;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&gt;
    /DEU&amp;lt;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&gt;
    /ESP&amp;lt;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&gt;
    /ETI&amp;lt;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&gt;
    /FRA&amp;lt;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&gt;
    /GRE&amp;lt;FEFF03a703c103b703c303b903bc03bf03c003bf03b903ae03c303c403b5002003b103c503c403ad03c2002003c403b903c2002003c103c503b803bc03af03c303b503b903c2002003b303b903b1002003bd03b1002003b403b703bc03b903bf03c503c103b303ae03c303b503c403b5002003ad03b303b303c103b103c603b1002000410064006f006200650020005000440046002003c003bf03c5002003b503af03bd03b103b9002003ba03b103c42019002003b503be03bf03c703ae03bd002003ba03b103c403ac03bb03bb03b703bb03b1002003b303b903b1002003c003c103bf002d03b503ba03c403c503c003c903c403b903ba03ad03c2002003b503c103b303b103c303af03b503c2002003c503c803b703bb03ae03c2002003c003bf03b903cc03c403b703c403b103c2002e0020002003a403b10020005000440046002003ad03b303b303c103b103c603b1002003c003bf03c5002003ad03c703b503c403b5002003b403b703bc03b903bf03c503c103b303ae03c303b503b9002003bc03c003bf03c103bf03cd03bd002003bd03b1002003b103bd03bf03b903c703c403bf03cd03bd002003bc03b5002003c403bf0020004100630072006f006200610074002c002003c403bf002000410064006f00620065002000520065006100640065007200200035002e0030002003ba03b103b9002003bc03b503c403b103b303b503bd03ad03c303c403b503c103b503c2002003b503ba03b403cc03c303b503b903c2002e&gt;
    /HEB&amp;lt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gt;
    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)
    /HUN&amp;lt;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&gt;
    /ITA&amp;lt;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&gt;
    /JPN&amp;lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002&gt;
    /KOR&amp;lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e&gt;
    /LTH&amp;lt;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&gt;
    /LVI&amp;lt;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&gt;
    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)
    /NOR&amp;lt;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&gt;
    /POL&amp;lt;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&gt;
    /PTB&amp;lt;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&gt;
    /RUM&amp;lt;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&gt;
    /RUS&amp;lt;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&gt;
    /SKY&amp;lt;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&gt;
    /SLV&amp;lt;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&gt;
    /SUO&amp;lt;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&gt;
    /SVE&amp;lt;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&gt;
    /TUR&amp;lt;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&gt;
    /UKR&amp;lt;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&gt;
    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)
  &gt;&gt;
  /Namespace [
    (Adobe)
    (Common)
    (1.0)
  ]
  /OtherNamespaces [
   &amp;lt;&lt;
      /AsReaderSpreads false
      /CropImagesToFrames true
      /ErrorControl /WarnAndContinue
      /FlattenerIgnoreSpreadOverrides false
      /IncludeGuidesGrids false
      /IncludeNonPrinting false
      /IncludeSlug false
      /Namespace [
        (Adobe)
        (InDesign)
        (4.0)
      ]
      /OmitPlacedBitmaps false
      /OmitPlacedEPS false
      /OmitPlacedPDF false
      /SimulateOverprint /Legacy
    &gt;&gt;
   &amp;lt;&lt;
      /AddBleedMarks false
      /AddColorBars false
      /AddCropMarks false
      /AddPageInfo false
      /AddRegMarks false
      /ConvertColors /ConvertToCMYK
      /DestinationProfileName ()
      /DestinationProfileSelector /DocumentCMYK
      /Downsample16BitImages true
      /FlattenerPreset&amp;lt;&lt;
        /PresetSelector /MediumResolution
      &gt;&gt;
      /FormElements false
      /GenerateStructure false
      /IncludeBookmarks false
      /IncludeHyperlinks false
      /IncludeInteractive false
      /IncludeLayers false
      /IncludeProfiles false
      /MultimediaHandling /UseObjectSettings
      /Namespace [
        (Adobe)
        (CreativeSuite)
        (2.0)
      ]
      /PDFXOutputIntentProfileSelector /DocumentCMYK
      /PreserveEditing true
      /UntaggedCMYKHandling /LeaveUntagged
      /UntaggedRGBHandling /UseDocumentProfile
      /UseDocumentBleed false
    &gt;&gt;
  ]
&gt;&gt; setdistillerparams
&lt;&lt;
  /HWResolution [2400 2400]
  /PageSize [612.000 792.000]
&gt;&gt; setpagedevice



&lt;&lt;
  /ASCII85EncodePages false
  /AllowTransparency false
  /AutoPositionEPSFiles true
  /AutoRotatePages /None
  /Binding /Left
  /CalGrayProfile (Dot Gain 20%)
  /CalRGBProfile (sRGB IEC61966-2.1)
  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)
  /sRGBProfile (sRGB IEC61966-2.1)
  /CannotEmbedFontPolicy /Error
  /CompatibilityLevel 1.4
  /CompressObjects /Tags
  /CompressPages true
  /ConvertImagesToIndexed true
  /PassThroughJPEGImages true
  /CreateJobTicket false
  /DefaultRenderingIntent /Default
  /DetectBlends false
  /DetectCurves 0.0000
  /ColorConversionStrategy /CMYK
  /DoThumbnails false
  /EmbedAllFonts true
  /EmbedOpenType false
  /ParseICCProfilesInComments true
  /EmbedJobOptions true
  /DSCReportingLevel 0
  /EmitDSCWarnings false
  /EndPage -1
  /ImageMemory 1048576
  /LockDistillerParams false
  /MaxSubsetPct 100
  /Optimize false
  /OPM 1
  /ParseDSCComments true
  /ParseDSCCommentsForDocInfo true
  /PreserveCopyPage true
  /PreserveDICMYKValues true
  /PreserveEPSInfo true
  /PreserveFlatness true
  /PreserveHalftoneInfo false
  /PreserveOPIComments true
  /PreserveOverprintSettings true
  /StartPage 1
  /SubsetFonts true
  /TransferFunctionInfo /Apply
  /UCRandBGInfo /Preserve
  /UsePrologue false
  /ColorSettingsFile ()
  /AlwaysEmbed [ true
  ]
  /NeverEmbed [ true
  ]
  /AntiAliasColorImages false
  /CropColorImages true
  /ColorImageMinResolution 300
  /ColorImageMinResolutionPolicy /OK
  /DownsampleColorImages true
  /ColorImageDownsampleType /Bicubic
  /ColorImageResolution 300
  /ColorImageDepth -1
  /ColorImageMinDownsampleDepth 1
  /ColorImageDownsampleThreshold 1.00333
  /EncodeColorImages true
  /ColorImageFilter /DCTEncode
  /AutoFilterColorImages true
  /ColorImageAutoFilterStrategy /JPEG
  /ColorACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /ColorImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000ColorACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000ColorImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasGrayImages false
  /CropGrayImages true
  /GrayImageMinResolution 300
  /GrayImageMinResolutionPolicy /OK
  /DownsampleGrayImages true
  /GrayImageDownsampleType /Bicubic
  /GrayImageResolution 300
  /GrayImageDepth -1
  /GrayImageMinDownsampleDepth 2
  /GrayImageDownsampleThreshold 1.00333
  /EncodeGrayImages true
  /GrayImageFilter /DCTEncode
  /AutoFilterGrayImages true
  /GrayImageAutoFilterStrategy /JPEG
  /GrayACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /GrayImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000GrayACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000GrayImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasMonoImages false
  /CropMonoImages true
  /MonoImageMinResolution 1200
  /MonoImageMinResolutionPolicy /OK
  /DownsampleMonoImages true
  /MonoImageDownsampleType /Bicubic
  /MonoImageResolution 1200
  /MonoImageDepth -1
  /MonoImageDownsampleThreshold 1.00833
  /EncodeMonoImages true
  /MonoImageFilter /CCITTFaxEncode
  /MonoImageDict&amp;lt;&lt;
    /K -1
  &gt;&gt;
  /AllowPSXObjects false
  /CheckCompliance [
    /None
  ]
  /PDFX1aCheck false
  /PDFX3Check false
  /PDFXCompliantPDFOnly false
  /PDFXNoTrimBoxError true
  /PDFXTrimBoxToMediaBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXSetBleedBoxToMediaBox true
  /PDFXBleedBoxToTrimBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXOutputIntentProfile (None)
  /PDFXOutputConditionIdentifier ()
  /PDFXOutputCondition ()
  /PDFXRegistryName ()
  /PDFXTrapped /False

  /CreateJDFFile false
  /Description&amp;lt;&lt;
    /ARA&amp;lt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gt;
    /BGR&amp;lt;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&gt;
    /CHS&amp;lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002&gt;
    /CHT&amp;lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002&gt;
    /CZE&amp;lt;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&gt;
    /DAN&amp;lt;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&gt;
    /DEU&amp;lt;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&gt;
    /ESP&amp;lt;FEFF005500740069006c0069006300650020006500730074006100200063006f006e0066006900670075007200610063006900f3006e0020007000610072006100200063007200650061007200200064006f00630075006d0065006e0074006f00730020005000440046002000640065002000410064006f0062006500200061006400650063007500610064006f00730020007000610072006100200069006d0070007200650073006900f3006e0020007000720065002d0065006400690074006f007200690061006c00200064006500200061006c00740061002000630061006c0069006400610064002e002000530065002000700075006500640065006e00200061006200720069007200200064006f00630075006d0065006e0074006f00730020005000440046002000630072006500610064006f007300200063006f006e0020004100630072006f006200610074002c002000410064006f00620065002000520065006100640065007200200035002e003000200079002000760065007200730069006f006e0065007300200070006f00730074006500720069006f007200650073002e&gt;
    /ETI&amp;lt;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&gt;
    /FRA&amp;lt;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&gt;
    /GRE&amp;lt;FEFF03a703c103b703c303b903bc03bf03c003bf03b903ae03c303c403b5002003b103c503c403ad03c2002003c403b903c2002003c103c503b803bc03af03c303b503b903c2002003b303b903b1002003bd03b1002003b403b703bc03b903bf03c503c103b303ae03c303b503c403b5002003ad03b303b303c103b103c603b1002000410064006f006200650020005000440046002003c003bf03c5002003b503af03bd03b103b9002003ba03b103c42019002003b503be03bf03c703ae03bd002003ba03b103c403ac03bb03bb03b703bb03b1002003b303b903b1002003c003c103bf002d03b503ba03c403c503c003c903c403b903ba03ad03c2002003b503c103b303b103c303af03b503c2002003c503c803b703bb03ae03c2002003c003bf03b903cc03c403b703c403b103c2002e0020002003a403b10020005000440046002003ad03b303b303c103b103c603b1002003c003bf03c5002003ad03c703b503c403b5002003b403b703bc03b903bf03c503c103b303ae03c303b503b9002003bc03c003bf03c103bf03cd03bd002003bd03b1002003b103bd03bf03b903c703c403bf03cd03bd002003bc03b5002003c403bf0020004100630072006f006200610074002c002003c403bf002000410064006f00620065002000520065006100640065007200200035002e0030002003ba03b103b9002003bc03b503c403b103b303b503bd03ad03c303c403b503c103b503c2002003b503ba03b403cc03c303b503b903c2002e&gt;
    /HEB&amp;lt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gt;
    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)
    /HUN&amp;lt;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&gt;
    /ITA&amp;lt;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&gt;
    /JPN&amp;lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002&gt;
    /KOR&amp;lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e&gt;
    /LTH&amp;lt;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&gt;
    /LVI&amp;lt;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&gt;
    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)
    /NOR&amp;lt;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&gt;
    /POL&amp;lt;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&gt;
    /PTB&amp;lt;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&gt;
    /RUM&amp;lt;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&gt;
    /RUS&amp;lt;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&gt;
    /SKY&amp;lt;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&gt;
    /SLV&amp;lt;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&gt;
    /SUO&amp;lt;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&gt;
    /SVE&amp;lt;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&gt;
    /TUR&amp;lt;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&gt;
    /UKR&amp;lt;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&gt;
    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)
  &gt;&gt;
  /Namespace [
    (Adobe)
    (Common)
    (1.0)
  ]
  /OtherNamespaces [
   &amp;lt;&lt;
      /AsReaderSpreads false
      /CropImagesToFrames true
      /ErrorControl /WarnAndContinue
      /FlattenerIgnoreSpreadOverrides false
      /IncludeGuidesGrids false
      /IncludeNonPrinting false
      /IncludeSlug false
      /Namespace [
        (Adobe)
        (InDesign)
        (4.0)
      ]
      /OmitPlacedBitmaps false
      /OmitPlacedEPS false
      /OmitPlacedPDF false
      /SimulateOverprint /Legacy
    &gt;&gt;
   &amp;lt;&lt;
      /AddBleedMarks false
      /AddColorBars false
      /AddCropMarks false
      /AddPageInfo false
      /AddRegMarks false
      /ConvertColors /ConvertToCMYK
      /DestinationProfileName ()
      /DestinationProfileSelector /DocumentCMYK
      /Downsample16BitImages true
      /FlattenerPreset&amp;lt;&lt;
        /PresetSelector /MediumResolution
      &gt;&gt;
      /FormElements false
      /GenerateStructure false
      /IncludeBookmarks false
      /IncludeHyperlinks false
      /IncludeInteractive false
      /IncludeLayers false
      /IncludeProfiles false
      /MultimediaHandling /UseObjectSettings
      /Namespace [
        (Adobe)
        (CreativeSuite)
        (2.0)
      ]
      /PDFXOutputIntentProfileSelector /DocumentCMYK
      /PreserveEditing true
      /UntaggedCMYKHandling /LeaveUntagged
      /UntaggedRGBHandling /UseDocumentProfile
      /UseDocumentBleed false
    &gt;&gt;
  ]
&gt;&gt; setdistillerparams
&lt;&lt;
  /HWResolution [2400 2400]
  /PageSize [612.000 792.000]
&gt;&gt; setpagedevice



&lt;&lt;
  /ASCII85EncodePages false
  /AllowTransparency false
  /AutoPositionEPSFiles true
  /AutoRotatePages /None
  /Binding /Left
  /CalGrayProfile (Dot Gain 20%)
  /CalRGBProfile (sRGB IEC61966-2.1)
  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)
  /sRGBProfile (sRGB IEC61966-2.1)
  /CannotEmbedFontPolicy /Error
  /CompatibilityLevel 1.4
  /CompressObjects /Tags
  /CompressPages true
  /ConvertImagesToIndexed true
  /PassThroughJPEGImages true
  /CreateJobTicket false
  /DefaultRenderingIntent /Default
  /DetectBlends false
  /DetectCurves 0.0000
  /ColorConversionStrategy /CMYK
  /DoThumbnails false
  /EmbedAllFonts true
  /EmbedOpenType false
  /ParseICCProfilesInComments true
  /EmbedJobOptions true
  /DSCReportingLevel 0
  /EmitDSCWarnings false
  /EndPage -1
  /ImageMemory 1048576
  /LockDistillerParams false
  /MaxSubsetPct 100
  /Optimize false
  /OPM 1
  /ParseDSCComments true
  /ParseDSCCommentsForDocInfo true
  /PreserveCopyPage true
  /PreserveDICMYKValues true
  /PreserveEPSInfo true
  /PreserveFlatness true
  /PreserveHalftoneInfo false
  /PreserveOPIComments true
  /PreserveOverprintSettings true
  /StartPage 1
  /SubsetFonts true
  /TransferFunctionInfo /Apply
  /UCRandBGInfo /Preserve
  /UsePrologue false
  /ColorSettingsFile ()
  /AlwaysEmbed [ true
  ]
  /NeverEmbed [ true
  ]
  /AntiAliasColorImages false
  /CropColorImages true
  /ColorImageMinResolution 300
  /ColorImageMinResolutionPolicy /OK
  /DownsampleColorImages true
  /ColorImageDownsampleType /Bicubic
  /ColorImageResolution 300
  /ColorImageDepth -1
  /ColorImageMinDownsampleDepth 1
  /ColorImageDownsampleThreshold 1.00333
  /EncodeColorImages true
  /ColorImageFilter /DCTEncode
  /AutoFilterColorImages true
  /ColorImageAutoFilterStrategy /JPEG
  /ColorACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /ColorImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000ColorACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000ColorImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasGrayImages false
  /CropGrayImages true
  /GrayImageMinResolution 300
  /GrayImageMinResolutionPolicy /OK
  /DownsampleGrayImages true
  /GrayImageDownsampleType /Bicubic
  /GrayImageResolution 300
  /GrayImageDepth -1
  /GrayImageMinDownsampleDepth 2
  /GrayImageDownsampleThreshold 1.00333
  /EncodeGrayImages true
  /GrayImageFilter /DCTEncode
  /AutoFilterGrayImages true
  /GrayImageAutoFilterStrategy /JPEG
  /GrayACSImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /GrayImageDict&amp;lt;&lt;
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  &gt;&gt;
  /JPEG2000GrayACSImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /JPEG2000GrayImageDict&amp;lt;&lt;
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  &gt;&gt;
  /AntiAliasMonoImages false
  /CropMonoImages true
  /MonoImageMinResolution 1200
  /MonoImageMinResolutionPolicy /OK
  /DownsampleMonoImages true
  /MonoImageDownsampleType /Bicubic
  /MonoImageResolution 1200
  /MonoImageDepth -1
  /MonoImageDownsampleThreshold 1.00833
  /EncodeMonoImages true
  /MonoImageFilter /CCITTFaxEncode
  /MonoImageDict&amp;lt;&lt;
    /K -1
  &gt;&gt;
  /AllowPSXObjects false
  /CheckCompliance [
    /None
  ]
  /PDFX1aCheck false
  /PDFX3Check false
  /PDFXCompliantPDFOnly false
  /PDFXNoTrimBoxError true
  /PDFXTrimBoxToMediaBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXSetBleedBoxToMediaBox true
  /PDFXBleedBoxToTrimBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXOutputIntentProfile (None)
  /PDFXOutputConditionIdentifier ()
  /PDFXOutputCondition ()
  /PDFXRegistryName ()
  /PDFXTrapped /False

  /CreateJDFFile false
  /Description&amp;lt;&lt;
    /ARA&amp;lt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gt;
    /BGR&amp;lt;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&gt;
    /CHS&amp;lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002&gt;
    /CHT&amp;lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002&gt;
    /CZE&amp;lt;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&gt;
    /DAN&amp;lt;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&gt;
    /DEU&amp;lt;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&gt;
    /ESP&amp;lt;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&gt;
    /ETI&amp;lt;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&gt;
    /FRA&amp;lt;FEFF005500740069006c006900730065007a00200063006500730020006f007000740069006f006e00730020006100660069006e00200064006500200063007200e900650072002000640065007300200064006f00630075006d0065006e00740073002000410064006f00620065002000500044004600200070006f0075007200200075006e00650020007100750061006c0069007400e90020006400270069006d007000720065007300730069006f006e00200070007200e9007000720065007300730065002e0020004c0065007300200064006f00630075006d0065006e00740073002000500044004600200063007200e900e90073002000700065007500760065006e0074002000ea0074007200650020006f007500760065007200740073002000640061006e00730020004100630072006f006200610074002c002000610069006e00730069002000710075002700410064006f00620065002000520065006100640065007200200035002e0030002000650074002000760065007200730069006f006e007300200075006c007400e90072006900650075007200650073002e&gt;
    /GRE&amp;lt;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&gt;
    /HEB&amp;lt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gt;
    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)
    /HUN&amp;lt;FEFF004b0069007600e1006c00f30020006d0069006e0151007300e9006701710020006e0079006f006d00640061006900200065006c0151006b00e90073007a00ed007401510020006e0079006f006d00740061007400e100730068006f007a0020006c006500670069006e006b00e1006200620020006d0065006700660065006c0065006c0151002000410064006f00620065002000500044004600200064006f006b0075006d0065006e00740075006d006f006b0061007400200065007a0065006b006b0065006c0020006100200062006500e1006c006c00ed007400e10073006f006b006b0061006c0020006b00e90073007a00ed0074006800650074002e0020002000410020006c00e90074007200650068006f007a006f00740074002000500044004600200064006f006b0075006d0065006e00740075006d006f006b00200061007a0020004100630072006f006200610074002000e9007300200061007a002000410064006f00620065002000520065006100640065007200200035002e0030002c0020007600610067007900200061007a002000610074007400f3006c0020006b00e9007301510062006200690020007600650072007a006900f3006b006b0061006c0020006e00790069007400680061007400f3006b0020006d00650067002e&gt;
    /ITA&amp;lt;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&gt;
    /JPN&amp;lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002&gt;
    /KOR&amp;lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e&gt;
    /LTH&amp;lt;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&gt;
    /LVI&amp;lt;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&gt;
    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)
    /NOR&amp;lt;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&gt;
    /POL&amp;lt;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&gt;
    /PTB&amp;lt;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&gt;
    /RUM&amp;lt;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&gt;
    /RUS&amp;lt;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&gt;
    /SKY&amp;lt;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&gt;
    /SLV&amp;lt;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&gt;
    /SUO&amp;lt;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&gt;
    /SVE&amp;lt;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&gt;
    /TUR&amp;lt;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&gt;
    /UKR&amp;lt;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&gt;
    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)
  &gt;&gt;
  /Namespace [
    (Adobe)
    (Common)
    (1.0)
  ]
  /OtherNamespaces [
   &amp;lt;&lt;
      /AsReaderSpreads false
      /CropImagesToFrames true
      /ErrorControl /WarnAndContinue
      /FlattenerIgnoreSpreadOverrides false
      /IncludeGuidesGrids false
      /IncludeNonPrinting false
      /IncludeSlug false
      /Namespace [
        (Adobe)
        (InDesign)
        (4.0)
      ]
      /OmitPlacedBitmaps false
      /OmitPlacedEPS false
      /OmitPlacedPDF false
      /SimulateOverprint /Legacy
    &gt;&gt;
   &amp;lt;&lt;
      /AddBleedMarks false
      /AddColorBars false
      /AddCropMarks false
      /AddPageInfo false
      /AddRegMarks false
      /ConvertColors /ConvertToCMYK
      /DestinationProfileName ()
      /DestinationProfileSelector /DocumentCMYK
      /Downsample16BitImages true
      /FlattenerPreset&amp;lt;&lt;
        /PresetSelector /MediumResolution
      &gt;&gt;
      /FormElements false
      /GenerateStructure false
      /IncludeBookmarks false
      /IncludeHyperlinks false
      /IncludeInteractive false
      /IncludeLayers false
      /IncludeProfiles false
      /MultimediaHandling /UseObjectSettings
      /Namespace [
        (Adobe)
        (CreativeSuite)
        (2.0)
      ]
      /PDFXOutputIntentProfileSelector /DocumentCMYK
      /PreserveEditing true
      /UntaggedCMYKHandling /LeaveUntagged
      /UntaggedRGBHandling /UseDocumentProfile
      /UseDocumentBleed false
    &gt;&gt;
  ]
&gt;&gt; setdistillerparams
&lt;&lt;
  /HWResolution [2400 2400]
  /PageSize [612.000 792.000]
&gt;&gt; setpagedevice



</field>
	</doc>
</add>